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This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health 
effects information for the hazardous substance described therein.  Each peer-reviewed profile identifies 
and reviews the key literature that describes a hazardous substance's toxicologic properties.  Other 
pertinent literature is also presented, but is described in less detail than the key studies.  The profile is not 
intended to be an exhaustive document; however, more comprehensive sources of specialty information 
are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological 
profile begins with a public health statement that describes, in nontechnical language, a substance's 
relevant toxicological properties.  Following the public health statement is information concerning levels 
of significant human exposure and, where known, significant health effects.  The adequacy of information 
to determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.  
 
Each profile includes the following: 
 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant 
human exposure for the substance and the associated acute, subacute, and chronic health 
effects; 
 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public.  We plan 
to revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use. 
 
Comments should be sent to: 
 
    Agency for Toxic Substances and Disease Registry 
    Division of Toxicology and Environmental Medicine 
    1600 Clifton Road, N.E. 
     Mail Stop F-32 










The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This 
public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List and that pose the most significant potential 
threat to human health, as determined by ATSDR and the EPA.  The availability of the revised priority 
list of 275 hazardous substances was announced in the Federal Register on December 7, 2005 (70 FR 
72840).   For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 
(52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 
FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801);  February 28, 1994 (59 
FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 
56792); October 25, 2001 (66 FR 54014); and  November 7, 2003 (68 FR 63098). Section 104(i)(3) of 
CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each 
substance on the list.    
 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile.  In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review.  Final responsibility for the 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
 
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
 
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section.  
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
 
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues: 
 Section 1.6 How Can (Chemical X) Affect Children? 
 Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 Section 3.7 Children’s Susceptibility 
 Section 6.6 Exposures of Children 
 
Other Sections of Interest: 
 Section 3.8  Biomarkers of Exposure and Effect 
 Section 3.11  Methods for Reducing Toxic Effects 
 
 
ATSDR Information Center  
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   Fax:   (770) 488-4178 
 E-mail:   cdcinfo@cdc.gov  Internet:   http://www.atsdr.cdc.gov 
 
The following additional material can be ordered through the ATSDR Information Center: 
 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III—
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
 
 
Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-
1998 • Phone: 800-35-NIOSH. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 





The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-
4976 • FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
 
 
1. Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
 
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
 
3. Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 
 
4. Green Border Review.  Green Border review assures the consistency with ATSDR policy. 
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A peer review panel was assembled for ethylene glycol.  The panel consisted of the following members:  
 
1. Phillip Goad, Ph.D., Center for Toxicology and Environmental Health, LLC, North Little Rock, 
Arkansas; 
 
2. Jerrold Leiken, M.D., ENH-OMEGA, Glenview, Illinois; and 
 
3. Kenneth McMartin, Ph.D., Louisiana State University, Shreveport, Louisiana. 
 
These experts collectively have knowledge of ethylene glycol's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content.  The responsibility for the content of this profile lies with the ATSDR. 
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1.  PUBLIC HEALTH STATEMENT 
 
This public health statement tells you about ethylene glycol and the effects of exposure to it. 
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  Ethylene glycol has been found in at least 37 of the 1,689 current or former 
NPL sites.  Although the total number of NPL sites evaluated for this substance is not known, the 
possibility exists that the number of sites at which ethylene glycol is found may increase in the future as 
more sites are evaluated.  This information is important because these sites may be sources of exposure 
and exposure to this substance may harm you. 
 
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
 
If you are exposed to ethylene glycol, many factors will determine whether you will be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with it.  You 
must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, 
and state of health. 
 
What is ethylene glycol? 
 
Colorless liquid 
that is odorless 
Ethylene glycol is a synthetic liquid substance that absorbs water.  It is 




Ethylene glycol is used to make antifreeze and de-icing solutions for cars, 
airplanes, and boats.  
 
Consumer products containing ethylene glycol include:  
 
• Antifreeze 
• Hydraulic brake fluids 
• Inks used in stamp pads, ballpoint pens, and print shops 
 
For more information on the sources, properties, and uses of ethylene glycol, see Chapters 4 and 5. 
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What happens to ethylene glycol when it enters the environment? 
 
Released into 
air, water, and 
soil  
The primary source of ethylene glycol in the environment is from run-off at 
airports where is used in de-icing agents for runways and airplanes.  Ethylene 




Air:  Ethylene glycol in air will break down in about 10 days  
 
Water and soil:  Ethylene glycol in water and in soil will breakdown within 
several days to a few weeks.   
 
See Chapters 5 and 6 for more information on ethylene glycol in the environment.   
 
How might I be exposed to ethylene glycol? 
 
Antifreeze The general public can be exposed to ethylene glycol through skin contact 
when using automobile antifreeze.  Accidental or intentional ingestion can 
occur because antifreeze is a sweet tasting, brightly colored liquid. 
Air, water, soil Background concentrations of ethylene glycol in air, surface water, 
groundwater, drinking water, soil, and sediment have not been reported.  
Exposure to ethylene glycol in air, drinking water, or soil is not expected. 
Workplace air People who work in industries that use ethylene glycol may be exposed by 
touching products such as solvents, antifreeze, and feedstocks that contain 
this substance  
 
Workers can also be exposed to low levels from ethylene glycol-containing 
products such as airplane de-icing solutions that have been sprayed into the 
air. 
 
See Chapter 6 for more information on exposure to ethylene glycol.   
 
How can ethylene glycol enter and leave my body? 
 
Enters your body 
after ingestion, 
inhalation, or 
dermal contact  
Ingested ethylene glycol is quickly absorbed in large amounts.  
 
There is some information suggesting that inhaled ethylene glycol is also 
absorbed. 
 
Ethylene glycol can also slowly enter your bloodstream through your skin if 
you come in direct contact with it and do not wash it off.   
Typically leaves 
your body within 
1–2 days 
Once in your body, most of the ethylene glycol is broken down (into other 
more toxic chemicals) and some of it remains unchanged.  Ethylene glycol 
and its break down products are removed from your body through the 
excretion of urine. 
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How can ethylene glycol affect my health? 
 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find ways 
for treating persons who have been harmed. 
 
The effect of ethylene glycol on human health depends on how much ethylene glycol is present. 
 
Very small 
amounts will not 
affect your health 
Your health is not likely to be seriously affected by the very small amounts 
of ethylene glycol that could be tasted or otherwise accidentally eaten (for 
example, by putting your fingers in your mouth after getting them wet with 
antifreeze).  Accidental or intentional ingestion of larger amounts of ethylene 
glycol can cause serious illness or death. 
Large amounts 
can damage the 
kidneys, nervous 
system, and heart  
When ethylene glycol breaks down in the body, it forms chemicals that 
crystallize, and the crystals can collect in your kidneys and affect kidney 
function.   
 
Ethylene glycol also forms acidic chemicals in the body, which can change 





Treatment after early diagnosis has been very successful in people drinking 
large amounts of ethylene glycol.   
 
Further information on the health effects of ethylene glycol in humans and animals can be found in 
Chapters 2 and 3. 
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How can ethylene glycol affect children? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age. 
 
Children are likely 
to have similar 
effects as adults 
Clinical findings in children who were poisoned by accidentally or 
intentionally drinking ethylene glycol indicate that it is likely that children 
would show the same health effects as adults.  We do not know whether 
children differ in their susceptibility to the effects of ethylene glycol. 
Birth defects We do not know whether ethylene glycol causes birth defects in people.  
Skeletal defects and low birth weights have occurred in newborn animals 
whose mothers ingested large amounts of ethylene glycol during pregnancy.
Lactation 
exposure 
We do not know whether ethylene glycol can accumulate in breast milk. 
 
How can families reduce the risk of exposure to ethylene glycol? 
 




Antifreeze products should be used with caution and kept out of the reach of 
children.  Open bottles of antifreeze should not be left on or near the ground 
where children can reach them.   
 
Antifreeze should not be stored in anything other than the original container, 
such as in a cup or soft drink bottle, to avoid someone mistaking it for a 
beverage.  Antifreeze containers should have a child-proof cap, be stored 





Ethylene glycol poisoning can be effectively treated, but early diagnosis is 
needed to prevent serious injury.  Medical attention should be sought as 






Minimize skin contact when using antifreeze and other consumer products 
containing ethylene glycol.  Avoid spilling or draining antifreeze on the 
ground to prevent children from playing in a puddle of ethylene glycol. 
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Is there a medical test to determine whether I have been exposed to ethylene 
glycol? 
 
Analysis of blood 
and urine 
 
Ethylene glycol and its effects can be measured in blood and urine.  The 
metabolites cause characteristic chemical changes in the blood and urine 
that help to diagnose ethylene glycol poisoning. 
 
You should have these tests done within a few hours after exposure occurs 
because ethylene glycol leaves the body very quickly and early diagnosis is 
necessary for effective treatment.   
 
The presence of crystals in the urine may indicate kidney damage.   
 
Refer to Chapters 3 and 7 for more information on these tests. 
 
What recommendations has the federal government made to protect human 
health? 
 
The federal government develops regulations and recommendations to protect public health.  Regulations 
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that 
affect animals; they are then adjusted to levels that will help protect humans.  Sometimes these not-to-
exceed levels differ among federal organizations because they used different exposure times (an 8-hour 
workday or a 24-hour day), different animal studies, or other factors. 
 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it.   
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Some regulations and recommendations for ethylene glycol include the following: 
 
Levels in drinking 
water set by EPA 
The EPA has determined that exposure to ethylene glycol in drinking water 
at concentrations of 20 milligrams per liter (mg/L) for 1 day or 6 mg/L for 
10 days is not expected to cause any adverse effects in a child. 
 
The EPA has determined that lifetime exposure to 14 mg/L ethylene glycol 
in drinking water is not expected to cause any adverse effects. 
 
For more information on the regulations and guidelines that apply to ethylene glycol, see Chapter 8.   
 
Where can I get more information? 
 
If you have any more questions or concerns, please contact your regional poison control center (1-800-
222-1222), community or state health or environmental quality department, or contact ATSDR at the 
address and phone number below. 
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may 
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:  
 
  Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
  1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
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Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
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2.  RELEVANCE TO PUBLIC HEALTH 
 
2.1   BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ETHYLENE GLYCOL IN 
THE UNITED STATES  
 
Ethylene glycol is a colorless, odorless liquid that mixes completely with water.  It is released into the 
environment primarily through industrial emissions and through the use and disposal of ethylene glycol-
based automobile antifreeze and airport de-icing formulations.  Ethylene glycol that is released into the 
environment does not persist since it is degraded within days to a few weeks in air, water, and soil.  
Available monitoring data indicate that ethylene glycol is only found near areas of release.  Ethylene 
glycol vapor concentrations measured in the air at airports during de-icing spray operations ranged from 
0.05 to 22 mg/m3.  Ethylene glycol has also been detected in airport stormwater.  Background 
concentrations of ethylene glycol in the environment are not available. 
 
Since ethylene glycol is not expected to be present away from areas where it is released, background 
exposure of the general population to this substance is not expected to be important.  The most common 
route of exposure to ethylene glycol for the general population is through dermal contact with ethylene 
glycol-containing automobile antifreeze.  However, accidental or intentional ingestion of antifreeze is the 
most serious route of exposure, resulting in thousands of poisonings reported each year in the United 
States.  Ethylene glycol concentrations in blood, urine, tissue, or breast milk are not available for the 
general population. 
 
Individuals who live near hazardous waste sites, industrial facilities where ethylene glycol is produced or 
used, or areas where ethylene glycol-based de-icing formulations are used may be exposed to ethylene 
glycol through dermal contact with contaminated soil or water, inhalation of ethylene glycol vapor or 
mist, or ingestion of contaminated groundwater.  Occupational exposure through dermal contact and 
inhalation of ethylene glycol vapor or mist is expected for individuals involved in airport de-icing spray 
operations.  Ethylene glycol has been detected in urine samples collected from airport de-icing workers.  
 
Ingestion of ethylene glycol containing antifreeze is a potential route of exposure for children since they 
are attracted to the bright colors of antifreeze formulations and the sweet taste of ethylene glycol.  
Exposure through ingestion is more likely to occur when adults leave opened antifreeze containers within 
reach or store antifreeze in other types of containers such as beverage bottles.  A bittering agent has been 
added to some ethylene glycol antifreeze formulations in order to deter ingestion; however, caution 
should still be used since ingestion poisoning has occurred even when a bittering agent was present. 
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2.2   SUMMARY OF HEALTH EFFECTS  
 
Ethylene glycol is quickly and extensively absorbed through the gastrointestinal tract of many species, but 
dermal absorption is slow in rodents and is expected to be slow in humans.  Limited information is 
available on absorption of inhaled ethylene glycol, but the existing toxicity studies suggest absorption via 
the respiratory tract by both humans and rodents.  Following absorption, ethylene glycol is distributed in 
aqueous compartments throughout the body.  Ethylene glycol is initially metabolized to glycolaldehyde 
by alcohol dehydrogenase (with possible contribution from cytochrome P-450 enzymes).  Glycolaldehyde 
is rapidly converted to glycolate and glyoxal by aldehyde oxidase and aldehyde dehydrogenase.  
Metabolism of glycolate by glycolate oxidase or lactate dehydrogenase results in the formation of 
glyoxylate, which may be further metabolized to formate, oxalate, glycine, and carbon dioxide.  
Elimination of ethylene glycol occurs via exhaled carbon dioxide and urinary elimination of both ethylene 
glycol and glycolic acid.  The half-life for elimination in humans has been estimated to be in the range of 
2.5–8.4 hours.  
 
The vast majority of information relating to the toxicity of ethylene glycol is from studies of oral 
exposure.  Information on the health effects of oral exposure in humans is largely limited to case reports 
of acute accidental or intentional ingestion of ethylene glycol.  These case reports have identified three 
stages of acute oral ethylene glycol toxicity in humans.  These stages are well documented and occur 
within 72 hours after ingestion.  The first stage involves central nervous system depression, metabolic 
changes (hyperosmolality), and gastrointestinal upset, and spans the period from 30 minutes to 12 hours.  
During the second stage (12–24 hours after ingestion), metabolic acidosis and associated cardio-
pulmonary symptoms (tachypnea, hyperpnea, tachycardia, cyanosis, pulmonary edema, and/or cardiac 
failure) become evident.  During stage three, which covers the period 24–72 hours after ethylene glycol 
ingestion, renal involvement becomes evident.  The third stage is characterized by flank pain and 
oliguria/anuria.  Histopathological findings show renal tubular necrosis and deposition of calcium oxalate 
crystals.  Often, the cardiopulmonary effects in the second stage are not evident, so the distinguishing 
symptoms of ethylene glycol intoxication are central nervous system depression, acidosis, and 
nephrotoxicity.  Limited information suggests that a fourth stage involving cranial nerves may occur 6 or 
more days after exposure.  This stage is characterized by neurological symptoms including deafness, 
facial paralysis, and other sequelae.   
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Reports of fatalities following ingestion of ethylene glycol indicate that a volume of 150–1,500 mL 
consumed at one time may cause death.  In humans, the lethal dose of ethylene glycol is estimated to be in 
the range of 1,400–1,600 mg/kg.  Based on these estimates, it appears that humans may be more 
susceptible to the acute lethality of ingested ethylene glycol than other species.  In laboratory animals 
(rats, mice, monkeys), oral doses of ≥4,000 mg/kg were needed to cause death.  However, difficulties in 
quantifying the amounts consumed by persons who have succumbed to the toxic effects lead to 
uncertainty in the human lethal dose estimates.   
 
A study with human subjects found that inhalation exposure to ethylene glycol vapor at an average 
concentration of 30 mg/m3 for 20–22 hours/day for 30 days was well tolerated, with effects that were 
essentially limited to occasional complaints of mild upper respiratory tract irritation.  There were no 
indications of renal or other systemic effects as shown by urinalysis, hematology and clinical chemistry 
evaluations, and neurobehavioral tests throughout the exposure period.  Short-term, high-exposure 
sessions found that respiratory tract irritation became common at approximately 140 mg/m3, and was 
tolerated for only 15 minutes at 188 mg/m3, 2 minutes at 244 mg/m3, and one or two breaths at 
308 mg/m3.  This study was used as the basis for an acute-duration inhalation MRL for ethylene glycol 
(see Section 2.3). 
 
Animal studies indicate that oral exposure to ethylene glycol can cause effects in a number of different 
organ systems, although the developing fetus and kidneys are particularly sensitive and well-documented 
targets of toxicity.  Oral effects have also been observed in the central and peripheral nervous systems, 
heart, liver, hematopoietic system, and immunological and lymphoreticular systems.  Available 
information suggests that the neurological and cardiopulmonary effects stem from metabolic acidosis 
associated with acute, high-dose exposures.  Reported effects on the immunological and lymphoreticular 
systems are limited to suppressed immune responses in mice given a single near-lethal oral dose, and 
neutrophilia and lymph node hemosiderosis in rats orally exposed for 2 years.  Effects on hematological 
parameters have largely been observed at high doses in longer-term studies, and are not consistently 
reported across studies or across species.   
 
Oral studies in animals have identified the developing fetus as the most sensitive target for acute-duration 
exposure to ethylene glycol.  Gavage exposure of laboratory rodents to ethylene glycol during gestation 
results in a consistent pattern of developmental effects including reduced fetal body weight and increases 
in malformations, particularly axial skeletal malformations.  Developmental toxicity has also been 
assessed by the inhalation and dermal routes.  Results of the inhalation developmental studies are 
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generally consistent with the oral findings, but are confounded by concurrent oral exposure via ingestion 
of aerosolized ethylene glycol on the fur of exposed animals.  A single study of dermal exposure to 
ethylene glycol in pregnant mice did not indicate developmental effects.   
 
The kidney is clearly identified as the most sensitive target organ in rats and mice after intermediate-
duration oral exposure.  Typical renal effects included oxalate crystal deposition and renal tubular 
dilation, vacuolation, and degeneration.  Oxalate, a metabolite of glycolic acid, forms a precipitate in the 
presence of calcium, and the deposition of these crystals in the renal tubules are hallmarks of ethylene 
glycol toxicity.  Glycolic acid accumulation and metabolic acidosis do not contribute to renal toxicity, 
which is solely caused by oxalate crystal accumulation.  Males were more sensitive than females, and rats 
were more sensitive than mice.  Chronic oral studies confirm that the kidney is a main target organ in 
male rats, although a minor liver effect (slight fatty metamorphosis) occurred in female rats at doses 
lower than those inducing kidney effects.  No hepatic effects were observed in intermediate-duration 
studies. 
 
There is no indication that ethylene glycol is carcinogenic based on results of a limited renal cancer 
mortality study in chemical plant workers and well-designed chronic oral bioassays in rats (one study) 
and mice (two studies). 
 
A more detailed discussion of the developmental and renal effects associated with ethylene glycol 
exposure follows.  The reader is referred to Section 3.2, Discussion of Health Effects by Route of 
Exposure, for additional information on these and other health effects. 
 
Developmental Effects.    No studies have addressed the developmental toxicity of ethylene glycol in 
humans.  The developmental toxicity of ethylene glycol in animals has been assessed by inhalation, oral, 
and dermal exposure in acute-duration studies and by oral exposure in intermediate-duration studies.  The 
acute oral studies indicate that developmental effects (a skeletal variation and total malformations) occur 
at doses of ≥500 mg/kg/day when administered by gavage during gestation days (Gd) 6–15 to CD-1 mice.  
Dose-response data for these developmental effects in mice were used to derive an acute-duration oral 
MRL for ethylene glycol (see Section 2.3).  Reduced fetal body weight occurred in mice given gavage 
doses of ≥750 mg/kg/day.  In CD rats, doses of ≥1,000 mg/kg/day by gavage on Gd 6–15 have resulted in 
increased incidences of skeletal malformations.  In F344 rats dosed on Gd 6–15 with 1,000 mg/kg/day in 
feed, skeletal malformations were not observed, suggesting the possible importance of dose-rate in 
producing developmental effects; however, strain differences in response cannot be ruled out.  No 
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teratogenic effects were observed in rabbits exposed to maternally lethal oral doses of 2,000 mg/kg/day 
during gestation.  In the only dermal exposure study, no developmental toxicity occurred in pregnant 
CD-1 mice that were treated with 6-hour daily exposures to ethylene glycol (estimated doses up to 
3,549 mg/kg/day) by occluded cutaneous application on Gd 6–15.   
 
Developmental toxicity studies of inhaled ethylene glycol in mice and rats found effects consistent with 
the oral findings, but all of the studies are confounded by concurrent ingestion of ethylene glycol 
deposited on the fur.  In inhalation studies using whole-body exposure, significant effects on implant 
viability, weight of live fetuses, and incidence of external, visceral, and skeletal malformations were 
observed in mice exposed to ≥1,000 mg/m3 for 6 hours/day on Gd 6–15.  In rats exposed similarly, 
reduced ossification at some sites in the axial skeleton occurred at ≥1,000 mg/m3; however, in an Expert 
Panel Review, the National Toxicology Program-Center for the Evaluation of Risks to Human 
Reproduction concluded that the relationship of this effect to treatment was uncertain due to the lack of a 
dose-response relationship.  In a follow-up study aimed at reducing the confounding oral exposure, 
pregnant CD-1 mice were exposed nose-only to 500–2,500 mg/m3 aerosolized ethylene glycol.  At 
2,500 mg/m3, live fetal body weight was significantly reduced, and there was a significant increase in the 
one type of skeletal malformation (fused ribs).  Increases in some skeletal variations were also observed 
at 2,500 mg/m3, and one type (extra ossification sites in the sagittal suture) was significantly increased at 
≥500 mg/m3.  The authors observed that the animals in the nose-only experiment were also exposed by 
ingestion of ethylene glycol deposited on the face.  Furthermore, one study noted that stress from restraint 
in the nose-only exposure study may have contributed to the developmental effects observed with 
ethylene glycol, which were similar in nature to effects observed in a study of restrained nose-only 
exposure to water vapor.  Because of the confounding oral exposure in both the whole-body and nose-
only experiments, a study concluded that the data from these studies were not suitable for evaluation of 
effect levels from inhalation exposure to ethylene glycol.   
 
Developmental effects of intermediate-duration oral exposure to ethylene glycol include kidney effects in 
offspring and decreased pup body weights.  In mice tested in a continuous breeding assay, pup body 
weights were reduced in both F1 and F2 generations at drinking water doses of ≥897 mg/kg/day.  In a 
15-day gestational exposure study (Gd 6–20), postnatal effects on kidney weights were observed in pups 
of CD rats exposed to gavage doses of ≥1,250 mg/kg/day in utero.  In a three-generation study of rats, no 
effects on gestation survival or pup body weight through postpartum day (ppd) 21 were observed in F1 or 
F2 pups after parental exposure to dietary doses up to 1,000 mg/kg/day. 
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Recent reviews of mechanistic studies on ethylene glycol developmental toxicity have concluded that 
glycolic acid, alone or in combination with its downstream metabolites and resultant metabolic acidosis, 
was likely the proximate toxicant responsible for the developmental effects of ethylene glycol.  Using a 
physiologically based pharmacokinetic (PBPK) model developed for humans, a study estimated that the 
glycolic acid blood threshold concentration for developmental effects in rodents would only be reached in 
human females ingesting doses of 350 mg/kg (assuming a 58-kg female).  While the model has been 
validated against data from acute human oral and inhalation exposures to ethylene glycol, the model was 
not calibrated to pregnancy, and it is not clear whether physiological and/or biochemical changes that 
could affect ethylene glycol toxicokinetics might occur during pregnancy.  Further, one study noted that 
additional data were needed to fully delineate the rate of glycolic acid metabolism in humans; such 
additional data may alter the model predictions of peak glycolic acid concentrations in humans exposed to 
ethylene glycol. 
 
Renal Effects.    The renal toxicity of ethylene glycol in humans is well documented in numerous case 
reports of accidental or intentional ingestion.  Adverse renal effects occur in the third stage of human 
ethylene glycol poisoning, which occurs 24–72 hours after acute exposure.  The hallmark of renal toxicity 
is the presence of calcium oxalate monohydrate crystals in the renal tubules and urine following ingestion 
of large amounts of ethylene glycol.  Characteristic histopathological changes include renal tubular focal 
degeneration, atrophy, and interstitial inflammation.  Renal damage, if untreated, can lead to renal failure.  
With therapy, normal or near-normal renal function can be restored. 
 
Humans who inhaled ethylene glycol showed no indications of impaired renal function.  No significant 
alterations in renal end points were found in volunteers exposed to ethylene glycol aerosol at an average 
concentration of 30 mg/m3 for 20–22 hours/day for 30 days.  Evaluations were performed throughout the 
study and included examination of urine for presence of oxalate crystals and erythrocytes; determinations 
of urine volume, specific gravity, color, clarity, pH, amino acid nitrogen, and creatinine; and 
determination of blood urea nitrogen.  There also was no indication of renal impairment in aviation 
workers who were intermittently exposed to ethylene glycol during airplane de-icing operations over a 
2-month winter period.  Ethylene glycol concentrations as high as 22 mg/m3 for vapor and 190 mg/m3 for 
mist were measured, although the vast majority of samples were below the limit of quantification 
(2.5 mg/m3 for vapor and 17 mg/m3 for mist); the frequency and average levels and durations of exposure 
were not reported.  Measurements of urinary albumin, β-N-acetyl-glucosaminidase, β-2-microglobulin, 
and retinol-binding protein were used to assess kidney function. 
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Renal effects in orally exposed animals are consistent with those observed in humans.  In acute-duration 
studies, effects occurred in the kidneys of rats exposed to 1,250–2,500 mg/kg/day by gavage or 2,615–
5,270 mg/kg/day in drinking water for 9–29 days, and rabbits exposed to 2,000 mg/kg/day by gavage for 
13 days.  Evaluation of these animals showed effects that generally included increased kidney weight and 
renal tubular calcium oxalate deposits, dilation, degeneration, and/or necrosis. 
 
The renal effects of intermediate-duration oral exposure to ethylene glycol are well characterized in a 
number of studies in rats and mice.  These studies indicate that renal toxicity varies with sex, species, and 
strain, with males more sensitive than females, rats more sensitive than mice, and Wistar rats more 
sensitive than other strains of rats.  Renal effects in Sprague-Dawley rats that were exposed to ethylene 
glycol in drinking water for 90 days included renal tubular oxalate crystal deposition, dilation, and 
degeneration in males at ≥947 mg/kg/day and females at 3,087 mg/kg/day.  Findings in F344 rats exposed 
for 13 weeks via diet included renal tubular dilation, necrosis, fibrosis, and oxalate crystal deposition in 
males at ≥2,500 mg/kg/day, and mild renal lesions (e.g., inflammation and vacuolation) with no crystal 
deposition in females at 10,000 mg/kg/day.  Results of 16-week dietary studies showed that male Wistar 
rats are approximately twice as sensitive as male F344 rats to ethylene glycol nephrotoxicity, and that 
kidney lesions in male Wistar rats occurred at average doses as low as 180 mg/kg/day.  In a 13-week 
dietary study in B6C3F1 mice, effects were observed in the kidneys (minimal to mild tubule dilation, 
cytoplasmic vacuolation, and regenerative hyperplasia, without tubular oxalate crystal deposition) of 
males at ≥6,450 mg/kg/day, with no renal effects in females at doses ≤16,000 mg/kg/day. 
 
Chronic toxicity studies provide information on renal effects in rats and mice exposed to ethylene glycol 
in the diet for up to 2 years.  Males were more sensitive than females and rats were more sensitive than 
mice.  Renal effects in rats included oxalate nephrosis in Wistar males at ≥300 mg/kg/day, oxalate crystal 
deposition and apparent tubular degenerative changes in Sprague-Dawley males at ≥375 mg/kg/day and 
females at ≥750 mg/kg/day, and oxalate nephrosis (and consequent mortality) in F344 males at 
1,000 mg/kg/day, with changes in F344 females at this dose limited to increased kidney weight and 
crystalluria without histopathology.  No kidney histopathology occurred in male or female CD-1 mice 
exposed to 1,000 mg/kg/day or female B6C3F1 mice exposed to ≤12,000 mg/kg/day, and effects in male 
B6C3F1 mice were limited to small numbers of oxalate-like crystals and/or calculi in the renal tubules, 
urethrae, and urinary bladder in a few animals at 6,000 mg/kg/day. 
 
ETHYLENE GLYCOL  16 
 







***DRAFT FOR PUBLIC COMMENT*** 
2.3   MINIMAL RISK LEVELS (MRLs) 
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for ethylene glycol.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 




• An MRL of 2 mg/m3 has been derived for acute-duration inhalation exposure (14 days or less) to 
ethylene glycol. 
 
Information on the toxicity of acute-duration inhalation exposure to ethylene glycol is available from an 
experimental study in humans (Wills et al. 1974) and three developmental toxicity studies in rats and 
mice (Tyl 1988a; Tyl et al. 1995a, 1995b).  In the human study, exposure to ethylene glycol aerosol at an 
average concentration of 23 mg/m3 for 20–22 hours/day for 14 days was well tolerated, with effects that 
were essentially limited to occasional complaints of mild upper respiratory tract irritation (Wills et al. 
1974).  There were no indications of renal or other systemic effects as shown by urinalysis and 
hematology, clinical chemistry, and neurobehavioral evaluations.  Short-term high-exposure sessions 
showed that respiratory tract irritation became common at approximately 140 mg/m3 and intolerable for 
more than a few minutes at approximately 200 mg/m3.   
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Developmental toxicity studies were conducted in rats and mice using whole-body exposure to 150, 
1,000, or 2,500 mg/m3 of ethylene glycol aerosol for 6 hours/day on Gd 6–15 (Tyl 1988a; Tyl et al. 
1995a).  Reduced ossification at some sites in the axial skeleton occurred in rats at ≥1,000 mg/m3, 
although an Expert Panel Review (NTP-CERHR 2004) concluded that the relationship of this effect to 
treatment was uncertain due to the lack of a dose-response relationship.  In mice, significant effects on 
implant viability, weight of live fetuses, and incidence of external, visceral, and skeletal malformations 
were observed at ≥1,000 mg/m3.  Maternal toxicity (e.g., increased liver weight in rats and reduced body 
weight gain in mice) was evident at 2,500 and 1,000 mg/m3 in rats and mice, respectively (Tyl et al. 
1995a).  Both of these whole-body exposure studies were confounded by concurrent ingestion exposure to 
ethylene glycol deposited on the fur.  In a follow-up study aimed at reducing concurrent exposure from 
ingestion, mice were exposed nose-only to 500, 1,000, or 2,500 mg/m3 aerosolized ethylene glycol for 
6 hours/day on Gd 6–15 (Tyl 1988a; Tyl et al. 1995b).  In maternal animals, there were no effects other 
than changes in kidney weights.  Absolute kidney weight was significantly increased at 1,000 and 
2,500 mg/mg3, and relative kidney weight was increased at 2,500 mg/m3; however, the increases were 
small (6.6–9.5% higher than controls) and microscopic examination of kidneys showed no 
histopathological changes.  At 2,500 mg/m3, live fetal body weight was significantly reduced, and there 
was a significant increase in the one type of skeletal malformation (fused ribs).  Increases in some skeletal 
variations were observed at 2,500 mg/m3, and one type (extra ossification sites in the sagittal suture) was 
significantly increased at concentrations of ≥500 mg/m3.  The authors observed that the animals in the 
nose-only experiment were also exposed by ingestion of ethylene glycol deposited on the face (Tyl 
1988a; Tyl et al. 1995a).  Furthermore, stress from restraint in the nose-only exposure study may have 
contributed to the developmental effects observed with ethylene glycol (NTP-CERHR 2004; Tyl et al. 
1995a), which were similar in nature to effects observed in a study of restrained nose-only exposure to 
water vapor (Tyl et al. 1994).   
 
Because of the confounding oral exposures in both the whole-body and nose-only developmental toxicity 
studies, NTP-CERHR (2004) concluded that the data from these studies were not suitable for evaluation 
of effect levels from inhalation exposure to ethylene glycol.  The available data do, however, provide a 
conservative estimate of the inhalation no-observed-adverse-effect level (NOAEL), with the caveat that 
total exposure to ethylene glycol in these studies included intake via ingestion.  Collectively, these studies 
suggest that inhalation exposure to ethylene glycol at a nominal concentration of about 150 mg/m3 is not 
associated with developmental toxicity in mice or rats, or renal toxicity in mice (kidney histopathology 
not assessed in rats).  The next highest concentration (500 mg/m3 in the nose-only study) was associated 
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with developmental effects (increased incidence of skeletal variations), but it is not possible to 
conclusively relate these effects to inhalation of ethylene glycol. 
 
As indicated above, the developmental studies (Tyl 1988a; Tyl et al. 1995a, 1995b) collectively suggest 
that 150 mg/m3 is a conservative NOAEL for developmental toxicity in rats and kidney toxicity in mice.  
This concentration is similar to the 140 mg/m3 lowest-observed-adverse-effect level (LOAEL) for 
respiratory tract irritation in humans (Wills et al. 1974).  The human NOAEL of 23 mg/m3 is a suitable 
basis for MRL derivation because it is based on evaluations for renal and other systemic effects as well as 
local irritation, and is well within the NOAEL range for developmental toxicity in animals.  As 
summarized below, the human study (Wills et al. 1974) was conducted in prisoners.  ATSDR recognizes 
that there is some ethical concern about using a study in prisoners for MRL derivation, but the protocol 
was acceptable at the time the study was conducted. 
 
In the human study, health effects were assessed in 19 male prisoners who voluntarily were exposed to 
ethylene glycol aerosol for 20–22 hours/day for 30 days (Wills et al. 1974).  The diameter of the aerosol 
droplets ranged from 1 to 5 μm.  Mean daily and mean weekly concentrations during the first 14 days of 
the study were 0.8–44.8 and 17–29 mg/m3, respectively.  Mean daily and mean weekly concentrations 
during the entire 30-day exposure period were 0.8–67 and 17–49 mg/m3, respectively.  The average mean 
weekly exposure was 23 mg/m3 for days 1–14 and 30 mg/m3 for days 1–30.  Calculations of the average 
exposure levels did not include brief periods in which the concentration was intentionally raised to higher 
levels to assess acute responses.  A control group consisted of 14 male prisoners; 10 of these men were 
never exposed to ethylene glycol, whereas the remaining 4 men had been exposed to a mean 
concentration of 37 mg/m3 for 20–22 hours/day for 7 days during the week that preceded the start of the 
study.  Subjective responses (symptoms) were monitored throughout the study.  During the last 10 days of 
the study, the concentration of ethylene glycol was occasionally intentionally increased to various high 
levels (up to 308 mg/m3) when the volunteers left the exposure chamber during meals; subjective 
responses to short exposures to the high concentrations were assessed when they reentered the chamber.  
Complete physical examinations that included slit-lamp, electrocardiographic, and electroencephalo-
graphic studies, and a battery of psychological tests designed to reveal effects on simple reaction time, 
reaction time with discrimination, visual-motor coordination, depth perception, and mental ability 
(encoding and subtraction accuracy), were conducted on all subjects pre-exposure and after 14 and 
30 days of exposure.  Blood samples were collected on days 0, 1, 3, 5, 8, 12, 19, 22, 26, and 29 for 
evaluation of hematology, clinical chemistry (including blood urea nitrogen, serum creatinine, and liver 
enzymes), and ethylene glycol concentration.  Urine was evaluated daily for oxalate crystals, 
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erythrocytes, and ethylene glycol, and twice weekly for volume, specific gravity, color, clarity, pH, amino 
acid nitrogen, and creatinine.  Concentrations of ethylene glycol in the blood and urine were similar in the 
exposed and control groups.  The near-continuous exposure levels (average 23 mg/m3 for days 1–14 and 
30 mg/m3 for days 1–30) were tolerated with effects that were limited to occasional complaints of upper 
respiratory tract irritation, slight headache, and low backache (incidences and other information not 
reported).  The short-term, high-exposure sessions showed that the irritation became common at 
approximately 140 mg/m3, and tolerated for only 15 minutes at 188 mg/m3, 2 minutes at 244 mg/m3, and 
one or two breaths at 308 mg/m3.  Based on these results and those of other trials, the investigators 
concluded that concentrations of about ≥200 mg/m3 were intolerable due to strong irritation of the upper 
respiratory tract that included a burning sensation in the trachea and a burning cough.  Because the near-
continuous exposures were tolerated with respiratory irritation that was infrequent and not serious, and 
not accompanied by neurological, hematology, clinical chemistry, or urinalysis findings indicative of 
renal or other systemic effects, the interim (12–14-day) findings in this study identified a NOAEL of 
23 mg/m3 for acute-duration exposure in humans.  The LOAEL in humans was 140 mg/m3 because brief 
exposures to this concentration commonly caused respiratory irritation. 
 
The NOAEL of 23 mg/m3 for respiratory tract irritation and systemic toxicity in humans (Wills et al. 
1974) was divided by an uncertainty factor of 10 (for human variability) to derive an MRL of 2 mg/m3 for 
acute inhalation exposure to ethylene glycol.  The NOAEL was not adjusted for discontinuous daily 
exposure (20 hours/24 hours) because the critical effect is concentration dependent and not duration 
dependent. 
 
An MRL has not been derived for intermediate-duration inhalation exposure (15–364 days) to ethylene 
glycol.  Information on the toxicity of intermediate-duration inhalation exposure to ethylene glycol is 
available from two studies in humans (Gérin et al. 1997; Wills et al. 1974) and one multiple species study 
in animals (Coon et al. 1970).   
 
In one of the human studies, health effects were assessed in 19 male prisoners who voluntarily were 
exposed to ethylene glycol aerosol at an average concentration of 30 mg/m3 for 20–22 hours/day for 
30 days (Wills et al. 1974).  The exposure was well tolerated, with effects that were essentially limited to 
occasional complaints of mild upper respiratory tract irritation; there were no indications of renal or other 
systemic effects as shown by urinalysis and hematology, clinical chemistry, and neurobehavioral 
evaluations.  This study is summarized in detail in the acute inhalation MRL section.  The other human 
study assessed kidney function in 33 male aviation workers who were intermittently exposed to ethylene 
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glycol-based de-icing fluid during airplane de-icing operations during a 2-month winter period (Gérin et 
al. 1997).  Personal exposures to ethylene glycol ranged up to 22 mg/m3 for vapor and 190 mg/m3 for 
mist, although the vast majority of samples were below the limits of quantification (2.5 mg/m3 for vapor 
and 17 mg/m3 for mist).  The frequency and average levels and durations of exposure were not reported.  
Measurements of urinary albumin, β-N-acetyl-glucosaminidase, β-2-microglobulin, and retinol-binding 
protein indicated no impairment of renal function. 
 
In the animal study, Sprague-Dawley and Long-Evans rats (15/concentration, mixed strains and sexes), 
Princeton-derived guinea pigs (15/concentration, mixed sexes), New Zealand rabbits (3 males/
concentration), Beagle dogs (2 males/concentration), and Squirrel monkeys (2–3 males/concentration) 
were exposed to apparently aerosolized ethylene glycol in concentrations of 0, 10, or 57 mg/m3 for 
8 hours/day, 5 days/week for 6 weeks, or to 0 or 12 mg/m3 continuously for 90 days (Coon et al. 1970).  
Evaluations included clinical signs, limited hematology, serum liver enzymes, gross pathology, and 
limited histology (mainly kidney, liver, spleen, heart, and lung).  No clear treatment-related effects were 
observed in the intermittent exposure 6-week study.  In the 90-day study, continuous exposure to 
12 mg/m3 caused moderate to severe eye irritation in 3/3 rabbits and corneal opacity with possible 
blindness in 2/15 rats, and mortality in 1/3 rabbits, 1/15 rats, and 3/15 guinea pigs. 
 
The experimental study in humans (Wills et al. 1974) identified a NOAEL of 30 mg/m3 for respiratory 
irritation and systemic effects for near-continuous exposure to ethylene glycol for 30 days.  Urinalysis in 
this study showed no indications of renal effects (e.g., presence of oxalate crystals in urine), and are 
consistent with the negative results of kidney function evaluations in the aviation workers who were 
intermittently exposed to lower levels of ethylene glycol for 2 months (Gérin et al. 1997).  The 6-week 
intermittent exposure study in rats, guinea pigs, and small numbers of rabbits, dogs, and monkeys (Coon 
et al. 1970) identified a NOAEL of 57 mg/m3 for kidney histopathology and other systemic effects in all 
species.  Continuous exposure to 12 mg/m3 for 90 days caused ocular irritation in rats and rabbits (Coon 
et al. 1970), but confidence in this LOAEL is low due to small numbers of affected animals, and its 
relevance is unclear because there was no eye irritation in the humans near-continuously exposed to 
30 mg/m3 for 30 days (Wills et al. 1974).  Continuous exposure to 12 mg/m3 for 90 days also caused 
mortality in rats, rabbits, and guinea pigs, although the reliability of this LOAEL is low due to low 
incidences, small numbers of animals, and likely confounding by oral exposure from ingestion of aerosol 
deposited on the fur.  Documentation for this probable confounder is provided by the developmental 
toxicity studies (Tyl et al. 1995a, 1995b) discussed in the acute inhalation MRL derivation.  The human 
NOAEL of 30 mg/m3 is not a suitable basis for intermediate-duration MRL derivation due to insufficient 
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information on renal and other possible systemic effects of exposures longer than 30 days.  Although 
exposures as long as 90 days were conducted in the animal study, it was limited in scope (e.g., lacked 
sufficient numbers of animals and urinalysis) and likely confounded by oral exposure. 
 
An MRL has not been derived for chronic-duration inhalation exposure (365 days or more) to ethylene 
glycol.  Information on the health effects of chronic exposure to ethylene glycol is essentially limited to 
the negative results of an epidemiologic study on renal cancer mortality in humans (Bond et al. 1985).  
This study does not provide a basis for MRL consideration because it lacks noncancer end points, 




• An MRL of 0.8 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
ethylene glycol. 
 
Information on effects of acute-duration oral exposure to ethylene glycol is available from human case 
reports, a 10-day drinking water study in rats (Robinson et al. 1990), a 4-day gavage study examining 
effects on hematology and reproductive organs (Hong et al. 1988), and developmental toxicity studies in 
mice, rats, and rabbits (Maronpot et al. 1983; Marr et al. 1992; Neeper-Bradley et al. 1995, Price et al. 
1985; Schuler et al. 1984; Tyl 1989; Tyl et al. 1993).   
 
The available human studies consist of clinical case reports of high-dose intentional or accidental 
ingestion of ethylene glycol, and thus, are not suitable for dose-response assessment.  Although the 4-day 
gavage study reported by Hong et al. (1988) identified bone marrow effects at doses of 50–
250 mg/kg/day, the biological significance of these effects is considered uncertain in light of the lack of 
supporting evidence for effects on bone marrow, spleen, or hematology in longer-duration studies of mice 
and rats exposed to much higher doses (DePass et al. 1986a; Gaunt et al. 1974; Melnick 1984; NTP 1993; 
Robinson et al. 1990; Schladt et al. 1998).  The remaining animal studies collectively identify the 
developing fetus as the most sensitive target of acute oral exposure to ethylene glycol.  
 
In acute-duration oral developmental toxicity studies in rodents, fetal effects have consistently been 
observed at doses that are not maternally toxic.  Furthermore, the developmental effects observed after 
ethylene glycol exposure appear to be generally consistent across studies and across rodent species, with 
the primary end point consisting of skeletal malformations.  The incidence of malformations was 
increased in CD-1 mice at doses of ≥500 mg/kg/day when administered by gavage during gestation 
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(Gd 6–15) (Neeper-Bradley et al. 1995; Tyl 1989).  Embyrotoxicity was also manifested as a reduction in 
fetal body weight in CD-1 mice given doses of ≥750 mg/kg/day on Gd 6–15 (Neeper-Bradley 1990; Price 
et al. 1985; Tyl 1989).  In rats, doses of ≥1,000 mg/kg/day by gavage on Gd 6–15 resulted in an increased 
incidence of skeletal malformations in offspring (Neeper-Bradley 1990; Neeper-Bradley et al. 1995; Price 
et al. 1985).  Decreases in pup body weight and increases in both the number of litters with malformations 
and the number of malformed fetuses per litter were observed in rats treated during Gd 6–15 with doses of 
≥2,500 mg/kg/day (Neeper-Bradley 1990; Neeper-Bradley et al. 1995; Price et al. 1985).  In mice given 
doses of 3,000 mg/kg/day during Gd 6–15, neural tube and craniofacial defects were increased and the 
number of live fetuses per litter was decreased (Price et al. 1985).  In contrast to the results in rodents, no 
developmental effects were observed in rabbits exposed to maternally lethal doses of 2,000 mg/kg/day 
during gestation (Tyl et al. 1993). 
 
Among the available studies, the study by Neeper-Bradley et al. (1995; Tyl 1989) in mice identified the 
lowest LOAEL; thus, these data were selected for use in deriving the acute oral MRL for ethylene glycol.  
This study was well-conducted, using adequate numbers of animals (30/dose), including four dose levels 
in addition to controls, and evaluating relevant end points (skeletal and other malformations as well as 
reproductive and litter parameters).   
 
In the mouse study by Neeper-Bradley et al. (1995; Tyl 1989), groups of 30 timed-pregnant CD-1 mice 
were given doses of 50, 150, 500, or 1,500 mg/kg ethylene glycol daily by gavage on Gd 6–15; vehicle 
controls were given water on the same schedule.  Maternal animals were observed daily for clinical signs 
and weighed periodically; water intake was measured throughout gestation.  At sacrifice on Gd 18, body 
weight, gravid uterine weight, liver weight, and kidney weight were measured in dams.  Kidneys from 
control and high-dose dams were examined microscopically.  Corpora lutea and uterine contents were 
evaluated, and live fetuses were weighed and sexed.  External, visceral, and skeletal malformations and 
variations in the fetuses were evaluated.   
 
No effects on maternal body weight, water consumption, or liver or kidney weight were observed.  There 
were no significant effects on the number of corpora lutea/dam, number of total, nonviable, or viable 
implants/litter, or sex ratio.  Average fetal body weight per litter was reduced (13% below controls) at 
1,500 mg/kg/day.  The incidence of individual external or visceral malformations was not significantly 
increased in any treatment group relative to the vehicle control; however, exencephaly (a malformation 
observed by Price et al. [1985] at higher doses) was observed in two fetuses in the 500 mg/kg/day group 
and in three fetuses of the 1,500 mg/kg/day dose group.  There was a significant increase in the incidence 
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of two skeletal malformations (fused ribs or thoracic arches) in the 1,500 mg/kg/day group (15/21 litters 
with fused ribs vs. 1/19 controls; 8/21 litters with fused thoracic arches vs. 0/19 controls).  Further, the 
incidence of total malformations per litter (external, visceral, and skeletal) was significantly increased 
both at 500 and 1,500 mg/kg/day (3/19, 7/20, 5/24, 12/24, and 17/21 from control to high dose).  The 
incidences of 23 skeletal variations were increased in the 1,500 mg/kg/day group.  One of these variations 
(bilateral extra rib 14) was also significantly increased at ≥500 mg/kg/day (4/19, 4/20, 6/24, 17/24, and 
21/21 in control through high dose groups, respectively).  This study identified a developmental NOAEL 
of 150 mg/kg/day and LOAEL of 500 mg/kg/day for increased incidence of total malformations and 
bilateral extra rib 14.  The high dose (1,500 mg/kg/day) was a NOAEL for maternal effects. 
 
To derive a point of departure for MRL derivation, benchmark dose (BMD) modeling was conducted 
using the mouse data on the incidence of litters with malformations (of any kind) and on the incidence of 
one skeletal variation (bilateral extra rib 14).  These two end points were observed at lower doses than 
other observed effects (skeletal malformations, pup body weight reductions).  All dichotomous variable 
models in the EPA Benchmark Dose Software (Version 1.4.1) were fit to the malformation and skeletal 
variation data.  Although one of the end points modeled (total malformations) represents a more serious 
effect, the group sizes in this study (19–24 litters/dose examined) did not support a benchmark response 
(BMR) lower than 10%; thus, an extra risk incidence of 10% above controls was selected as the BMR.  
The multistage and quantal linear models converged on the same model providing the best fit to the data 
on total malformations; these models both predicted a BMD10 of 113.84 mg/kg/day and a BMDL10 of 
75.59 mg/kg/day.  For the data on bilateral extra rib 14, the probit model provided the best fit, and 
predicted a BMD10 of 99.35 mg/kg/day and a BMDL10 of 75.56 mg/kg/day.  Modeling of both the 
malformation and skeletal variation end points resulted in the same BMDL10, indicating that an acute oral 
MRL based on this point of departure should provide protection against both effects.  The BMDL10 of 
76 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans 
and 10 for human variability) to derive an MRL of 0.8 mg/kg/day for acute-duration oral exposure to 
ethylene glycol.   
 
Although some mechanistic information suggests that humans may be less sensitive than rodents to the 
developmental effects of ethylene glycol, the available data are not adequate to support a lower 
interspecies uncertainty factor; thus, a full 10-fold uncertainty factor was used for interspecies 
extrapolation.  While in vitro data suggest that humans metabolize glycolic acid (the proximate 
developmental toxicant) more efficiently than rats (Booth et al. 2004; Corley et al. 2005a), NTP-CERHR 
(2004) observed that the data supporting the glycolic acid metabolic rate in humans are limited.  In 
ETHYLENE GLYCOL  24 
 







***DRAFT FOR PUBLIC COMMENT*** 
addition, NTP-CERHR (2004) reviewed preliminary data indicating that the inverted yolk sac placenta, a 
stage in placental development that does not exist in humans, tends to concentrate weak acids such as 
glycolic acid in the embryonic fluids.  These data suggest enhanced sensitivity to ethylene glycol 
developmental effects in rodents compared with humans; however, NTP-CERHR (2004) characterized 
the available data as inconclusive.  A 10-fold uncertainty factor for human variability was also used.  
Ethylene glycol metabolism is known to involve alcohol dehydrogenase and aldehyde dehydrogenase, 
and may also involve cytochrome p450 isozymes (NTP-CERHR 2004).  Polymorphisms in the genes 
encoding these enzymes may lead to wide variability in the production and elimination of glycolic acid 
and other metabolites in humans exposed to ethylene glycol, but data quantifying the range of variability 
are not currently available (NTP-CERHR 2004).  In addition, fetal and/or placental differences in 
expression of these enzymes over the course of gestation will affect local concentrations of glycolic acid 
and other metabolites to which the developing conceptus is exposed, yet little is known about these 
differences (NTP-CERHR 2004). 
 
Corley et al. (2005a) published a PBPK model for rats, but no model has yet been developed for mice, the 
species used in the study selected for MRL derivation.  As a result, available data do not support the use 
of PBPK modeling to derive an acute oral MRL for ethylene glycol based on developmental toxicity in 
mice. 
 
A key uncertainty in the acute-duration oral MRL stems from the use of gavage administration in the 
critical study.  Bolus doses from gavage administration lead to higher peak concentrations of glycolic acid 
in the blood than occur with equivalent doses at slower dose-rates associated with environmentally-
relevant exposures (Carney et al. 2001; NTP-CERHR 2004).  Because the key study used gavage 
administration, the dose at which effects were observed may be lower than would be observed with non-
bolus dosing.  In support of this, Maronpot et al. (1983) observed neither fetal nor maternal toxicity at 
dietary doses up to 1,000 mg/kg in F344 rats, while Neeper-Bradley et al. (1995) reported skeletal 
malformations and effects on fetal body weight in CD rats given 1,000 mg/kg via gavage.  While strain 
differences in susceptibility to ethylene glycol cannot be ruled out as the source of the differing results, 
the data supporting glycolic acid as the proximate toxicant, and the evidence for much lower serum levels 
of glycolic acid with continuous dosing than with bolus dosing, suggest that the lack of developmental 
toxicity observed by Maronpot et al. (1983) likely resulted from the difference in dose-rate. 
 
• An MRL of 0.8 mg/kg/day has been adopted for intermediate-duration oral exposure (15–
364 days) to ethylene glycol.   
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Information on the toxicity of intermediate-duration oral exposure to ethylene glycol essentially consists 
of several well-designed studies in rats (Cruzan et al. 2004; Gaunt et al. 1974; Melnick 1984; Robinson et 
al. 1990) and mice (Melnick 1984; NTP 1993).  Based on generally comprehensive evaluations that 
included body and organ weights, food and water consumption, hematology, blood chemistry, urinalysis, 
and histopathology in adequate numbers of animals, these studies consistently showed that the kidney is 
the predominant and most sensitive target of ethylene glycol toxicity.  As summarized below, renal 
toxicity varied with sex, species, and strain, with males more sensitive than females, rats more sensitive 
than mice, and Wistar rats more sensitive than other strains of rats. 
 
Renal effects in Sprague-Dawley rats that were exposed to ethylene glycol in drinking water for 90 days 
included renal tubular oxalate crystal deposition, dilation, and degeneration in males at ≥947 mg/kg/day 
and females at 3,087 mg/kg/day (Robinson et al. 1990).  Key findings in F344 rats exposed for 13 weeks 
via diet consisted of renal tubular dilation, necrosis, fibrosis, and oxalate crystal deposition in males at 
≥2,500 mg/kg/day, mortality in males at 5,000 mg/kg/day, and mild renal lesions (e.g., inflammation and 
vacuolation) with no crystal deposition or mortality in females at 10,000 mg/kg/day (Melnick 1984).  
Results of 16-week dietary studies showed that male Wistar rats are approximately twice as sensitive as 
male F344 rats to ethylene glycol nephrotoxicity (Cruzan et al. 2004), and that kidney lesions in male 
Wistar rats occurred at average doses as low as 180 mg/kg/day (Gaunt et al. 1974).  In a 13-week dietary 
study in B6C3F1 mice, effects were observed in the kidneys (minimal to mild tubule dilation, cytoplasmic 
vacuolation, and regenerative hyperplasia, without tubular oxalate crystal deposition) and liver 
(centrilobular hyaline degeneration) of males at ≥6,450 mg/kg/day, with no effects in females at doses 
≤16,000 mg/kg/day (Melnick 1984; NTP 1993). 
 
The 16-week study by Cruzan et al. (2004) compared the renal toxicity of ethylene glycol in male Wistar 
and F344 rats.  The comparison was conducted to confirm an apparent greater sensitivity of the Wistar 
strain indicated by seemingly inconsistent renal effect levels in key intermediate- and chronic-duration 
studies (i.e., a LOAEL of 180 mg/kg/day in Wistar rats exposed for 16 weeks [Gaunt et al. 1974] that was 
lower than a NOAEL of 200 mg/kg/day in F344 rats exposed for 2 years [DePass et al. 1986a]).  In the 
Cruzan et al. (2004) study, groups of 10 male Wistar rats and 10 male F-344 rats were administered 
ethylene glycol in the diet in constant dose levels of 0, 50, 150, 500, or 1,000 mg/kg/day for 16 weeks.  
Clinical signs, body weight, and food intake were evaluated throughout the study.  Water consumption 
was measured and urine was collected for urinalysis during the 24 hours prior to sacrifice; parameters 
included specific gravity, pH, color, appearance, protein, glucose, bilirubin, urobilinogen, ketones, occult 
blood, leukocytes, nitrites, volume, and microscopy of sediment.  Following sacrifice, complete 
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necropsies were performed, and kidneys were evaluated for organ weight and histological changes and 
presence of alpha 2-μ-globulin.  Effects observed in Wistar rats included reduced body weight gain at 
500 and 1,000 mg/kg/day (final weight 9 and 23% lower than controls), and reduced food intake and 
2/10 deaths at 1,000 mg/kg/day; these end points were not affected in F344 rats.  Significantly increased 
water intake (~200% higher than controls) and urine volume, decreased urine specific gravity, and 
increased occurrence of white blood cells in urine occurred in Wistar rats at ≥500 mg/kg/day and 
F344 rats at 1,000 mg/kg/day.  Calcium oxalate crystals in the urine were increased in both strains of rats 
at ≥150 mg/kg/day; incidences at 0, 50, 150, 500, and 1,000 mg/kg/day were 0/10, 1/10, 5/10, 10/10, and 
4/8 in Wistar rats, and 1/10, 0/10, 3/10, 10/10, and 7/10 in F344 rats.  Absolute and relative kidney 
weights were significantly increased at ≥500 mg/kg/day in Wistar rats and 1,000 mg/kg/day in F344 rats.  
No treatment-related increases in alpha 2-μ-globulin were observed in either strain of rats.  The 
histological examinations showed crystal deposition in the kidneys and associated nephropathy in both 
strains of rats at ≥500 mg/kg/day, with greater severity in the Wistar rats.  Respective incidences of 
nephropathy with crystal deposition at 0, 50, 150, 500, and 1,000 mg/kg/day were 0/10, 0/10, 0/10, 10/10, 
and 10/10 in Wistar rats, and 0/10, 0/10, 0/10, 1/10, and 10/10 in F344 rats.  Because crystal-induced 
nephropathy occurred in only 1/10 F344 rats at 500 mg/kg/day (compared to 10/10 Wistar rats at this 
dose), and six additional F344 rats at 500 mg/kg/day had crystals in the kidney tubules without 
nephropathy, this dose is a less serious LOAEL in the F344 rats.  The severity of the crystal nephropathy 
in the Wistar rats at 500 mg/kg/day was approximately equivalent to that in the F344 rats at 
1,000 mg/kg/day.  Due to the higher incidence and greater severity of the crystal nephropathy, as well as 
the accompanying impairment of kidney function (i.e., compromised kidney water regulation as indicated 
by increased urine volume and decreased urine specific gravity leading to increased water consumption), 
500 mg/kg/day is a serious LOAEL in the Wistar rats.  The only effect observed at doses lower than 
500 mg/kg/day was calcium oxalate crystals in the urine of both strains at 150 mg/kg; this is a NOAEL 
because excretion of crystals in the urine reflects a detoxification process and is not considered adverse in 
the absence of crystal deposition in the renal tubule epithelium and associated histopathology. 
 
The 16-week study by Gaunt et al. (1974) exposed male and female weanling Wistar rats to diets 
containing 0, 0.05, 0.1, 0.25, or 1.0% ethylene glycol for 2 weeks (5/sex/dose), 6 weeks (5/sex/dose), or 
16 weeks (15/sex/dose).  Reported calculated average daily chemical intakes were 35, 71, 180, and 
715 mg/kg/day in males, and 0, 38, 85, 185, and 1,128 mg/kg/day in females.  Intakes were averaged 
among rats house five per cage and decreased throughout the study because the amount of ethylene glycol 
in the diet was not adjusted for changing food consumption and body weight.  Survival, clinical signs, 
food and water intake, and body weight were evaluated throughout the exposure period.  Hematology 
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(hemoglobin, hematocrit, packed cell volume, total erythrocytes, reticulocytes, total and differential 
leukocytes), serum chemistry (urea, glucose, protein, albumin, glutamic-oxaloacetic transaminase, 
glutamic-pyruvic transaminase, and lactic dehydrogenase), organ weights (including kidneys, liver, 
spleen, brain, heart, stomach, small intestines, caecum, adrenals, pituitary, thyroid, and gonads), and 
histology (organs that were weighed and 19 additional tissues) were evaluated at the 2-, 6-, and 16-week 
sacrifices.  Urinalysis (glucose, ketones, bile salts, blood, protein, and presence of oxalic acid crystals, 
cells and other microscopic constituents) and renal function (urine concentration and dilution tests 
measuring volume and specific gravity, and cell excretion) were evaluated at weeks 2 and 16.  Urine was 
additionally analyzed for oxalic acid at weeks 2, 6, 12, 14, and 16.  There were no clear exposure-related 
effects on survival, clinical signs, body weight, hematology, or serum chemistry.  Pneumonial changes 
occurred in the lungs of most males and females and salivary adenitis occurred in 90% of the males and 
45% of the females, but these effects were not considered exposure-related.  Urinary excretion of oxalic 
acid was significantly increased in males at 715 mg/kg/day at weeks 2–16 and in females at 
1,128 mg/kg/day at weeks 6–16, with the magnitude of the effect markedly greater in males (100–500% 
of control levels) than females (40–100% of control values).  Increased absolute kidney weight, oxalic 
acid crystals in urine, and excretion of a larger volume of urine with a lower specific gravity after a 
prolonged period (16 hours) without water were observed in the 715 mg/kg/day males at week 16.  
Exposure-related histopathologic changes occurred only in the kidneys.  Incidences of kidney lesions 
were statistically significantly increased in males at ≥180 mg/kg/day.  Specific renal histopathologic 
findings in the males at 16 weeks included individual nephrons with degenerative changes (incidences of 
0/15, 1/15, 1/15, 2/15, and 5/15 [p<0.05] in the control to high-dose groups), individual nephrons with 
degenerative changes and occasional oxalate crystals (0/15, 0/15, 0/15, 1/15, and 4/15 [p<0.05]), and 
generalized tubular damage and heavy oxalate crystals (0/15, 0/15, 0/15, 0/15, and 4/15 [p<0.05]).  At 0, 
35, 71, 180, and 715 mg/kg/day, the total incidence of male rats with oxalate crystals was 0/15, 0/15, 
0/15, 1/15, and 10/15 (p<0.001), and the total incidence of male rats with renal tubular damage was 0/15, 
1/15, 1/15, 4/15 (p<0.05), and 15/15 (p<0.001).  Females had an increased incidence of renal tubular 
damage at 1,128 mg/kg/day, but the increase was not statistically significant.  The histological evaluations 
of the kidneys in the five rats/sex/dose exposed for 2 or 6 weeks showed no statistically significant 
increases in incidences of specific changes, although the total incidence of animals with tubular damage 
was significantly increased in the 715 mg/kg/day males at 6 weeks.  Based on the 16-week kidney 
histopathology data in male Wistar rats, this study identified a NOAEL of 71 mg/kg/day and LOAEL of 
180 mg/kg/day for intermediate-duration exposure. 
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The 16-week studies of Cruzan et al. (2004) and Gaunt et al. (1974) provide dose-response data for the 
critical effect in the most sensitive species, strain, and sex (i.e., kidney lesions in male Wistar rats).  The 
respective NOAEL and LOAEL values were 150 and 500 mg/kg/day in the Cruzan et al. (2004) study and 
71 and 180 mg/kg/day in the Gaunt et al. (1974) study.  Although Gaunt et al. (1974) identified a lower 
apparent LOAEL, this study is not suitable for MRL consideration because the animal care was 
questionable and the daily dose was not constant.  Nearly all of the rats, possibly from the beginning of 
the study, showed evidence of respiratory infection (pneumonia) and infectious salivary adenitis, either of 
which could have confounded the results.  Also, the rats were fed a constant dietary percentage of 
ethylene glycol, such that daily consumption varied throughout the study.  For example, in the 
180 mg/kg/day LOAEL group, the rats were exposed to approximately 300 mg/kg/day for the first 
2-weeks, which is a level above the threshold for renal toxicity in male Wistar rats in a 12-month study 
(Wilson et al. 2005) (see chronic-duration MRL discussion).  Further, the rats were housed in groups of 
five, such that consumption of individual rats among the groups likely varied.  Hence, the dose levels in 
the Gaunt et al. (1974) study are not reliably consistent, unlike the study by Cruzan et al. (2004), which 
was conducted in the same rat strain and sex for the same duration.  An additional reason to use the 
Cruzan et al. (2004) study for MRL derivation is that the 12-month study (Wilson et al. 2005) showed the 
same NOAEL of 150 mg/kg/day and a LOAEL of 300 mg/kg/day, thus appearing to substantiate the 
results of Cruzan et al. (2004) but not Gaunt et al. (1974). 
 
The Cruzan et al. (2004) 16-week study is better basis for intermediate-duration MRL derivation because 
it identified the lowest reliable LOAEL and has no confounding factors.  The incidences of the critical 
effect, crystal nephropathy, were 0/10, 0/10, 0/10, 10/10, and 10/10 at 0, 50, 150, 500, and 
1,000 mg/kg/day, respectively.  This data set is not appropriate for BMD analysis because the incidences 
increased from 0% in the rats exposed to ≤150 mg/kg/day to 100% in the rats exposed to 
≥500 mg/kg/day; the lack of a low-response data point(s) limits the accuracy of dose-response modeling.  
Basing the MRL on the NOAEL of 150 mg/kg/day and using an uncertainty factor of 100 (10 for animal 
to human extrapolation and 10 for human variability) yields an MRL of 1.5 mg/kg/day, but this value is 
higher than the acute-duration oral MRL of 0.8 mg/kg/day.  It is against ATSDR policy to derive an 
intermediate-duration MRL that is higher than the acute-duration MRL.  The acute MRL is based on a 
NOAEL of 150 mg/kg/day for developmental toxicity in mice (Neeper-Bradley et al. 1995; Tyl 1989), 
which is the same as the intermediate- and chronic-duration NOAELs for kidney effects in male Wistar 
rats (Cruzan et al. 2004; Wilson et al. 2005).  Because available evidence indicates that the acute-duration 
oral MRL for ethylene should be protective for kidney effects following longer-term exposure, the acute-
duration value of 0.8 mg/kg/day is adopted for intermediate-duration exposure. 
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An MRL has not been derived for chronic-duration oral exposure (365 days or more) to ethylene glycol.  
The chronic oral toxicity of ethylene glycol has been evaluated in three studies in rats (Blood 1965; 
DePass et al. 1986a; Wilson et al. 2005) and two studies in mice (DePass et al. 1986a; NTP 1993) using 
dietary exposure.  As summarized below, the main target organs were the kidneys in rats and liver in 
mice, and rats were more sensitive than mice.   
 
Male Wistar rats (20/dose) were exposed to ethylene glycol in dietary doses of 0, 50, 150, 300 or 
400 mg/kg/day for 12 months (Wilson et al. 2005).  Ten rats/group (main group) were used to assess 
toxicity; end points included clinical observations, body weight, feed and water consumption, urinalysis, 
organ weights, gross necropsy, and kidney and bladder histopathology.  Urinalysis was performed the 
week prior to study termination and included color, appearance, specific gravity, volume, pH, bilirubin, 
glucose, proteins, ketones, blood, urobilinogen, and microscopic evaluation for crystal types.  Five 
rats/group were used to determine renal clearance of 14C-oxalate and 3H-inulin, and five rats/group were 
used to evaluate concentrations of ethylene glycol and its glycolate and oxalate metabolites in blood, 
urine, and kidneys.  No adverse effects occurred at 50 or 150 mg/kg/day, but toxicity was pronounced at 
300 and 400 mg/kg/day.  Effects at 400 mg/kg/day included mortality (4/10 died or were moribund on 
days 43-193) and weight loss, which led to early termination of the remaining animals on day 203.  
Mortality was also increased at 300 mg/kg/day (4/10 died or were moribund on days 111–221).  Other 
effects at ≥300 mg/kg/day included increased water consumption with corresponding increased urine 
volume and decreased urine specific gravity, increased absolute and relative kidney weights, and gross 
and histopathological changes in the kidneys and bladder.  Gross pathology included calculi, dilatation, 
and hemorrhage in the bladder at ≥300 mg/kg/day and calculi and dilatation in the renal pelvis and ureter 
at 400 mg/kg/day.  Renal histopathology occurred in the majority of animals at 300 mg/kg/day and in all 
animals at 400 mg/kg/day; lesions included crystalluria-related nephropathy, tubule dilatation, 
birefringent crystals (particularly in the pelvic fornix), pelvic dilatation, and transitional cell hyperplasia.  
Incidences of crystal nephropathy, the most prevalent lesion, were 0/14, 0/15, 0/15, 12/13, and 10/10 at 0, 
50, 150, 300, and 400 mg/kg/day, respectively.  Histopathological changes in the bladder occurred in the 
majority of animals at ≥300 mg/kg/day; the basic change was transitional cell hyperplasia, progressing to 
acute inflammation and hemorrhage in severe cases.  The early deaths were considered related to the 
inflammation and hemorrhage of the bladder wall.  Decreased urinary pH and increased urinary oxalate 
crystals occurred at all treatment levels (≥50 mg/kg/day); these effects were not considered adverse, but 
rather normal metabolic/physiological consequences of ethylene glycol exposure.  There were no 
treatment-related effects on renal clearance of oxalate or inulin.  Urinary levels of oxalate were 
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unchanged at all doses, urinary ethylene glycol followed a linear dose-response relationship, and urinary 
glycolic acid was linear between 50 and 150 mg/kg with a disproportionate nonlinear increase at 
300 mg/kg/day.  Kidney concentrations of glycolate and oxalate were unchanged at 50 and 
150 mg/kg/day, but clear nonlinear increases in both of these metabolites occurred at ≥300 mg/kg/day, 
indicating that the accumulation of calcium oxalate in the kidneys correlated with the appearance of renal 
toxicity.  A NOAEL of 150 mg/kg/day and a LOAEL of 300 mg/kg/day were identified in male Wistar 
rats based on histopathology in the kidneys (crystal nephropathy) and bladder (inflammation and 
hemorrhage). 
 
Sprague-Dawley rats (16/sex/dose) were fed ethylene glycol in estimated dietary doses of 0, 75, 150, 375, 
750, or 3,000 mg/kg/day for up to 2 years (Blood 1965).  Evaluations included food and water 
consumption, body and organ weights, hematology, urinary protein, and limited histopathology.  
Decreased body weight gain, increased water consumption, proteinuria, and mortality occurred in males 
at ≥750 mg/kg/day and females at 3,000 mg/kg/day.  Incidences of calcification (oxalate crystal 
deposition) in the kidneys were increased in both sexes at ≥750 mg/kg/day, and oxalate-containing calculi 
were increased in males at ≥750 mg/kg/day and females at 3,000 mg/kg/day.  Oxalate crystal deposition 
also occurred in males at 375 mg/kg/day (4/10 compared to 0/7 controls), although the increase was not 
statistically significantly.  The report implied, but did not adequately document, that many of the animals 
with crystal deposition in the renal tubules also had degenerative changes in the tubular epithelium.  Due 
to the insufficiently reported histopathology findings and lack of a clear (statistically significant) increase 
in oxalate crystal deposition at 375 mg/kg/day due to small number of animals, this study provides limited 
evidence that 375 mg/kg/day was a LOAEL for kidney toxicity in male Sprague-Dawley rats; the 
NOAEL was 150 mg/kg/day. 
 
F344 rats (130/sex/dose) were fed ethylene glycol in approximate dietary doses of 0, 40, 200, or 
1,000 mg/kg/day for up to 2 years (DePass et al. 1986a).  End points included food and water 
consumption, body and organ weights, hematology, clinical chemistry, extensive urinalysis, and 
comprehensive histopathology.  No treatment-related or statistically significant changes occurred in the 
male rats at 40 or 200 mg/kg/day.  Toxicity was pronounced in males at 1,000 mg/kg/day as shown by 
increased mortality from month 9 (100% day 475), and various other effects that included increased water 
consumption and urine volume, increased blood urea nitrogen (BUN) and serum creatinine, decreased 
urine specific gravity and pH, increased urinary calcium oxalate crystals, and increased kidney weight and 
lesions.  All 1,000 mg/kg/day males sacrificed at 12 months had calcium oxalate crystalluria and multiple 
severe renal lesions that included tubular dilation, proteinosis, hyperplasia, glomerular shrinkage, and/or 
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chronic interstitial nephritis.  Most of the 1,000 mg/kg/day males that died during the study or were 
sacrificed when moribund had oxalate nephrosis, which was the primary cause of death, as well as 
hydronephrosis.  In the male rats at 0, 40, 200, and 1,000 mg/kg/day, the total incidences of oxalate 
nephrosis were 0/256, 0/129, 0/129, and 95/116, respectively.  Non-neoplasic lesions in several non-renal 
tissues were also significantly increased in the 1,000 mg/kg/day males; these included cellular hyperplasia 
in the parathyroids and mineralization in the heart (vessels and muscle), lungs (interstitial), stomach, and 
vascular system.  A NOAEL of 200 mg/kg/day and a serious LOAEL of 1,000 mg/kg/day were identified 
in male F344 rats based on kidney toxicity (oxalate nephrosis)-induced mortality.   
 
In the female F344 rats, effects occurred in kidneys and lymph nodes at 1,000 mg/kg/day and liver at 
≥200 mg/kg/day (DePass et al. 1986a).  Renal effects in females were limited to increased kidney weight 
and calcium oxalate crystals and uric acid crystals in the urine at 1,000 mg/kg/day; no kidney 
histopathology or mortality occurred as in males (DePass et al. 1986a).  Hemosiderosis in the mesenteric 
lymph nodes was increased at 1,000 mg/kg/day.  Hepatic effects included increases in mononuclear cell 
infiltrates at 1,000 mg/kg/day and fatty metamorphosis (slight) at ≥200 mg/kg/day.  Total incidences of 
liver fatty metamorphosis in the 0, 40, 200, and 1,000 mg/kg/day females were 34/256, 16/129, 27/125, 
and 35/128, respectively; the increases at 200 and 1,000 mg/kg/day were statistically significant.  The 
liver fatty metamorphosis is not considered to be adverse because the effect was slight and there was no 
other evidence of hepatotoxicity; at no time (6, 12, 18, or 24 months) was there an increase in liver 
function parameters (serum chemistry) or in liver weight, even in animals dosed at 1,000 mg/kg/day.  
Additionally, this was the only long-term study (intermediate- or chronic-duration) to find liver lesions in 
rats, and the mode of action supports the kidney as the critical target.  Based on the kidney effects, a 
NOAEL of 200 mg/kg/day and a LOAEL of 1,000 mg/kg/day were identified in female F344 rats. 
 
CD-1 mice (80/sex/dose) were fed ethylene glycol in approximate dietary doses of 0, 40, 200, or 
1,000 mg/kg/day for up to 2 years (DePass et al. 1986a).  Evaluations were limited to clinical signs, body 
weight, food consumption, and comprehensive histopathology.  No clear treatment-related effects were 
observed in either sex, indicating that this study identified a NOAEL of 1,000 mg/kg/day and no LOAEL 
in CD-1 mice.  In the other mouse study, B6C3F1 mice (60/sex/dose) were exposed to ethylene glycol in 
the diet for up to 2 years (NTP 1993).  Estimated average doses were 0, 1,500, 3,000, and 
6,000 mg/kg/day in males and 0, 3,000, 6,000, and 12,000 mg/kg/day in females.  Evaluations included 
hematology, clinical chemistry, organ weights (limited), and comprehensive histopathology.  Effects were 
essentially limited to increased incidences of hepatocellular hyaline degeneration in males at 
≥3,000 mg/kg/day and females at 12,000 mg/kg/day, and medial hyperplasia of the pulmonary arterioles 
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in females at ≥3,000 mg/kg/day; the biological significance of the pulmonary lesion was unclear (NTP 
1993).  Small numbers of oxalate-like crystals and/or calculi were noted in the renal tubules, urethrae, and 
urinary bladder in a few males at 6,000 mg/kg/day.  A NOAEL of 1500 mg/kg/day and LOAEL of 
3,000 mg/kg/day for liver histopathology were identified in male B6C3F1 mice. 
 
Key findings in the chronic toxicity studies were kidney lesions (oxalate nephrosis) and mortality at 
≥300 mg/kg/day in male Wistar rats (Wilson et al. 2005), kidney lesions (oxalate crystal deposition and 
implied degenerative changes) at ≥375 mg/kg/day and mortality at 750 mg/kg/day in male Sprague-
Dawley rats (Blood 1965), kidney lesions (oxalate nephrosis) and mortality at 1,000 mg/kg/day in male 
F344 rats (DePass et al. 1986a), no kidney or liver histopathology in male or female CD-1 mice at 
1,000 mg/kg/day (DePass et al. 1986a), and liver lesions (hepatocellular hyaline degeneration) in male 
B6C3F1 mice at ≥3,000 mg/kg/day (NTP 1993).  The kidney lesions and mortality in male rats occurred 
at doses that were NOAELs in mice, indicating that rats were more sensitive than mice and the most 
appropriate species for MRL consideration. 
 
Chronic effect levels for kidney lesions and mortality in male rats included a NOAEL of 150 mg/kg/day 
and a serious LOAEL of 300 mg/kg/day in Wistar males (Wilson et al. 2005), a NOAEL of 
200 mg/kg/day and a serious LOAEL of 1,000 mg/kg/day in F344 males (DePass et al. 1986a), and a 
NOAEL of 150 mg/kg/day and a serious LOAEL of 750 mg/kg/day in Sprague-Dawley males (Blood 
1965).  An apparent increase in kidney lesions without mortality occurred in Sprague-Dawley males at 
375 mg/kg/day (Blood 1965), suggesting that this dose was a less serious LOAEL for renal effects in this 
strain of rats.  The 150 mg/kg/day NOAEL for renal effects in Wistar males (Wilson et al. 2005) and 
Sprague-Dawley males (Blood 1965) is consistent with the 200 mg/kg/day NOAEL for renal effects in 
F344 males (DePass et al. 1986a).   
 
The study in male Wistar rats (Wilson et al. 2005) is the most appropriate basis for chronic MRL 
derivation because it identified the lowest LOAEL (300 mg/kg/day) and is the only study providing 
information on effects of chronic exposure in Wistar rats, a strain shown to be approximately twice as 
sensitive as F344 rats to kidney toxicity in a 16-week study (Cruzan et al. 2004) (see intermediate-
duration MRL discussion).  The incidences of the critical chronic effect, oxalate nephropathy, were 0/14, 
0/15, 0/15, 12/13, and 10/10 at 0, 50, 150, 300, and 400 mg/kg/day, respectively (Wilson et al. 2005).  
This data set is not appropriate for BMD analysis because the incidences increased from 0% in the rats 
exposed to ≤150 mg/kg/day to 92% at 300 mg/kg/day and 100% at 400 mg/kg/day; the lack of a low-
response data point(s) limits the accuracy of dose-response modeling.  Basing the MRL on the NOAEL of 
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150 mg/kg/day and using an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for 
human variability) yields an MRL of 1.5 mg/kg/day, but this value is higher than the acute-duration oral 
MRL of 0.8 mg/kg/day.  It is against ATSDR policy to derive a chronic-duration MRL that is higher than 
the acute-duration MRL.  The acute MRL is based on a NOAEL of 150 mg/kg/day for developmental 
toxicity in mice (Neeper-Bradley et al. 1995; Tyl 1989), which is the same as the intermediate- and 
chronic-duration NOAELs for kidney effects in male Wistar rats (Cruzan et al. 2004; Wilson et al. 2005).  
The available evidence therefore indicates that the acute-duration oral MRL should be protective for 
chronic kidney effects. 
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3.  HEALTH EFFECTS 
 
3.1   INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of ethylene glycol.  
It contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
 
The general population may be exposed to ethylene glycol.  Ethylene glycol is widely sold in grocery 
stores and in automobile supply, discount, drug, and other stores throughout the United States for general 
use as an antifreeze/coolant in automobile radiators.  Additionally, it is used in the manufacturing or 
blending of polyester products; aircraft and runway de-icing fluids; heat transfer fluids used in heating, 
ventilation, and air conditioning systems; humectants; polyester and alkyd resins; plasticizers; electrolytic 
capacitors; low freeze dynamite; and brake and shock solutions.   
 
Dermal exposure, through activities such as changing antifreeze, is the most likely route of exposure to 
ethylene glycol, but dermal exposure is not likely to lead to toxic effects.  Only oral exposure, through 
accidental or intentional ingestion, is likely to lead to such effects, and then only if a sufficient amount is 
swallowed at one time.  A review of the literature for ethylene glycol indicated that the stages of oral 
ethylene glycol poisoning in humans are well understood and documented.  There is adequate knowledge 
of ethylene glycol metabolism to permit successful treatment of ethylene glycol intoxication, and 
substantial information concerning pathology and pathophysiology of the organ systems involved is 
available.  Although the majority of the studies in humans represent descriptions of case studies of 
accidental or intentional poisoning, or exposure in industrial settings, they have been collected for a 
period of >60 years.  Animal studies corroborate human findings and were used to provide quantitative 
data to support observations made in humans. 
 
3.2   DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
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developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into “less serious” or “serious” effects.  “Serious” effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.   
 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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3.2.1   Inhalation Exposure  
 
Information regarding health effects of ethylene glycol following inhalation exposure is limited.  Health 
effects in humans were found in only a few studies (Bond et al. 1985; Troisi 1950; Wills et al. 1974).  
Animal studies were described by Tyl (1985, 1988a).   
 
3.2.1.1   Death  
 
No studies were located regarding death in humans after inhalation exposure to ethylene glycol. 
 
Mortality occurred in 1/15 rats, 3/15 guinea pigs, 1/3 rabbits, 0/3 dogs, and 0/3 monkeys that were 
continuously whole-body exposed to 12 mg/m3of ethylene glycol aerosol for 90 days, although none of 
the affected animals showed “any specific signs of toxicity” (Coon et al. 1970).  This concentration is not 
a reliable LOAEL for mortality because intake of ethylene glycol from ingestion of aerosol deposited on 
the fur likely significantly contributed to total dose (Tyl et al. 1995a, 1995b).  Exposure to 10 or 
57 mg/m3 ethylene glycol aerosol for 8 hours/day, 5 days/week for 6 weeks caused no mortality in rats 
(15/concentration), guinea pigs (15/concentration), rabbits (3/concentration), dogs (2/concentration), or 
monkeys (2/concentration) (Coon et al. 1970). 
 
3.2.1.2   Systemic Effects  
 
No studies were located regarding gastrointestinal, musculoskeletal, endocrine, dermal, ocular, body 
weight, or metabolic effects in humans or respiratory, gastrointestinal, musculoskeletal, dermal, or body 
weight effects in animals after inhalation exposure to ethylene glycol.  The highest NOAEL values and all 
reliable LOAEL values for systemic effects in each species and duration category for ethylene glycol after 
inhalation exposure are reported in Table 3-1 and plotted in Figure 3-1.   
 
Respiratory Effects.    Tolerable nose and throat irritation were occasional complaints in 19 volunteers 
(incidence and frequency not reported) who were exposed to ethylene glycol aerosol for 20–22 hours/day 
for 30 days in a controlled study (Wills et al. 1974).  The average mean weekly exposure concentration 
was 23 mg/m3 for days 1–14 and 30 mg/m3 for days 1–30.  Sessions in which the concentration was 
increased for short periods during the last 10 days of the study showed that upper respiratory tract 
irritation became common at approximately 140 mg/m3, and caused exposure to be tolerated for only 
15 minutes at 188 mg/m3, 2 minutes at 244 mg/m3, and one or two breaths at 308 mg/m3 due to symptoms 





































































a The number corresponds to entries in Figure 3-1.
b Used to derive an acute-duration inhalation minimal risk level (MRL) of 2 mg/m3; the NOAEL of 23 mg/m3 was divided by an uncertainty factor of 10 for human variability.
d = day(s); Gastro = gastrointestinal; Gd = gestational day; Hemato = hematological; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); NOAEL
= no-observed-adverse-effect level; Resp = respiratory
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  Cancer Effect Level-Animals
  LOAEL, More Serious-Animals
  LOAEL, Less Serious-Animals
  NOAEL - Animals
  Cancer Effect Level-Humans
  LOAEL, More Serious-Humans
  LOAEL, Less Serious-Humans
  NOAEL - Humans
  LD50/LC50
   for effects
   other than
   Cancer
mg/m3
Figure 3-1  Levels of Significant Exposure to Ethylene Glycol - Inhalation
Acute (≤14 days)
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days 1–14 was used to derive an acute-duration inhalation MRL of 2 mg/m3 as indicated in the footnote to 
Table 3-1 and discussed in Chapter 2 and Appendix A. 
 
Cardiovascular Effects.    Electrocardiographs conducted after 14 and 30 days of exposure were 
normal in a controlled study of 19 volunteers who were exposed to ethylene glycol aerosol for 20–
22 hours/day for 30 days (Wills et al. 1974).  The average mean weekly exposure concentration was 
23 mg/m3 for days 1–14 and 30 mg/m3 for days 1–30.   
 
No gross or histological effects in the heart occurred in rats (15/concentration), guinea pigs 
(15/concentration), rabbits (3/concentration), dogs (2/concentration), or monkeys (2–3/concentration) that 
were whole-body exposed to apparently aerosolized ethylene glycol in concentrations of 10 or 
57 mg/m3 for 8 hours/day, 5 days/week for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 
1970).  The histology examinations in the rats and guinea pigs were limited to eight animals each.  This 
study identified NOAELs of 57 mg/m3 (intermittent exposure) and 12 mg/m3 (continuous exposure) for 
cardiovascular effects, but the relevance of these NOAELs is unclear because intake of ethylene glycol 
from ingestion of aerosol deposited on the fur likely significantly contributed to total dose (Tyl et al. 
1995a, 1995b). 
 
Hematological Effects.    No significant hematologic alterations were found in a controlled study of 
19 volunteers who were exposed to ethylene glycol aerosol for 20–22 hours/day for 30 days (Wills et al. 
1974).  The average mean weekly exposure concentration was 23 mg/m3 for days 1–14 and 30 mg/m3 for 
days 1–30.  Evaluations were performed approximately every 2–3 days and included hematocrit, 
hemoglobin, total and differential leucocyte counts, and prothrombin time. 
 
No treatment-related hematological effects were found in rats (15/concentration), guinea pigs 
(15/concentration), rabbits (3/concentration), dogs (2/concentration), or monkeys (2–3/concentration) that 
were whole-body exposed to apparently aerosolized ethylene glycol in concentrations of 10 or 
57 mg/m3 for 8 hours/day, 5 days/week for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 
1970).  Evaluations included hemoglobin concentration, packed erythrocyte volume, total leukocyte 
counts, and prothrombin time.  This study identified NOAELs of 57 mg/m3 (intermittent exposure) and 
12 mg/m3 (continuous exposure) for hematological effects, but the relevance of these NOAELs is unclear 
because intake of ethylene glycol from ingestion of aerosol deposited on the fur likely significantly 
contributed to total dose (Tyl et al. 1995a, 1995b). 
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Hepatic Effects.    No significant alterations in serum hepatic end points were found in a controlled 
study of 19 volunteers who were exposed to ethylene glycol aerosol for 20–22 hours/day for 30 days 
(Wills et al. 1974).  The average mean weekly exposure concentration was 23 mg/m3 for days 1–14 and 
30 mg/m3 for days 1–30.  Clinical chemistry was evaluated approximately every 2–3 days and included 
serum glutamate-oxaloacetate transferase (SGOT), alkaline phosphatase, cholesterol, and bilirubin. 
 
No treatment-related hepatic effects were found in rats (15/concentration), guinea pigs (15/concentration), 
rabbits (3/concentration), dogs (2/concentration), or monkeys (2–3/concentration) that were whole-body 
exposed to apparently aerosolized ethylene glycol in concentrations of 10 or 57 mg/m3 for 8 hours/day, 
5 days/week for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 1970).  Evaluations included 
serum enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline 
phosphatase, and lactate dehydrogenase), gross pathology, and histopathology; the histology 
examinations in the rats and guinea pigs were limited to eight animals each.  This study identified 
NOAELs of 57 mg/m3 (intermittent exposure) and 12 mg/m3 (continuous exposure) for hepatic effects, 
but the relevance of these NOAELs is unclear because intake of ethylene glycol from ingestion of aerosol 
deposited on the fur likely significantly contributed to total dose (Tyl et al. 1995a, 1995b). 
 
Renal Effects.    No significant alterations in renal end points were found in a controlled study of 
19 volunteers who were exposed to ethylene glycol aerosol for 20–22 hours/day for 30 days (Wills et al. 
1974).  The average mean weekly exposure concentration was 23 mg/m3 for days 1–14 and 30 mg/m3 for 
days 1–30.  End points included daily examination of urine for occurrence of oxalate crystals and 
erthyrocytes, twice weekly evaluations of urine volume, specific gravity, color, clarity, pH, amino acid 
nitrogen, and creatinine, and evaluation of blood urea nitrogen every 2–3 days.  There also was no 
indication of renal impairment in 33 aviation workers who were intermittently exposed to ethylene glycol 
during airplane de-icing operations over a 2-month winter period (Gérin et al. 1997).  Personal exposures 
to ethylene glycol vapor and aerosol were <2.5–22 and <17–190 mg/m3, respectively.  Pre- and post-shift 
measurements of urinary albumin, β-N-acetyl-glucosaminidase, β-2-microglobulin, and retinol-binding 
protein were used to assess kidney function. 
 
No gross or histological effects occurred in the kidneys of rats (15/concentration), guinea pigs 
(15/concentration), rabbits (3/concentration), dogs (2/concentration), or monkeys (2–3/concentration) that 
were whole-body exposed to apparently aerosolized ethylene glycol in concentrations of 10 or 57 mg/m3 
for 8 hours/day, 5 days/week for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 1970).  The 
histology examinations in the rats and guinea pigs were limited to eight animals each.  This study 
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identified NOAELs of 57 mg/m3 (intermittent exposure) and 12 mg/m3 (continuous exposure) for kidney 
effects, but known sensitive renal end points for ethylene glycol (e.g., organ weight and urinalysis 
parameters) were not evaluated.  The relevance of these NOAELs is additionally unclear because intake 
of ethylene glycol from ingestion of aerosol deposited on the fur likely significantly contributed to total 
dose (Tyl et al. 1995a, 1995b). 
 
Endocrine Effects.    No gross or histological effects occurred in the adrenals in dogs (2/concentration) 
or monkeys (2–3/concentration), or thyroid in dogs (2/concentration), following whole-body exposure to 
apparently aerosolized ethylene glycol in concentrations of 10 or 57 mg/m3 for 8 hours/day, 5 days/week 
for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 1970).  Additional endocrine end points 
were not evaluated.  The relevance of these NOAELs is unclear because intake of ethylene glycol from 
ingestion of aerosol deposited on the fur likely significantly contributed to total dose (Tyl et al. 1995a, 
1995b). 
 
Ocular Effects.    Rats (15/concentration), guinea pigs (15/concentration), rabbits (3/concentration), 
dogs (2/concentration), and monkeys (2–3/concentration) were exposed to apparently aerosolized 
ethylene glycol in concentrations of 10 or 57 mg/m3 for 8 hours/day, 5 days/week for 6 weeks, or 
12 mg/m3 continuously for 90 days (Coon et al. 1970).  No signs of ocular or nasal irritation were 
observed in any of the animals that were intermittently exposed to ≤57 mg/m3 in the 6-week study.  In the 
90-day study, continuous exposure to 12 mg/m3 caused moderate to severe eye irritation (erythema, 
edema, and discharge) in all (3/3) rabbits and corneal opacity with possible blindness in 2/15 rats; both 
species were affected within 8 days of the initial exposure.   
 
3.2.1.3   Immunological and Lymphoreticular Effects  
 
No studies were located specifically regarding adverse immunological effects in humans or animals after 
inhalation exposure to ethylene glycol.  There were no significant alterations in total or differential white 
blood cell counts in a controlled study of 19 volunteers who were exposed to ethylene glycol aerosol for 
20–22 hours/day for 30 days (Wills et al. 1974).  The average mean weekly exposure concentration was 
23 mg/m3 for days 1–14 and 30 mg/m3 for days 1–30 (Wills et al. 1974). 
 
3.2.1.4   Neurological Effects  
 
Slight headache and backache were occasional complaints in 19 volunteers (incidence and frequency not 
reported) who were exposed to ethylene glycol aerosol for 20–22 hours/day for 30 days in a controlled 
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study (Wills et al. 1974).  The average mean weekly exposure concentration was 23 mg/m3 for days 1–
14 and 30 mg/m3 for days 1–30.  No effects were seen in electroencephalographs or a battery of 
psychological tests conducted after 14 and 30 days of exposure; the tests evaluated simple reaction time, 
reaction time with discrimination, visual-motor coordination, depth perception, and mental ability 
(encoding and subtraction accuracy). 
 
No gross or histological effects in the brain or spinal cord occurred in dogs (2/concentration) that were 
whole-body exposed to apparently aerosolized ethylene glycol in concentrations of 10 or 57 mg/m3 for 
8 hours/day, 5 days/week for 6 weeks, or 12 mg/m3 continuously for 90 days (Coon et al. 1970).  This 
study identified NOAELs of 57 mg/m3 (intermittent exposure) and 12 mg/m3 (continuous exposure) for 
neurological effects based on small numbers of animals.  The relevance of these NOAELs is unclear 
because neurobehavioral function was not evaluated and intake of ethylene glycol from ingestion of 
aerosol deposited on the fur likely significantly contributed to total dose (Tyl et al. 1995a, 1995b). 
 
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category for ethylene glycol after inhalation exposure are reported in Table 3-1, and plotted in 
Figure 3-1.  
 
3.2.1.5   Reproductive Effects  
 
No studies were located regarding reproductive effects in humans after inhalation exposure to ethylene 
glycol. 
 
Acute-duration developmental toxicity studies of inhaled ethylene glycol in mice and rats are available, 
but all of the studies are confounded by concurrent ingestion exposure to ethylene glycol deposited on the 
fur.  Whole-body exposure of pregnant CD-1 mice to 150–2,500 mg/m3 aerosolized ethylene glycol for 
6 hours/day on gestation days (Gd) 6–15 caused a decrease in the number of live fetuses per litter at 
≥1,000 mg/m3, but no effect on reproductive parameters was observed in CD rats dosed under the same 
regimen (Tyl 1985, 1988a; Tyl et al. 1995a).  Both the mouse and rat studies were confounded by 
ingestion of ethylene glycol deposited on the fur of exposed animals and consumed during grooming; the 
authors estimated that ingestion comprised the majority of exposure.  In a companion study, nose-only 
exposure of CD-1 mice to 500–2,500 mg/m3 aerosolized ethylene glycol using the same study design 
resulted in no effects on pre- or postimplantation loss (Tyl 1988a; Tyl et al. 1995a).  Although this study 
was aimed at reducing confounding from concurrent ingestion exposure, the authors noted that the 
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animals in the nose-only experiment were also exposed by ingestion of ethylene glycol deposited on the 
face during nose-only exposure.   
 
As a result of confounding from exposure via ingestion, NTP-CERHR (2004) characterized the 
developmental toxicity studies as inadequate for the purpose of identifying effect levels for inhalation 
exposure; thus, there are no reliable NOAEL or LOAEL values.  
 
3.2.1.6   Developmental Effects  
 
No studies were located regarding developmental effects in humans after inhalation exposure to ethylene 
glycol. 
 
Acute-duration developmental toxicity studies of inhaled ethylene glycol in mice and rats are available, 
but all of the studies are confounded by concurrent ingestion exposure to ethylene glycol deposited on the 
fur.  Groups of 25 pregnant CD-1 mice and CD rats were exposed (whole-body) to target concentrations 
of 0, 150, 1,000, or 2,500 mg/m3 aerosolized ethylene glycol (mass median aerodynamic diameter 
[MMAD] of 2.3 μm) for 6 hours/day on Gd 6–15 (Tyl 1985, 1988a; Tyl et al. 1995a).  Fetal evaluations 
included litter size, fetal weight, and external, visceral, and skeletal malformations.  Maternal toxicity 
(e.g., increased liver weight in rats and reduced body weight gain in mice) was evident at 2,500 and 
1,000 mg/m3 in rats and mice, respectively (Tyl et al. 1995b).  In mice, significant decreases in the 
number of live fetuses per litter and in the weight of live fetuses, as well as increases in the number of late 
resorptions per litter and the incidence of external, visceral, and skeletal malformations were observed at 
target concentrations of ≥1,000 mg/m3.  In rats, reduced ossification at some sites in the axial skeleton 
was observed with exposure to 1,000 and 2,500 mg/m3 (Tyl 1985; Tyl et al. 1995a); however, in an 
Expert Panel Review, NTP-CERHR (2004) concluded that the relationship of this effect to treatment was 
uncertain due to the lack of a dose-response relationship.  This study was confounded by significant 
ingestion of ethylene glycol deposited on the fur and consumed during grooming; the authors estimated 
that the ingestion dose comprised the majority of exposure.   
 
In a follow-up study aimed at reducing the confounding from ingestion exposure, pregnant CD-1 mice 
were exposed nose-only to 0, 500, 1,000, or 2,500 mg/m3 aerosolized ethylene glycol (MMAD 2.6 μm) 
(Tyl 1988a; Tyl et al. 1995b).  Fetal weight and incidence of external, visceral, and skeletal 
malformations were evaluated in the offspring.  In maternal animals, there were no effects other than 
changes in kidney weights.  Absolute kidney weight was significantly increased at 1,000 and 
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2,500 mg/mg3, and relative kidney weight was increased at 2,500 mg/m3; however, the increases were 
small (6.6–9.5% higher than controls) and microscopic examination of kidneys showed no 
histopathological changes.  At 2,500 mg/m3, live fetal body weight was significantly reduced, and there 
was a significant increase in the one type of skeletal malformation (fused ribs).  Increases in some skeletal 
variations were observed at 2,500 mg/m3, and one type (extra ossification sites in the sagittal suture) was 
significantly increased at all concentrations.  Although this study used restraint to minimize oral exposure, 
the authors noted that oral exposure was possible via grooming of the face after exposure.  In addition, 
NTP-CERHR (2004) noted that stress from restraint during nose-only exposure (struggling was observed) 
may have contributed to the developmental effects observed with ethylene glycol, which were similar in 
nature to effects observed in a study of restrained nose-only exposure to water vapor (Tyl et al. 1994).   
 
All of the available studies of developmental effects after inhalation exposure to ethylene glycol are 
confounded by concurrent ingestion exposure and the single nose-only exposure study is also confounded 
by stress related to restraint during exposure.  In its review of these studies, NTP-CERHR (2004) 
concluded that the data are insufficient to identify effect levels from inhaled ethylene glycol in animals; 
thus, there are no reliable NOAEL or LOAEL values. 
 
3.2.1.7   Cancer  
 
An epidemiologic study on renal cancer mortality examined the work and health histories of 
1,666 chemical plant employees and found no elevation in the odds ratio for workers exposed to ethylene 
glycol (Bond et al. 1985), although the sample size was quite small.  Exposure was presumed to be by 
inhalation.   
 
No studies were located regarding cancer effects in animals after inhalation exposure to ethylene glycol. 
 
3.2.2   Oral Exposure  
 
Ethylene glycol is a colorless, water-soluble liquid with a sweet taste and little or no odor, most 
commonly used as an antifreeze fluid.  The ready availability of antifreeze mixtures makes ethylene 
glycol intoxication a significant medical and veterinary problem.  Antifreeze mixtures contain up to 95% 
ethylene glycol (Mallya et al. 1986; Siew et al. 1975a).  The exposure route most commonly associated 
with adverse effects is oral ingestion.   
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3.2.2.1   Death  
 
The American Association of Poison Control Centers (AAPCC) reported 25 fatalities for 2005 due to 
ethylene glycol ingestion (Lai et al. 2006).  Other fatal ethylene glycol poisonings included case reports of 
deaths resulting from accidental or intentional ingestion of ethylene glycol or antifreeze containing 99% 
ethylene glycol (Froberg et al. 2006; Godolphin et al. 1980; Gordon and Hunter 1982; Hantson et al. 
2002; Hewlett et al. 1986; Jacobsen et al. 1984; Leth and Gregersen 2005; Siew et al. 1975a; Zeiss et al. 
1989).  A 22-year-old male who ingested 300 mL of antifreeze (approximately 4,071 mg/kg ethylene 
glycol) lapsed into a coma 24 hours after hospital admission and died 24 hours later (Siew et al. 1975a).  
A dose of 7,850 mg/kg can be estimated in the case of a 73-year-old male who consumed 500 mL of 95% 
ethylene glycol and died of myocardial failure after 68 hours (Gordon and Hunter 1982).  A 25-year-old 
male who ingested ethylene glycol-based antifreeze in an apparent amount of 225 cc (approximately 
3,600 mg/kg) died within 24 hours of hospital admission (Froberg et al. 2006).  In five other fatal cases of 
accidental or intentional poisoning, the amount of ingested ethylene glycol ranged from 150 to 1,500 mL 
(2,379–23,786 mg/kg) (Karlson-Stiber and Persson 1992; Walton 1978).  Thus, oral dose of ethylene 
glycol required to cause death in humans is not well defined in the literature.  The minimum lethal dose 
for adults is thought to be 1.4 mL/kg of 95% ethylene glycol, or about 1,330 mg ethylene glycol/kg body 
weight (Parry and Wallach 1974; Robinson and McCoy 1989; Siew et al. 1975a). 
 
A single dose oral LD50 of 4,000 mg/kg was determined in female F344 rats (Clark et al. 1979).  Male 
Wistar rats administered 12,900 mg/kg ethylene glycol in a single oral dose had 55% mortality within 
48 hours (Richardson 1973).  Pregnant CD-1 mice given 11,090 mg/kg/day ethylene glycol orally on 
Gd 7–14 showed 10% mortality (Schuler et al. 1984) and pregnant rabbits exhibited 42% mortality after 
receiving 2,000 mg/kg/day ethylene glycol orally on Gd 6–19 (Tyl et al. 1993).  Cats administered a 
single 4,440–8,880 mg/kg dose by gavage had 100% mortality within 20–36 hours (Penumarthy and 
Oehme 1975).  A single gavage dose of 4,180–12,540 mg/kg/day caused 17–100% mortality in dogs 
within 72 hours (Kersting and Nielsen 1965).  Dogs administered a single oral dose of 4,880 mg/kg in 
food had 100% mortality within 6 days (Beckett and Shields 1971). 
 
Intermediate-duration dietary exposure to 1,000 mg/kg/day for 16 weeks caused 20% mortality in male 
Wistar rats, with no deaths occurring in similarly treated male F344 rats; females were not tested (Cruzan 
et al. 2004).  Male F344/N rats fed 5,000 mg/kg/day ethylene glycol had 40% mortality after 13 weeks, 
whereas similarly treated females did not die (Melnick 1984).  A chronic dietary study of ethylene glycol 
in Sprague-Dawley rats found 100% mortality after 12–24 months in males at 750 mg/kg/day and females 
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at 3,000 mg/kg/day (Blood 1965).  Male F344 rats given 1,000 mg/kg/day ethylene glycol in the feed all 
died within 16 months (DePass et al. 1986a; Woodside 1982).  In a 12-month dietary study in male 
Wistar rats, exposure to 300 mg/kg/day caused 40% mortality (died or were moribund) on days 111–221 
(Wilson et al. 2005). 
 
All reliable LOAEL and LD50 values for death in each species and duration category for ethylene glycol 
after oral exposure are reported in Table 3-2, and plotted in Figure 3-2.   
 
3.2.2.2   Systemic Effects  
 
No studies were located regarding hematological, musculoskeletal, endocrine, hepatic, dermal, ocular, or 
body weight effects in humans after oral exposure to ethylene glycol.   
 
The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and 
duration category for ethylene glycol after oral exposure are reported in Table 3-2 and Figure 3-2. 
 
Respiratory Effects.    Respiratory system involvement occurs 12–24 hours after ingestion of 
sufficient amounts of ethylene glycol and is considered to be part of a second stage in ethylene glycol 
poisoning (Davis et al. 1997; Hess et al. 2004; Vale 1979).  The symptoms include hyperventilation 
(Godolphin et al. 1980; Gordon and Hunter 1982), shallow rapid breathing (Woolf et al. 1992; Zeiss et al. 
1989), and generalized pulmonary edema with calcium oxalate crystals occasionally present in the lung 
parenchyma (Friedman et al. 1962; Johnson et al. 1999; Leth and Gregersen 2005; Pellegrino et al. 2006; 
Vale 1979).  Respiratory system involvement appears to be dose-dependent and occurs concomitantly 
with cardiovascular changes.  Pulmonary infiltrates and other changes compatible with adult respiratory 
distress syndrome (ARDS) may characterize the second stage of ethylene glycol poisoning (Bey et al. 
2002; Piagnerelli et al. 1999; Taylor et al. 1997).  Pulmonary edema can be secondary to cardiac failure, 
ARDS, or aspiration of gastric contents (Walder and Tyler 1994).  Symptoms related to acidosis such as 
hyperpnea and tachypnea are frequently observed; however, major respiratory morbidities such as 
pulmonary edema and bronchopneumonia are relatively rare and usually only observed with extreme 
poisoning (e.g., in only 5 of 36 severely poisoned cases) (Friedman et al. 1962; Johnson et al. 1999; 
Karlson-Stiber and Persson 1992; Leth and Gregersen 2005; Parry and Wallach 1974; Piagnerelli et al. 
1999; Verrilli et al. 1987).  In one case, respiratory failure occurred in a woman who had consumed 
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a The number corresponds to entries in Figure 3-2.
b An acute-duration oral minimal risk level (MRL) of 0.8 mg/kg/day was derived from a BMDL10 of 76 mg/kg/day based on benchmark dose analysis of the incidences of litters with
total malformations and incidences of bilateral extra rib 14; the BMDL10 was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human
variability.
c An intermediate-duration oral MRL of 1.5 mg/kg/day was calculated by dividing the NOAEL of 150 mg/kg/day for kidney lesions by an an uncertainty factor of 100 (10 for
extrapolation from animals to humans and 10 for human variability).  This value is higher than the acute-duration oral MRL of 0.8 mg/kg/day.  It is against ATSDR policy to derive an
intermediate-duration MRL that is higher than the acute-duration MRL.  Because available evidence indicates that the acute-duration MRL should be protective for kidney effects
following longer-term exposure, the acute-duration value of 0.8 mg/kg/day was adopted for intermediate-duration exposure.
Bd Wt = body weight; Cardio = cardiovascular; CFU = colony forming unit; d = day(s); (F)= feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; GI =
gastrointestinal; (GW) = gavage in water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL =
lowest-observed-adverse-effect level; M = male; mo = month(s); Metab = metabolic; NOAEL = no-observed-adverse-effect level; ppd = post-parturition day; Resp = respiratory; x =
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral
Acute (≤14 days)
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral (Continued)
Acute (≤14 days)
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral (Continued)
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral (Continued)
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral (Continued)
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Figure 3-2  Levels of Significant Exposure to Ethylene Glycol - Oral (Continued)
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Pulmonary hyperemia and edema were frequent findings in dogs that ingested unknown lethal amounts of 
ethylene glycol in cases of antifreeze poisoning (Kersting and Nielsen 1965).  A generalized soft tissue 
mineralization that included the lungs (interstitial) occurred in male F344 rats exposed to 
1,000 mg/kg/day in the diet for 1 year (DePass et al. 1986a; Woodside 1982).  Histological examinations 
of the lungs showed no effects in Sprague-Dawley rats exposed to ≤7,327 mg/kg/day in drinking water 
for 10 days or ≤5,744 mg/kg/day in drinking water for 90 days (Robinson et al. 1990), Wistar rats 
exposed to ≤2,000 mg/kg/day by gavage for 4 weeks (Schladt et al. 1998), Wistar rats exposed to 
≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), F344 rats exposed to ≤10,000 mg/kg/day 
in the diet for 13 weeks (Melnick 1984), Sprague-Dawley rats exposed to ≤3,000 mg/kg/day in the diet 
for 2 years (Blood 1965), B6C3F1 mice exposed to ≤250 mg/kg/day by gavage for 4 days (Hong et al. 
1988), B6C3F1 mice exposed to ≤16,000 mg/kg/day in the diet for 13 weeks or ≤12,000 mg/kg/day in the 
diet for 2 years (Melnick 1984; NTP 1993), or CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 
2 years (DePass et al. 1986a; Woodside 1982).  The 10- and 90-day drinking water studies in rats also 
found no histopathological changes in the nasal cavity or turbinates (Robinson et al. 1990). 
 
Cardiovascular Effects.    Cardiovascular system involvement in humans occurs at the same time as 
respiratory system involvement, during the second phase of oral ethylene glycol poisoning, which is 12–
24 hours after acute exposure (Vale 1979).  The symptoms of cardiac involvement include tachycardia, 
ventricular gallop (Morgan et al. 2000; Parry and Wallach 1974; Siew et al. 1975a), and cardiac 
enlargement (Friedman et al. 1962; Vale 1979; Verrilli et al. 1987).  Repeated cardiac arrhythmias were 
observed prior to cardiac arrest and death in a 22-year-old man who ingested 4,071 mg/kg of ethylene 
glycol (Siew et al. 1975a).  Ingestion of ethylene glycol may also cause hypertension or hypotension, 
which may progress to cardiogenic shock (Chung and Tuso 1989; Jobard et al. 1996; Morgan et al. 2000; 
Rasic et al. 1999; Walder and Tyler 1994).  Episodes of hypotension were observed prior to renal failure 
and death in a 73-year-old man who ingested 7,850 mg/kg ethylene glycol, contained in antifreeze 
(Gordon and Hunter 1982).  Myocarditis has been observed at autopsy in cases of people who died 
following acute ingestion of ethylene glycol (Friedman et al. 1962).  As in the case of respiratory effects, 
cardiovascular involvement occurs with ingestion of relatively high doses of ethylene glycol.  
Nevertheless, circulatory disturbances are a rare occurrence, having been reported in only 8 of 36 severely 
poisoned cases (Karlson-Stiber and Persson 1992).  Therefore, it appears that acute exposure to high 
levels of ethylene glycol can cause serious cardiovascular effects in humans.  The effects of a long-term, 
low-dose exposure are unknown. 
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Edema of the heart was occasionally observed in dogs that ingested unknown lethal amounts of ethylene 
glycol in cases of antifreeze poisoning (Kersting and Nielsen 1965).  A generalized soft tissue 
mineralization that included the heart (vessels and muscle) occurred in male F344 rats exposed to 
1,000 mg/kg/day in the diet for 1 year (DePass et al. 1986a; Woodside 1982).  Histological examinations 
of the heart showed no effects in Wistar rats exposed to ≤2,000 mg/kg/day by gavage for 4 weeks 
(Schladt et al. 1998), F344 rats exposed to ≤10,000 mg/kg/day in the diet for 13 weeks (Melnick 1984), 
Wistar rats exposed to ≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), B6C3F1 mice 
exposed to ≤250 mg/kg/day by gavage for 4 days (Hong et al. 1988), B6C3F1 mice exposed to 
≤16,000 mg/kg/day in the diet for 13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; 
NTP 1993), or CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; 
Woodside 1982). 
 
Gastrointestinal Effects.    Nausea, vomiting with or without blood, pyrosis, and abdominal cramping 
and pain are common early effects of acute ethylene glycol ingestion (Davis et al. 1997; Johnson et al. 
1999; Moossavi et al. 2003; Singh et al. 2001; Verrilli et al. 1987).  Hemorrhagic areas in the gastric 
mucosa were observed at autopsy in a case of fatal oral poisoning with ethylene glycol (Hantson et al. 
2002).  Ischemic hemorrhagic necrosis of the colon was possibly ethylene glycol-related in a case of acute 
oral poisoning due to the absence of any other apparent causes (Singh et al. 2001).  Acute effects of 
ethylene glycol ingestion in another patient included intermittent diarrhea and abdominal pain, which 
were attributed to mild colonic ischemia; severe abdominal pain secondary to colonic stricture and 
perforation developed 3 months after ingestion, and histology of the resected colon showed birefringent 
crystals highly suggestive of oxalate deposition (Gardner et al. 2003, 2004).   
 
A 33-year-old man who drank a quart of ethylene glycol (12,840 mg/kg) developed upper gastrointestinal 
tract bleeding secondary to multiple gastric lesions (Spillane et al. 1991).  It is not clear whether or not the 
gastric lesions were a pre-existing condition in this patient.   
 
A generalized soft tissue mineralization that included the stomach, but not other parts of the 
gastrointestinal tract, occurred in male F344 rats exposed to 1,000 mg/kg/day in the diet for 1 year 
(DePass et al. 1986a; Woodside 1982).  Histological examinations of the gastrointestinal tract showed no 
effects in Sprague-Dawley rats exposed to ≤7,327 mg/kg/day in drinking water for 10 days or 
≤5,744 mg/kg/day in drinking water for 90 days (Robinson et al. 1990), F344 rats exposed to 
≤10,000 mg/kg/day in the diet for 13 weeks (Melnick 1984), Wistar rats exposed to ≤1,128 mg/kg/day in 
the diet for 16 weeks (Gaunt et al. 1974), Sprague-Dawley rats exposed to ≤3,000 mg/kg/day in the diet 
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for 2 years (Blood 1965), B6C3F1 mice exposed to ≤250 mg/kg/day by gavage for 4 days (Hong et al. 
1988), B6C3F1 mice exposed to ≤16,000 mg/kg/day in the diet for 13 weeks or ≤12,000 mg/kg/day in the 
diet for 2 years (Melnick 1984; NTP 1993), or CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 
2 years (DePass et al. 1986a; Woodside 1982). 
 
Hematological Effects.    Initial laboratory findings in cases of acute ethylene glycol poisoning may 
include moderate leukocytosis with a predominance of polymorphonuclear neutrophils and a normal 
hematocrit (Davis et al. 1997; Parry and Wallach 1974; Reddy et al. 2007; Verrilli et al. 1987).   
 
No effects were observed on hematology parameters, but dose-related effects on bone marrow and 
erythropoietic parameters were observed when gavage doses up to 250 mg/kg/day ethylene glycol were 
given for 4 consecutive days to B6C3F1 mice (Hong et al. 1988).  Granulocyte-macrophage progenitor 
formation was suppressed in males exposed to 50 mg/kg/day and in both sexes at higher doses.  Ethylene 
glycol treatment resulted in bone marrow hypocellularity in both sexes up to 14 days after dosing at 
100 mg/kg/day.  Iron uptake in the bone marrow was suppressed in males exposed to 250 mg/kg/day; 
erythroid precursor colony-forming units were not significantly affected in mice at any dose.  The 
biological significance of the bone marrow effects is uncertain in the absence of supporting data from 
other studies, as summarized below. 
 
No histological changes in the bone marrow were observed in mice or rats exposed to higher doses of 
ethylene glycol for longer durations; these included F344 rats exposed to ≤10,000 mg/kg/day in the diet 
for 13 weeks (Melnick 1984), Sprague-Dawley rats exposed to ≤7,327 mg/kg/day in drinking water for 
10 or 90 days (Robinson et al. 1990), and B6C3F1 mice exposed to ≤16,000 mg/kg/day in the diet for 
13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; NTP 1993).  Results of routine 
hematology evaluations in these studies were unremarkable except for some alterations in 10- and 90-day 
studies in rats.  In the 10-day study, statistically significant decreases in hemoglobin, hematocrit, 
erythrocytes, and total leukocytes (7.3, 8.9, 8.5, and 34.8% less than controls, respectively) occurred in 
female rats at 7,327 mg/kg/day (Robinson et al. 1990).  In the 90-day study, total leukocyte counts were 
significantly reduced in female rats at 597, 3,087 and 5,744 mg/kg/day (32, 30, and 50% less than 
controls, respectively) (Robinson et al. 1990).  Results of differential counts were not reported and no 
clear hematological changes occurred in male rats in either study.  Hematology evaluations were also 
negative in studies that did not examine bone marrow histology; these included studies of Wistar rats 
exposed to ≤2,000 mg/kg/day by gavage for 33 days (Schladt et al. 1998), Wistar rats exposed to 
≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), and CD-1 mice exposed to 
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≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a).  Hematological changes (decreased 
erythrocyte count and hematocrit and hemoglobin concentration, and increased neutrophil count) were 
observed in male F344 rats exposed to 1,000 mg/kg/day in the diet for 1 year, although this dose was a 
serious LOAEL for renal toxicity and mortality (DePass et al. 1986a).   
 
Musculoskeletal Effects.    Reported musculoskeletal effects in cases of acute ethylene glycol 
poisoning have included diffuse muscle tenderness and myalgias associated with elevated serum 
creatinine phosphokinase levels, and myoclonic jerks and tetanic contractions associated with 
hypocalcemia (Davis et al. 1997; Friedman et al. 1962; Parry and Wallach 1974; Verrilli et al. 1987).  In 
some of these cases, autopsies showed interstitial and parenchymatous myositis in skeletal muscle 
(Friedman et al. 1962; Verrilli et al. 1987). 
 
Histological examinations of skeletal muscle and/or bone in acute-, intermediate- and chronic-duration 
studies of ethylene glycol showed no effects in rats or mice.  These studies included Sprague-Dawley rats 
exposed to ≤7,327 mg/kg/day in drinking water for 10 days or ≤5,744 mg/kg/day in drinking water for 
90 days (Robinson et al. 1990), Wistar rats exposed to ≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt 
et al. 1974), F344 rats exposed to ≤10,000 mg/kg/day in the diet for 13 weeks (Melnick 1984) or 
1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; Woodside 1982), B6C3F1 mice exposed to 
≤16,000 mg/kg/day in the diet for 13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; 
NTP 1993), or CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; 
Woodside 1982). 
 
Hepatic Effects.    Central hydropic or fatty degeneration, parenchymal necrosis, and calcium oxalate 
crystals in the liver have been observed at autopsy in cases of people who died following acute ingestion 
of ethylene glycol (Friedman et al. 1962; Leth and Gregersen 2005; Verrilli et al. 1987). 
 
Acute-duration studies of ethylene glycol showed no effects on liver weight or liver histology in Sprague-
Dawley rats exposed to ≤7,327 mg/kg/day in drinking water for 10 days (Robinson et al. 1990) or 
B6C3F1 mice exposed to ≤250 mg/kg/day by gavage for 4 days (Hong et al. 1988).  Developmental 
toxicity studies found no effect on maternal liver weight (histology not examined) in CD rats exposed to 
≤5,000 mg/kg/day by gavage on Gd 6–15 (Neeper-Bradley 1990; Neeper-Bradley et al. 1995; Price et al. 
1985), CD-1 mice exposed to ≤3,000 mg/kg/day by gavage on Gd 6–15 (Neeper-Bradley et al. 1995; 
Price et al. 1985; Tyl 1989), or New Zealand rabbits exposed to ≤2,000 mg/kg/day by gavage on Gd 6–19 
(Tyl et al. 1993). 
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Histopathologic changes in the liver were reported in one intermediate-duration study in mice (Melnick 
1984), one chronic study in mice (NTP 1993), and one chronic study in rats (DePass et al. 1986a; 
Woodside 1982).   
 
A centrilobular degenerative change occurred in the liver of male B6C3F1 mice exposed to ethylene 
glycol in estimated dietary doses of 6,450 or 12,900 mg/kg/day for 13 weeks (Melnick 1984; NTP 1993).  
This effect was characterized by the accumulation of a non-birefringent eosinophilic hyaline material in 
the cytoplasm of hepatocytes adjacent to or close to the central veins, and was not observed in females 
similarly exposed to ≤16,000 mg/kg/day (Melnick 1984; NTP 1993).  No liver lesions or changes in liver 
weight were observed in CD-1 mice exposed to ≤2,500 mg/kg/day by gavage for 17 days (Harris et al. 
1992) or ≤2,826 mg/kg/day in the diet for one or two generations (Bolon et al. 1997; Morrissey et al. 
1989; NTP 1986), Wistar rats exposed to ≤2,000 mg/kg/day by gavage for 33 days (Schladt et al. 1998) or 
≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), F344 rats exposed to ≤10,000 mg/kg/day 
in the diet for 13 weeks (Melnick 1984), or Sprague-Dawley rats exposed to ≤5,744 mg/kg/day in 
drinking water for 90 days (Robinson et al. 1990).  There were no effects on serum alanine transaminase 
(ALT), aspartate transaminase (AST), alkaline phosphatase (AP), lactate dehydrogenase (LDH), 
cholesterol, and/or bilirubin in the 33- and 90-day studies in rats (Robinson et al. 1990; Schladt et al. 
1998); clinical chemistry was not evaluated in the other intermediate-duration studies. 
 
A 2-year study of ethylene glycol in B6C3F1 mice found significantly increased incidences of 
centrilobular hepatocyte hyaline degeneration in males at estimated dietary doses of 3,000 and 
6,000 mg/kg/day (45 and 67% compared to 0% in controls) and females at 12,000 mg/kg/day (52% 
compared to 0% in controls) (NTP 1993).  The lesions appeared similar to the hyaline degeneration in the 
13-week study by the same investigators (Melnick 1984; NTP 1993) and consisted of cytoplasmic 
accumulations of non-birefringent, eosinophilic, granular to globular material resembling erythrocytes in 
size, shape, and tinctorial properties.  Severity did not increase with dose.  In another chronic study, 
CD-1 mice and F344 rats of both sexes were exposed to doses as high as 1,000 mg/kg/day in the diet for 
up to 2 years (DePass et al. 1986a; Woodside 1982).  There were no effects on liver weight or 
histopathology in mice of either sex or male rats, or on serum parameters of liver function in male or 
female rats (not evaluated in mice).  The female F344 rats had significantly increased incidences of slight 
liver fatty metamorphosis at ≥200 mg/kg/day and liver mononuclear cell infiltrates at 1,000 mg/kg/day; 
the incidences of slight fatty metamorphosis were 13% (34/256), 12% (16/129), 22% (27/125), and 27% 
(35/128) at 0, 40, 200, and 1,000 mg/kg/day, respectively.  The biological significance of these minor 
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hepatic lesions is questionable because of the lack of effects on liver weight and liver function measures, 
even at the highest dose.  A 2-year dietary study in Sprague-Dawley rats found no effects on liver weight 
or histopathology in males at ≤375 mg/kg/day (higher doses caused early mortality) or females at 
≤3,000 mg/kg/day (Blood 1965). 
 
Renal Effects.    Adverse renal effects after ethylene glycol ingestion in humans can be observed during 
the third stage of ethylene glycol toxicity 24–72 hours after acute exposure (Davis et al. 1997; Hess et al. 
2004).  The hallmark of renal toxicity is the presence of birefringent calcium oxalate monohydrate 
crystals deposited in renal tubules and their presence in urine after ingestion of relatively high amounts of 
ethylene glycol (CDC 1987; Baum et al. 2000; Blakeley et al. 1993; Boyer et al. 2001; Chung and Tuso 
1989; Davis et al. 1997; Factor and Lava 1987; Froberg et al. 2006; Godolphin et al. 1980; Hantson et al. 
2002; Heckerling 1987; Huhn and Rosenberg 1995; Leth and Gregersen 2005; Olivero 1993; Parry and 
Wallach 1974; Rasic et al. 1999; Rothman et al. 1986; Siew et al. 1975a; Takayesu et al. 2006; 
Underwood and Bennett 1973).  In addition to birefringent oxalate crystals in the tubular lumens, other 
signs of nephrotoxicity can include tubular cell degeneration and necrosis and tubular interstitial 
inflammation (Davis et al. 1997; Factor and Lava 1987; Froberg et al. 2006; Hantson et al. 2002; Rasic et 
al. 1999; Tobe et al. 2002).  In a case study of a 38-year-old female who consumed 240 mL of antifreeze 
(3,454 mg ethylene glycol/kg/day), crystalluria was not present upon hospital admission (about 12 hours 
after ingestion).  Within 5 hours, excretion of calcium oxalate dihydrate crystals was evident, although 
monohydrate crystals became the primary form in the urine thereafter (2–3 hours) (Jacobsen et al. 1988).  
In the course of ethylene glycol intoxication, serum creatinine (Factor and Lava 1987; Spillane et al. 
1991) and serum blood urea nitrogen (BUN) (Chung and Tuso 1989; Factor and Lava 1987) levels may 
be increased.  If untreated, the degree of renal damage caused by high doses of ethylene glycol progresses 
and leads to hematuria (Baum et al. 2000; CDC 1987; Davis et al. 1997; Rothman et al. 1986; Underwood 
and Bennett 1973), proteinuria (Davis et al. 1997; Rothman et al. 1986), decreased renal function, 
oliguria, anuria (Davis et al. 1997; Mallya et al. 1986; Parry and Wallach 1974; Spillane et al. 1991; 
Woolf et al. 1992; Zeiss et al. 1989), and ultimately renal failure (Chung and Tuso 1989; Gordon and 
Hunter 1982; Jacobsen et al. 1984; Johnson et al. 1999; Mallya et al. 1986; Takayesu et al. 2006).  These 
changes in the kidney are linked to acute tubular necrosis (Factor and Lava 1987), but normal or near 
normal renal function can return with adequate supportive therapy (see Section 3.11, Methods for 
Reducing Toxic Effects). 
 
In acute-duration studies in rats, kidney effects occurred at doses as low as 1,250 mg/kg/day by gavage 
and 1,400 mg/kg/day in drinking water.  Renal tubular dilation and regeneration were increased in female 
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Sprague-Dawley rats that were exposed to 1,250 or 2,250 mg/kg/day ethylene glycol by gavage on Gd 6–
20 and examined on postnatal day (Pnd) 1 (NTP 1988).  Increased relative and absolute kidney weights, 
but no renal histopathology, occurred in female CD rats exposed to 2,500 mg/kg/day by gavage on Gd 6–
15 and examined on Gd 21 (Neeper-Bradley 1990; Neeper-Bradley et al. 1995).  In a 10-day drinking 
water systemic toxicity study, the incidence and severity of renal lesions were significantly increased in 
male Sprague-Dawley rats exposed to 2,615 and 5,270 mg/kg/day, but not at doses ≤1,343 mg/kg/day; 
lesions included tubular dilation, degeneration, necrosis, and intratubular calcium oxalate crystals 
(Robinson et al. 1990).  Exposure to 1,400 mg/kg/day in the drinking water for 15–29 days caused renal 
tubular oxalate deposits, but apparently no nephrosis, in male Sprague-Dawley rats (Khan et al. 1993).  
Mice that were administered doses ≤1,000 mg/kg by gavage for 4 days had no histopathological changes 
in the kidneys (Hong et al. 1988).  Renal toxicity occurred in female New Zealand white rabbits that were 
exposed to 2,000 mg/kg/day by gavage on Gd 6–19 and examined on Gd 30; lesions that included tubule 
dilatation and regeneration, epithelial necrosis, and intraluminal oxalate crystal deposition were increased 
at this dose level, but not at doses ≤1,000 mg/kg/day (Tyl et al. 1993). 
 
Limited data are available on acute renal effects in other species.  A single oral dose of 4,440 mg/kg in 
cats (Penumarthy and Oehme 1975) or 4,880 or 10,743 mg/kg in dogs (Beckett and Shields 1971; Grauer 
et al. 1987) caused kidney damage leading to oliguria and renal failure.  Dogs administered a single dose 
of 10,600 mg/kg ethylene glycol as antifreeze or as reagent-grade ethylene glycol in feed exhibited 
polyuria, azotemia, and renal failure (Dial et al. 1994).  Serum BUN and creatinine were not increased in 
two dogs given a single gavage dose of approximately 1,000 mg/kg/day, suggesting that renal function 
was not altered (Hewlett et al. 1989).  Histopathological changes in the kidneys of dogs given a single 
3,300 mg/kg gavage dose of ethylene glycol first appeared at 12 hours post-dosing; effects were most 
common in the proximal convoluted tubules and included interstitial edema, tubular dilation, and cellular 
degeneration and necrosis (Smith et al. 1990).  Crystal formation was observed mainly within tubular 
lumina (most frequently in the proximal convoluted tubules), but generally not before 24 hours post-
dosing.  In male macaque monkeys exposed to ethylene glycol in drinking water, five of seven animals 
receiving doses ranging from 1,665 to 146,520 mg/kg/day for 6–13 days had calcium oxalate crystals and 
evidence of necrosis in the kidneys (Roberts and Seibold 1969).  
 
The renal effects of intermediate-duration oral exposure to ethylene glycol are well characterized in a 
number of studies in rats and mice (Cruzan et al. 2004; Gaunt et al. 1974; Melnick 1984; NTP 1993; 
Robinson et al. 1990).  As summarized below, the results of these studies indicate that renal toxicity 
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varies with sex, species, and strain, with males more sensitive than females, rats more sensitive than mice, 
and Wistar rats more sensitive than other strains of rats. 
 
In a 90-day drinking water study with Sprague-Dawley rats (Robinson et al. 1990), incidences of renal 
lesions were significantly increased in males at ≥947 mg/kg/day and females at ≥3,087 mg/kg/day.  Males 
showed a greater number and severity of lesions than females; lesions included tubular dilation and 
degeneration, acute and subacute inflammation, calcium oxalate crystals in tubules and pelvis epithelium, 
dilation of urinary pelvis, and hyperplasia and degeneration of pelvis epithelium.  The male rats also had 
increases in relative kidney weight and serum creatinine at ≥947 mg/kg/day and BUN at 
3,134 mg/kg/day.  A 13-week dietary study in F344 rats (Melnick 1984) found renal effects that included 
increased relative kidney weight at ≥2,500 mg/kg/day in males and ≥5,000 mg/kg/day in females, 
increased BUN and serum creatinine in males at ≥2,500 mg/kg/day, and histopathology in males 
≥2,500 mg/kg/day and females at 10,000 mg/kg/day.  The lesions were more severe in the males (e.g., 
dilation, necrosis, fibrosis, and crystal deposition in renal tubules) than in the females (e.g., inflammation 
and vacuolation without crystal deposition).  The NOAELs for renal toxicity in this study were 
1,250 mg/kg/day in males and 2,500 mg/kg/day in females.   
 
In a 16-week dietary study in Wistar rats (Gaunt et al. 1974), renal findings in males included no effects 
at 71 mg/kg/day, increased incidences of kidney lesions at ≥180 mg/kg/day, and oxalic acid crystals in 
urine, increased absolute kidney weight, increased urine volume, and decreased urine specific gravity at 
715 mg/kg/day.  The lesions ranged from degenerative changes in individual nephrons with occasional 
oxalate crystals to generalized tubular damage with heavy crystal deposition.  At the 0, 35, 71, 180, and 
715 mg/kg/day dose levels for the male rats in this study, the overall incidence of renal tubular damage 
was 0/15, 1/15, 1/15, 4/15, and 15/15, respectively.  The only effect observed in females was a non-
statistically significant increase in kidney lesions at 1,128 mg/kg/day, the highest tested dose.  Limitations 
of this study include questionable animal care and dose levels that were not constant.  Most of the rats 
showed evidence of respiratory infection (pneumonia) and infectious salivary adenitis, either of which 
could have confounded the results.  The dose levels decreased throughout the exposure period because the 
amount of ethylene glycol in the diet was not adjusted for changing food consumption and body weight.  
For example, at the apparent LOAEL of 180 mg/kg/day, the rats were exposed to approximately 
300 mg/kg/day for the first 2 weeks of the study; this level is above the threshold for renal toxicity in 
male Wistar rats shown in a 12-month study (Wilson et al. 2005).  Further, the rats were housed in groups 
of five, such that consumption of individual rats among the groups likely varied. 
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In another 16-week dietary study (Cruzan et al. 2004), male Wistar and male F344 rats were exposed to 
dose levels of 0, 50, 150, 500, or 1,000 mg/kg/day.  Effects included calcium oxalate crystals in the urine 
of both strains of rats at ≥150 mg/kg/day and increased absolute and relative kidney weights, increased 
water intake, increased urine volume, and decreased urine specific gravity at ≥500 mg/kg/day in Wistar 
rats and 1,000 mg/kg/day in F344 rats.  No treatment-related increases in alpha 2-μ-globulin were 
observed in the kidneys of either strain of rats.  No histological effects occurred in the kidneys of either 
strain of rats at 50 or 150 mg/kg/day.  At higher doses, histopathological findings included calcium 
oxalate crystal deposition in the renal tubules with associated nephropathy in all Wistar rats (10/dose) at 
≥500 mg/kg/day.  Histological findings in the F344 rats included crystals in the tubules without 
nephropathy in 6/10 animals at 500 mg/kg/day, and crystal nephropathy in 1/10 animals at 500 mg/kg/day 
and 10/10 animals at 1,000 mg/kg/day.  The severity of the crystal nephropathy in the Wistar rats at 
500 mg/kg/day was approximately equivalent to that in the F344 rats at 1,000 mg/kg/day.  Although the 
male Wistar rats were more sensitive than the male F344 rats, the LOAEL for kidney toxicity was 
500 mg/kg/day in both strains.  The NOAEL in both strains of rats is 150 mg/kg/day because the only 
effect at this dose, crystalluria, reflects a detoxification process and is not adverse in the absence of 
crystal deposition in the renal tubule epithelium and associated histopathology.   
 
Information on the intermediate-duration renal toxicity of ethylene glycol is also available in mice.  In a 
13-week dietary study in B6C3F1 mice, effects were observed in the kidneys of males at 
≥6,450 mg/kg/day (minimal to mild tubule dilation, cytoplasmic vacuolation, and regenerative 
hyperplasia, without tubular oxalate crystal deposition), with no effects on kidney histology or urinalysis 
in females at doses ≤16,000 mg/kg/day (Melnick 1984; NTP 1993).  No histopathological changes were 
observed in the kidneys of male CD-1 mice that were administered doses as high as 2,500 mg/kg/day by 
gavage for 17 days (Harris et al. 1992).  Kidney weight and histology were evaluated in F0 and F1 parental 
male and female CD-1 mice that were exposed to 2,826 mg/kg/day in the drinking water in a two-
generation reproduction study (Bolon et al. 1997; Morrissey et al. 1989; NTP 1986).  The exposure period 
of both generations included 14 weeks of cohabitation through gestation and lactation.  Kidney lesions 
occurred in 60% of the F0 male mice; the lesions included tubular degeneration, dilation, and 
regeneration, as well as a low incidence of oxalate crystal deposition (3/20 treated vs. 0/21 controls).  
There was no effect on kidney weight in the F0 males or on kidney weight or histology in the F0 females 
or F1 males or females.  
 
A 1-year study in rats (Wilson et al. 2005) and 2-year studies in rats (Blood 1965; DePass et al. 1986a) 
and mice (DePass et al. 1986a; NTP 1993) provide information on chronic renal toxicity of ethylene 
ETHYLENE GLYCOL  94 
 







***DRAFT FOR PUBLIC COMMENT*** 
glycol.  Males were more sensitive than females, rats were more sensitive than mice, and Wistar rats 
appear to be the most sensitive strain to ethylene glycol nephrotoxicity.   
 
Male Wistar rats were exposed to ethylene glycol in dietary doses of 0, 50, 150, 300, or 400 mg/kg/day 
for 12 months (Wilson et al. 2005).  Decreased urinary pH and increased urinary oxalate crystals occurred 
at all dose levels; these effects were not considered adverse, but rather normal metabolic/physiological 
consequences of ethylene glycol exposure.  Effects at ≥300 mg/kg/day included increased water 
consumption with corresponding increased urine volume and decreased urine specific gravity, increased 
absolute and relative kidney weights, and gross and histopathological changes in the kidneys and bladder.  
Gross pathology included calculi, dilatation, and hemorrhage in the bladder at ≥300 mg/kg/day and 
calculi and dilatation in the renal pelvis and ureter at 400 mg/kg/day.  Renal histopathology occurred in 
the majority of animals at 300 mg/kg/day and in all animals at 400 mg/kg/day; lesions included 
crystalluria-related nephropathy, tubule dilatation, birefringent crystals (particularly in the pelvic fornix), 
pelvic dilatation, and transitional cell hyperplasia.  Incidences of crystal nephropathy, the most prevalent 
lesion, were 0/14, 0/15, 0/15, 12/13, and 10/10 at 0, 50, 150, 300, and 400 mg/kg/day, respectively.  
Histopathological changes in the bladder occurred in the majority of animals at ≥300 mg/kg/day; the basic 
change was transitional cell hyperplasia, progressing to acute inflammation and hemorrhage in severe 
cases.  Inflammation and hemorrhage of the bladder wall apparently contributed to mortality at 
≥300 mg/kg/day.  There were no treatment-related effects on renal clearance of oxalate or inulin.  Kidney 
concentrations of glycolate and oxalate were unchanged at 50 and 150 mg/kg/day, but clear nonlinear 
increases in both of these metabolites occurred at ≥300 mg/kg/day, indicating that the accumulation of 
calcium oxalate in the kidneys correlated with the appearance of renal toxicity.  A NOAEL of 
150 mg/kg/day and a LOAEL of 300 mg/kg/day were identified in male Wistar rats based on 
histopathology in the kidneys (crystal nephropathy) and bladder (inflammation and hemorrhage). 
 
In Sprague-Dawley rats that were fed ethylene glycol for 2 years, effects included increased water 
consumption, proteinuria, and mortality in males at ≥750 mg/kg/day and females at 3,000 mg/kg/day.  
Incidences of calcification (oxalate crystal deposition) in the kidneys were increased in both sexes at 
≥750 mg/kg/day, and oxalate-containing calculi were increased in males at ≥750 mg/kg/day and females 
at 3,000 mg/kg/day.  The incidences of oxalate crystal deposition in the males were 0/7, 0/12, 0/10, 4/10, 
7/7, and 15/15 at 0, 75, 150, 375, 750 and 3,000 mg/kg/day; the increase at 375 mg/kg/day was not 
statistically significant.  The report implied, but did not adequately document, that many of the animals 
with crystal deposition in the renal tubules also had degenerative changes (mainly cytoplasmic 
vacuolation) in the tubular epithelium.  Due to the insufficiently reported histopathology findings and lack 
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of a clear (statistically significant) increase in oxalate crystal deposition at 375 mg/kg/day due to small 
numbers of animals, this study provides limited evidence that 375 mg/kg/day was a chronic LOAEL for 
kidney toxicity in male Sprague-Dawley rats. 
 
F344 rats (130/sex/dose) were fed ethylene glycol in the dietary concentrations that yielded reported 
approximate doses of 0, 40, 200, or 1,000 mg/kg/day for up to 2 years (DePass et al. 1986a).  No 
treatment-related or statistically significant changes occurred in the male rats at 40 or 200 mg/kg/day.  A 
number of renal effects were observed in the 1,000 mg/kg/day males after 12 months (subsequent 
sacrifices at this dose level were precluded by early mortality), including increased water consumption 
and urine volume, decreased urine specific gravity and pH, increased urinary calcium oxalate crystals, 
increased BUN and serum creatinine.  Increases in absolute and relative kidney weights and incidences of 
kidney lesions were increased at 1,000 mg/kg/day at 6 and 12 months.  At 6 months, incidences of the 
following renal lesions were significantly increased in the 1,000 mg/kg/day males:  calcium oxalate 
crystalluria, tubular hyperplasia, tubular dilation, and peritubular nephritis.  All of the 1,000 mg/kg/day 
males that were sacrificed at 12 months had calcium oxalate crystalluria as well as multiple severe renal 
lesions that included tubular dilation, proteinosis and hyperplasia, glomerular shrinkage, and/or chronic 
interstitial nephritis.  Most of the 1,000 mg/kg/day males that died during the study or were sacrificed 
when moribund had oxalate nephrosis, which was the primary cause of death, and hydronephrosis.  The 
female rats were less sensitive to kidney toxicity than the males as shown by renal effects that were 
limited to increases in kidney weight and calcium oxalate crystals and uric acid crystals in the urine at 
1,000 mg/kg/day; no histopathological changes occurred in the kidneys.  A NOAEL of 200 mg/kg/day 
and serious LOAEL of 1,000 mg/kg/day were identified in male F344 rats based on kidney toxicity 
(oxalate nephrosis)-induced mortality. 
 
CD-1 mice (80/sex/dose) were also fed ethylene glycol in the dietary concentrations that yielded reported 
approximate doses of 0, 40, 200, or 1,000 mg/kg/day for up to 2 years (DePass et al. 1986a).  No 
treatment-related kidney histopathology occurred in either sex; water consumption, clinical chemistry, 
urinalysis, and organ weight were not evaluated as in the companion study in rats.  B6C3F1 mice 
(60/sex/dose) were exposed to ethylene glycol in the diet for up to 2 years at estimated doses as high as 
6,000 mg/kg/day in males and 12,000 mg/kg/day in females (NTP 1993).  Histopathological evaluations 
of the kidneys showed effects that were limited to small numbers of oxalate-like crystals and/or calculi 
were noted in the renal tubules, urethrae, and urinary bladder in a few males at 6,000 mg/kg/day.   
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Endocrine Effects.    Histological examinations of endocrine organs in acute-, intermediate- and 
chronic-duration studies of ethylene glycol showed no effects in rats or mice.  As indicated in Table 3-2, 
the evaluations included the adrenals, pancreas, pituitary, thyroid, and/or parathyroids in Sprague-Dawley 
rats exposed to ≤7,327 mg/kg/day in drinking water for 10 days or ≤5,744 mg/kg/day in drinking water 
for 90 days (Robinson et al. 1990), Wistar rats exposed to ≤2,000 mg/kg/day by gavage for 4 weeks 
(Schladt et al. 1998), F344 rats exposed to ≤10,000 mg/kg/day in the diet for 13 weeks (Melnick 1984), 
Wistar rats exposed to ≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), Sprague-Dawley 
rats exposed to ≤3,000 mg/kg/day in the diet for 2 years (Blood 1965), F344 rats exposed to 
1,000 mg/kg/day in the diet for 1 year (DePass et al. 1986a; Woodside 1982), B6C3F1 mice exposed to 
≤250 mg/kg/day by gavage for 4 days (Hong et al. 1988), B6C3F1 mice exposed to ≤16,000 mg/kg/day in 
the diet for 13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; NTP 1993), or 
CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; Woodside 1982).  
None of these studies included assessments of endocrine function. 
 
Dermal Effects.    Histological examinations of the skin showed no effects in Sprague-Dawley rats 
exposed to ≤7,327 mg/kg/day in drinking water for 10 days or ≤5,744 mg/kg/day in drinking water for 
90 days (Robinson et al. 1990), F344 rats exposed to 1,000 mg/kg/day in the diet for 1 year (DePass et al. 
1986a; Woodside 1982), B6C3F1 mice exposed to ≤12,000 mg/kg/day in the diet for 2 years (Melnick 
1984; NTP 1993), or CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 
1986a; Woodside 1982). 
 
Ocular Effects.    Histological examinations of the eyes showed no effects in Wistar rats exposed to 
≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), or in F344 rats or CD-1 mice exposed to 
≤1,000 mg/kg/day in the diet for 1–2 years (DePass et al. 1986a; Woodside 1982). 
 
Body Weight Effects.    In an acute-duration study, male Sprague-Dawley rats exposed to 
5,279 mg/kg/day ethylene glycol in the diet for 10 days experienced 13% body weight loss; no effect 
occurred in females at doses as high as 7,327 mg/kg/day (Robinson et al. 1990).  Administration of 
ethylene glycol by gavage during gestation (Gd 6–15 or 6–20) caused 17–31% decreases in maternal 
body weight gain in CD and Sprague-Dawley rats exposed to 1,250–2,500 mg/kg/day and B6C3F1 mice 
exposed to 1,500 mg/kg/day (Marr et al. 1992; Neeper-Bradley 1990, Neeper-Bradley et al. 1995; NTP 
1988; Price et al. 1985).  Body weight gain corrected for gravid uterine weight was generally similar to 
controls, indicating that intrauterine loss was a significant contributor to the reduced maternal weight gain 
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during pregnancy.  New Zealand white rabbits showed no changes in maternal body weight after gavage 
exposure to 2,000 mg/kg/day ethylene glycol on Gd 6–19 (Tyl et al. 1993).   
 
In intermediate-duration studies, body weight gain was 9–30% lower than controls in Wistar rats exposed 
to 500 mg/kg/day in the diet for 16 weeks, Sprague-Dawley rats exposed to 750 mg/kg/day in the diet or 
3,134 mg/kg/day in drinking water for 90–100 days, and F344 rats exposed to 2,500 mg/kg/day in the diet 
for 13 weeks (Blood 1965; Cruzan et al. 2004; Melnick 1984; NTP 1993; Robinson et al. 1990).  No 
adverse effects on body weight occurred in CD-1 mice exposed to 2,500 mg/kg/day by gavage for 17 days 
(Harris et al. 1992) or B6C3F1 mice exposed 16,000 mg/kg/day in the diet for 13 weeks (Melnick 1984; 
NTP 1993).   
 
Chronic (2-year) dietary studies of ethylene glycol found decreased body weight gain (15% less than 
controls) in male F344 rats at 1,000 mg/kg/day, but not in male F344 or Sprague-Dawley rats at 200–
375 mg/kg/day (Blood 1965; DePass et al. 1986b); decreased body weight gain in female Sprague-
Dawley rats at 3,000 mg/kg/day, but not in female Sprague-Dawley or F344 rats at 750–1,000 mg/kg/day 
(Blood 1965; DePass et al. 1986b); and no effects on body weight in CD-1 or B6C3F1 mice at 1,000–
12,000 mg/kg/day (DePass et al. 1986a; Melnick 1984; NTP 1993; Woodside 1982).  In a 12-month 
dietary study in male Wistar rats, body weight gain was reduced 8.4% on day 365 at 300 mg/kg/day and 
31.3% on day 197 at 400 mg/kg/day (Wilson et al. 2005).  
 
Metabolic Effects.    One of the major adverse effects following acute oral exposure of humans to 
ethylene glycol involves metabolic changes.  These changes occur as early as 12 hours after ethylene 
glycol exposure.  Ethylene glycol intoxication is accompanied by metabolic acidosis which is manifested 
by decreased pH and bicarbonate content of serum and other bodily fluids caused by accumulation of 
excess glycolic acid (CDC 1987; Berger and Ayyar 1981; Blakeley et al. 1993; Cheng et al. 1987; Chung 
and Tuso 1989; Gordon and Hunter 1982; Heckerling 1987; Jacobsen et al. 1988; Parry and Wallach 
1974; Pellegrino et al. 2006; Siew et al. 1975a; Spillane et al. 1991; Takayesu et al. 2006; Woolf et al. 
1992; Zeiss et al. 1989).  There is an inverse relationship between the decreasing plasma pH and 
increasing plasma glycolic acid concentrations (Clay and Murphy 1977).  The normal level of bicarbonate 
of 24 mmol/L can be depleted in cases of severe ethylene glycol intoxication to reach concentrations as 
low as 2 mmol/L (Jacobsen et al. 1984).  This decrease in base concentration indicates that a similar 
quantity of acid has to be present to achieve such a depletion.  Glycolic acid is the only acidic metabolite 
present in such quantities.  Humans highly intoxicated with ethylene glycol had glycolate concentrations 
of 17–29 and <1 mmol of glyoxalate and oxalate, respectively (Jacobsen et al. 1984).  Similar 
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observations were made in animals.  Metabolic acidosis due to glycolate accumulation was observed after 
acute oral exposure of dogs to 1,000–1,360 mg/kg of ethylene glycol (Hewlett et al. 1989) and of rats to 
1,000 mg/kg (Marshall 1982).  These results indicate that glycolic acid is the major toxic metabolite 
causing metabolic acidosis, and that its high serum levels are likely responsible for systemic toxicity 
observed after ethylene glycol exposure.   
 
Other characteristic metabolic effects of ethylene glycol poisoning are increased serum anion gap, 
increased osmolal gap, and hypocalcemia.  Serum anion gap is calculated from concentrations of sodium, 
chloride, and bicarbonate, is normally 12–16 mM, and is typically elevated after ethylene glycol ingestion 
due to increases in unmeasured metabolite anions (mainly glycolate) (Chung and Tuso 1989; Curtin et al. 
1992; Davis et al. 1997; Factor and Lava 1987; Heckerling 1987; Hess et al. 2004; Jacobsen et al. 1984; 
Pellegrino et al. 2006; Spillane et al. 1991; Takayesu et al. 2006; Taylor et al. 1997; Walder and Tyler 
1994; Zeiss et al. 1989).  Osmolal gap represents the difference between the measured and calculated 
osmolalities and is also typically elevated during ethylene glycol intoxication (Baum et al. 2000; Boyer et 
al. 2001; Curtin et al. 1992; Davis et al. 1997; Taylor et al. 1997; Walder and Tyler 1994).  The normal 
value for osmolal gap in humans is 10–15 mOsm/kg water (Egbert and Abraham 1999; Leth and 
Gregersen 2005; Scalley et al. 2002).  Each 16 mM (100 mg/dL) increment in ethylene glycol 
concentration contributes to about 16 mOsm/kg water (Hess et al. 2004).  Amounts of ethylene glycol 
causing these in humans effects have ranged from 1,628 to 12,840 mg/kg/day (Chung and Tuso 1989; 
Heckerling 1987; Spillane et al. 1991).  Dogs receiving a single dose of 10,600 mg/kg ethylene glycol as 
antifreeze or as reagent grade ethylene glycol in feed exhibited metabolic acidosis and hyperosmolality 
(Dial et al. 1994).  Although a high anion gap metabolic acidosis and an increased osmolal gap are 
common metabolic changes associated with ethylene glycol intoxication, clinically significant ingestions 
are possible without substantially elevating either of these parameters (Davis et al. 1997; Huhn and 
Rosenberg 1995; Moossavi et al. 2003; Pellegrino et al. 2006; Taylor et al. 1997).  One case report 
presented a patient who developed recurrent severe anion gap metabolic acidosis with no osmolar gap 
consequent to episodic ethylene glycol ingestion (Moossavi et al. 2003).  Hypocalcemia is occasionally 
reported and occurs when oxalate chelates with calcium ions forming insoluble calcium oxalate 
monohydrate crystals (Davis et al. 1997; Takayesu et al. 2006).  This affects the overall ion concentration 
and can lead to an imbalance of divalent ion concentrations (Zeiss et al. 1989).   
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3.2.2.3   Immunological and Lymphoreticular Effects  
 
No specific information was located regarding immunological and lymphoreticular effects in humans 
orally exposed to ethylene glycol.  Moderate leukocytosis has been observed in some cases of acute oral 
poisoning (Davis et al. 1997; Parry and Wallach 1974; Reddy et al. 2007; Verrilli et al. 1987).   
 
Immune responses were investigated in male CBA mice that were treated with a single 12,000 mg/kg 
dose of ethylene glycol by gavage (Zabrodskii and Germanchuk 2000; Zabrodskii et al. 2003).  Exposure-
related effects were observed on all tested end points; results included increased mortality from 
Escherichia coli-induced infection (peritonitis), decreased number of spleen colony-forming units, 
decreased numbers of antibody-producing cells in spleen to sheep erythrocytes (T cell-dependent antigen) 
and Vi-agglutinin (T cell-independent antigen), decreased activity of natural killer cells, decreased 
antibody-dependent cytotoxicity of splenocytes to sheep erythrocytes, and decreased delayed-type 
hypersensitivity to sheep erythrocytes.   
 
No information is available on immune function in animals following intermediate- or chronic-duration 
exposure to ethylene glycol. 
 
Histological examinations of immune and lymphoreticular system tissues in acute-, intermediate-, and 
chronic-duration studies of ethylene glycol showed no effects in rats or mice.  As indicated in Table 3-2, 
the evaluations included spleen, lymph nodes, and/or thymus in Wistar rats exposed to ≤2,000 mg/kg/day 
by gavage for 4 weeks (Schladt et al. 1998), Sprague-Dawley rats exposed to ≤7,327 mg/kg/day in 
drinking water for 10 days or ≤5,744 mg/kg/day in drinking water for 90 days (Robinson et al. 1990), 
Wistar rats exposed to ≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), F344 rats exposed 
to ≤10,000 mg/kg/day in the diet for 13 weeks (Melnick 1984), F344 rats exposed to 1,000 mg/kg/day in 
the diet for 1 year (DePass et al. 1986a; Woodside 1982), Sprague-Dawley rats exposed to 
≤3,000 mg/kg/day in the diet for 2 years (Blood 1965), B6C3F1 mice exposed to ≤250 mg/kg/day by 
gavage for 4 days (Hong et al. 1988), B6C3F1 mice exposed to ≤16,000 mg/kg/day in the diet for 
13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; NTP 1993), or CD-1 mice exposed 
to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; Woodside 1982). 
 
Leukocyte counts were generally unaffected in the acute-, intermediate- and chronic-duration studies of 
ethylene glycol cited above.  Exceptions included statistically significant decreased total leukocyte counts 
in female Sprague-Dawley rats exposed to 7,327 mg/kg/day for 10 days (34.8% less than controls) or 
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597–5,744 mg/kg/day for 90 days (30–50% less than controls) (Robinson et al. 1990), and significantly 
increased neutrophil count (38% higher than controls) in male F344 rats exposed to 1,000 mg/kg/day for 
1 year (DePass et al. 1986a).   
 
The highest NOAEL values and all reliable LOAEL values for immunological and lymphoreticular 
effects in rats after intermediate-duration oral exposure to ethylene glycol are reported in Table 3-2 and 
plotted in Figure 3-2.   
 
3.2.2.4   Neurological Effects  
 
Adverse neurological reactions are among the first symptoms to appear in humans after ethylene glycol 
ingestion.  These early neurotoxic effects are also the only symptoms attributed to unmetabolized 
ethylene glycol.  Together with metabolic changes, they occur during the period of 30 minutes to 12 hours 
after exposure and are considered to be part of the first stage in ethylene glycol intoxication (Davis et al. 
1997; Hess et al. 2004; Robinson and McCoy 1989; Vale 1979).  In cases of acute intoxication, in which 
a large amount of ethylene glycol is ingested over a very short time period, there is a progression of 
neurological manifestations which, if not treated, may lead to generalized seizures and coma (Chung and 
Tuso 1989; Froberg et al. 2006; Hantson et al. 2002; Jobard et al. 1996; Leth and Gregersen 2005; 
Olivero 1993; Siew et al. 1975a; Takayesu et al. 2006; Zeiss et al. 1989).  Ataxia, slurred speech, 
confusion, and somnolence are common during the initial phase of ethylene glycol intoxication (Boyer et 
al. 2001; Buell et al. 1998; CDC 1987; Parry and Wallach 1974; Reddy et al. 2007; Takayesu et al. 2006; 
Tobe et al. 2002; Zeiss et al. 1989), as are irritation, restlessness, and disorientation (Cheng et al. 1987; 
Factor and Lava 1987; Gordon and Hunter 1982; Rothman et al. 1986; Woolf et al. 1992), and 
semiconsciousness and unresponsiveness (Blakeley et al. 1993; Chung and Tuso 1989; Heckerling 1987; 
Spillane et al. 1991; Underwood and Bennett 1973).  In an unusual case of ethylene glycol poisoning, 
initial neurological symptoms of confusion, slurred speech, and somnolence were followed by the 
development of deafness, dysphagia, and dysarthria after 7 days and full paralysis after 12 days (Tobe et 
al. 2002).  The patient was completely unresponsive to any stimulus, all brainstem reflexes were absent, 
clinical neurophysiological examination showed a severe axonal polyneuropathy, and sural nerve biopsy 
findings showed severe axonal degeneration and oxalate deposits. 
 
Cerebral edema and crystalline deposits of calcium oxalate in the walls of small blood vessels in the brain 
were found at autopsy in people who died after acute ethylene glycol ingestion (Friedman et al. 1962; 
Froberg et al. 2006; Hantson et al. 2002; Leth and Gregersen 2005; Zeiss et al. 1989).  In one case of fatal 
ETHYLENE GLYCOL  101 
 







***DRAFT FOR PUBLIC COMMENT*** 
ethylene glycol poisoning, the development of rapid cerebral edema was documented by computed 
tomography (CT) scan and was accompanied by definitive evidence of calcium oxalate crystals within 
walls of central nervous system blood vessels, with associated inflammation and edema (Froberg et al. 
2006).  In a case of nonfatal poisoning, CT showed a marked edema and leukoencephalopathy of both 
cerebral hemispheres on the tenth day after ingestion that conformed to a toxic or inflammatory 
encephalopathy (Chung and Tuso 1989).  The cerebral edema decreased drastically during the next 
20 days, although some residual temporal lobe dysfunctions and auditory verbal agnosis developed.  
Unusual brain findings in other cases of ethylene glycol poisoning included bilateral pallidal hemorrhage 
(Capparros-Lefebvre et al. 2005) and acute hemorrhagic necrosis of the basal ganglia that resulted in 
acute Parkinson’s syndrome (Reddy et al. 2007).   
 
Effects on cranial nerves appear late (generally 5–20 days post-ingestion), are relatively rare, and 
according to some investigators constitute a fourth, late cerebral phase in ethylene glycol intoxication 
(Chung and Tuso 1989; Gardner et al. 2004; Lewis et al. 1997).  Clinical manifestations of the cranial 
neuropathy commonly involve lower motor neurons of the facial and bulbar nerves and are reversible 
over many months.  In one case, facial paralysis and bilateral optic nerve dysfunction were noted in a 
patient 13 days after ethylene glycol ingestion (Factor and Lava 1987).  Delay in treatment may have 
contributed to the development of these symptoms; the patient was not treated until 3 days after ingesting 
ethylene glycol.  Severe cranial nerve dysfunction including nerves VII, IX, and X was noted in a man 
5 days after he ingested 12,840 mg/kg of ethylene glycol (Spillane et al. 1991).  In another case of 
ethylene glycol poisoning, bilateral facial paralysis and peripheral neurosensory hearing loss were 
observed in a patient 18 days after ingestion of 2,714 mg/kg of ethylene glycol; this effect was only 
partially reversible (Mallya et al. 1986).  Bilateral paralysis of cranial nerve VII, as well as bilateral 
dysfunction of cranial nerves II, V, VIII, IX, X, and XII, developed in a woman 10–11 days after 
dyspnea, nausea, confusion, metabolic acidosis, and other initial effects of acute toxic ingestion; the 
cranial neuropathy resolved over a period of 11 months (Lewis et al. 1997).  In another case, a CT scan 
3 days after ingestion of approximately 24,000 mg/kg of ethylene glycol showed low density areas in the 
basal ganglia, thalami, midbrain, and upper pons (Morgan et al. 2000).  Clinical findings reflected 
dysfunction in all the areas of hypodensity on the CT scan and included gaze-directed nystagmus with 
bilateral sixth cranial nerve palsies that developed 7 days following ingestion.  Although a magnetic 
resonance imaging (MRI) of the brain 24 days after ingestion revealed bilateral putamen necrosis, the 
patient’s neurologic sequelae resolved over the following 4 months.   
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Information on the neurotoxicity of ethylene glycol in orally-exposed animals is essentially limited to 
results of clinical observations and histopathology evaluations, as summarized below; tests of 
neurobehavioral function have not been conducted. 
 
Ataxia, convulsions, and/or central nervous system depression occurred in dogs given a single nonlethal 
dose of 4,880–10,743 mg/kg ethylene glycol in food (Beckett and Shields 1971; Dial et al. 1994; Grauer 
et al. 1987).  Clinical signs of neurotoxicity were observed prior to death in cats given a single 
4,440 mg/kg dose by gavage; effects included abnormal gait, loss of reflexes, central nervous system 
depression (symptoms not specified), and convulsions (Penumarthy and Oehme 1975).  In F344 rats, a 
single gavage dose of 4,000 mg/kg ethylene glycol caused ataxia and coma prior to death (Clark et al. 
1979).  There were no clinical signs of neurotoxicity or histopathological changes in brain or sciatic nerve 
tissue in Sprague-Dawley rats exposed to 7,327 mg/kg/day in drinking water for 10 days (Robinson et al. 
1990). 
 
Calcium oxalate crystals were observed in the brain of male F344 rats exposed to 5,000 mg/kg/day 
ethylene glycol in the diet for 13 weeks (Melnick 1984).  The authors reported no significant tissue 
response to the crystals or clinical signs of neurotoxicity, and the effect did not occur in males at 
2,500 mg/kg/day or in females at doses as high as 10,000 mg/kg/day (highest tested dose).  As indicated 
above, a similar effect occurred in humans who died from acute ethylene glycol poisoning (Friedman et 
al. 1962; Froberg et al. 2006; Hantson et al. 2002; Leth and Gregersen 2005; Zeiss et al. 1989). 
 
There were no clinical signs of neurotoxicity or histopathological changes in nervous system tissue in 
other intermediate- or chronic-duration studies of ethylene glycol in rats or mice.  As indicated in 
Table 3-2, the histopathological evaluations included brain, spinal cord, and/or sciatic nerve in Wistar rats 
exposed to ≤2,000 mg/kg/day by gavage for 4 weeks (Schladt et al. 1998), Sprague-Dawley rats exposed 
≤5,744 mg/kg/day in drinking water for 90 days (Robinson et al. 1990), Wistar rats exposed to 
≤1,128 mg/kg/day in the diet for 16 weeks (Gaunt et al. 1974), F344 rats exposed to 1,000 mg/kg/day in 
the diet for 1 year (DePass et al. 1986a; Woodside 1982), Sprague-Dawley rats exposed to 
≤3,000 mg/kg/day in the diet for 2 years (Blood 1965), B6C3F1 mice exposed to ≤16,000 mg/kg/day in 
the diet for 13 weeks or ≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; NTP 1993), or 
CD-1 mice exposed to ≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; Woodside 1982).   
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The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category for ethylene glycol after oral exposure are reported in Table 3-2 and plotted in 
Figure 3-2.   
 
3.2.2.5   Reproductive Effects  
 
No studies were located regarding reproductive effects in humans after oral exposure to ethylene glycol. 
 
Ethylene glycol treatment did not affect gestational length in CD rats given 2,500 mg/kg/day ethylene 
glycol by gavage administration on Gd 6–15 (Marr et al. 1992).  Testis and uterine weights and 
histopathology were not affected in B6C3F1 mice treated with ethylene glycol for 4 consecutive days at 
doses up to 250 mg/kg/day and evaluated 1 day later (Hong et al. 1988). 
 
Reproductive function after intermediate-duration oral exposure to ethylene glycol has been tested in 
three multi-generation studies (one in rats and two in mice) and several shorter studies (15–20 days in rats 
and mice).  In these studies, effects on fertility, fetal viability, and male reproductive organs were 
observed in mice, while the only effect in rats was an increase in gestational duration.   
 
In a continuous breeding study in which CD-1 mice were exposed to ethylene glycol in drinking water, 
there were slight, but statistically significant, reductions in the number of litters per fertile pair and in the 
mean number of live pups per litter at 1,640 mg/kg/day of the F0 generation (Lamb et al. 1985; Morrissey 
et al. 1989).  In mated F1 offspring, there were no differences between high-dose and control groups in 
fertility or live litter size.  In a follow-up to this study using the same overall protocol, the number of live 
female pups and the number of live pups per litter were significantly reduced at 2,826 mg/kg/day in the 
F0 generation of mice, but there were no effects on reproductive parameters in the F1 generation 
(Morrissey et al. 1989; NTP 1986).  Ethylene glycol treatment did not affect mating or fertility rate in 
either generation, or in F0 parents used in a crossover mating trial (20/sex high dose mice mated to 20/sex 
controls) (Morrissey et al. 1989; NTP 1986).  Female Swiss CD-1 mice given ethylene glycol at 
2,500 mg/kg/day by gavage for 20 days including a 5-day mating period (days 8–12) with concurrently 
treated males had significantly fewer live and significantly more dead implants as well as complete 
resorption of two of six litters (Harris et al. 1992).  Total number of implantation sites was not affected. 
 
In a three-generation reproductive toxicity and dominant lethality study in F344 rats exposed via the diet, 
no treatment-related effects on fertility index, gestation index, gestation survival index, or days from first 
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mating to litter were observed in any generation at doses up to 1,000 mg/kg/day (DePass et al. 1986b).  
Number of implantation sites was not affected at doses up to 2,250 mg/kg/day in timed pregnant CD rats 
given gavage doses of ethylene glycol on Gd 6–20 (NTP 1988). 
 
Effects on the male reproductive system, manifested mainly as changes in sperm parameters and testicular 
lesions, occurred in CD-1 mice exposed to ethylene glycol in drinking water in a continuous breeding 
study (Morrissey et al. 1989; NTP 1986).  Sperm number was decreased in F1 males at doses as low as 
897 mg/kg/day, but the effect did not exhibit a dose-response relationship.  Sperm motility, absolute 
seminal vesicle weight, relative epididymis weight, and absolute and relative testis weights were 
significantly reduced in F1 males at ≥1,798 mg/kg/day.  Effects at 2,826 mg/kg/day included increased 
incidence of abnormal sperm and decreased sperm motility in F0 males, and increased incidence and 
severity of testicular and epididymal lesions in F0 males (seminiferous tubule degeneration, loss of 
spermatozoa, spermatic, spermatogonia and spermocytes, vacuolization of epithelial cells, and interstitial 
cell hyperplasia) and F1 males (seminiferous tubule degeneration and intersitital cell hyperplasia).  An 
Expert Panel review of this study (NTP-CERHR 2004) concluded that, while this study provided some 
evidence for testicular changes and effects on sperm parameters, the high incidence of testicular effects in 
the control animals limited the ability to draw conclusions about the relationship of this effect to 
treatment.  Ethylene glycol treatment did not affect testis weight, epididymis weight, sperm count, sperm 
motility, or microscopic findings in testis or epididymis of male Swiss CD-1 mice treated by gavage at 
doses up to 2,500 mg/kg/day for 17 days (Harris et al. 1992).  In a three-generation reproductive toxicity 
study in F344 rats exposed via the diet, no treatment-related effects on histopathology of male 
reproductive organs were observed in any generation at doses up to 1,000 mg/kg/day (DePass et al. 
1986b). 
 
Limited information is available on reproductive effects of ethylene glycol in female animals.  In a 
continuous breeding study in which CD-1 mice were exposed to ethylene glycol in drinking water, there 
were no effects on estrous cyclicity, or weights or microscopic findings in the ovary, uterus, or vagina in 
either generation (Morrissey et al. 1989; NTP 1986).  Bolon et al. (1997) sectioned the ovaries of 
10 female mice/dose from the NTP continuous breeding study (Morrissey et al. 1989; NTP 1986) and 
evaluated differential follicular counts (small, growing, and antral), observing no difference in follicular 
counts attributable to ethylene glycol treatment.  In a three-generation reproductive toxicity study in 
F344 rats exposed via the diet, no treatment-related effects on gestation index or on histopathology of 
female reproductive organs were observed in any generation at doses up to 1,000 mg/kg/day (DePass et 
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al. 1986b).  Average gestational length was significantly longer in pregnant CD rats given gavage doses 
of 1,250 and 2,250 mg/kg/day on Gd 6–20 (NTP 1988). 
 
In summary, oral exposure to ethylene glycol can affect fertility and fetal viability at high doses 
(≥1,640 mg/kg/day in mice and ≥2,500 mg/kg/day in rats), and there is suggestive evidence for an effect 
on male reproductive function in mice at doses ≥897 mg/kg/day and on gestational duration in rats 
exposed to ≥1,250 mg/kg/day.  The highest NOAEL values and all reliable LOAEL values for 
reproductive effects in each species and duration category for ethylene glycol after oral exposure are 
reported in Table 3-2 and plotted in Figure 3-2.   
 
3.2.2.6   Developmental Effects  
 
No studies were located regarding developmental effects in humans after oral exposure to ethylene glycol.   
 
The developmental toxicity of ethylene glycol has been assessed in several acute-duration studies using 
mice, rats, and rabbits.  Available studies indicate that malformations, especially skeletal malformations 
occur in both mice and rats exposed during gestation; mice are apparently more sensitive to the 
developmental effects of ethylene glycol.  Other evidence of embyrotoxicity in laboratory animals 
exposed to ethylene glycol exposure includes reduction in fetal body weight. 
 
Studies in laboratory animals indicate that acute-duration exposure to high doses of ethylene glycol 
during gestation can affect fetal viability and postimplantation loss.  Of 37 pregnancies in CD-1 mice 
receiving gavage doses of 11,090 mg/kg/day on Gd 7–14, only 15 litters had at least 1 live-born pup, 
compared with 29/29 control pregnancies (Schuler et al. 1984).  In the treated group, there was a 
significant decrease in the number of live pups per litter and a significant increase in the number of dead 
pups per litter at birth.  Ethylene glycol treatment (up to 2,500 mg/kg/day) of mated female Swiss 
CD-1 mice during Gd 8–14 did not affect the number of females littering, number of implantation sites, or 
number of live pups at birth (Harris et al. 1992).  The percentage of postimplantation loss per litter was 
significantly increased in CD rats treated by gavage on Gd 6–15 with 5,000 mg/kg/day and the number of 
live fetuses per litter was reduced at both 2,500 and 5,000 mg/kg/day (Price et al. 1985).  There were no 
significant effects of treatment on total implantations, preimplantation loss, or litter size when pregnant 
F344 rats were given ethylene glycol in the diet at target doses of up to 1,000 mg/kg/day on Gd 6–15 
(Maronpot et al. 1983).  In New Zealand white rabbits given gavage doses of up to 2,000 mg/kg/day 
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ethylene glycol on Gd 6–19, the numbers of pre- or post-implantation losses were not increased in any 
treatment group, although 42% of the high-dose dams died prior to sacrifice (Tyl et al. 1993). 
 
The most sensitive indicator of the developmental toxicity of acute oral exposure to ethylene glycol 
appears to be an increased incidence of malformations, primarily skeletal malformations, in both mice and 
rats.  Available data suggest that malformations appear in mice at lower gavage doses than those that 
cause malformations in rats.  The incidence of skeletal and other malformations was increased at all doses 
when groups of at least 20 timed-pregnant CD-1 mice were treated by gavage with doses of 0, 750, 1,500, 
or 3,000 mg/kg/day ethylene glycol on Gd 6–15 (Price et al. 1985).  The percentages of malformed 
fetuses per litter and of litters with one or more malformed fetuses were significantly increased at all 
doses.  The malformations primarily consisted of neural tube, craniofacial, and axial skeletal defects, with 
skeletal defects comprising the majority.  Minimal maternal toxicity (decreased body weight gain and 
liver weight) was observed at doses of 1,500 mg/kg/day and higher.  In a later study aimed at identifying 
a NOAEL for developmental effects in CD-1 mice, an increased incidence of malformations was 
observed at doses of ≥500 mg/kg/day by gavage on Gd 6–15 (Neeper-Bradley et al. 1995; Tyl 1989).  The 
incidence of total malformations per litter (external, visceral, and skeletal) was significantly increased at 
both 500 and 1,500 mg/kg/day.  There was a significant increase in the incidence of two skeletal 
malformations (fused ribs or thoracic arches) in the 1,500 mg/kg/day group, and the incidences of 
23 skeletal variations were also increased in this group.  One of these variations (bilateral extra rib 14) 
was also significantly increased at 500 mg/kg/day.  The incidence of individual external or visceral 
malformations was not significantly increased in any treatment group relative to the vehicle control; 
however, exencephaly (a malformation observed by Price et al. [1985] at higher doses) was observed in 
two fetuses in the 500 mg/kg/day group and in three fetuses of the 1,500 mg/kg/day dose group (Neeper-
Bradley et al. 1995; Tyl 1989).  No evidence of maternal toxicity was observed at any dose in this study. 
 
In rats, gestational doses of at least 1,000 mg/kg/day by gavage were required to induce malformations.  
The number of litters with malformations, number of malformed fetuses per litter, and number of litters 
with skeletal malformations were increased at doses of ≥2,500 mg/kg/day in CD rats treated by gavage on 
Gd 6–15 (Price et al. 1985).  At 5,000 mg/kg/day, the number of litters with fetuses having external and 
visceral malformations (primarily neural tube and craniofacial defects) was also increased.  The authors 
reported a significant increase in visceral malformations at 1,250 mg/kg/day, but NTP-CERHR (2004) 
classified the observed effects (hydroureter, hydronephrosis, and great artery anomalies) as variations 
rather than malformations, and characterized the 1,250 mg/kg/day dose as a developmental NOAEL.  In 
later studies using lower doses, the incidence of litters with fetuses having two skeletal malformations 
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(missing thoracic arch and missing ribs) was increased in CD rats exposed by gavage to 
≥1,000 mg/kg/day on Gd 6–15 (Neeper-Bradley 1990; Neeper-Bradley et al. 1995).  The incidences of 
total skeletal malformations and skeletal variations (delayed ossification) were also significantly 
increased at ≥1,000 mg/kg/day.  The highest dose (2,500 mg/kg/day) was associated with increased 
frequencies of visceral and external malformations, including gastroschisis, hydrocephaly, lateral 
ventricle dilation, umbilical hernia, and atelectasis (Neeper-Bradley 1990; Neeper-Bradley et al. 1995).  
No evidence of maternal toxicity was observed at doses as high as 1,000 mg/kg/day in this study.   
 
Reduced ossification of the vertebral centra was observed in the 1,000 mg/kg/day dose group when 
F344 rats were given ethylene glycol in the diet on Gd 6–15 (Maronpot et al. 1983).  However, an Expert 
Panel Review of this study (NTP-CERHR 2004) identified the high dose (1,000 mg/kg/day) as a 
developmental NOAEL, noting the lack of other findings (change in body weights or consistent 
alterations in skeletal integrity) to support the authors’ suggestion that reduced ossification was indicative 
of minimal embryotoxicity.  No maternal toxicity was observed (Maronpot et al. 1983). 
 
When developmental effects were assessed over the course of postnatal development, there were 
significant reductions in percentages of total ossification, sternebral ossification, and vertebral centra 
ossification on Gd 20 and at all postnatal evaluations up to ppd 63 in CD rats given 2,500 mg/kg/day 
ethylene glycol by gavage administration on Gd 6–15 (Marr et al. 1992).  The percent of malformed 
fetuses per litter was also significantly increased at all scheduled sacrifice times other than ppd 63.  The 
percent of litters with skeletal malformations (primarily skeletal axial defects) was 100% in the treated 
litters at all time points other than ppd 63 (Marr et al. 1992).  Maternal toxicity (reduced weight gain) was 
also observed at this dose (2,500 mg/kg/day) (Marr et al. 1992). 
 
Fetal body weight and postnatal weight gain are also sensitive indicators of embyrotoxicity after ethylene 
glycol treatment, albeit at higher doses than skeletal and other malformations in mice.  Average fetal body 
weight per litter was significantly decreased in CD-1 mice treated by gavage with doses of 
≥750 mg/kg/day ethylene glycol on Gd 6–15 (Price et al. 1985), although in a later study in the same 
strain, average fetal body weight per litter was reduced only at gavage doses of 1,500 mg/kg/day on 
Gd 6–15 (Neeper-Bradley et al. 1995; Tyl 1989).  Ethylene glycol treatment of Swiss Crl:CD-1 mice by 
gavage at 2,500 mg/kg/day on Gd 8–14 resulted in decreased pup body weight on ppd 1 and 4 (Harris et 
al. 1992).  There were significant decreases in pup birth weight as well as pup weight gain and survival 
over ppd 1–3 in CD-1 mice given 11,090 mg/kg/day ethylene glycol by gavage on Gd 7–14 (Schuler et al. 
1984).  In CD rats, fetal body weight was significantly decreased at gavage doses of ≥1,000 mg/kg/day 
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(Neeper-Bradley 1990; Neeper-Bradley et al. 1995) or ≥2,500 mg/kg/day (Price et al. 1985) on Gd 6–15.  
In another study, when CD rats were given 2,500 mg/kg/day ethylene glycol by gavage on Gd 6–15, mean 
pup body weight per litter was significantly lower than controls on ppd 1, but was not different from 
controls at later postnatal evaluations (Marr et al. 1992).   
 
A single study in rabbits suggests that, in this species, developmental toxicity may not occur at acute 
doses that are not maternally toxic.  There was significant mortality (42%) at 2,000 mg/kg/day in New 
Zealand white rabbits given gavage doses of ethylene glycol on Gd 6–19 (Tyl et al. 1993).  One doe 
aborted and three delivered early at this dose, but there was no evidence of developmental toxicity in live 
litters at any exposure level. 
 
One gestational exposure study, a 20-day exposure study, and three multi-generation reproductive toxicity 
studies with some developmental toxicity end points are available to assess developmental effects of 
intermediate-duration exposure to ethylene glycol.  As with acute exposure, intermediate-duration 
exposure was associated with malformations, decreases in pup body weight, and effects on fetal viability 
in both rats and mice.   
 
In a continuous breeding study, skeletal evaluation of F1 offspring of CD-1 mice exposed to 
1,640 mg/kg/day exhibiting facial anomalies indicated a pattern of skeletal defects affecting the skull, 
sternebrae, ribs, and vertebrae in both sexes (Lamb et al. 1985; Morrissey et al. 1989).  Bone morphology, 
but not histology, differed in the affected mice.  In a follow-up study using a similar design, similar facial 
abnormalities were observed in F1 mice treated with 1,798 or 2,826 mg/kg/day (Morrissey et al. 1989; 
NTP 1986).  There was a significant increase in the incidence of skeletal malformations (rib, sternebral, 
and vertebral defects) at 2,250 mg/kg/day ethylene glycol when CD rats were given gavage doses on 
Gd 6–20; the authors noted that 9/443 pups in this group also had hydrocephaly (NTP 1988).  In this 
study, evidence of maternal effects (increased gestational length and renal lesions) occurred at a lower 
dose (1,250 mg/kg/day) (NTP 1988). 
 
Average pup weight was reduced in the F0 generation at 1,640 mg/kg/day in a continuous breeding study 
in CD-1 mice (Lamb et al. 1985; Morrissey et al. 1989), but female pup body weights and pup weight 
adjusted for litter size were significantly reduced at doses as low as 897 mg/kg/day in both F0 and 
F1 generations in a follow-up study (Morrissey et al. 1989; NTP 1986).  In a crossover mating trial using 
the F0 parents, pup body weight were reduced when 2,826 mg/kg/day females were mated to control 
males (Morrissey et al. 1989; NTP 1986).  In studies on the postnatal effects of intrauterine exposure, 
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average pup body weights were not affected on ppd 4, 14, or 21 in F344 rats exposed via the diet to doses 
up to 1,000 mg/kg/day in a three-generation reproductive toxicity study (DePass et al. 1986b); however, 
pup body weights were lower than controls at various times between ppd 1 and 22 when CD rats were 
given gavage doses of 2,250 mg/kg/day ethylene glycol on Gd 6–20 (NTP 1988).  Postnatal decreases in 
kidney weight (1,250 and 2,250 mg/kg/day groups) and brain weight (2,250 mg/kg/day group), without 
corresponding histopathology changes, have also been observed in the offspring of rats exposed in utero 
(Gd 6–20) to ethylene glycol (NTP 1988).   
 
Dams exposed to 2,500 mg/kg/day ethylene glycol had significantly fewer live implants and significantly 
more dead implants as well as complete resorption of two of six litters in a study exposing female Swiss 
CD-1 mice by gavage at doses up to 2,500 mg/kg/day for 20 days including a period of mating to 
concurrently treated males (Harris et al. 1992).  In a study of postnatal effects of intrauterine exposure, 
cumulative pup mortality was significantly higher on ppd 1 and 4 in CD rats exposed to gavage doses of 
2,250 mg/kg/day ethylene glycol on Gd 6–20 (NTP 1988). 
 
In summary, there is a substantial database demonstrating developmental toxicity at ethylene glycol doses 
that are not maternally toxic.  Mice appear to be more vulnerable to the developmental effects of ethylene 
glycol, responding at lower doses than rats.  Skeletal and other malformations appear to be the most 
sensitive indicators of toxicity, with effects observed at bolus doses of ≥500 mg/kg/day in mice and 
≥1,000 mg/kg/day in rats.  Effects on fetal body weight and fetal viability occur at higher doses.  The 
highest NOAEL values and all reliable LOAEL values for developmental effects in each species and 
duration category for ethylene glycol after oral exposure are reported in Table 3-2 and plotted in 
Figure 3-2.   
 
3.2.2.7   Cancer  
 
No studies were located regarding carcinogenicity in humans after oral exposure to ethylene glycol. 
 
Comprehensive histopathological evaluations showed no evidence of carcinogenicity in Sprague-Dawley 
rats exposed to ≤3,000 mg/kg/day in the diet for 2 years (Blood 1965), F344 rats exposed to 
1,000 mg/kg/day in the diet for 1 year (DePass et al. 1986a; Woodside 1982), B6C3F1 mice exposed to 
≤12,000 mg/kg/day in the diet for 2 years (Melnick 1984; NTP 1993), or CD-1 mice exposed to 
≤1,000 mg/kg/day in the diet for 2 years (DePass et al. 1986a; Woodside 1982). 
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3.2.3   Dermal Exposure  
 
Dermal exposure, through activities such as changing antifreeze, is the most likely route of exposure to 
ethylene glycol, but dermal exposure is not likely to lead to toxic effects.   
 
3.2.3.1   Death  
 
No studies were located regarding death in humans or animals after dermal exposure to ethylene glycol.   
 
3.2.3.2   Systemic Effects  
 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, dermal, ocular, body weight, or metabolic effects in humans or 
respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, endocrine, or metabolic 
effects in animals after dermal exposure to ethylene glycol.   
 
The highest NOAEL values for systemic effects in each species and duration category for ethylene glycol 
after dermal exposure are reported in Table 3-3.   
 
Hepatic Effects.    Maternal liver weight was not affected in female CD-1 mice exposed to 
3,549 mg/kg/day ethylene glycol for 6 hours/day on Gd 6–15 by occluded dermal application; liver 
histopathology was not evaluated (Tyl 1988b; Tyl et al. 1995c).  
 
Renal Effects.    Evaluations of maternal kidney weight and kidney histopathology showed no effects 
female CD-1 mice exposed to 3,549 mg/kg/day ethylene glycol for 6 hours/day on Gd 6–15 by occluded 
dermal (Tyl 1988b; Tyl et al. 1995c).  
 
Dermal Effects.    Minimal skin irritation occurred in New Zealand white rabbits 24–72 hours after 
application of 0.5 mL (550 mg) ethylene glycol to shaved skin (Clark et al. 1979).  Female mice exposed 
to 3,549 mg/kg/day ethylene glycol for 6 hours/day on Gd 6–15 by occluded dermal application showed 
no dermal effects (Tyl 1988b; Tyl et al. 1995c).   
 
Ocular Effects.    Ocular instillation of 0.1 mL (110 mg) ethylene glycol caused mild eye irritation in 
rabbits; transient conjunctival redness was the most prominent response (Clark et al. 1979). 
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Body Weight Effects.    Maternal CD-1 mice showed no changes in body weight after exposure to 
3,549 mg/kg/day ethylene glycol for 6 hours/day on Gd 6–15 by occluded dermal application (Tyl 1988b; 
Tyl et al. 1995c).  
 
3.2.3.3   Immunological and Lymphoreticular Effects  
 
No studies were located regarding immunological and lymphoreticular effects in humans or animals after 
dermal exposure to ethylene glycol. 
 
3.2.3.4   Neurological Effects  
 
No studies were located regarding neurological effects in humans or animals after dermal exposure to 
ethylene glycol. 
 
3.2.3.5   Reproductive Effects  
 
No studies were located regarding reproductive effects in humans after dermal exposure to ethylene 
glycol. 
 
Reproductive function has not been assessed in animals exposed dermally to ethylene glycol.  In an acute- 
duration developmental toxicity study, pregnant CD-1 mice exposed to ethylene glycol at doses up to 
3,549 mg/kg on Gd 6–15 by occluded dermal application exhibited no adverse effects on the number of 
resorptions or number of total, viable, or nonviable implants per litter (Tyl 1988b; Tyl et al. 1995c). 
 
The highest NOAEL value for reproductive effects in mice for the acute-duration category for ethylene 
glycol after dermal exposure is reported in Table 3-3. 
 
3.2.3.6   Developmental Effects  
 
No studies were located regarding developmental effects in humans after dermal exposure to ethylene 
glycol. 
 
In the single acute-duration dermal study of developmental toxicity, groups of 30 pregnant CD-1 mice 
were treated with 6-hour daily dermal exposures to ethylene glycol by occluded cutaneous application on 
Gd 6–15 (Tyl et al. 1995c).  The authors estimated the applied doses to be 404, 1,677, or 
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3,549 mg/kg/day.  Neither implantations nor resorptions were affected by treatment.  The incidence of 
malformations (individual or total external, visceral, or skeletal) was not significantly increased in any 
ethylene glycol dermal treatment group, but was significantly increased in the positive (ethylene glycol by 
gavage) control group.  There were significant increases in the incidence of litters with two skeletal 
variations (reduced ossification of the skull bone and phalanges) at 3,549 mg/kg/day. 
 
The highest NOAEL value for developmental effects in mice for the acute-duration category for ethylene 
glycol after dermal exposure is reported in Table 3-3. 
 
3.2.3.7   Cancer  
 
No studies were located regarding cancer effects in humans or animals after dermal exposure to ethylene 
glycol. 
 
3.3   GENOTOXICITY  
 
Studies in humans have not addressed the genotoxic effects of ethylene glycol.  However, available 
in vivo and in vitro laboratory studies provide consistently negative genotoxicity results for ethylene 
glycol. 
 
In F344 rats that received oral doses of 40, 200, and 1,000 mg/kg/day for three generations, there were no 
dominant lethal mutations (DePass et al. 1986b). 
 
Table 3-4 summarizes information from available in vitro studies.  Ethylene glycol produced consistently 
negative results in the Ames assay for reverse mutation in several strains of Salmonella typhimurium (Clark 
et al. 1979; Kubo et al. 2002; McCann et al. 1975; Pfeiffer and Dunkelberg 1980; Zeiger et al. 1987).  No 
growth inhibition due to DNA damage by ethylene glycol was observed in a battery of E. coli repair-
deficient strains (McCarroll et al. 1981).  Negative results were also obtained in two sets of studies when 
ethylene glycol was tested for gene mutation in the yeast, Schizosaccharomyces pombe (Abbondandolo et 
al. 1980), and for aneuploidy induction in the fungus, Neurospora crassa (Griffiths 1979, 1981).  Ethylene 
glycol did not induce gene mutations in L5178Y mouse lymphoma cells (McGregor et al. 1991) 
deoxyribonucleic acid (DNA) strand breaks in primary rat hepatocytes (Storer et al. 1996). 
 
Two recent genotoxicity assays have been developed and tested against results of standard genotoxicity 
assays for a variety of chemicals, including ethylene glycol.  Ethylene glycol did not induce gene mutation  
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Table 3-4.  Genotoxicity of Ethylene Glycol In Vitro 
 
Results 






 Salmonella typhimurium 
(Ames test in strains TA98, 




– – Clark et al. 1979 
 S. typhimurium 
(Ames test in strains TA97, 
TA98, TA100) 
Gene mutation – – Kubo et al. 2002 
 S. typhimurium 
(Ames test in strains TA98, 
TA100, TA1535, TA1537) 
Gene mutation – No data McCann et al. 1975 
 S. typhimurium 
(Ames test in strains TA98, 
TA100, TA1535, TA1537) 
Gene mutation No data – Pfeiffer and Dunkelberg 
1980 
 S. typhimurium 
(Ames test in strains TA97, 
TA98, TA100, TA1535, 
TA1537) 
Gene mutation – – Zeiger et al. 1987 
 S. typhimurium 
(Forward mutation in TA100 
derived 5-fluorouracil- 
resistant strain) 
Gene mutation – – Miller et al. 2005 





Gene mutation – – Abbondandolo et al. 1980 
 Fungi: 
 Neurospora crassa Aneuploidy 
induction 
No data – Griffiths 1979, 1981 
 Mammalian cells: 
 Mouse (L5178Y cells) Gene mutation – – McGregor et al. 1991 
 Rat (hepatocytes) DNA breaks No data – Storer et al. 1996 
 Human (GreenScreen HC 
assay using TK6 cell line) 
DNA damage No data – Hastwell et al. 2006 
 
C = negative result 
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in a low volume, high-throughput forward mutation assay using a TA100-derived 5-fluorouracil-resistant 
strain of S. typhimurium (Miller et al. 2005).  Ethylene glycol did not induce DNA damage in a high-
throughput (GreenScreen HC) assay that links the regulation of the human GADD45a gene to the 
production of Green Fluorescent Protein (Hastwell et al. 2006). 
 
3.4   TOXICOKINETICS  
 
Ethylene glycol is quickly and extensively absorbed through the gastrointestinal tract.  Limited 
information suggests that it is also absorbed through the respiratory tract; dermal absorption is apparently 
slow.  Following absorption, ethylene glycol is distributed throughout the body according to total body 
water.  In most mammalian species, including humans, ethylene glycol is initially metabolized by alcohol 
dehydrogenase to form glycolaldehyde, which is rapidly converted to glycolic acid and glyoxal by 
aldehyde oxidase and aldehyde dehydrogenase.  These metabolites are oxidized to glyoxylate; glyoxylate 
may be further metabolized to formic acid, oxalic acid, and glycine.  Breakdown of both glycine and 
formic acid can generate CO2, which is one of the major elimination products of ethylene glycol.  In 
addition to exhaled CO2, ethylene glycol is eliminated in the urine as both the parent compound and 
glycolic acid.  Elimination of ethylene glycol from the plasma in both humans and laboratory animals is 
rapid after oral exposure; elimination half-lives are in the range of 1–4 hours in most species tested. 
 
3.4.1   Absorption  
 
3.4.1.1   Inhalation Exposure  
 
Limited information suggests that ethylene glycol is absorbed across the human respiratory tract.  
Inhalation of aerosolized ethylene glycol from an automobile heater resulted in a blood ethylene glycol 
level of 28 mg/dL (Wezorek et al. 1995).  When two male volunteers inhaled 13C-labeled ethylene glycol 
vapor (estimated to result in inhaled doses of 0.96 and 1.51 mg/kg body weight), labeled ethylene glycol 
and glycolic acid were detected in the plasma and urine, providing evidence of absorption (Carstens et al. 
2003).  No increase, as compared to controls, in serum or urinary levels of ethylene glycol was recorded 
in men exposed to 17–49 mg/m3 ethylene glycol aerosol for 30 days (Wills et al. 1974).  However, in a 
review of this study, NTP-CERHR (2004) noted that the analytical techniques used for serum and urine 
analysis of ethylene glycol may not have been adequately sensitive to detect a difference. 
 
In rats exposed nose-only for 30 minutes to 14C-labeled ethylene glycol vapor (32 mg/mg3) or for 
17 minutes to 14C-ethylene glycol aerosol (184 mg/m3) on gallium oxide particles, between 75 and 85% of 
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the deposited radiolabel was found to be distributed throughout the body regardless of the form of the 
compound (Marshall and Cheng 1983).  In its review, NTP-CERHR (2004) estimated that 60–90% of the 
inhaled dose was absorbed in this study. 
 
3.4.1.2   Oral Exposure  
 
Indirect evidence of the oral absorption of ethylene glycol by humans is available from case reports of 
clinical symptoms in persons accidentally or intentionally ingesting ethylene glycol (Hewlett et al. 1986; 
Jacobsen et al. 1988; Robinson and McCoy 1989; Walton 1978).  Direct evidence of absorption comes 
from measurements of the plasma concentration of ethylene glycol after acute poisoning (studies report 
levels ranging from 1 to 40 mmol/L; Hewlett et al. 1986; Jacobsen et al. 1988); however, because the 
amounts ingested in these events were generally unknown, and blood analyses were performed at varying 
times after exposure, the data are not useful for quantifying the rate or extent of oral absorption in 
humans. 
 
In rats, ingested ethylene glycol is rapidly absorbed, usually reaching peak blood levels within 1 hour 
after single gavage doses of 150–20,000 mg/kg (Frantz et al. 1989, 1996a, 1996c; Pottenger et al. 2001; 
Winek et al. 1978).  Absorption is equally rapid in other species, with peak blood levels reached within 1–
3 hours after gavage exposure in mice, monkeys, and dogs (Frantz et al. 1991, 1996a, 1996b; Grauer et al. 
1987; Hewlett et al. 1989; McChesney et al. 1971).  In addition, available data suggest near complete 
absorption of ingested ethylene glycol in both rats and mice.  After gavage doses of 10 and 1,000 mg/kg 
14C-ethylene glycol to both rats and mice, the areas under the ethylene glycol plasma concentration versus 
time curves were comparable to those observed with equivalent intravenous doses (Frantz et al. 1989, 
1991, 1996a). 
 
Results of one study suggest that pregnancy does not alter absorption kinetics in rats dosed once on 
Gd 10.  The time course and peak plasma levels of ethylene glycol did not differ between pregnant and 
nonpregnant rats given 10 or 2,500 mg/kg by gavage (Pottenger et al. 2001). 
 
3.4.1.3   Dermal Exposure  
 
There are no data quantifying dermal absorption of ethylene glycol after in vivo human exposure.   
 
In vivo studies with rats and mice suggest incomplete dermal absorption of ethylene glycol.  In rats 
exposed to occluded dermal doses (applied to thoracic dorsal area after light clipping of fur) of 10 or 
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1,000 mg/kg 14C-ethylene glycol or 1,000 mg/kg of a 50% solution of 14C-ethylene glycol, measurement 
of radioactivity recovered in body tissues, excreta, and exhaled air suggested apparent absorption of 26–
32% of the administered dose (Frantz et al. 1989, 1996b).  In the same study, similar treatment of mice 
with 100 or 1,000 mg/kg 14C-ethylene glycol or 1,000 mg/kg of 50% 14C-ethylene glycol lead to apparent 
absorption estimates ranging from 60 to 84% (Frantz et al. 1991, 1996b).   
 
3.4.2   Distribution  
 
3.4.2.1   Inhalation Exposure  
 
Data on the tissue distribution of ethylene glycol in humans exposed via inhalation are not available.  
Based on plasma concentrations of ethylene glycol in two volunteers who inhaled doses of 0.96 and 
1.51 mg/kg, Carstens et al. (2003) estimated the volumes of distribution (Vd) to be 0.78 and 0.91 L/kg. 
 
In rats inhaling 14C-ethylene glycol vapor (32 mg/m3 for 30 minutes) or aerosol (184 mg/mg3 for 
17 minutes), radioactivity was distributed quickly (Marshall and Cheng 1983).  The authors estimated that 
60% of ethylene glycol (in either form) was deposited in the respiratory tract, primarily in the nasal 
cavity, and 75–80% of the initial body burden was distributed throughout the body upon sacrifice 
immediately after exposure (Marshall and Cheng 1983). 
 
3.4.2.2   Oral Exposure  
 
After oral exposure, ethylene glycol is distributed throughout the body according to total body water.  The 
apparent volume of distribution of ethylene glycol in humans exposed orally has been estimated to be 
0.54–0.56 L/kg based on clearance data in two patients poisoned with ethylene glycol (Jacobsen et al. 
1988).  The ratios of urine to plasma ethylene glycol concentration in one patient were similar to those of 
ethanol, indicating distribution with total body water.   
 
In rats, 6–22% of the radioactivity derived from single oral doses of 10 and 1,000 mg/kg of 14C-ethylene 
glycol were recovered from body tissues and carcass (combined) 96 hours after exposure (Frantz et al. 
1989, 1996b, 1996c); mice retained similar percentages (3–11%) in their tissues following single oral 
doses across the same range (Frantz et al. 1991, 1996b).  Among the few tissues examined individually 
(liver, kidney, brain, fat, and lung), the highest radioactivity was found in the liver of both species (see 
Table 3-5).  In two rhesus monkeys given single oral doses of about 1,100 mg/kg unlabeled ethylene 
glycol, the parent compound was evenly distributed throughout the tissues 4 hours after exposure; tissue  
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Table 3-5.  Distribution of Radioactivity (Percent of Administered Dose) in 
Tissues 96 Hours After Oral or Percutaneous Exposure to  
14C-Ethylene Glycol 
 
 Oral Percutaneous 
 







Female rats      
 Liver 2.43±0.44a 0.74±0.22 0.69±0.38 0.47±0.07 0.48±0.11 
 Kidney 0.20±0.02 0.10±0.01 0.06±0.03 0.03±0.00 0.03±0.00 
 Brain 0.05±0.01 0.02±0.01 0.01±0.01 0.01±0.00 0.01±0.00 
 Lung 0.14±0.01 0.06±0.01 0.04±0.02 0.02±0.00 0.02±0.00 
 Carcass 9.58±1.24 4.20±0.13 2.24±1.25 1.39±0.18 1.70±0.35 
 Pelt 2.78±0.34 1.21±0.16 5.09±4.28 5.24±2.53 5.84±1.04 
Male rats      
 Liver 2.29±0.39 0.88± 0.17  1.06±0.10 0.53±0.09 0.39±0.09 
 Kidney 0.24±0.03  0.88±0.17 0.09±0.01 0.05± 0.01 0.03±0.01 
 Brain 0.04±0.00  0.01±0.00 0.02±0.00 0.01±0.00 0.01±0.00 
 Lung 0.13±0.02 0.06±0.01 0.04±0.01 0.02±0.01 0.01±0.00 
 Testis 0.12±0.02 0.06±0.01 0.05±0.00 0.03± 0.01 0.01±0.00 
 Carcass 11.60±1.09 4.97±0.52 3.39±0.72 2.10±0.48 1.34±0.20 
 Pelt 7.28±0.99 3.67±1.21 3.36±0.26 6.94±3.90 5.18±1.18 
Female mice      
 Liver 3.02±0.95 0.63±0.16 0.60±0.06 0.59±0.16 0.58±0.07 
 Kidney 0.30±0.13 0.11±0.01 0.06±0.01 0.07±0.02 0.06±0.02 
 Brain 0.09±0.04 0.05±0.00 0.02±0.01 0.02±0.01 0.02±0.01 
 Lung 0.11±0.05 0.05±0.01 0.02±0.00 0.28±0.01 0.02±0.01 
 Carcass/pelt 7.21±2.01 2.56±0.28 14.77±3.85 7.59±2.03 10.10±0.79 
 
aMean±standard deviation from groups of four animals. 
 
Source:  Frantz et al. 1996b, 1996c 
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to plasma concentration ratios ranged from 0.85 to 1.91 for the brain, heart, kidney, gastrointestinal tract, 
liver, lung, muscle, pancreas, and spleen (McChesney et al. 1971).   
 
3.4.2.3   Dermal Exposure  
 
Frantz et al. (1989, 1996b, 1996c) evaluated the distribution of a 10 or 1,000 mg/kg dose of undiluted 
14C-ethylene glycol or a 1,000 mg/kg dose of 50% aqueous 14C-ethylene glycol applied dermally to rats 
under an occlusive bandage.  Table 3-6 shows the disposition of radioactivity.  The pelt contained the 
highest radioactivity (5–6% of applied dose) among the tissues examined (liver, kidney, brain, lung, pelt, 
and remaining carcass) (Frantz et al. 1989, 1996b).  Similar experiments in mice at doses of 100 or 
1,000 mg/kg undiluted 14C-ethylene glycol or 1,000 mg/kg 50% aqueous solution of 14C-ethylene glycol 
showed the highest radioactivity in the carcass and pelt combined (~8–15%) (Frantz et al. 1991, 1996b). 
 
3.4.3   Metabolism  
 
The metabolic pathway for ethylene glycol is shown in Figure 3-3.  Asterisks indicate rate-limiting steps 
in the pathway.  The metabolism of ethylene glycol was reviewed by NTP-CERHR (2004).  Ethylene 
glycol is first converted to glycolaldehyde by nicotinamide adenine dinucleotide (NAD)-dependent 
alcohol dehydrogenase.  Subsequent reduction of NAD results in the formation of lactic acid from 
pyruvate.  Glycolaldehyde has a brief half-life and is rapidly converted to glycolic acid (and to a lesser 
extent glyoxal) by aldehyde dehydrogenase and aldehyde oxidase, respectively.  Glycolic acid is oxidized 
to glyoxylic acid by glycolic acid oxidase or lactic dehydrogenase.  Glyoxylic acid can be metabolized to 
formate, glycine, or malate, all of which may be further broken down to generate respiratory CO2, or to 
oxalic acid, which is excreted in the urine.  In excess, oxalic acid can form calcium oxalate crystals.  
Rate-limiting steps in the metabolism of ethylene glycol include the initial formation of glycolaldehyde 
and the conversion of glycolic acid to glyoxylic acid, both of which are saturable processes. 
 
Both glycolic and oxalic acids are found in the blood and urine of unexposed individuals as a result of 
normal metabolism of proteins and carbohydrates (NTP-CERHR 2004).  The ranges of background levels 
of glycolic acid are 0.0044–0.0329 mM (plasma) and 0.075–0.790 mM (urine) (NTP-CERHR 2004).  For 
oxalic acid, the background ranges are 0.002–0.0233 mM (plasma) and 0.086–0.444 mM (urine) (NTP-
CERHR 2004). 
 
In two volunteers who inhaled 14C-ethylene glycol for 4 hours, glycolic acid concentrations in the plasma 
peaked at about 4–5 hours after the commencement of exposure (Carstens et al. 2003).  About 1% of the  
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Table 3-6.  Radioactivity (Percent of Administered Dose) in Excreta 96 Hours 
After 6-Hour Occluded Percutaneous Exposure to 14C-Ethylene Glycol 
 
 Undiluted 50% Aqueous solution 
 10 mg/kg  1,000 mg/kg  1,000 mg/kg 
Female rats 
 Expired CO2 13.1±7.2a 11.4±1.8 9.3±1.9 
 Urine 8.2±4.7 7.6±0.9 4.4±0.7 
 Feces 1.1±0.7 1.4±1.0 0.5±0.2 
 Tissues 6.0±4.6 5.8±2.5 6.4±1.2 
 Carcass 2.2±1.2 1.4±0.2 1.7±0.4 
 Occlusion materials and skin 10.9±3.3 55.6±2.2 56.8±4.2 
 Total recoveryb 42.4±19.2 84.7±2.0 82.7±4.5 
Male rats    
 Expired CO2 14.0±1.1 14.4±4.4 5.9±2.0 
 Urine 6.7±0.8 8.1±2.5 4.6±1.4 
 Feces 1.1±0.5 0.6±0.1 0.6±0.1 
 Tissues 4.7±0.4 7.6±3.9 5.6±1.2 
 Carcass 3.4±0.7 2.1±0.5 1.3±0.2 
 Occlusion materials and skin 17.4±3.1 48.2±9.4 59.2±6.7 
 Total recoveryc 48.9±5.0 83.8±4.1 81.2±3.8 
Female mice    
 Expired CO2 10.4±2.0 15.9±4.8 10.4±3.2 
 Exhaled VOCs 34.0±5.9 33.1±8.6 20.9±2.6 
 Urine 6.7±2.8 12.3±5.6 5.4±1.6 
 Feces 6.1±2.4 7.5±1.7 6.4±2.4 
 Tissues 0.7±0.1 0.7±0.2 0.7±0.1 
 Carcass 14.8±3.8 7.6±2.0 10.0±0.8 
 Occlusion materials and skin 23.0±4.6 4.8±4.2 25.4±15.3 
 Total recoveryd 99.5±9.4 89.2±3.9 85.2±6.7 
 
aMean±standard deviation from groups of four animals 
bCage wash accounted for 0.9–4% 
cCage wash accounted for 2–4% 
dCage wash accounted for 4–7% 
 
CO2 = carbon dioxide; VOCs = volatile organic compounds 
 
Source:  Frantz et al. 1996b, 1996c 
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estimated dose of 0.96–1.51 mg/kg was excreted in the urine as glycolic acid, and 0.08–0.28% was 
excreted as oxalic acid over 30 hours.  Expired CO2 was not measured in this study.   
 
Plasma glycolate levels of 12.2 and 15.4 mmol/L were reported upon hospital admission of an infant 
female and an adult male, respectively, with ethylene glycol intoxication after oral exposure (Hewlett et 
al. 1986).  The infant survived, while the adult male died, probably due to delayed treatment.  In a case 
report of six adult male patients with ethylene glycol intoxication, one of whom died, plasma glycolate 
levels on admission ranged from 17.0 to 29.3 mmol/L (Jacobsen et al. 1984).   
 
Glycolic acid was the major metabolite in the plasma of male rats exposed orally to single gavage doses 
of 10, 100, or 1,000 mg/kg 14C-ethylene glycol (Frantz et al. 1989, 1996c).  During the first 12 hours after 
dosing, no oxalate was detected in the plasma at any dose, but glyoxylate and glyoxal, as well as trace 
amounts of glycoaldehyde, were detected in plasma samples from the lower dose groups (100 and 
1,000 mg/kg).  In the 10 mg/kg group, glyoxylate levels exceeded glycolate levels throughout the 
12 hours postdosing.   
 
In rats given 2,000 mg/kg ethylene glycol by gavage, peak plasma levels of ethylene glycol occurred 
2 hours after administration, while plasma glycolate levels peaked 6 hours after dosing (Hewlett et al. 
1989).  Dogs receiving 1,000 or 1,360 mg/kg ethylene glycol by gavage exhibited peak plasma ethylene 
glycol levels at 2 hours after dosing and peak plasma glycolate levels 4 hours after dosing (Hewlett et al. 
1989).  
 
Carney et al. (2001) showed that enzymes metabolizing glycolate are more quickly saturated with bolus 
subcutaneous dosing than with slow, continuous dosing (i.e., via infusion pump), leading to higher peak 
plasma glycolate levels (~3–10-fold higher) with bolus dosing.  This study demonstrates the importance 
of dose rate on the dose at which glycolic acid metabolism is saturated. 
 
In vivo studies in rats and mice show increasing urinary excretion (as a percent of dose) of glycolic acid 
and other metabolites with increasing dose, probably corresponding to saturation of glycolic acid 
metabolism.  In male rats exposed to 10 or 1,000 mg/kg 14C-ethylene glycol via gavage, most of the 
urinary radioactivity consisted of unmetabolized ethylene glycol at the low dose (>90% of urinary 
radioactivity) (Frantz et al. 1996c).  At the high dose, glycolic acid comprised 25% of the urinary 
radioactivity in the first 12 hours after dosing and 37% during the following 12 hours.  Oxalic acid was 
detected in the urine sample from the 12–24-hour interval, accounting for 7.4% of the urinary 
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radioactivity in that sample (Frantz et al. 1989, 1996c).  The urinary metabolite pattern was similar in 
female rats treated at these doses (Frantz et al. 1989, 1996b).  In mice exposed orally to 10, 100, 200, 400, 
or 1,000 mg/kg 14C-ethylene glycol, the proportion of urinary radioactivity excreted as ethylene glycol or 
glycolate also varied with dose, with increasing excretion of glycolate at higher doses (Frantz et al. 1991, 
1996b).  No other metabolites were detected in mouse urine after oral doses.   
 
In both rats and mice exposed percutaneously to 10 or 1,000 mg/kg (rats) or 100 or 1,000 mg/kg (mice) 
undiluted 14C ethylene glycol, or 1,000 mg/kg 50% aqueous solution, most of the urinary radioactivity 
was excreted as ethylene glycol (Frantz et al. 1989, 1991, 1996b, 1996c).  In rats, 87–100% of the urinary 
radioactivity apparently was parent compound, regardless of dermal dose.  In mice, glycolate represented 
a greater proportion of urinary radioactivity after exposure to 1,000 mg/kg of 50% ethylene glycol (up to 
20% in the 12–24-hour interval).   
 
Urinary excretion of ethylene glycol and glycolate accounted for 20.7 and 4.5% (respectively) of a 
2,000 mg/kg dose of ethylene glycol in rats over the course of 24 hours post-dosing (Hewlett et al. 1989).  
Male Porton rats receiving 1,000–1,110 mg/kg ethylene glycol in the drinking water for 21 days had 
urinary oxalate levels equivalent to 1.18% conversion of ethylene glycol to oxalate; rats given diets 
supplemented with 30 or 60% sucrose (administered to evaluate the role of carbohydrates in calcium 
oxalate crystal formation) excreted oxalate equivalent to 1.11 and 0.7% conversion of ethylene glycol, 
respectively (Rofe et al. 1986). 
 
Corley and Soelberg (2005) evaluated levels of ethylene glycol, glycolic acid, and oxalate in the blood, 
urine, and/or kidneys of male Wistar rats treated with ethylene glycol doses up to 400 mg/kg/day for 
12 months.  In the kidneys, levels of glycolic acid and oxalate did not differ from controls at doses up to 
150 mg/kg/day, but at ≥300 mg/kg/day, concentrations were substantially higher than controls and 
increased with dose.  Levels of oxalate in the kidneys of rats exposed to 400 mg/kg/day averaged 
18,800 µg/g, with large interindividual variability.  Similar results were observed with glycolic acid in 
blood, with no difference from control at doses up to 150 mg/kg/day but 3.3-fold higher concentrations in 
rats dosed with 300 mg/kg/day.  Ethylene glycol was excreted in the urine at levels proportional to dose 
across all doses tested.  A disproportionate increase in urinary excretion of glycolic acid occurred at 
300 mg/kg/day, suggesting that the metabolism of glycolic acid is saturated at doses between 150 and 
300 mg/kg/day in male Wistar rats.  Oxalate concentrations in blood and urine were similar across all 
doses, reflecting the low solubility of this compound in physiological fluids (Corley and Soelberg 2005). 
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In vitro data suggest that humans may metabolize glycolic acid at a higher rate than rats do.  In vitro 
metabolism studies using liver homogenates from female humans and Sprague-Dawley rats generated 
Vmax/Km estimates of 2.16 and 0.68 L/hour/g for humans and rats, respectively (Corley et al. 2005a).  
Booth et al. (2004) reported Vmax/Km values of 0.43 and 0.28 L/hour/g (humans and rats, respectively) 
from a study using human and rat liver slices.   
 
3.4.4   Elimination and Excretion  
 
Little information is available on the elimination of ethylene glycol in humans; most of the elimination 
data are from humans accidentally poisoned and given therapeutic treatments to reduce the metabolism of 
ethylene glycol or extract it from the blood.  In laboratory animals treated with 14C-ethylene glycol, the 
primary routes of excretion are exhaled air and urine, regardless of the route of exposure.  After oral 
exposure, saturation of metabolic pathways at higher doses leads to a shift in excretory pattern, with 
greater urinary excretion (and corresponding decreases in elimination via expired air) at higher doses. 
 
3.4.4.1   Inhalation Exposure  
 
Carstens et al. (2003) evaluated the urinary excretion of ethylene glycol and its two primary metabolites 
(glycolic and oxalic acids) in two volunteers who inhaled 14C-ethylene glycol at doses estimated by the 
authors to be 0.96 and 1.51 mg/kg.  Urinary excretion of 14C-ethylene glycol up to 30 hours after exposure 
constituted 6.4–9.3% of the inhaled dose, while 13C-glycolic acid and 13C-oxalic acid together comprised 
1–2% of the inhaled dose.  However, the dose estimates are highly uncertain, as they were calculated by 
estimating the loss of 14C-ethylene glycol from an inhalation vessel in which the compound was 
“warmed”.  Air concentrations to which the volunteers were exposed were not measured, and the 
warming temperature was not reported.  The authors reported that 14C-ethylene glycol was not detectable 
in exhaled air, but did not assess expiration of 14CO2. 
 
In rats, the major route of elimination for inhaled ethylene glycol is expiration of CO2.  Rats exposed for 
30 minutes to 14C-ethylene glycol vapor (32 mg/m3) or for 17 minutes to 14C-ethylene glycol aerosol 
(184 mg/m3) excreted 63% (over 4 days) and 75% (over 6 days), respectively, of the initial body burden 
as 14CO2 (Marshall and Cheng 1983).  Urinary excretion constituted 20 and 12% of the initial body 
burden after vapor and aerosol exposures, respectively, while fecal excretion was 3% and 1% (Marshall 
and Cheng 1983). 
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3.4.4.2   Oral Exposure  
 
In untreated adults, the serum half-life has been estimated to be between 3.0 and 8.4 hours (Jacobsen et al. 
1988; Peterson et al. 1981).  In a series of 19 patients, the mean half-life of ethylene glycol during a 
period without ADH inhibitor treatment and without dialysis was 8.6 hours, while elimination after 
fomepizole therapy was slower, with a half-life of 19.7 hours (Sivilotti et al. 2000).  In another study, the 
half-life of ethylene glycol during fomepizole therapy was 11–14.75 hours (Baud et al. 1988).  The 
approximate serum half-life of ethylene glycol was 1.5–3.0 hours in a child treated with hemodialysis and 
mannitol therapy (Rothman et al. 1986), and 2.7 hours in an adult male during hemodialysis and 
intravenous ethanol treatment (Cheng et al. 1987).  As these half-lives indicate, the rate of ethylene glycol 
elimination is greatly increased by dialysis.   
 
In laboratory animals, the elimination half-lives for ethylene glycol in the plasma have been estimated at 
1.4–2.5 hours in rats given between 10 and 2,000 mg/kg; 0.3–1.1 hours in mice given doses between 
10 and 1,000 mg/kg; 3.5 hours in dogs given 1,000–1,360 mg/kg; and 2.7–3.7 hours in monkeys given 
1,110 mg/kg (Frantz et al. 1989, 1991, 1996a, 1996c; Hewlett et al. 1989; McChesney et al. 1971).  The 
plasma elimination half-life for ethylene glycol was similar (1.4–1.7 hours) in pregnant rats treated with 
single oral doses of 10 or 2,500 mg/kg on Gd 10 (Pottenger et al. 2001).  Data from intravenous 
administration of ethylene glycol show similar elimination half-lives (Frantz et al. 1989, 1991, 1996a, 
1996c; Martis et al. 1982).   
 
Frantz et al. (1989, 1991, 1996b, 1996c) treated rats and mice with single oral doses of 14C-ethylene 
glycol between 10 and 1,000 mg/kg and measured radioactivity in exhaled air, excreta, tissues, and 
carcass up to 96 hours after exposure.  Table 3-7 shows the disposition of radioactivity.  In male and 
female rats, the major excretory routes were via CO2 exhalation (27–48% of the administered 
radioactivity) and urinary elimination (21–43%); 2–4% was excreted via the feces (Frantz et al. 1989, 
1996b, 1996c).  Female mice showed a similar profile when exposed over the same dose range, exhaling 
22–55% of the dose as CO2 and 3–11% as exhaled volatile organic compounds (VOCs), while excreting 
24–56% in the urine and 5–16% in the feces (Frantz et al. 1991, 1996b).  In mice, the majority of the 
exhaled radioactivity was eliminated during the first 12 hours after dosing (Frantz et al. 1991, 1996b).  
Both mice and rats exhibited a dose-dependent shift in excretory patterns, as shown in the data in 
Table 3-7.  An increase in urinary excretion of radioactivity was evident between 10 and 100 mg/kg in 
female mice, between 10 and 400 mg/kg in female rats, and between 800 and 1,000 mg/kg in male rats.  
In its review of these data, NTP-CERHR (2004) noted that the increased urinary excretion of radioactivity  
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Table 3-7.  Radioactivity (Percent of Administered Dose) in Excreta 96 Hours 
After Oral or Exposure to 14C-Ethylene Glycol 
 
 10 mg/kg 400 mg/kg 600 mg/kg  800 mg/kg  1,000 mg/kg 
Female rats 
 Expired CO2 47.9±0.8a 39.4±1.0 32.8±3.4 32.1±2.3 28.2±2.1 
 Urine 25.5±3.8 38.0±7.6 37.1±17.0 41.0±5.1 35.0±13.2 
 Feces 2.8±0.8 NA NA NA 4.4±3.4 
 Tissues 5.7±0.5 NA NA NA 2.2±0.4 
 Carcass 9.6±1.2 NA NA NA 4.2±0.1 
 Total recoveryb 91.8±3.4 NA NA NA 83.3±3.5 
Male rats 
 Expired CO2 42.2±0.3 38.77±0.85 34.00±1.5 30.12±2.13 27.3±1.4 
 Urine 26.2±2.1 20.52±9.44 25.78±10.25 26.69±6.41 42.7±7.1 
 Feces 2.9±0.6 NA NA NA 2.4±0.8 
 Tissues 10.1±1.1 NA NA NA 4.8±2.2 
 Carcass 11.6±1.1 NA NA NA 5.0±0.5 
 Total recoveryc 93.4±2.1 NA NA NA 83.2±7.2 
Female mice 
 Expired CO2 55.4±10.2 42.3±2.7 31.4±5.5 26.1±5.3 21.6±1.7 
 Exhaled VOCs 3.1±2.0 2.5±0.7 3.8±1.5 11.5±3.8 4.2±1.2 
 Urine 23.6±12.1 43.0±3.4 43.6±13.1 44.8±10.4 55.7±10.9 
 Feces 6.6±4.1 4.5±1.5 10.9±4.2 16.2±9.8 3.7±0.8 
 Tissues 3.6±1.1 2.3±0.9 1.3±0.3 1.1±0.7 0.8±0.2 
 Carcass 7.2±2.0 5.0±1.4 3.7±0.8 4.2±1.6 2.6±0.3 
 Total recoveryd 102.1±12.9 100.1±1.6 96.4±3.8 106.7±7.6 94.1±6.6 
 
aMean±standard deviation from groups of four animals 
bCage wash accounted for 0.3–9% 
cCage wash accounted for 0.3–1% 
dCage wash accounted for 0.5–6% 
 
CO2 = carbon dioxide; NA = not applicable; VOCs = volatile organic compounds 
 
Source:  Frantz et al. 1996b, 1996c 
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probably resulted from saturation of the enzymes that metabolize glycolic acid, leading to increased 
excretion of this metabolite in the urine.  Pottenger et al. (2001) provided data on urinary levels of 
ethylene glycol and glycolate in female rats exposed to doses of 10–2,500 mg/kg that confirmed the 
saturation of glycolic acid metabolism in the dose range between 150 and 500 mg/kg. 
 
Monkeys given a single oral dose of 1 mL/kg 14C-ethylene glycol (equivalent to 1,110 mg/kg) excreted 
about 24% of the administered dose as unchanged parent compound in the urine within 48 hours 
(McChesney et al. 1971).  In dogs, approximately 50% of an oral dose of ethylene glycol (173 mmol/kg) 
was excreted via the urine within 72 hours after exposure (Grauer et al. 1987).   
 
3.4.4.3   Dermal Exposure  
 
Rats and mice were treated with dermal application of doses of 10–1,000 mg/kg undiluted 14C-ethylene 
glycol or 1,000 mg/kg 50% aqueous solution of 14C-ethylene glycol under occlusion for 6 hours, and 
radioactivity was measured in expired air, excreta, tissues, remaining carcass, and occlusion materials and 
skin (unabsorbed dose) for 96 hours after dosing (Frantz et al. 1989, 1991, 1996b, 1996c).  Table 3-6 
shows the disposition of radioactivity.  In male and female rats, 6–14% of the administered dose was 
expired, while 4–8% was excreted in the urine, and ~1% was recovered from the feces (Frantz et al. 1989, 
1996b, 1996c).  In female mice treated similarly (except with a low dose of 100 mg/kg undiluted ethylene 
glycol), most of the administered dose was recovered as exhaled volatile organic compounds (21–34%) or 
CO2 (10–16%) (Frantz et al. 1991, 1996b).  Urine and feces each accounted for another 5–12% of the 
dose (Frantz et al. 1991, 1996b).  No dose-related shift in excretory patterns was observed in either 
species, suggesting that metabolic pathways were not saturated under the slower absorption conditions 
observed with dermal exposure. 
 
3.4.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
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PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between:  (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.   
 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions.   
 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-4 shows a conceptualized representation of a PBPK model. 
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Figure 3-4.  Conceptual Representation of a Physiologically Based 












































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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If PBPK models for ethylene glycol exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
 
PBPK models are available for ethylene glycol and its intermediate metabolite, glycolic acid, in rats and 
humans (Corley et al. 2005a).  The models include the inhalation, oral, dermal, intravenous, and 
subcutaneous routes of exposure.  Models for ethylene glycol consist of eight compartments connected by 
blood flow (lungs, richly perfused tissues, poorly perfused tissues, fat, skin, gastrointestinal tract, liver, 
and kidney); models for glycolic acid have a similar structure except that the lung is included in the richly 
perfused tissue group.  Gastrointestinal tract, lung, and skin were included separately in order to permit 
simulation of different exposure routes.  Models for both compounds assume instantaneous dispersion of 
the compound through each compartment based on blood perfusion rates and partition coefficients.  The 
models for ethylene glycol and glycolic acid are connected via a saturable metabolic route in the liver, 
and renal elimination of both compounds was modeled.  
 
Physiological parameters used in the model are shown in Table 3-8.  Tissue volumes were scaled to body 
weight; alveolar ventilation and cardiac output were scaled as (body weight)0.75; blood flows were scaled 
to cardiac output; and kidney parameters (glomerular filtration, tubule urine volume, and urine 
production) were scaled as a fraction of kidney weights.  Partition coefficients used in the model are given 
in Table 3-9.  Blood:air partition coefficients were measured in vitro using human and female Sprague-
Dawley rat blood; tissue:blood coefficients were measured in rats, and human partition coefficients were 
assumed to equal those of rats.   
 
A simplified metabolic pathway simulating metabolism of ethylene glycol to glycolic acid and from 
glycolic acid to glyoxylic acid (the rate-limiting steps) with saturable Michaelis-Menten kinetics was used 
in the model.  Metabolic rate constants were estimated from in vitro data.  Elimination via the kidneys 
was initially simulated as a first-order equation, but was modified to allow for reabsorption of glycolic 
acid in the renal tubules by a saturable Michaelis-Menten-like process in order to better predict 
elimination of this metabolite at low doses (<200 mg/kg).  Table 3-9 shows the metabolic and renal 
elimination parameters used in the study. 
 
The model was validated against several pharmacokinetic studies in rats and humans (Corley and 
McMartin 2005; Corley et al. 2005a).  In the examples reported by Corley et al. (2005a), the model  
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Table 3-8.  Physiological Parameters in PBPK Models for Ethylene Glycol 
 
Parameter SD rat Human 
Physiologic parameters 
Body weight (kg) 0.23 60 
Tissue volumes (fraction of body weight)   
 Blood 0.059 0.059 
 Liver 0.034 0.0314 
 Kidneys 0.007 0.0044 
 Lungs 0.005 0.0115 
 Gastrointestinal tract 0.05 0.034 
 Fat 0.07 0.231 
 Skin 0.19 0.051 
 Richly perfused 0.0423 0.0371 
 Slowly perfused 0.91, sum other tissues  
Flows (liter/hour/kg)  
 Cardiac output  15 15 
 Alveolar ventilation  15 15 
Blood flows (fraction of cardiac output)   
 Liver 0.18 0.25 
 Gastrointestinal tract 0.15 0.21 
 Kidney 0.141 0.25 
 Fat 0.07 0.05 
 Skin 0.058 0.03 
 Richly perfused 1.0, sum other tissues  
 Slowly perfused 0.17 0.17 
 
Source:  Corley et al. 2005a 
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Table 3-9.  Biochemical Parameters in PBPK Models for Ethylene Glycol 
 
 Ethylene glycol Glycolic acid 
Parameter SD rat Human SD Rat Human 
Absorption rate (hour-1)     
 Oral gavage 1–5 1 1 1 
 Subcutaneous 1 - 1 - 
 Intraperitoneal  1 - - - 
Partition coefficients     
 Blood:air 17,901 17,542 - - 
 Blood:saline 1.14 1.14 3.36 3.36 
 Skin:saline 1.36 1.36 2.51 2.51 
 Skin:air 17,901 17,542 - - 
 Liver:blood 0.96 0.96 0.97 0.97 
 Kidney:blood 1.22 1.22 1.40 1.40 
 Lung:blood 0.96 0.96 - - 
 Fat:blood 0.64 0.64 1.09 1.09 
 Skin:blood 1.19 1.19 0.75 0.75 
 Gastrointestinal tract:blood 1.48 1.48 0.95 0.95 
 Richly perfused:blood 0.96 0.96 0.97 0.97 
 Slowly perfused:blood 0.67 0.67 0.70 0.70 
Elimination (L/hour/kg)     





SD = Sprague-Dawley 
 
Source:  Corley et al. 2005a 
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predictions provided reasonably good fit to measured plasma concentrations of ethylene glycol and 
glycolic acid after oral exposure to ethylene glycol in female Sprague-Dawley rats and intraperitoneal 
exposure to male Wistar rats, although predictions of glycolic acid concentrations after low-dose 
(10 mg/kg) oral exposure were not as reliable.  The authors suggested that differences in analytical 
methods used to measure glycolic acid in the dataset used to determine model parameters and the 
validation dataset may have contributed to the less reliable prediction after low-dose exposure.  
Validation against human data was complicated by the need to incorporate effects of therapeutic 
interventions on blood levels of ethylene glycol and glycolic acid in humans acutely poisoned with 
ethylene glycol.  With modifications to simulate these effects, the model provided reasonably good 
predictions of blood levels reported in several clinical case reports over a broad range of oral doses 
(Corley and McMartin 2005). 
 
Using the model for humans, Corley et al. (2005a) estimated that the threshold glycolic acid concentration 
for developmental effects in rodents (considered by the authors to be a peak of 2 mM) would only be 
reached in human females ingesting doses of 350 mg/kg (assuming a 58-kg female).  However, the model 
was not calibrated to pregnancy, and it is not clear whether physiological and/or biochemical changes that 
could affect ethylene glycol toxicokinetics might occur during pregnancy (NTP-CERHR 2004).  
Furthermore, uncertainty in the glycolic acid saturation concentration in humans somewhat limits the 
usefulness of this model for predicting developmental toxicity in human embryos. 
 
Data from a single study (Pottenger et al. 2001) suggested that pregnancy status did not affect the time 
course of ethylene glycol, glycolic acid, or oxalic acid pharmacokinetics in maternal blood and urine 
(including peak concentration, time of peak concentration, area under the concentration vs. time curve, or 
elimination half-time) when groups of pregnant and nonpregnant rats were treated by gavage with doses 
of 10 or 2,500 mg/kg ethylene glycol (pregnant rats treated on Gd 10).  While Gd 10 is a sensitive time 
point for developmental effects, NTP-CERHR (2004) observed that pregnancy-related changes in 
metabolism would not be captured in this study due to the narrow exposure window.  In their review, 
NTP-CERHR (2004) noted that there were no data to assess whether maternal levels of enzymes involved 
in ethylene glycol metabolism might change over the course of gestation.  In addition, the study measured 
maternal, not fetal, levels of ethylene glycol and its metabolites.  However, Corley et al. (2002) showed 
that levels of glycolic acid in rat embryos and extraembryonic fluid paralleled those of maternal blood, 
albeit at levels 1.4–4-fold higher than maternal levels.  Slikker et al. (2004) reported that there are 
species-specific differences in the transfer of glycolic acid from maternal blood to conceptus.  Likewise, 
fetal and/or placental differences in expression of enzymes metabolizing ethylene glycol and glycolic acid 
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over the course of gestation may affect local concentrations of glycolic acid to which the developing 
conceptus is exposed, yet little is known about these differences (NTP-CERHR 2004).  In particular, there 
are no data on the ontogeny of glycolate oxidase (the enzyme that breaks down glycolic acid) expression 
in rodent or human embyros (NTP-CERHR 2004) 
 
Additional data are needed to reduce uncertainty in the saturation concentration of glycolic acid in 
humans, and such data may alter the model predictions of peak glycolic acid concentrations in humans 
exposed to ethylene glycol.  Although in vitro data suggest that humans may metabolize glycolic acid 
more efficiently than rats, based on comparisons of apparent Vmax/Km values obtained using liver 
homogenates and liver slices, there are no in vivo human data with which to predict the saturation point in 
humans (NTP-CERHR 2004).   
 
3.5   MECHANISMS OF ACTION  
 
3.5.1   Pharmacokinetic Mechanisms  
 
Absorption.    No studies investigating the mechanism by which ethylene glycol is absorbed from the 
lung, gastrointestinal tract, or skin were located. 
 
Distribution.    As discussed in more detail in Section 3.4.2, there are limited data on the distribution of 
ethylene glycol after inhalation exposure.  Studies in rats, mice, and monkeys, as well as limited data in 
humans, suggest that ethylene glycol is distributed according to total body water (Frantz et al. 1989, 1991, 
1996b, 1996c; Jacobsen et al. 1988).  There are no data on the sites of ethylene glycol metabolism or on 
the distribution of its primary metabolite (glycolic acid) in the body.  The inverted yolk sac placenta, 
which develops in both mice and rats, tends to concentrate weak acids such as glycolic acid; neither 
humans nor rabbits develop a yolk sac placenta, and a preliminary study showed that glycolic acid does 
not concentrate in rabbit embryonic fluids (NTP-CERHR 2004).  Corley et al. (2002) confirmed that the 
rat embryo and embryonic fluid concentrate glycolic acid, reaching levels roughly 2–4-fold higher than 
maternal blood.  No additional data are available to characterize the mechanisms by which ethylene 
glycol is transported to the kidneys or developing fetus, the primary sites of toxic action. 
 
Metabolism.    As discussed in more detail in Section 3.4.3, ethylene glycol metabolism has been well 
characterized.  Glycolic acid has been identified as the primary metabolite and putative developmental 
toxicant associated with ethylene glycol exposure, while a downstream metabolite (oxalate) is associated 
with renal toxicity.  There are no data on the tissues most responsible for metabolism of ethylene glycol.  
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Two of the primary enzymes involved in ethylene glycol metabolism (alcohol dehydrogenase and 
aldehyde dehydrogenase) are also responsible for ethanol metabolism, and ethanol metabolism largely 
takes place in the liver.  Thus, it is likely that the liver is also the primary site of ethylene glycol 
metabolism; however, other tissues, including the placenta, also produce these enzymes.  Pharmacokinetic 
parameters (e.g., plasma half-life, area under the curve, and peak ethylene glycol concentration) are 
similar after both oral and intravenous exposure (Frantz et al. 1989, 1991, 1996a, 1996b, 1996c), 
indicating that a first-pass effect, if any, has a negligible effect on the toxicokinetics. 
 
Excretion.    As discussed in more detail in Section 3.4.4, studies in mice and rats of ethylene glycol 
excretion after oral, dermal, and intravenous exposure indicate that ethylene glycol is principally excreted 
as expired CO2 and as both parent compound and glycolic acid in the urine (Frantz et al. 1989, 1991, 
1996b, 1996c).  At higher doses, oxalate was also excreted at measurable levels.   
 
3.5.2   Mechanisms of Toxicity  
 
There are three main effects responsible for the toxicity of ethylene glycol:  increased osmolal gap, 
metabolic acidosis, and formation of calcium oxalate crystals.  Several lines of evidence suggest that 
metabolites of ethylene glycol (Figure 3-3) are responsible for these effects.  First, there is a latent period 
before the symptoms of acidosis appear; second, there is no correlation between observed toxicity and 
ethylene glycol blood concentration; and third, inhibition of ethylene glycol oxidation prevents toxicity 
(Jacobsen and McMartin 1986).   
 
In the initial stages after ingestion (there are no reports of clinical toxicity in humans following inhalation 
or dermal exposure), the ethylene glycol concentration in extracellular fluids increases, leading to 
increased osmolality.  This increased osmolality (hyperosmolarity) causes increased osmolal gap, one of 
the hallmarks of ethylene glycol intoxication.  Osmolal gap is defined as a difference between the 
measured and calculated osmolality.  Osmolality (calculated) can be estimated from the formula that takes 
into account normal serum concentrations of sodium, glucose, and BUN.  This calculated osmolality is 
then compared to the serum osmolality measured following ethylene glycol ingestion; a difference 
>10 indicates an increased osmolal gap (Fligner et al. 1985).  The increased osmolal gap is not specific to 
ethylene glycol intoxication and can occur when any unmeasured, osmotically active, low molecular 
weight solute (e.g., methanol or ethanol) is present in the serum.  In dogs given oral doses of 
10,743 mg/kg ethylene glycol, serum osmolality peaked (460 milliosmoles/kg) at 3–6 hours, and the 
osmolal gap peaked (134 milliosmoles/kg) at 3 hours, coinciding with peak serum ethylene glycol levels 
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at 3 hours (Grauer et al. 1984).  In these animals, the anion gap was also significantly increased at 3 hours 
(19 Meq/L).   
 
The second characteristic of ethylene glycol intoxication is metabolic acidosis.  Ethylene glycol itself has 
low toxicity (Godolphin et al. 1980; Jacobsen and McMartin 1986), but it is metabolized to a variety of 
toxic metabolites such as glycolaldehyde, glycolic acid (glycolate), glyoxylic acid (glyoxylate), and 
oxalic acid (oxalate) (Jacobsen et al. 1988; Parry and Wallach 1974; Vale 1979; Wiener and Richardson 
1988).  In general, the accumulation of acids leads to acidosis, a state that is characterized by actual or 
relative decrease of alkali in body fluids in relation to the acid content.  In the case of ethylene glycol, 
metabolic processes that follow ethylene glycol ingestion lead to the accumulation of glycolic and lactic 
acids resulting in metabolic acidosis.  Glycolic acid is the most abundant ethylene glycol metabolite 
(Jacobsen et al. 1984).  Following ingestion of high doses of ethylene glycol, glycolic acid tends to 
accumulate as a result of metabolic saturation.  The accumulation of metabolites such as glycolic acid and 
oxalate, as well as lactic acid formed through the reduction of NAD, leads to an increased serum anion 
gap (the difference between the sum of the measured cations and anions) and metabolic acidosis, which 
are responsible for toxicity observed after ethylene glycol exposure.  While lactate levels increase in some 
human cases up to 5–7 mmol (Jacobsen et al. 1984, 1988; Parry and Wallach 1974), glycolate levels 
range up to 20–25 mmol, thus accounting for a greater portion of the anion gap.  Glycolic acid accounts 
for approximately 96% of the anion gap in ethylene glycol-poisoned patients (Gabow et al. 1986; 
Jacobsen et al. 1984).  In dogs given oral doses of 10,743 mg/kg ethylene glycol, the anion gap was 
significantly increased at 3 hours (19 Meq/L) coinciding with peak serum ethylene glycol levels (Grauer 
et al. 1984).  The maximum production of metabolites occurs 6–12 hours after ethylene glycol ingestion 
and coincides with development of respiratory and cardiovascular symptoms. 
 
Nephrotoxicity and neurotoxicity can follow because oxalate can produce renal and brain damage as it 
chelates with calcium ions forming insoluble calcium oxalate monohydrate crystals, another characteristic 
of ethylene glycol poisoning (Jacobsen et al. 1988).  Glycolic acid accumulation and metabolic acidosis 
do not contribute to renal toxicity, which is solely caused by oxalate crystal accumulation (Cruzan et al. 
2004; Green et al. 2005).  Oxalate crystal formation may lead to hypocalcemia and imbalance of serum 
divalent ion concentrations (Zeiss et al. 1989).  Although the mechanism of ethylene glycol neurotoxicity 
is not completely understood, the available information on humans suggests that it occurs in two stages, 
an early one (30 minutes to 12 hours after exposure) and a late one (several days after exposure).  The 
early-stage symptoms are due to the direct toxicity of ethylene glycol, while the late-stage neurotoxicity is 
due to metabolic acidosis caused by the accumulation of ethylene glycol metabolites, primarily glycolic 
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acid, which leads to metabolic acidosis.  Additional evidence for this late neurotoxicity is crystalline 
deposits of calcium oxalate in the walls of small blood vessels found in the brain of humans who died of 
acute ethylene glycol poisoning (Froberg et al. 2006; Zeiss et al. 1989).  Similar effects were observed in 
rats fed 2,500 mg/kg/day ethylene glycol for 13 weeks (Melnick 1984).  The role of calcium in ethylene-
glycol-induced neurotoxicity is not known but the formation of calcium oxalate crystals may cause 
perturbation of intracellular calcium homeostasis causing membrane abnormalities generally associated 
with cell injury and cell death.  A generalized soft tissue mineralization that included the heart (vessels 
and muscle), lungs (interstitial), stomach, and vascular system occurred in male F344 rats exposed to 
1,000 mg/kg/day in the diet for 1 year (DePass et al. 1986a; Woodside 1982).  These histopathological 
changes may be the result of altered calcium metabolism (Rajagopal et al. 1977).  Other effects of 
ethylene glycol metabolites include inhibition of oxidative phosphorylation, respiration, glucose 
metabolism, protein synthesis, DNA replication, ribosomal ribonucleic acid (RNA) synthesis, central 
nervous system respiration, and serotonin metabolism (Vale 1979).   
 
The presented data indicate that glycolic acid is the major toxic metabolite contributing to metabolic 
acidosis, which is a primary cause of systemic toxicity following exposure to ethylene glycol.  Glycolic 
acid has also been identified as the proximate cause of developmental effects observed with ethylene 
glycol exposure (NTP-CERHR 2004; Slikker et al. 2004).  A number of mechanistic studies have ruled 
out both ethylene glycol itself and other metabolites as the primary developmental toxicants, while 
metabolic acidosis was shown to interact with glycolic acid at high doses to enhance developmental 
effects.  The available data suggest that peak concentrations in the range of 2–3 mM glycolic acid are 
necessary for developmental toxicity to occur in rodents (Carney et al. 2001; Corley et al. 2002; NTP-
CERHR 2004; Slikker et al. 2004). 
 
Klug et al. (2001) compared the effects of several ethylene glycol metabolites on rat whole embryos 
(Gd 9.5) in culture, observing that only glycolic acid affected embryonic development at metabolite 
concentrations observed in in vivo studies of ethylene glycol.  Ethylene glycol and other metabolites did 
not affect development except at much higher concentrations than have been seen in vivo. 
 
Using rat whole embryos (Gd 10) exposed to either ethylene glycol or glycolic acid for 46 hours in vitro, 
Carney et al. (1996) showed that concentrations up to 50 mM ethylene glycol did not cause 
morphological changes, while glycolic acid caused changes in the skeletal and craniofacial regions at 
concentrations of ≥12 mM.  These changes are consistent with the dysmorphogenesis observed in rats 
after in vivo exposure to ethylene glycol.  In the same study, the role of medium acidification in the 
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observed effects was investigated by comparing the effects of 12.5 mM glycolic acid (pH 6.7), 12.5 mM 
sodium glycolate (pH 7.4), and control medium (pH 7.4 or 6.7) on rat whole embryos in culture.  The 
incidence of affected embryos was 67% in the glycolic acid group, 58% in the sodium glycolate group, 
8% in the pH 6.7 controls, and 0% in the pH 7.4 controls.  The authors concluded that glycolic acid was 
the primary developmental toxicant, and that medium acidification was a minor contributor to the 
observed effects. 
 
In vivo studies have shown similar results.  When glycolic acid was administered to CD rats via gavage 
on Gd 6–15, the observed effects on offspring were similar to those observed after ethylene glycol 
exposure (Munley et al. 1999).  In an effort to determine the extent to which metabolic acidosis 
contributed to the developmental effects induced by glycolic acid, Carney et al. (1999) treated time-mated 
Sprague-Dawley rats with ethylene glycol (2,500 mg/kg) or glycolic acid (650 mg/kg) via gavage or 
sodium glycolate via subcutaneous injection on Gd 6–15.  Metabolic acidosis was induced in both the 
ethylene glycol and glycolic acid groups, but not in the sodium glycolate treatment group.  Upon sacrifice 
on Gd 21, fetal body weights were decreased and malformations were increased in all three groups, 
indicating that glycolate was capable of inducing effects in the absence of metabolic acidosis.  The 
authors reported that developmental toxicity was enhanced by an interaction between metabolic acidosis 
and glycolate at high doses (Carney et al. 1999). 
 
3.5.3   Animal-to-Human Extrapolations  
 
Toxicokinetic and mechanistic data suggest that humans may be less sensitive than rodents to systemic 
and developmental effects of ingested ethylene glycol.  In vitro studies by Corley et al. (2005a) and Booth 
et al. (2004) found that human liver tissue was more effective than liver tissue from rats and rabbits in 
metabolizing glycolic acid to glyoxylic acid, suggesting that humans are less likely to accumulate glycolic 
acid (the proximate developmental toxicant).  In addition, NTP-CERHR (2004) reviewed preliminary data 
by Carney and coworkers indicating that the inverted yolk sac placenta, a stage in placental development 
that does not exist in humans or rabbits, tends to concentrate weak acids such as glycolic acid in the 
embryonic fluids.  Corley et al. (2002) confirmed that the rat embryo and embryonic fluid concentrate 
glycolic acid, reaching levels roughly 2–4-fold higher than maternal blood.  These data suggest enhanced 
sensitivity to ethylene glycol developmental effects in rodents compared with humans. 
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3.6   TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
 
Insufficient information is available to adequately assess the endocrine disruptor potential of ethylene 
glycol.  No studies were located regarding endocrine disruption in humans after exposure to ethylene 
glycol.   
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No histopathological changes occurred in endocrine organs of rats or mice in acute-, intermediate- and 
chronic-duration oral studies of ethylene glycol.  As discussed in the Endocrine Effects subsection of 
Section 3.2.2.2, histological examinations in these studies included the adrenals, pancreas, pituitary, 
thyroid, and/or parathyroids (Blood 1965; DePass et al. 1986a; Hong et al. 1988; Melnick 1984; NTP 
1993; Robinson et al. 1990; Schladt et al. 1998; Woodside 1982).  Assessments of endocrine function 
(e.g., hormone levels) were not conducted in these or other studies of ethylene glycol. 
 
Reproductive toxicity studies showed that oral exposure to high doses of ethylene glycol affected fertility 
and fetal viability in mice and rats (Harris et al. 1992; Lamb et al. 1985; Morrissey et al. 1989; NTP 1986; 
Price et al. 1985; Schuler et al. 1984), and possibly male reproductive function in mice (Morrissey et al. 
1989; NTP 1986) and gestational duration in rats (NTP 1988).   
 
Ethylene glycol had no estrogenic or antiestrogenic activity in an in vitro MVLN cell-based 
transactivation assay (Freyberger and Schmuck 2005).  MVLN cells constitutively express the estrogen 
receptor (ER) and are stably transfected with the luciferase reporter gene and the corresponding hormone 
responsive element derived from the Xenopus Vitellogenin A2 gene.  Evaluations included cytotoxicity 
and luciferase gene expression in the absence and presence of estradiol stimulation, as well as ER-α 
binding affinity.   
 
3.7   CHILDREN’S SUSCEPTIBILITY  
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
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(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
 
Young children are susceptible to ethylene glycol poisoning through the accidental ingestion of antifreeze 
because it is a brightly colored, sweet tasting liquid that can be mistaken for a beverage (Leth and 
Gregersen 2005).  Many ethylene glycol poisonings occur when an antifreeze bottle is in use or when 
antifreeze is not kept in its original container (e.g., if it is poured into a cup or soft drink bottle), because 
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children can ingest ethylene glycol from an accessible open container (EPA 2004b; Leth and Gregersen 
2005).  Children also may play in a puddle of antifreeze that has been spilled or drained onto the ground.  
Children and adolescents comprise a significant percentage of ethylene glycol acute intoxications from 
accidental or intentional ingestion.  For example, in a total of 735 exposures voluntarily reported to U.S. 
poison control centers in 2003, 150 (20%) were younger than 19 years old and 84 (11%) were younger 
than 6 years old (Watson et al. 2004).  Similarly, of 751 total exposures reported in 2005, 167 (22%) were 
≤19 years old and 69 (9%) were younger than 6 years old (Lai et al. 2006).  It has been reported that 
ingestion of as little as 10–15 mL ethylene glycol can be fatal in small children (White and Liebelt 2006). 
 
A limited amount of information on health effects of ethylene glycol in children is available from several 
case reports of patients admitted to hospitals for treatment of acute oral poisoning.  A 4-year-old girl 
(14 kg) who accidentally ingested an unknown amount of antifreeze containing 41% ethylene glycol 
vomited and was admitted to a hospital 4 hours later, where drowsiness, hypotonia, and metabolic 
acidosis subsequently developed (Harry et al. 1998).  A 13-year-old girl (80 kg) who intentionally 
ingested approximately 4 fluid ounces of antifreeze (ethylene glycol concentration not reported) was 
brought to a hospital approximately 30 minutes after ingestion with no evidence of intoxication, but 
subsequently developed ataxia, dysarthria, metabolic acidosis, and oxalate crystals in the urine (Boyer et 
al. 2001).  An 8-month-old boy (7.7 kg) who drank up to 120 mL ethylene glycol (95%) was taken to a 
hospital where he appeared lethargic; metabolic acidosis, increased osmolal gap, and oxalate crystals in 
the urine were detected 3–4 hours post-ingestion (Baum et al. 1999).  Six children ranging in age from 
22 months to 14 years were admitted to a hospital for treatment of ethylene glycol poisoning over a 4-year 
period (Caravati et al. 2004).  Four of the children (7–13 years old, 22–50 kg) ingested between 30 and 
120 mL (alleged doses) of antifreeze (ethylene glycol concentration not reported); the amounts ingested 
by the other two children were unknown.  Presenting symptoms included dizziness, slurred speech, 
nausea, ataxia, and lethargy.  Varying degrees of metabolic acidosis were also observed, but renal 
function was normal. 
 
The effects in the pediatric patients summarized above are largely consistent with the first stage of 
ethylene glycol poisoning in adults (e.g., central nervous system depression, metabolic changes, 
gastrointestinal upset).  Treatment with fomepizole (4-methylpyrazole), alone or in combination with 
other methods (see Section 3.11, Methods for Reducing Toxic Effects), generally mitigated the 
progression of the clinical course to the second and third stages of ethylene glycol poisoning (pronounced 
metabolic acidosis, cardiopulmonary compromise, and renal insufficiency) and led to full recovery.  The 
case reports are consistent with an expectation that health effects in children and adults are similar.  
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Although there are no known differences in the toxicity of ethylene glycol between adults and children, 
there is no evidence to substantiate the presumption.  There is no evidence to indicate that children are 
likely to be exposed to higher (or lower) amounts of ethylene glycol from everyday living, suggesting that 
children are perhaps equally at risk for non-accidental or non-intentional exposure and potential toxic side 
effects. 
 
Information on the developmental toxicity of ethylene glycol is available from oral, inhalation, and 
dermal studies in rats, mice, and rabbits.  Oral studies in animals have identified the developing fetus as 
the most sensitive target for acute-duration exposure to ethylene glycol.  Gavage exposure of rats and 
mice to ethylene glycol during gestation results in a consistent pattern of developmental effects including 
reduced fetal body weight and increases in malformations, particularly axial skeletal malformations 
(Neeper-Bradley 1990; Neeper-Bradley et al. 1995; Price et al. 1985).  No teratogenic effects were 
observed in rabbits orally exposed during gestation (Tyl et al. 1993).  Results of inhalation developmental 
studies in rats and mice are generally consistent with the oral findings, but are confounded by concurrent 
oral exposure (Tyl 1985, 1988a; Tyl et al. 1995a, 1995b).  A single study of dermal exposure to ethylene 
glycol in pregnant mice did not indicate developmental effects (Tyl 1988b; Tyl et al. 1995c).   
 
Developmental effects of intermediate-duration oral exposure to ethylene glycol in animals include 
decreased body weight and kidney effects in offspring.  In mice exposed via drinking water in a 
continuous breeding assay, pup body weights were reduced in both F1 and F2 generations (Morrissey et al. 
1989; NTP 1986).  Effects on postnatal kidney weight were observed in pups of rats exposed by gavage 
for 15 days during gestation (NTP 1988).  In a three-generation dietary study in rats, no effects on 
gestation survival or pup body weight through postnatal day 21 were observed in F1 or F2 pups (DePass et 
al. 1986b).  The available animal data are insufficient for determining whether postnatal developmental 
toxicity is a potential concern in exposed children.  Effects of ethylene glycol on the immune and 
endocrine systems have not been adequately studied.  Ethylene glycol did not induce dominant lethal 
mutations in orally-exposed rats (DePass et al. 1986b) and was consistently negative in in vitro 
genotoxicity assays in a variety of test systems, indicating that it is unlikely to affect DNA in parental 
germ cells. 
 
No studies are available that describe potential differences in the toxicokinetics or the mechanism of 
action of ethylene glycol in children.  As discussed in Section 3.5.2, Mechanisms of Toxicity, glycolic 
acid is the major toxic metabolite contributing to metabolic acidosis, which is a primary cause of systemic 
toxicity in children as well as adults following exposure to ethylene glycol.  Glycolic acid has also been 
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identified as the proximate cause of the developmental effects in animals observed with ethylene glycol 
exposure (NTP-CERHR 2004; Slikker et al. 2004).   
 
Ethylene glycol metabolism is known to involve alcohol dehydrogenase and aldehyde dehydrogenase, 
and may also involve cytochrome P450 isozymes (NTP-CERHR 2004).  Polymorphisms in the genes 
encoding these enzymes may lead to wide variability in the production and elimination of glycolic acid 
and other metabolites in humans exposed to ethylene glycol, but data quantifying the range of variability 
are not currently available (NTP-CERHR 2004).  In addition, fetal and/or placental differences in 
expression of these enzymes over the course of gestation will affect local concentrations of glycolic acid 
and other metabolites to which the developing conceptus is exposed, yet little is known about these 
differences (NTP-CERHR 2004). 
 
A PBPK model for ethylene glycol in adult humans has been developed and has been used to estimate 
that the threshold glycolic acid concentration for developmental effects in rodents would only be reached 
in human females ingesting doses of 350 mg/kg (assuming a 58-kg female) (Corley et al. 2005a).  
However, the model was not calibrated to pregnancy, and it is not clear whether physiological and/or 
biochemical changes that could affect ethylene glycol toxicokinetics might occur during pregnancy.  No 
models are available for children or lactating women.  A PBPK model has also been developed for rats 
(Corley et al. 2005a), but there is no model for mice, which are more sensitive than rats to ethylene glycol 
developmental toxicity.  Biomonitoring data for children, including levels of ethylene glycol in placental 
tissue, cord blood, neonatal blood, meconium fluid, or breast milk, have not been located.   
 
3.8   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
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interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to ethylene glycol are discussed in Section 3.8.1. 
 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by ethylene glycol are discussed in Section 3.8.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible. 
 
3.8.1   Biomarkers Used to Identify or Quantify Exposure to Ethylene Glycol  
 
The presence of parent compound in the blood and urine serves as the only biomarker of exposure that is 
specific to ethylene glycol.  The half-life of ethylene glycol in plasma is estimated to be 3–7 hours in 
laboratory animals (Marshall 1982; Winek et al. 1978).  Available human data indicate a similar half-life 
for ethylene glycol in human plasma (Eder et al. 1998).  The elimination half-life of ethylene glycol in the 
urine of acutely intoxicated humans ranges from 3.0 to 8.4 hours (Jacobsen et al. 1988; Peterson et al. 
1981).  Based on the relatively short half-life in the blood and urine, the presence of parent compound 
would serve as a reliable biomarker of exposure only within the first day following exposure.  Rapid 
methods for determining ethylene glycol in serum and urine are available for use in the clinical setting 
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(Aarstad et al. 1993; Blandford and Desjardins 1994), but may not always be readily available in 
emergency situations. 
 
Other biomarkers of exposure are typically used in conjunction with serum and urinary ethylene glycol 
levels to assist in confirmation and quantitation of ethylene glycol intoxication.  For example, levels of 
glycolic, lactic, and oxalic acid metabolites of ethylene glycol may be useful indicators of ethylene 
glycol-induced toxicity.  However, these other biomarkers are not specific to ethylene glycol.  As 
discussed in detail in Section 3.4, ethylene glycol is rapidly metabolized to glycolic acid, which 
accumulates in the blood and causes metabolic acidosis (Gabow et al. 1986; Jacobsen et al. 1984).  
Glycolic acid blood levels have been more closely correlated to clinical symptoms than ethylene glycol 
blood levels (Hewlett et al. 1986).  Due to the rapid formation of glycolic acid in the body and its 
correlation to clinical symptoms of ethylene glycol poisoning, measurements of both parent compound 
and glycolic acid levels are important in diagnosis and treatment (Hess et al. 2004).  Although glycolate is 
not a specific biomarker for ethylene glycol exposure (because it is an endogenous chemical that can also 
be obtained from the diet), an increase in plasma glycolate above the general background level (<1 mM) 
is a good indication of ethylene glycol exposure (McMartin 2007).  It is particularly useful in situations 
where there is a lengthy period between exposure and blood sampling; in these situations, there is often 
no ethylene glycol in the plasma (due to its metabolism and elimination), whereas there still are elevated 
levels of glycolate.  Only a few clinical toxicology laboratories routinely offer glycolic acid analyses 
(Hess et al. 2004; Pellegrino et al. 2006).  Lactic acid may contribute to metabolic acidosis, whereas 
oxalic acid forms calcium oxalate crystals that are considered to be the cause of ethylene glycol-induced 
nephrotoxicity (Jacobsen and McMartin 1986; Moossavi et al. 2003; Pellegrino et al. 2006; Wiley 1999). 
 
Metabolic acidosis with increased serum anion and osmolal gaps are suggestive of ethylene glycol 
poisoning, but do not provide a specific diagnosis.  Serum anion gap is calculated from concentrations of 
sodium, chloride, and bicarbonate, is normally 12–16 mM, and is elevated after ethylene glycol ingestion 
(Chung and Tuso 1989; Factor and Lava 1987; Heckerling 1987; Hess et al. 2004; Spillane et al. 1991; 
Zeiss et al. 1989).  The increase in the anion gap correlates with the elevation in plasma glycolate levels 
(Hess et al. 2004; Jacobsen et al. 1984).  Osmolal gap represents the difference between the measured and 
calculated osmolalities and is also elevated during ethylene glycol intoxication.  As unmetabolized 
ethylene glycol accounts for most of the osmolality gap, it is only raised in the initial stages of toxicity, 
and decreases later as anion gap increases due to metabolism of the parent compound to acidic 
intermediates (Hess et al. 2004; Leth and Gregersen 2005).  The normal value for osmolal gap in humans 
is 10–15 mOsm/kg water (Egbert and Abraham 1999; Leth and Gregersen 2005; Scalley et al. 2002).  
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Normal osmolality gap does not exclude ethylene glycol poisoning, although an elevated osmolality gap 
is suggestive (Leth and Gregersen 2005). 
 
The presence of calcium oxalate monohydrate crystals is an indicator of possible ethylene glycol 
intoxication, although not specific to ethylene glycol.  The crystals can be found in renal tubules and/or 
urine after exposure to relatively large amounts of ethylene glycol (CDC 1987; Chung and Tuso 1989; 
Factor and Lava 1987; Godolphin et al. 1980; Heckerling 1987; Parry and Wallach 1974; Rothman et al. 
1986; Siew et al. 1975a; Underwood and Bennett 1973). 
 
3.8.2   Biomarkers Used to Characterize Effects Caused by Ethylene Glycol 
 
Biomarkers of effects exist for ethylene glycol poisoning, but none are specific to ethylene glycol.  These 
include clinical manifestations of nervous system, cardiopulmonary toxicity, renal toxicity, and laboratory 
findings of metabolic acidosis and calcium oxalate crystalluria.   
 
Clinical manifestations progress in three main stages, although the course may vary between individuals.  
Signs of central nervous system toxicity appear within 0.5–12 hours following acute ingestion exposure 
and include ataxia, slurred speech, nystagmus, semiconsciousness, unresponsiveness, and somnolence 
that can culminate in convulsions and coma (CDC 1987; Cheng et al. 1987; Chung and Tuso 1989; Factor 
and Lava 1987; Hess et al. 2004; Leth and Gregersen 2005; Parry and Wallach 1974; Rothman et al. 
1986; Spillane et al. 1991; Underwood and Bennett 1973; Zeiss et al. 1989).  Neurological manifestations 
suggestive of cranial nerve damage, including facial paralysis and impaired vision, may appear in 
survivors as late as 1–2 weeks after an acute exposure to ethylene glycol (Chung and Tuso 1989; Factor 
and Lava 1987; Lewis et al. 1997; Mallya et al. 1986; Spillane et al. 1991).  Cardiopulmonary 
manifestations, including respiratory distress and congestive heart failure, generally develop after 12–
24 hours and usually in patients with coma; signs include tachycardia, dyspnea, tachypnea, hypertension, 
and pulmonary edema (Godolphin et al. 1980; Hess et al. 2004; Leth and Gregersen 2005; Parry and 
Wallach 1974; Siew et al. 1975a; Vale 1979; Zeiss et al. 1989).  Renal failure occurs 24–72 hours after 
ingestion with clinical manifestations that include flank pain, hematuria, proteinuria, or anuria (Leth and 
Gregersen 2005). 
 
Metabolic acidosis occurs approximately 12–24 hours following ethylene glycol ingestion, results from 
accumulation of acid metabolites (primarily glycolic acid), and is characterized by pronounced serum 
osmolal and anion gaps (Hess et al. 2004; Leth and Gregersen 2005).  Serum osmolality is determined 
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from the concentrations of sodium, urea nitrogen, and glucose, and increased osmolality (osmolal gap) 
suggests the presence of unmeasured osmotically active substances such as ethylene glycol, methanol, 
ethanol, or acetone (Eder et al. 1998; Hoffman et al. 1993).  As ethylene glycol is metabolized, the 
osmolal gap is decreased and the anion gap (the difference between the sum of the measured cations and 
anions) is increased (Jacobsen et al. 1988).  Organic acids increase the anion gap; glycolic acid accounts 
for approximately 96% of the anion gap in ethylene glycol-poisoned patients (Gabow et al. 1986; 
Jacobsen et al. 1984).   
 
Calcium oxalate crystals in the urine can appear 4–8 hours after ethylene glycol ingestion, and deposition 
of calcium oxalate monohydrate crystals in the renal tubules can subsequently result in nephropathy and 
eventual renal failure 24–72 hours after ingestion (CDC 1987; Chung and Tuso 1989; Factor and Lava 
1987; Godolphin et al. 1980; Heckerling 1987; Jacobsen et al. 1988; Leth and Gregersen 2005; Parry and 
Wallach 1974; Rothman et al. 1986; Siew et al. 1975a; Underwood and Bennett 1973).  Two forms of 
oxalate crystals may be found in the urine; the monohydrate form is an elongated crystal, and the 
anydrous form is octahedral (pyramid in shape).  Renal toxicity can also be indicated by increased serum 
levels of BUN or creatinine (Grauer et al. 1987). 
 
For more information on biomarkers for renal effects of chemicals see ATSDR/CDC Subcommittee Report 
on Biological Indicators of Organ Damage (Agency for Toxic Substances and Disease Registry 1990) 
and for information on biomarkers for neurological effects see OTA (1990). 
 
3.9   INTERACTIONS WITH OTHER CHEMICALS  
 
Information regarding the influence of other chemicals on the toxicity of ethylene glycol comes from case 
studies describing treatment after accidental or intentional ingestion of ethylene glycol.  The toxic effects 
of ethylene glycol result from its metabolic conversion by alcohol dehydrogenase into glycolic acid, 
which is further metabolized to oxalate.  The formation of oxalate crystals is associated with renal toxicity 
encountered after exposure to ethylene glycol.  Administration of ethanol, 4-methyl pyrazole, or 
1,3-butanediol reduces or eliminates ethylene glycol toxicity.  This is accomplished by the following 
mechanisms:  (1) ethanol, which is also metabolized by alcohol dehydrogenase, competes with ethylene 
glycol for the enzyme, thus preventing the formation of potentially toxic ethylene glycol metabolites; 
(2) 4-methyl pyrazole inhibits the activity of alcohol dehydrogenase (Baud et al. 1987, 1988); and 
(3) 1,3-butanediol is also a competitive inhibitor of ethylene glycol biotransformation and reduces the 
formation of glycolic acid (Hewlett et al. 1983).  Therefore, ethanol, 4-methyl pyrazole, and 
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1,3-butanediol reduce the toxicity of ethylene glycol by interacting with or inhibiting the activity of 
alcohol dehydrogenase, thus reducing the amount of glycolic acid and oxalate formed. 
 
Magnesium and vitamin B6 were found to affect the toxicity of ethylene glycol in animals.  In rats, 
vitamin B6 accelerates the oxidation of glyoxylate to carbon dioxide rather than to oxalate (Gershoff and 
Andrus 1962).  Vitamin B6 deficiency can cause inhibition of ethylene glycol's oxidation to carbon 
dioxide and thus cause an increase in ethylene glycol toxicity.  Magnesium may prevent renal deposition 
of calcium oxalate by altering solvent characteristics of oxalate in urine (Browning 1965; Gershoff and 
Andrus 1962; Khan et al. 1993). 
 
3.10   POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE  
 
A susceptible population will exhibit a different or enhanced response to ethylene glycol than will most 
persons exposed to the same level of ethylene glycol in the environment.  Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of ethylene glycol, or compromised 
function of organs affected by ethylene glycol.  Populations who are at greater risk due to their unusually 
high exposure to ethylene glycol are discussed in Section 6.7, Populations with Potentially High 
Exposures. 
 
Individuals deficient in vitamin B6 could be more sensitive to toxic effects of ethylene glycol because 
vitamin B6 may increase the accumulation of toxic metabolites (Browning 1965; Gershoff and Andrus 
1962).  Similarly, magnesium deficiency appears to encourage calcium oxalate deposition in the renal 
tubules, especially in the presence of high calcium levels (Ebisuno et al. 1987).  Thus, individuals who are 
deficient in magnesium and/or ingest high levels of calcium may be more sensitive to the toxic effects of 
ethylene glycol.   
 
3.11   METHODS FOR REDUCING TOXIC EFFECTS  
 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to ethylene glycol.  However, because some of the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment of exposures to ethylene glycol.  
When specific exposures have occurred, poison control centers and medical toxicologists should be 
consulted for medical advice.  The following texts provide specific information about treatment following 
exposures to ethylene glycol:   
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Egbert PA, Abraham K.  1999.  Ethylene glycol intoxication:  Pathophysiology, diagnosis, and 
emergency management.  ANNA J 26(3):295-300. 
 
Ellenhorn MJ, Schonwald S, Ordog G, et al, eds.  1997.  Ellenhorn's medical toxicology.  Diagnosis and 
treatment of human poisoning.  Baltimore, MD:  Williams & Wilkins, 1152-1156. 
 
Jolliff HA, Sivilotti MLA.  2004.  Ethylene glycol.  In:  Dart RC, ed.  Medical toxicology.  3rd. ed.  
Philadelphia, PA:  Lippicott Williams & Wilkins, 1223-1230. 
 
Mégarbane B, Borron SW, Baud FJ.  2005.  Current recommendations for treatment of severe toxic 
alcohol poisonings.  Intensive Care Med 31(2):189-195. 
 
Scalley RD, Ferguson DR, Piccaro JC, et al.  2002.  Treatment of ethylene glycol poisoning.  Am Fam 
Physician 66(5):807-812. 
 
Wiener SW.  2006.  Toxic alcohols.  In:  Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds.  
Goldfrank's toxicologic emergenices.  New York, NY:  McGraw-Hill Companies, Inc., 1447-1459. 
 
White ML, Liebelt EL.  2006.  Update on antidotes for pediatric poisoning.  Pediatr Emerg Care 
22(11):740-749. 
 
3.11.1   Reducing Peak Absorption Following Exposure  
 
No studies were found describing methods to reduce peak absorption of ethylene glycol after inhalation 
exposure.  After oral exposure, nasogastric lavage may be of benefit in reducing absorption, but only if 
performed within 1–2 hours following ingestion (Barceloux et al. 1999; Egbert and Abraham 1999; Leth 
and Gregersen 2005; Wiley 1999).  Activated charcoal is only partially effective at preventing 
gastrointestinal absorption of ethylene glycol because large amounts are needed to bind relatively small 
amounts of ethylene glycol, and the therapeutic window for this action is less than an hour (Scalley et al. 
2002).  The degree to which activated charcoal may lower absorption of ethylene glycol of may adsorb its 
toxic metabolites by entero-enteric dialysis is not known (Wiley 1999).  Administration of syrup of ipecac 
for gastric emptying is strongly contraindicated due to the potential for altered mental status, seizures, and 
cardiac dysrhythmias, which may occur abruptly in ethylene glycol poisoning (Barceloux et al. 1999; 
Leth and Gregersen 2005; Wiley 1999).  Dermal absorption can be minimized through washing the skin 
with soap to remove any existing ethylene glycol.  Copious irrigation with water or saline can aid in 
ocular decontamination. 
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3.11.2   Reducing Body Burden  
 
Clinical procedures for treating ethylene glycol poisoning focus on reduction of the body burden of 
ethylene glycol and its toxic metabolites, interference with toxic metabolite formation (which results in 
increased urinary excretion of parent compound), increased elimination of toxic metabolites produced, 
reduction of metabolic acidosis, and prevention of kidney failure.  Procedures include administration of 
antidotes (ethanol or fomepizole), intravenous bicarbonate and hydration for profound acidemia, and 
hemodialysis for refractory acidosis (Barceloux et al. 1999; Egbert and Abraham 1999; Gardner et al. 
2004; Leth and Gregersen 2005; Scalley et al. 2002). 
 
Antidotes for ethylene glycol include the alcohol dehydrogenase inhibitors, ethanol and fomepizole, 
which act to decrease the alcohol dehydrogenase-catalyzed metabolism of ethylene glycol, thus 
effectively increasing the urinary excretion of ethylene glycol.  Ethanol competes with ethylene glycol for 
alcohol dehydrogenase receptor sites and fomepizole acts as a potent inhibitor of alcohol dehydrogenase 
(Barceloux et al. 1999; Egbert and Abraham 1999; Gardner et al. 2004; Leth and Gregersen 2005).  
Antidotal therapy is indicated if ethylene glycol blood levels exceed 200 mg/L (Gardner et al. 2004).  
Hemodialysis (see below) may be avoided if patients are diagnosed and treated with fomepizole or 
ethanol early in the course of poisoning.   
 
Fomepizole treatment has repeatedly been demonstrated to be a particularly effective therapy for ethylene 
glycol poisoning and is the preferred treatment/antidote in adults and children (Boyer et al. 2001; Caravati 
et al. 2004; Harry et al. 1998; Pizon and Brooks 2006; Scalley et al. 2002; White and Liebelt 2006).  
When compared with ethanol, the advantages of fomepizole include a slower rate of excretion by the 
kidneys, lack of central nervous system depression and hypoglycemia (which are major hazards of 
ethanol therapy in children), and easier maintenance of effective plasma levels (Scalley et al. 2002), 
indicating that ethanol should only be used if fomepizole is not available.  The standard treatment 
regimen for fomepizole in adult and pediatric patients is an intravenous loading dose of 15 mg/kg 
followed by maintenance dosing of 10 mg/kg intravenous every 12 hours for four doses (Scalley et al. 
2002; White and Liebelt 2006).  Subsequent doses (if needed) are 15 mg/kg intravenous every 12 hours 
until plasma ethylene glycol level has been reduced below 20 mg/dL. 
 
Intravenous fluid administration may be initiated early to increase urine output, which effectively 
increases the excretion of ethylene glycol and toxic metabolites such as glycolic and oxalic acids (Egbert 
and Abraham 1999).  Sodium bicarbonate infusion is used to correct metabolic acidosis, increase 
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elimination of renal glycolic acid, and inhibit the precipitation of calcium oxalate crystals, although the 
latter benefit has not been demonstrated in clinical trials (Egbert and Abraham 1999; Leth and Gregersen 
2005; Scalley et al. 2002). 
 
Hemodialysis is indicated when initial serum ethylene glycol levels exceed 50 mg/dL or when ingestion 
of ethylene glycol results in refractory acidosis, deteriorating clinical status, or renal compromise (Egbert 
and Abraham 1999; Mégarbane et al. 2005; Scalley et al. 2002).  Hemodialysis can effectively remove 
ethylene glycol and the acid metabolites, glycolic and oxalic acids, because they have low molecular 
weights and do not exhibit protein binding (Egbert and Abraham 1999).  Hemodialysis is also effective in 
treating metabolic acidosis (Leth and Gregersen 2005; Scalley et al. 2002). 
 
Thiamine (vitamin B1) and pyroxidine (vitamin B6) are co-factors for the metabolism of ethylene glycol.  
Thiamine is believed to reduce the formation of toxic oxalic acid by shifting glyoxylic acid metabolism to 
the less toxic α-hydroxy-β-ketoadipic acid (Egbert and Abraham 1999; Goldfrank et al. 2002).  
Pyroxidine, in the presence of magnesium, may promote the conversion of glyoxylic acid to glycine and 
benzoic acid, which also results in reduced toxic oxalic acid formation (Egbert and Abraham 1999; 
Gardner et al. 2004; Goldfrank et al. 2002; Leth and Gregersen 2005; Scalley et al. 2002).  However, the 
efficacy of treatment with thiamine and pyroxidine has not been demonstrated in human cases of ethylene 
glycol poisoning. 
 
3.11.3   Interfering with the Mechanism of Action for Toxic Effects  
 
There are no documented methods for interfering with mechanisms of action for toxic effects of ethylene 
glycol and its potent metabolites.  As described in Section 3.11.2, clinical procedures for treating ethylene 
glycol poisoning consist of measures focused on reduction of the body burden of parent compound and its 
metabolites that are responsible for ethylene glycol-induced adverse neurological, cardiovascular, 
metabolic, and renal effects. 
 
3.12   ADEQUACY OF THE DATABASE  
 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylene glycol is available.  Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure 
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the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of ethylene glycol. 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
3.12.1   Existing Information on Health Effects of Ethylene Glycol  
 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
ethylene glycol are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of ethylene glycol.  Each dot in the figure indicates that one or 
more studies provide information associated with that particular effect.  The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
 
Information on the health effects of ethylene glycol inhalation in humans is limited to an experimental 
study of acute- to intermediate-duration exposure providing data on respiratory, renal, neurologic, and 
other systemic end points, an intermediate-duration study of kidney function in workers, and a chronic 
renal cancer mortality study in workers.  Inhalation data in animals are also limited, consisting of three 
acute-duration developmental toxicity studies in rats and mice and an intermediate-duration systemic 
toxicity studies in rats, guinea pigs, rabbits, dogs, and monkeys.   
 
Health effects data in orally exposed humans comprise numerous case reports of acute ingestion 
documenting the progression of neurologic, cardiovascular, renal, and other systemic effects.  The health 
effects of ethylene glycol in orally exposed animals are generally well documented in acute-, 
intermediate-, and chronic-duration studies of systemic, reproductive, and developmental toxicity and  
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carcinogenicity in rats and mice.  A limited amount of information is available on the immunologic, 
lymphoreticular, and neurological effects of oral exposure in animals.   
 
Information on the health effects of dermal exposure to ethylene glycol is essentially limited to two acute-
duration studies in animals investigating skin and eye irritation in rabbits and developmental toxicity in 
mice.   
 
3.12.2   Identification of Data Needs  
 
Acute-Duration Exposure.    Information on the toxicity of acute-duration inhalation exposure to 
ethylene glycol is available from an experimental study in humans (Wills et al. 1974) and three 
developmental toxicity studies in rats and mice (Tyl 1988a; Tyl et al. 1995a, 1995b).  In the human study, 
exposure to ethylene glycol aerosol at an average concentration of 23 mg/m3 for 20–22 hours/day for 
14 days was well-tolerated in 19 subjects with effects that were essentially limited to occasional 
complaints of mild upper respiratory tract irritation; there were no indications of renal or other systemic 
effects as shown by urinalysis and hematology, clinical chemistry, and neurobehavioral evaluations (Wills 
et al. 1974).  Short-term (e.g., 15-minute), high-exposure sessions showed that respiratory tract irritation 
became common at approximately 140 mg/m3.  The developmental studies (Tyl 1988a; Tyl et al. 1995a, 
1995b) are limited by confounding oral exposures, as discussed in data needs for Developmental Toxicity, 
but collectively suggest that 150 mg/m3 is a conservative NOAEL for developmental toxicity in rats and 
kidney toxicity in mice.  This concentration is similar to the 140 mg/m3 LOAEL for respiratory tract 
irritation in humans (Wills et al. 1974).  The human NOAEL of 23 mg/m3 is a suitable basis for acute 
inhalation MRL derivation because it is based on evaluations for renal and other systemic effects as well 
as local irritation, and is within the NOAEL range for developmental toxicity in animals.  Additional 
studies would help to better define the threshold for respiratory irritation in humans, particularly for acute 
exposures longer than several minutes, and confirm that the respiratory tract is the most sensitive target 
for acute exposure.  These inhalation studies could also address the potential increased toxicity of 
ethylene glycol when it is heated (e.g., through its use as an automobile antifreeze/coolant). 
 
Information on effects of acute-duration oral exposure to ethylene glycol is available from human case 
reports (Godolphin et al. 1980; Gordon and Hunter 1982; Hewlett et al. 1986; Jacobsen et al. 1984; Siew 
et al. 1975a; Zeiss et al. 1989), a 10-day drinking water study in rats (Robinson et al. 1990), a 4-day 
gavage study examining effects on hematology and reproductive organs (Hong et al. 1988), and 
developmental toxicity studies in mice, rats, and rabbits (Maronpot et al. 1983; Marr et al. 1992; Neeper-
ETHYLENE GLYCOL  156 
 







***DRAFT FOR PUBLIC COMMENT*** 
Bradley et al. 1995; Price et al. 1985; Schuler et al. 1984; Tyl 1989; Tyl et al. 1993).  The available 
human studies consist of clinical case reports of high-dose intentional or accidental ingestion of ethylene 
glycol, and thus, are not suitable for dose-response assessment or MRL consideration.  The 4-day gavage 
study (Hong et al. 1988) identified bone marrow effects in mice at doses of 50–250 mg/kg/day; these 
included suppressed granulocyte-macrophage progenitor formation at ≥50 mg/kg/day, bone marrow 
hypocellularity at ≥100 mg/kg/day, and suppressed iron uptake in the bone marrow at 250 mg/kg/day.  
The biological significance of these effects is uncertain in light of the lack of supporting evidence for 
effects on bone marrow, spleen, or hematology in longer-duration studies of mice and rats exposed to 
much higher doses (DePass et al. 1986a; Gaunt et al. 1974; Melnick 1984; NTP 1993; Robinson et al. 
1990; Schladt et al. 1998).  Additional testing for acute bone marrow effects is needed to corroborate the 
findings of the Hong et al. (1988) study, clarify their biological significance, and confirm that bone 
marrow effects are not an appropriate basis for MRL derivation.  The remaining animal studies 
collectively identify the developing fetus as the most sensitive target of acute oral exposure to ethylene 
glycol.  Among the developmental toxicity studies, the study by Neeper-Bradley et al. (1995; Tyl 1989) in 
mice identified the lowest LOAEL (500 mg/kg/day for increased incidence of total malformations and 
bilateral extra rib 14), and dose-response data for these effects were used in deriving the acute oral MRL 
for ethylene glycol.   
 
Information on the acute dermal toxicity of ethylene glycol is limited to one study in rabbits that found 
minimal skin and eye irritation following single applications (Clark et al. 1979) and one negative 
developmental toxicity study in mice exposed to 3,549 mg/kg/day for 6 hours/day on Gd 6–15 (Tyl 
1988b; Tyl et al. 1995c).  Additional dermal studies would be helpful in evaluating the potential for 
systemic toxicity by this route of exposure. 
 
Intermediate-Duration Exposure.    Information on the toxicity of intermediate-duration inhalation 
exposure to ethylene glycol is available from two studies in humans (Gérin et al. 1997; Wills et al. 1974) 
and one multiple species study in animals (Coon et al. 1970).  In one of the human studies, health effects 
were assessed in 19 subjects who were exposed to ethylene glycol aerosol at an average concentration of 
30 mg/m3 for 20–22 hours/day for 30 days (Wills et al. 1974).  Effects were essentially limited to 
occasional complaints of mild upper respiratory tract irritation; there were no indications of renal or other 
systemic effects as shown by urinalysis and hematology, clinical chemistry, and neurobehavioral 
evaluations.  This study identified a NOAEL of 30 mg/m3 for respiratory irritation and systemic effects 
for near-continuous exposure to ethylene glycol for 30 days.  The other human study found no effects on 
kidney function in 33 male aviation workers who were intermittently exposed to ethylene glycol during 
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airplane de-icing operations during a 2-month winter period (Gérin et al. 1997), but identification of a 
NOAEL is precluded by inadequate monitoring data.  In the animal study, rats, guinea pigs, and small 
numbers of rabbits, dogs, and monkeys were exposed to ethylene glycol aerosol in concentrations of 0, 
10, or 57 mg/m3 for 8 hours/day, 5 days/week for 6 weeks, or to 0 or 12 mg/m3 continuously for 90 days 
(Coon et al. 1970).  The 6-week intermittent exposure study identified a NOAEL of 57 mg/m3 for kidney 
histopathology and other systemic effects in all species.  Continuous exposure to 12 mg/m3 for 90 days 
caused ocular irritation and/or mortality in rats, rabbits, and guinea pigs (Coon et al. 1970), but 
confidence in this LOAEL is low due to small numbers of animals and likely confounding by oral 
exposure from ingestion of aerosol deposited on the fur, and its relevance is unclear because there were 
no eye irritation or other effects in humans near-continuously exposed to 30 mg/m3 for 30 days (Wills et 
al. 1974).  The human NOAEL of 30 mg/m3 is not a suitable basis for intermediate-duration MRL 
derivation due to insufficient information on renal and other possible systemic effects of exposures longer 
than 30 days.  Although exposures as long as 90 days were conducted in the animal study, it was limited 
in scope (e.g., lacked sufficient numbers of animals and urinalysis) and likely confounded by oral 
exposure.  A well-designed, intermediate-duration systemic toxicity study in animals is needed to provide 
a sufficient basis for inhalation MRL derivation. 
 
Information on intermediate-duration oral toxicity of ethylene glycol essentially consists of several 
generally well-designed studies in rats (Cruzan et al. 2004; Gaunt et al. 1974; Melnick 1984; Robinson et 
al. 1990) and mice (Melnick 1984; NTP 1993).  These studies consistently showed that the kidney is the 
predominant and most sensitive target of intermediate-duration oral exposure, and that renal toxicity 
varied with sex, species, and strain, with males more sensitive than females, rats more sensitive than 
mice, and Wistar rats more sensitive than other strains of rats.  The 16-week studies of Cruzan et al. 
(2004) and Gaunt et al. (1974) were considered for intermediate oral MRL consideration because they 
provide dose-response data for the critical effect in the most sensitive species, strain, and sex (i.e., kidney 
lesions in male Wistar rats).  The NOAEL and LOAEL values were 150 and 500 mg/kg/day in the Cruzan 
et al. (2004) study and 71 and 180 mg/kg/day in the Gaunt et al. (1974) study.  Although Gaunt et al. 
(1974) identified a lower apparent LOAEL, this study is not suitable for MRL consideration because the 
animal care was questionable and the daily dose was not constant.  Nearly all of the rats showed evidence 
of respiratory infection (pneumonia) and infectious salivary adenitis, either of which could have 
confounded the results.  Chemical intake varied throughout the study because the amount of ethylene 
glycol in the diet was not adjusted for changing food consumption and body weight.  The Cruzan et al. 
(2004) study does not have the limitations of the Gaunt et al. (1974) study, but the data set for the critical 
effect (crystal nephropathy) is not appropriate for BMD analysis because the incidences increased from 
ETHYLENE GLYCOL  158 
 







***DRAFT FOR PUBLIC COMMENT*** 
0% in rats exposed to ≤150 mg/kg/day to 100% at ≥500 mg/kg/day (i.e., at all higher doses).  Basing the 
intermediate-duration MRL on the NOAEL of 150 mg/kg/day yields a value that is higher than the acute-
duration oral MRL.  Because available evidence indicates that the acute-duration oral MRL for ethylene 
should be protective for kidney effects following longer-term exposure, the acute-duration value was 
adopted for intermediate-duration exposure.  An intermediate-duration oral toxicity study in male Wistar 
rats that provides dose-response data for kidney effects in the 150–300 mg/kg/day dose range is needed to 
provide a suitable basis for MRL derivation.   
 
No information is available on the intermediate-duration dermal toxicity of ethylene glycol.  Studies using 
the dermal route would be useful because absorption and systemic distribution of ethylene glycol has 
been shown in dermal toxicokinetic studies in rats and mice (Frantz et al. 1989, 1991, 1996b, 1996c).   
 
Chronic-Duration Exposure and Cancer.    Information on the health effects of chronic inhalation 
exposure to ethylene glycol is essentially limited to the negative results of an epidemiologic study on 
renal cancer mortality in humans (Bond et al. 1985).  This study is not suitable for assessing chronic 
inhalation toxicity because it lacks noncancer end points, measured exposure concentrations, and other 
relevant information.  Chronic testing in animals is needed to provide a basis for chronic inhalation MRL 
derivation and to adequately assess the potential for inhalation carcinogenicity. 
 
Chronic oral effects of ethylene glycol have been evaluated in three studies in rats (Blood 1965; DePass et 
al. 1986a; Wilson et al. 2005) and two studies in mice (DePass et al. 1986a; NTP 1993) using dietary 
exposure.  None of the studies provided evidence of carcinogenicity.  The main target organs for toxicity 
were the kidneys in rats and liver in mice, and rats were more sensitive than mice.  Effects in the rats 
included kidney lesions and mortality at ≥300 mg/kg/day in Wistar males (Wilson et al. 2005), kidney 
lesions at ≥375 mg/kg/day and mortality at 750 mg/kg/day in Sprague-Dawley males (Blood 1965), and 
kidney lesions and mortality at 1,000 mg/kg/day in F344 males (DePass et al. 1986a).  The study in male 
Wistar rats (Wilson et al. 2005) is the most appropriate basis for chronic MRL derivation because it 
identified the lowest LOAEL (300 mg/kg/day) and is the only study providing information on effects of 
chronic exposure in Wistar rats, a strain shown to be approximately twice as sensitive as F344 rats to 
kidney toxicity in a 16-week study (Cruzan et al. 2004).  The data set for the critical effect in this study, 
oxalate nephropathy is not appropriate for BMD analysis because the incidences increased from 0% in the 
rats exposed to ≤150 mg/kg/day to 92% at 300 mg/kg/day (next highest dose) and 100% at 
400 mg/kg/day (highest dose).  Basing the MRL on the NOAEL of 150 mg/kg/day yields an intermediate-
duration MRL that is higher than the acute-duration oral MRL.  It is against ATSDR policy to derive a 
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chronic-duration MRL that is higher than the acute-duration MRL, although available evidence indicates 
that the acute MRL should be protective for chronic kidney effects.  A chronic oral study in male Wistar 
rats that provides dose-response data for kidney effects in the 150–300 mg/kg/day dose range is needed to 
provide an appropriate basis for chronic-duration MRL derivation.  This study could also be used to 
confirm the lack of carcinogenicity in the available studies. 
 
Genotoxicity.    Human genotoxicity data were not located for ethylene glycol.  A single in vivo study 
was located in which ethylene glycol did not produce dominant lethality in orally-exposed rats (DePass et 
al. 1986b).  Available in vitro assays in a variety of test systems consistently provide negative results for 
genotoxicity (Abbondandolo et al. 1980; Clark et al. 1979; Griffiths 1979, 1981; Hastwell et al. 2006; 
Kubo et al. 2002; McCann et al. 1975; McCarroll et al. 1981; McGregor et al. 1991; Miller et al. 2005; 
Pfeiffer and Dunkelberg 1980; Storer et al. 1996; Zeiger et al. 1987).  Additional in vivo animal studies 
could be conducted to more completely assess the genotoxicity of ethylene glycol, although available data 
do not indicate that the compound is of genotoxicity concern. 
 
Reproductive Toxicity.    Studies have not addressed the reproductive toxicity of ethylene glycol in 
humans.  Reproductive testing in animals includes three multigeneration studies (one in rats and two in 
mice) and several shorter studies (15–20 days in rats and mice) by the oral route (DePass et al. 1986b; 
Harris et al. 1992; Lamb et al. 1985; Morrissey et al. 1989; NTP 1986. 1988).  The only effect in rats was 
an increase in gestational duration, whereas fertility and fetal viability were affected in mice.  Mice also 
showed some changes in sperm parameters, as well as testicular and epididymal lesions (Morrissey et al. 
1989; NTP 1986); however, the incidence of testicular effects was high in the control group, so the 
relationship to ethylene glycol exposure is uncertain.  Additional reproductive testing may not be needed 
because several multigeneration studies have been conducted, most studies suggest that reproductive 
effects occur at higher doses than developmental effects, and there are no toxicokinetic data suggesting 
that reproductive effects would be route-specific.   
 
Developmental Toxicity.    Studies have not addressed the developmental toxicity of ethylene glycol 
in humans.  The developmental toxicity of oral exposure to ethylene glycol has been studied in rats, mice 
and rabbits over a wide range of doses (DePass et al. 1986b; Harris et al. 1992; Lamb et al. 1985; 
Maronpot et al. 1983; Marr et al. 1992; Morrissey et al. 1989; Neeper-Bradley 1990; Neeper-Bradley et 
al. 1995; NTP 1986; Price et al. 1985; Schuler et al. 1984; Tyl 1989; Tyl et al. 1993), indicating that 
further evaluation of the developmental toxicity of orally-administered ethylene glycol toxicity may not 
be warranted.  The most sensitive indicator of developmental toxicity appears to be an increased 
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incidence of malformations, primarily skeletal malformations, in both mice and rats.  Available data 
suggest that malformations appear in mice at lower doses than those which cause malformations in rats.  
As indicated in the discussion of data needs for Acute-Duration Exposure, the acute oral MRL for 
ethylene glycol is based on developmental effects in mice exposed to ethylene glycol daily by gavage on 
Gd 6–15 (Neeper-Bradley et al. 1995; Tyl 1989).  An uncertainty in the acute-duration oral MRL that 
may need to be addressed stems from the use of gavage administration in the MRL study.  Bolus doses 
from gavage administration lead to higher peak blood concentrations of glycolic acid (the proximate 
developmental toxicant) than occur with slower dose-rates associated with environmentally-relevant 
exposures (Carney et al. 2001; Corley et al. 2002; NTP-CERHR 2004).  Because the MRL study used 
gavage administration, the dose at which effects were observed is likely lower than would be observed 
with non-bolus dosing. 
 
Developmental toxicity has also been assessed in rats and mice by the inhalation route.  Results of the 
inhalation developmental studies are generally consistent with the oral findings, but are confounded by 
concurrent oral exposure via ingestion of aerosolized ethylene glycol on the fur of exposed animals (Tyl 
1985, 1988a; Tyl et al. 1995a, 1995b).  The studies included a nose-only inhalation study in mice aimed 
at reducing the confounding oral exposure, but these animals had exposure by ingestion of ethylene glycol 
deposited on the face (Tyl 1988a; Tyl et al. 1995a).  Additionally, stress from restraint in the nose-only 
exposure study may have contributed to the developmental effects observed with ethylene glycol 
(NTP-CERHR 2004), which were similar in nature to effects observed in a study of restrained nose-only 
exposure to water vapor (Tyl et al. 1994).  Because of the confounding oral exposure in both the whole-
body and nose-only studies, as well as the confounding effect of stress due to restraint in the nose-only 
study, additional testing is needed to adequately evaluate developmental effect levels from inhalation 
exposure to ethylene glycol.  Given the problems of oral exposure from deposition of ethylene glycol on 
the fur, the feasibility of conducting an adequate inhalation study is unclear. 
 
A single well-designed study of dermal gestational exposure to ethylene glycol found no developmental 
toxicity in mice (Tyl 1988b; Tyl et al. 1995c).  Additional dermal testing could confirm the apparent low 
potential for developmental toxicity by this route of exposure. 
 
Immunological and Lymphoreticular Effects.    A limited amount of information on 
immunological and lymphoreticular effects of ethylene glycol is available from oral studies in animals.  
There were no histopathological alterations in the spleen, lymph nodes, or thymus, or consistent changes 
in leukocyte counts in rats or mice in acute-, intermediate-, and chronic-duration oral studies of ethylene 
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glycol (Blood 1965; DePass et al. 1986a; Gaunt et al. 1974; Hong et al. 1988; Melnick 1984; NTP 1993; 
Robinson et al. 1990; Schladt et al. 1998).  Immune responses were suppressed in mice administered a 
single 12,000 mg/kg (0.8 LD50) gavage dose of ethylene glycol; effects included increased mortality from 
E. coli-induced infection, decreased number of spleen colony-forming units, decreased numbers of 
antibody-producing cells in spleen to sheep erythrocytes and Vi-agglutinin, decreased activity of natural 
killer cells, decreased antibody-dependent cytotoxicity of splenocytes to sheep erythrocytes, and 
decreased delayed-type hypersensitivity to sheep erythrocytes (Zabrodskii and Germanchuk 2000; 
Zabrodskii et al. 2003).  Other dose levels were not tested in this study.  Although the findings indicate 
that a very high single dose of ethylene glycol was immunotoxic in mice, no studies of immune function 
following repeated acute exposure (e.g., 14 days) or intermediate- or chronic-duration exposure have been 
conducted.  Comprehensive immunological testing that includes a range of dose levels and repeated 
exposures is needed to adequately assess the immunotoxic potential of ethylene glycol. 
 
Neurological Effects.    Information on the neurotoxicity of inhaled ethylene glycol is essentially 
limited to a human study in which subjects were exposed to ethylene glycol aerosol for 20–22 hours/day 
for up to 30 days (Wills et al. 1974).  No effects were seen in electroencephalographs or a battery of 
psychological tests conducted after 14 and 30 days of exposure (23 and 30 mg/m3, respectively); the tests 
evaluated simple reaction time, reaction time with discrimination, visual-motor coordination, depth 
perception, and mental ability (encoding and subtraction accuracy).  There were no clear clinical signs of 
neurotoxicity; slight headache and backache were occasional complaints, but incidence and frequency 
were not reported.  No human or animal studies were located that provide information on neurological 
effects of dermal exposure. 
 
The neurotoxicity of acute oral exposure to large doses of ethylene glycol is well characterized in 
humans.  Adverse neurological reactions are among the first symptoms to appear in human ethylene 
glycol poisoning.  These symptoms are attributable directly to unmetabolized ethylene glycol, resemble 
ethanol intoxication, occur within 30 minutes to 12 hours after exposure, and include ataxia, 
disorientation, restlessness, slurred speech, and somnolence, progressing to convulsions and coma (Cheng 
et al. 1987; Factor and Lava 1987; Gordon and Hunter 1982; Robinson and McCoy 1989; Vale 1979; 
Woolf et al. 1992).  Some evidence exists that damage to the cranial nerves may occur much later in the 
toxic process, especially if supportive therapy is delayed (Chung and Tuso 1989; Factor and Lava 1987; 
Lewis et al. 1997; Mallya et al. 1986; Spillane et al. 1991).   
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Clinical signs of neurotoxicity similar to those in humans summarized above occurred in rats, dogs, and 
cats following administration of large oral bolus doses of ethylene glycol (Beckett and Shields 1971; 
Clark et al. 1979; Dial et al. 1994; Grauer et al. 1987; Penumarthy and Oehme 1975).  No clinical signs of 
neurotoxicity or histopathological changes in brain, spinal cord, or peripheral nerve tissue were observed 
in rats or mice exposed to ethylene glycol in the diet or drinking water in acute-, intermediate-, or 
chronic-duration studies (Blood 1965; DePass et al. 1986a; Gaunt et al. 1974; Melnick 1984; NTP 1993; 
Robinson et al. 1990; Schladt et al. 1998).  Tests of neurobehavioral function have not been conducted in 
orally-exposed animals.  Although there were no effects on neurobehavioral function in humans exposed 
by inhalation (Wills et al. 1974), neurobehavioral testing in orally-exposed animals is needed to 
adequately assess the neurotoxic potential of lower doses of ethylene glycol.   
 
Epidemiological and Human Dosimetry Studies.    A limited amount of epidemiological data on 
ethylene glycol is available from two studies of workers mainly exposed by inhalation with possible 
secondary exposure by the dermal route.  One of these occupational studies evaluated kidney function in a 
small number of aviation workers who were intermittently exposed to ethylene glycol during airplane de-
icing operations over a 2-month winter period (Gérin et al. 1997).  Personal exposures to ethylene glycol 
vapor and aerosol were measured, but most samples were below the detection limit and average levels 
were not reported.  This study found no indication of renal impairment based on a limited number of 
urinary end points (albumin, β-N-acetyl-glucosaminidase, β-2-microglobulin, and retinol-binding 
protein).  The other study assessed renal cancer mortality in 1,666 chemical plant employees and found no 
increase in a small number of workers exposed to unmeasured levels of ethylene glycol (Bond et al. 
1985).  Epidemiological studies of orally-exposed humans are not available, although numerous clinical 
case reports of intentional or accidental ingestion have documented neurological, renal, and other effects 
of high acute doses of ethylene glycol.  The available information suggests that ethylene glycol is likely to 
cause effects in humans similar to those found in animals.  Additional epidemiological studies 
investigating dose-response relationships between ethylene glycol exposure and likely target organ 
toxicity would be useful.  Potential study populations include individuals exposed through dermal contact 
with ethylene glycol-containing automobile antifreeze and individuals who live near hazardous waste 
sites, industrial facilities where ethylene glycol is produced or used, or areas where ethylene glycol-based 
de-icing formulations are used and may be exposed through dermal contact with contaminated soil or 
water, inhalation of ethylene glycol vapor or mist, or ingestion of contaminated groundwater.  
Additionally, occupational exposure through inhalation of ethylene glycol vapor or mist and dermal 
contact is expected for individuals involved in airport de-icing spray operations.  Background exposure of 
the general population is not expected to be important because ethylene glycol is rapidly degraded in air, 
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water, and soil, and available monitoring data indicate that it is only found near areas of release (Atkinson 
1989; Battersby and Wilson 1989; Conway et al. 1983; Kameya et al. 1995; McGahey and Bouwer 1992; 
Revitt and Worrall 2003; Schoenberg et al. 2001; Staples et al. 2001). 
 
Biomarkers of Exposure and Effect.     
 
Exposure.  The only biomarker of exposure that is specific to ethylene glycol is parent compound in the 
blood and urine.  Based on the relatively short half-life of ethylene glycol in the blood and urine (Eder et 
al. 1998; Jacobsen et al. 1988; Peterson et al. 1981), parent compound would likely be detectable only 
within a few hours to 1 day following acute ingestion.  Rapid methods for determining ethylene glycol in 
serum and urine are available for use in the clinical setting (Aarstad et al. 1993; Blandford and Desjardins 
1994), but are often not readily available in emergency situations. 
 
Other identified biomarkers of exposure are not specific to ethylene glycol.  They include ethylene glycol 
metabolites such as glycolic, lactic, and oxalic acids in blood and/or urine; and calcium oxalate 
monohydrate crystals in renal tubules and/or urine.  However, increased blood glycolate above normal 
human background levels is strongly indicative of ethylene glycol exposure and is often used for clinical 
diagnosis or confirmation. 
 
Based on available information regarding the toxicokinetics of ethylene glycol and its metabolites, and 
available methods for identifying parent compound and metabolites in body fluids, it appears that 
ethylene glycol poisoning can be adequately diagnosed in most cases.  Additional studies to assess 
additional potential biomarkers of exposure for ethylene glycol do not appear necessary at this time. 
 
Effect.  Biomarkers of effects exist for ethylene glycol poisoning, but none are specific to ethylene glycol.  
These include clinical manifestations of central nervous system, cardiopulmonary, and renal toxicity, and 
laboratory findings of metabolic acidosis and calcium oxalate crystalluria.  Clinical manifestations 
progress in three main stages.  Signs of central nervous system toxicity appear within 0.5–12 hours 
following acute ingestion, although manifestations suggestive of cranial nerve damage may appear as late 
as 1–2 weeks after exposure (CDC 1987; Cheng et al. 1987; Chung and Tuso 1989; Factor and Lava 
1987; Hess et al. 2004; Leth and Gregersen 2005; Lewis et al. 1997; Mallya et al. 1986; Parry and 
Wallach 1974; Rothman et al. 1986; Spillane et al. 1991; Underwood and Bennett 1973; Zeiss et al. 
1989).  Cardiopulmonary manifestations generally develop after 12–24 hours and renal failure occurs 
after 24–72 hours (Godolphin et al. 1980; Hess et al. 2004; Leth and Gregersen 2005; Parry and Wallach 
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1974; Siew et al. 1975a; Vale 1979; Zeiss et al. 1989).  Ethylene glycol-induced metabolic acidosis 
occurs approximately 12–24 hours following ingestion and is characterized by pronounced serum osmolal 
and anion gaps (Eder et al. 1998; Hess et al. 2004; Hoffman et al. 1993; Gabow et al. 1986; Jacobsen et 
al. 1984; Leth and Gregersen 2005).  Calcium oxalate crystals in the urine can appear 4–8 hours after 
ethylene glycol ingestion, and deposition of crystals in the renal tubules can subsequently result in 
nephropathy and eventual renal failure 24–72 hours after ingestion (CDC 1987; Chung and Tuso 1989; 
Factor and Lava 1987; Godolphin et al. 1980; Heckerling 1987; Jacobsen et al. 1988; Leth and Gregersen 
2005; Parry and Wallach 1974; Rothman et al. 1986; Siew et al. 1975a; Underwood and Bennett 1973).  
Based on the well-characterized sequence of events and toxicity targets of ethylene glycol poisoning, 
studies for additional biomarkers of effect for ethylene glycol do not appear necessary. 
 
Absorption, Distribution, Metabolism, and Excretion.    Additional data are needed to quantify 
the absorption, distribution, metabolism, and excretion of inhaled ethylene glycol across relevant 
concentration ranges in humans and animals.  Only one study evaluating toxicokinetic data in humans 
exposed via inhalation was identified (Carstens et al. 2003).  However, this study is limited by inadequate 
definition of exposure levels and a lack of data on expired CO2.  Similarly, one study of the toxicokinetics 
of inhaled ethylene glycol in animals used only a single vapor and a single aerosol concentration 
(Marshall and Cheng 1983).   
 
Although the human oral absorption of ethylene glycol has not been quantitatively characterized, case 
reports indicate that humans can absorb toxicologically significant amounts of this compound by the oral 
route (Godolphin et al. 1980; Gordon and Hunter 1982; Hewlett et al. 1986; Jacobsen et al. 1984, 1988; 
Karlson-Stiber and Persson 1992; Litovitz et al. 1990, 1991; Peterson et al. 1981; Siew et al. 1975a; 
Walton 1978; Zeiss et al. 1989).  In addition, several case reports (Cheng et al. 1987; Hewlett et al. 1986; 
Jacobsen et al. 1984, 1988; Peterson et al. 1981; Rothman et al. 1986) provide data on plasma levels of 
ethylene glycol or glycolate in humans acutely poisoned with ethylene glycol.  While the tissue levels of 
ethylene glycol in humans exposed orally have not been studied, information on the volume of 
distribution and urine-to-plasma concentration ratios suggest distribution with total body water (Jacobsen 
et al. 1988).  Data on the distribution of radioactivity in mice, rats, and monkeys exposed orally support 
this finding (Frantz et al. 1989, 1991, 1996b, 1996c; McChesney et al. 1971). 
 
The in vivo metabolism of ethylene glycol has been thoroughly studied in rats and mice exposed via 
intravenous, oral, and dermal routes (Frantz et al. 1989, 1991, 1996b, 1996c).  Data on plasma and urinary 
metabolites from these studies support the widely accepted metabolic scheme for ethylene glycol.  
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Because metabolites of ethylene glycol (glycolic and oxalic acids) have been identified as the probable 
proximate toxicants (for both renal and developmental effects), additional data on the specific isozymes 
responsible for metabolizing ethylene glycol and glycolic acid, inter-individual variability in metabolic 
parameters (e.g., polymorphisms in genes encoding these isozymes), and developmental ontogeny of 
these isozymes are needed to better characterize species differences and identify sensitive subpopulations.  
In addition, further information is needed on species differences in metabolic rates and saturation points, 
as available data provide inadequate information on the relative sensitivity of humans and laboratory 
rodents. 
 
Because most human exposure has been associated with acute accidental or intentional poisoning 
incidents, there are few data on the elimination kinetics of ethylene glycol after oral exposure in humans.  
Most of the available estimates of plasma elimination half-lives have been confounded by concurrent 
therapeutic treatments such as ethanol administration or hemodialysis that modify elimination kinetics.  
Elimination of orally-administered ethylene glycol across a broad dose range has been thoroughly studied 
in rats and mice (Frantz et al. 1989, 1991, 1996b, 1996c), and to a more limited extent in monkeys 
(McChesney et al. 1971).  
 
No data describing the kinetics of in vivo human dermal exposure were found in the literature.  The 
in vitro permeability of human skin to ethylene glycol has been studied, with widely varying results.  
Using full-thickness cadaver skin, Loden (1986) estimated a percutanous absorption rate of 
118 μg/cm2/hour with a steady-state concentration of 0.97 mg/cm2, while Driver et al. (1993) estimated 
absorption rates of 0.09–0.25 μg/cm2/hour for three different skin samples.  Although the absorption, 
distribution, metabolism, and elimination of ethylene glycol administered dermally has been thoroughly 
studied in rats and mice (Frantz et al. 1989, 1991, 1996b, 1996c), acute in vivo studies in humans are 
needed to better characterize the toxicokinetics for this route of exposure. 
 
All of the toxicokinetic data in humans and animals were collected after acute exposures to ethylene 
glycol; there are no data on toxicokinetics after intermediate- or chronic-duration exposures.  
Intermediate- and chronic-duration data are needed in order to adequately assess absorption, metabolism, 
and elimination with prolonged exposure.  Studies with heated ethylene glycol would be useful due to the 
potential increased toxicity of ethylene glycol when it is heated (e.g., through its use as an automobile 
antifreeze/coolant). 
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Comparative Toxicokinetics.    Species differences in in vivo toxicokinetics are not well 
characterized.  While there are high quality toxicokinetic data comparing absorption, distribution, 
metabolism, and excretion in mice and rats (Frantz et al. 1989, 1991, 1996a, 1996b, 1996c), available data 
in other species (Hewlett et al. 1989; McChesney et al. 1971) are more limited; in many cases, only single 
dose levels were used, the numbers of animals per dose were small, and mass balance information was 
incomplete.  Available data in humans are limited to acute, high-dose exposures, with toxicokinetic data 
often confounded by the effects of therapeutic interventions.   
 
Using a PBPK model for humans, Corley et al. (2005a) estimated that the threshold glycolic acid 
concentration for developmental effects in rodents (considered by the authors to be a peak of 2 mM) 
would only be reached in human females ingesting doses of 350 mg/kg (assuming a 58-kg female).  
However, the model was not calibrated to pregnancy, and it is not clear whether physiological and/or 
biochemical changes that could affect ethylene glycol toxicokinetics might occur during pregnancy. 
 
Slikker et al. (2004) reported that there are species-specific differences in the transfer of glycolic acid, the 
primary metabolite and putative developmental toxicant associated with ethylene glycol exposure, from 
maternal blood to conceptus.  NTP-CERHR (2004) noted that the inverted yolk sac placenta that develops 
in both mice and rats tends to concentrate weak acids including glycolic acid; neither humans nor rabbits 
develop a yolk sac placenta.  A preliminary study by Carney and coworkers (2001) showed that glycolic 
acid does not concentrate in rabbit embryonic fluids, while Corley et al. (2002) have shown in rats that 
glycolic acid is consistently higher in the conceptus compared to the maternal blood.  In addition, fetal 
and/or placental differences in expression of enzymes metabolizing ethylene glycol and glycolic acid over 
the course of gestation will affect local concentrations of glycolic acid to which the developing conceptus 
is exposed, yet little is known about species differences in the ontogeny of these enzymes (NTP-CERHR 
2004).   
 
Additional data are needed to reduce uncertainty in the saturation concentration of glycolic acid in 
humans.  Although in vitro data suggested that humans may metabolize glycolic acid more efficiently 
than rats (Corley et al. 2005a; Booth et al. 2004), there are no in vivo human data to confirm this 
observation. 
 
Methods for Reducing Toxic Effects.    No studies were found describing methods to reduce peak 
absorption of ethylene glycol after inhalation exposure.  After oral exposure, gastric lavage and possibly 
activated charcoal may be of benefit in reducing absorption, but only if performed within 1–2 hours 
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following ingestion (Barceloux et al. 1999; Egbert and Abraham 1999; Leth and Gregersen 2005).  
Dermal absorption can be minimized through washing the skin with soap to remove any existing ethylene 
glycol.  Copious irrigation with water or saline can aid in ocular decontamination. 
 
Clinical procedures for treating ethylene glycol poisoning focus on reducing the body burden of ethylene 
glycol and its toxic metabolites, interference with toxic metabolite formation (which results in increased 
urinary excretion of parent compound), increased elimination of toxic metabolites produced, reduction of 
metabolic acidosis, and prevention of kidney failure.  Procedures include administration of antidotes 
(ethanol or fomepizole), intravenous bicarbonate and hydration for profound acidemia, and hemodialysis 
for refractory acidosis (Barceloux et al. 1999; Egbert and Abraham 1999; Gardner et al. 2004; Leth and 
Gregersen 2005; Scalley et al. 2002). 
 
Antidotes for ethylene glycol include the alcohol dehydrogenase inhibitors, ethanol and fomepizole, 
which act to decrease the alcohol dehydrogenase-catalyzed metabolism of ethylene glycol, thus 
effectively increasing the urinary excretion of ethylene glycol (Barceloux et al. 1999; Egbert and 
Abraham 1999; Gardner et al. 2004; Leth and Gregersen 2005). 
 
Intravenous fluid administration may be initiated early to increase urine output, which effectively 
increases the excretion of ethylene glycol and toxic metabolites such as glycolic and oxalic acids (Egbert 
and Abraham 1999).  Sodium bicarbonate infusion is used to correct metabolic acidosis, increase 
elimination of renal glycolic acid, and inhibit the precipitation of calcium oxalate crystals (Egbert and 
Abraham 1999; Leth and Gregersen 2005; Scalley et al. 2002). 
 
Hemodialysis can effectively remove ethylene glycol and the acid metabolites, glycolic and oxalic acids, 
because they have low molecular weights and do not exhibit protein binding (Egbert and Abraham 1999). 
 
Thiamine (vitamin B1) and pyroxidine (vitamin B6) are co-factors for the metabolism of ethylene glycol 
and may reduce toxicity by assisting in the formation of relatively nontoxic metabolites (Egbert and 
Abraham 1999; Gardner et al. 2004; Goldfrank et al. 2002; Leth and Gregersen 2005; Scalley et al. 2002).  
However the efficacy of treatment with thiamine and pyroxidine has not been demonstrated in human 
cases of ethylene glycol poisoning. 
 
There are no documented methods for interfering with mechanisms of action for toxic effects of ethylene 
glycol and its potent metabolites. 
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Additional information that might be useful in treating ethylene glycol poisoning include studies designed 
to identify additional methods to reduce the body burden of ethylene glycol and its toxic metabolites and 
studies designed to elucidate methods for interfering with mechanisms of action. 
 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
 
A limited amount of information on health effects of ethylene glycol in children is available from several 
case reports of patients admitted to hospitals for treatment of acute oral poisoning (Baum et al. 1999; 
Boyer et al. 2001; Caravati et al. 2004; Harry et al. 1998).  The effects in these pediatric patients were 
largely consistent with the first stage of ethylene glycol poisoning in adults (e.g., central nervous system 
depression, metabolic changes, gastrointestinal upset).  Treatment with fomepizole (4-methylpyrazole), 
alone or in combination with other methods, generally mitigated the progression of the clinical course to 
the second and third stages of ethylene glycol poisoning (pronounced metabolic acidosis, 
cardiopulmonary compromise, and renal insufficiency) and led to full recovery.  The case reports are 
consistent with an expectation that health effects in children and adults are similar.  Although there are no 
known differences in the toxicity of ethylene glycol between adults and children, there is no evidence to 
substantiate the presumption.  There is no evidence to indicate that children are likely to be exposed to 
higher or lower amounts of ethylene glycol from everyday living, suggesting that children are perhaps 
equally at risk for non-accidental/non-intentional acute oral exposure and potential toxic side effects.  
Information is lacking on the toxicity of longer duration exposures in children, as well as on 
developmental effects in children. 
 
No studies are available that describe potential differences in the toxicokinetics or the mechanism of 
action of ethylene glycol in children.  Glycolic acid is the major toxic metabolite contributing to 
metabolic acidosis, which is a primary cause of systemic toxicity in children as well as adults following 
exposure to ethylene glycol.  Glycolic acid has also been identified as the proximate cause of the 
developmental effects in animals observed with ethylene glycol exposure (NTP-CERHR 2004; Slikker et 
al. 2004).   
 
Limited mechanistic information suggests that humans may be less sensitive than rodents to the 
developmental effects of ethylene glycol.  Two in vitro studies (Booth et al. 2004; Corley et al. 2005a) 
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suggested that humans metabolize glycolic acid more efficiently than rats, although the data supporting 
the glycolic acid metabolic rate in humans are limited (NTP-CERHR 2004).  Additionally, NTP-CERHR 
(2004) reviewed preliminary data indicating that the inverted yolk sac placenta, a stage in placental 
development that occurs in rats and mice but does not exist in humans or rabbits, tends to concentrate 
weak acids such as glycolic acid in the embryonic fluids.  These data suggest enhanced sensitivity to 
ethylene glycol developmental effects in rodents compared with humans, although NTP-CERHR (2004) 
characterized the available data as inconclusive.   
 
Ethylene glycol metabolism is known to involve alcohol dehydrogenase and aldehyde dehydrogenase, 
and may also involve cytochrome P450 isozymes (NTP-CERHR 2004).  Polymorphisms in the genes 
encoding these enzymes may lead to wide variability in the production and elimination of glycolic acid 
and other metabolites in humans exposed to ethylene glycol, but data quantifying the range of variability 
are not currently available (NTP-CERHR 2004).  In addition, fetal and/or placental differences in 
expression of these enzymes over the course of gestation will affect local concentrations of glycolic acid 
and other metabolites to which the developing conceptus is exposed, yet little is known about these 
differences (NTP-CERHR 2004). 
 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
 
3.12.3   Ongoing Studies  
 
No relevant health effects studies for ethylene glycol were located in the Federal Research in Progress 
database (FEDRIP 2007). 
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4.  CHEMICAL AND PHYSICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY  
 
Information regarding the chemical identity of ethylene glycol is located in Table 4-1.  This information 
includes synonyms, chemical formula and structure, and identification numbers. 
 
4.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
Information regarding the physical and chemical properties of ethylene glycol is located in Table 4-2. 
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Table 4-1.  Chemical Identity of Ethylene Glycola 
 
Characteristic Information 
Chemical name Ethylene glycol 
Synonyms and trade names 1,2-Dihydroxyethane; 1,2-ethandiol; 1,2-ethane-diol; 
2-hydroxyethanol; ethylene alcohol; ethylene dihydrate; glycol; 
monoethylene glycol; MEG; Lutrol-9; Dowtherm Sr 1; Fridex; 
Norkool; Ramp; Tescol; Ucar 17 





Identification numbers:  
 CAS registry 107-21-1 
 NIOSH RTECS KW2975000b 
 EPA hazardous waste No data 
 DOT/UN/NA/IMDG shipping No data 
 HSDB 5012 
 NCI C00920 
 
aAll information obtained from HSDB 2007 except where noted. 
bRTECS 2007 
 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances 
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Table 4-2.  Physical and Chemical Properties of Ethylene Glycola 
 
Property Ethylene glycol 
Molecular weight 62.07 
Color Clear, colorlessb 
Physical state Liquidb 
Melting point -12.69 °Cc 
Boiling point 197.3 °Cc 
Density:  
 at 20 °C (g/cm3) 1.1135d 
Vapor density 2.14 (air=1) 
Odor Odorless 
Odor threshold No data 
Solubility:   
 Water at 20 °C Miscible with water 
 Organic solvent(s) Soluble in lower aliphatic alcohols, glycerol, acetic acid, acetone; 
slightly soluble in ether; practically insoluble in benzene, chlorinated 
hydrocarbons, petroleum ether, oils. 
Partition coefficients:  
 Log Kow -1.36e 
 Koc 1 (estimated) 
Vapor pressure at 25 °C 0.089 mm Hg (extrapolated)f 
Henry's law constant at 25 °C 6x10-8 atm-m3/moleg 
Autoignition temperature 398 °C 
Flashpoint 127 °Ch 
Explosive limits 3.20–53%i 
Conversion factors 1 ppm = 2.58 mg/m3 
1 mg/m3 = 0.39 ppm 
 
aAll information obtained from HSDB 2007, except where noted. 
bLewis 2001 
cLide 2005 
dO'Neil et al. 2001 
eHansch et al. 1995 
fAIChE 1995 
gHine and Mookerjee 1975 
hForkner et al. 2004 
iRebsdat and Mayer 2005 
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
5.1   PRODUCTION 
 
Commercial production of ethylene glycol in the United States began in 1925 (McClelland and Rector 
1951; Miller 1966).  The reported U.S. production volume was 2.189 million pounds (993 metric tons) 
during that year (McClelland and Rector 1951).  Large-scale commercial use of ethylene glycol as an 
antifreeze began in 1930; this use led to a strong demand for ethylene glycol, especially during and after 
World War II (Brown et al. 1980; McClelland and Rector 1951).  Production volume information is not 
available for this period.  By 1950, the U.S. production volume had risen to 510 million pounds 
(230,000 metric tons) (Brown et al. 1980; McClelland and Rector 1951).  Production continued to rise 
steadily, reaching approximately 900,000 metric tons by 1968 (Brown et al. 1980).  Ethylene glycol 
production rose more dramatically in late 1960s and early 1970s due to the additional demand for use of 
this substance in the manufacturing of polyester fiber and film (Brown et al. 1980; CMR 1972, 1975).  
Production in 1970 was approximately 1,400,000 metric tons (Brown et al. 1980).  Production fluctuated 
between 1,500,000 and 1,800,000 metric tons over the next 18 years, reaching 1,820,000 metric tons by 
1978 (Brown et al. 1980). 
 
Production volume information is not available for years following 1978; however, production capacity 
data for the 1980s, 1990s, and early 2000s have been located.  Total reported U.S. production capacities 
were 2,638,000 metric tons during 1981, 2,820,000 metric tons during 1990, 3,727,000 metric tons during 
2001, and 3,402,000 metric tons during 2006 (CMR 1981, 1990, 2001; SRI 2006).  The growth of 
ethylene glycol production capacity over these decades has been attributed to the demand for this 
substance in the manufacture of plastics, especially polyethylene terephthalate (PET) resin bottles (CMR 
1981, 1987, 1984, 1990, 1993, 1998, 2001, 2004).  The companies that produced ethylene glycol in the 
United States, their production sites, and their annual capacities during 2006 (the most recent year for 
which figures are available) are shown in Table 5-1 (SRI 2006). 
 
Table 5-2 summarizes the number of facilities in each state that manufactured or processed ethylene 
glycol in 2005, the ranges of maximum amounts on site, if reported, and the activities and uses as 
reported in the Toxics Release Inventory (TRI) (TRI05 2007).  The data listed in this table should be used 
with caution since only certain types of facilities are required to report.  This is not an exhaustive list. 
 
The first method used in the commercial production of ethylene glycol in the United States was the 
conversion of chlorohydrin to ethylene oxide and subsequent hydrolysis to ethylene glycol (Forkner et al.  
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Table 5-1.  Companies that Produce Ethylene Glycol in the United States  







The Dow Chemical Company Plaquemine, Louisiana 550 249,500 
 Seadrift, Texas 625 283,600 
 Taft, Louisiana 1,700 771,300 
Eastman Chemical Company    
Voridian Division Longview, Texas 230 104,400 
Equistar Chemicals, LP Bayport, Texas 580 263,100 
Formosa Plastics Corporation, USA Point Comfort, Texas 693 314,400 
Huntsman LLC    
Huntsman Performance Products Port Neches, Texas 560 254,100 
Old World Industries, Inc. Pasadena, Texas 695 315,300 
PD Glycol Beaumont, Texas 790 358,400 
Shell Chemical Company Geismar Louisiana 1,075 487,700 
Total  7,498 3,402,000 
 
Source:  SRI 2006 
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amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
AK 8 10,000 9,999,999 2, 3, 4, 7, 9, 12 
AL 69 0 99,999,999 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14 
AR 42 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
AZ 32 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
CA 159 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 
CO 42 0 49,999,999 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12 
CT 21 1,000 999,999 1, 5, 6, 7, 8, 9, 11, 12 
DE 27 0 999,999 1, 5, 6, 7, 8, 10, 11, 12, 13 
FL 62 0 49,999,999 2, 3, 4, 6, 7, 8, 9, 10, 11, 12 
GA 99 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
HI 2 10,000 999,999 12 
IA 74 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
ID 27 0 999,999 1, 2, 3, 5, 7, 8, 10, 11, 12 
IL 147 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
IN 105 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
KS 58 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
KY 83 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 
LA 106 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
MA 64 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
MD 45 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
ME 18 1,000 999,999 1, 2, 3, 5, 6, 7, 9, 10, 11, 12, 14 
MI 134 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MN 65 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MO 108 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
MS 49 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
MT 18 1,000 999,999 2, 3, 4, 7, 8, 9, 10, 11, 12 
NC 136 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
ND 10 1,000 9,999,999 7, 8, 9, 10, 11, 12 
NE 24 0 9,999,999 2, 3, 4, 7, 8, 9, 10, 11, 12 
NH 21 0 99,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
NJ 152 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
NM 25 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
NV 15 0 999,999 1, 2, 3, 4, 5, 6, 7, 11, 12, 13 
NY 82 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OH 134 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
OK 54 0 9,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12 
OR 44 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
PA 114 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
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amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
PR 47 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
RI 31 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
SC 104 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
SD 5 1,000 99,999 7, 8, 11, 12 
TN 108 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
TX 251 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
UT 30 100 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 
VA 98 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
VT 8 0 99,999 11, 12 
WA 52 0 99,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 14 
WI 92 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
WV 82 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
WY 14 100 9,999,999 2, 3, 4, 7, 9, 10, 11, 12 
 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Onsite use/processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Impurity 
7.  Reactant 
8.  Formulation Component 
9.  Article Component 
10.  Repackaging 
11.  Chemical Processing Aid 
12.  Manufacturing Aid  
13.  Ancillary/Other Uses 
14.  Process Impurity 
 
Source:  TRI05 2007 (Data are from 2005) 
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2004; Rebsdat and Mayer 2005).  A second method was introduced in 1937, the direct oxidation of 
ethylene to ethylene oxide followed by hydrolysis to ethylene glycol (Brown et al. 1980; Forkner et al. 
2004).  This soon became the primary method for the production of ethylene glycol and is currently the 
only method used in the United States (Brown et al. 1980; Forkner et al. 2004; Rebsdat and Mayer 2005). 
 
Other methods that have been used to manufacture ethylene glycol include the direct oxidation of 
ethylene and synthesis from carbon monoxide, methanol, hydrogen, and formaldehyde (Forkner et al. 
2004; Rebsdat and Mayer 2005).  The methanol and formaldehyde used in the latter method is obtained 
from syngas, which is originally obtained from coal. 
 
Ethylene oxide is converted to ethylene glycol through uncatalyzed neutral hydrolysis (pH 6–10) in the 
presence of a large excess of water at high temperatures and pressures (Forkner et al. 2004; Rebsdat and 
Mayer 2005).  Selectivity of ethylene glycol is 89–91% in this process.  The primary byproduct is 
diethylene glycol with higher glycols such as triethylene and tetraethylene glycols formed in smaller 
amounts.  The product mixture is fed through a series of evaporators to remove the water and then 
through vacuum distillation for separation and refinement of the individual glycols.   
 
5.2   IMPORT/EXPORT  
 
Both U.S. imports and exports of ethylene glycol have increased since the 1970s.  Annual ethylene glycol 
imports rose from 29,300 metric tons in 1977 to 289,000 metric tons in 2006, while annual exports rose 
from 56,800 metric tons in 1978 to 573,000 metric tons in 2006 (HSDB 2007; ITA 2007).  From 2000 to 
2006, the average annual U.S. import and export quantities were 317,000 and 556,000 metric tons, 
respectively (ITA 2007).  Annual U.S. ethylene glycol import and export quantities reported for different 
years are listed in Table 5-3.  Over 70% of the ethylene glycol imported into the United States during 
2006 was imported from Saudi Arabia (114,846 metric tons) and Canada (93,669 metric tons) (ITA 
2007).  
 
5.3   USE  
 
Ethylene glycol has been used in a wide variety of industrial applications because of its unique chemical 
and physical properties.  Ethylene glycol dissolves in water and is miscible in alcohol and acetone, has the 
capacity to hold large amounts of heat before boiling, and lowers the freezing point of water (Lewis 2001; 
O'Neil et al. 2001; Rebsdat and Mayer 2005).  In addition, ethylene glycol is hygroscopic (has the ability 
to absorb twice its weight in water), is suitable for use as an industrial humectant (drying agent), and  
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Table 5-3.  U.S. Ethylene Glycol Imports and Exports by Year in Metric Tons 
 
Year Imports Exports Reference 
1977 29,300 NA HSDB 2007 
1978 NA 56,800 HSDB 2007 
1982 17,000 NA HSDB 2007 
1983 NA 31,600 HSDB 2007 
1985 130,000 270,000 HSDB 2007 
1986 156,980 NA CMR 1987 
1989 167,869 NA CMR 1990 
1994 239,000 423,000 CMR 1996 
1997 172,000 898,000 CMR 1998 
2000 287,000 534,000 ITA 2007 
2001 332,000 334,000 ITA 2007 
2002 363,000 527,000 ITA 2007 
2003 316,000 660,000 ITA 2007 
2004 277,000 724,000 ITA 2007 
2005 351,000 540,000 ITA 2007 
2006 289,000 573,000 ITA 2007 
 
NA = not available 
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possesses excellent solvent properties (Forkner et al. 2004; Lewis 2001; O'Neil et al. 2001).  
Approximately 35% of all ethylene glycol produced is used to make PET solid-state resins, 26% is used 
in antifreeze, 24% is used to make polyester fibers, 4% is used to make polyester film, 3% is used in PET 
chip resin exports, and 8% is used in surface coatings, polyester and alkyd resins, chemical intermediates, 
and other miscellaneous industrial applications (CMR 2004).  
 
Ethylene glycol plays an essential role in the transportation industry, where it is used as an ingredient in 
hydraulic brake fluids, as the major component in automotive antifreeze/coolant, and as a component of 
de-icing fluids for aircraft, runways, and taxiways (Forkner et al. 2004; Lewis 2001; O'Neil et al. 2001; 
Rebsdat and Mayer 2005).  Another important industrial use for ethylene glycol is as an intermediate in 
the synthesis of esters, ethers, and resinous products, particularly polyester fibers and resins (O'Neil et al. 
2001; Rowe and Wolf 1982).  As a solvent, ethylene glycol is used in the paint and plastic industries in 
the formulation of printers' inks, stamp pad inks, and inks for ball point pens, and as a softening agent in 
cellophane (O'Neil et al. 2001).  Ethylene glycol has also been used as a stabilizer for soy bean foam used 
in fire extinguishers and in the manufacture of explosives, plasticizers, elastomers, and synthetic waxes 
(Lewis 2001; O'Neil et al. 2001).  According to Browning (1965), small amounts of ethylene glycol have 
been used in pharmaceutical preparations (components of skin lotions and powders, and as a substitute for 
glycerin); more recent information describing this use has not been located.   
 
5.4   DISPOSAL  
 
Two promising methods for the complete (>99%) destruction of ethylene glycol in waste water are 
ultraviolet (UV) light-catalyzed oxidation and supercritical oxidation.  In the UV light-catalyzed 
oxidation method, ethylene glycol-containing waste water in the presence of 10% hydrogen peroxide is 
oxidized by UV irradiation (200–250 nm) with light from a mercury lamp (DOE 1993b).  The 
UV/hydrogen peroxide undergoes photochemical decomposition to produce OH radicals that are strong 
oxidants capable of oxidizing most organic compounds stepwise to complete mineralization (e.g., carbon 
dioxide and water).  In the supercritical water oxidation method, the waste water is subjected to oxidation 
at >550 °C and 4,000 psi pressure with a residence time of <30 seconds (DOE 1993a).  
 
A new technology, in situ vitrification (a thermal treatment technology) (Drajun 1991), has shown 
potential for the remediation of soil contaminated with ethylene glycol.  During the in situ vitrification 
process, contaminated soil is transformed into silicate glass using large amounts of electrical energy and a 
crystalline product similar to obsidian is formed.  Another novel approach involving an encapsulated 
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biooxidation method proposes that sodium percarbonate encapsulated in polyvinylidene chloride be 
inserted in subsurface soil by a method called hydraulic fracturing.  Oxygen slowly released from the 
encapsulated sodium percarbonate increases the number of glycol-degrading organisms.  This method is 
expected to remediate soils contaminated with glycols via enhanced aerobic biodegradation in subsurface 
soils (Vesper et al. 1994). 
 
Distillation of used automobile and heavy duty engine coolant under reduced pressure has been assessed 
to be an acceptable technology for recycling ethylene glycol in terms of economic potential, waste 
reduction potential, and product quality that meets both American Society for Testing and Materials 
(ASTM) and SAE standards (EPA 1993d).   
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6.  POTENTIAL FOR HUMAN EXPOSURE 
 
6.1   OVERVIEW  
 
Ethylene glycol has been identified in at least 37 of the 1,689 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number 
of sites evaluated for ethylene glycol is not known.  The frequency of these sites can be seen in 
Figure 6-1. 
 
Ethylene glycol is released to the environment in manufacturing and processing waste streams and as the 
result of disposal of industrial and consumer products containing this compound.  The major sources of 
release are from the disposal of used antifreeze and the use of de-icing solutions at airports.  When 
released to the environment, ethylene glycol is expected to partition to surface water and groundwater.  
Because of its high solubility in water and lack of adsorption or partitioning into soils, ethylene glycol 
will have a high mobility in soil and potential to leach into groundwater.  Volatilization from moist soil 
and water surfaces is not expected to be important based on its Henry's law constant. 
 
Ethylene glycol degrades rapidly in all environmental media and it does not bioaccumulate.  
Biodegradation is the most important transformation process in water and soil.  Based on available data, 
ethylene glycol is biodegraded in soil and water under both aerobic and anaerobic conditions within a day 
to a few weeks.  Aerosols or vapors released to the atmosphere readily undergo photochemical oxidation 
with an estimated half-life of 1.4 days.  Background concentrations of ethylene glycol in air, water, soil, 
and sediment are not available.  Reported ethylene glycol vapor concentrations up to 22 mg/m3 have been 
measured in the air surrounding airport de-icing operations. 
 
The most important routes of exposure to ethylene glycol for members of the general population are 
dermal contact with ethylene glycol-based antifreeze and intentional or accidental oral exposures.  In 
occupational settings, workers are exposed via dermal contact and possibly inhalation during activities 
involving the heating or spray application of fluids containing this compound.   
 
6.2   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time  
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employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005). 
 
6.2.1   Air  
 
Estimated releases of 2.9 million pounds (1,300 metric tons) of ethylene glycol to the atmosphere from 
1,487 domestic manufacturing and processing facilities in 2005, accounted for about 29% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are 
summarized in Table 6-1. 
 
During the application of de-icing solutions to aircraft, an estimated 49–80% of de-icing solutions 
containing ethylene glycol are released on airport runway aprons.  The remainder is retained on the 
aircraft or is immediately dispersed to the air (Sills and Blakeslee 1992). 
 
Ethylene glycol has been identified in air samples collected at 2 of the 37 NPL hazardous waste sites 
where it was detected in some environmental media (HazDat 2007).   
 
6.2.2   Water  
 
Estimated releases of 0.54 million pounds (250 metric tons) of ethylene glycol to surface water from 
1,487 domestic manufacturing and processing facilities in 2005, accounted for about 6% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).   
 
Ethylene glycol is released to surface waters in waste water from production and processing facilities, 
from spills, in runoff (e.g., through the use of the compounds as de-icing fluids), and in the disposal of 
used antifreeze (Christian and Moorehead 1985; EPA 2000; Ware 1988).  Ethylene and propylene glycol 
concentrations up to 19,000 mg/L (ppm) were detected in storm water runoff at the Salt Lake City Airport 
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Ethylene Glycola 
 
 Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and 
off-site 
AK 3 49 No data 0 0 0 49 0 49 
AL 28 21,793 5 0 125,255 3,996 146,803 4,246 151,049 
AR 9 10,109 3,936 9,149 50 0 23,244 0 23,244 
AZ 17 17,285 No data 0 11,005 0 28,290 0 28,290 
CA 90 78,185 15 1,021 91,829 39 151,955 19,134 171,088 
CO 16 6,418 1,534 0 5 440 7,957 440 8,397 
CT 8 485 0 0 11 0 485 11 496 
DE 5 265 441 0 0 250 706 250 956 
FL 32 13,489 0 1,780 3,647 0 15,359 3,557 18,916 
GA 56 13,540 1,255 0 12,250 273 20,558 6,760 27,318 
IA 31 17,944 630 0 1,973 19,150 18,574 21,123 39,697 
ID 3 256 0 0 11,983 0 11,989 250 12,239 
IL 91 66,545 6,094 0 49,449 2,470 72,644 51,914 124,558 
IN 51 21,299 12,805 2,200 184,206 816 37,709 183,617 221,326 
KS 15 17,961 No data 0 0 0 17,961 0 17,961 
KY 32 12,727 4,689 0 10,926 0 26,414 1,928 28,342 
LA 48 66,510 8,395 17,293 151,332 0 232,626 10,904 243,530 
MA 24 13,882 0 0 569 2,682 13,882 3,251 17,133 
MD 20 6,699 0 0 775 1,528 6,699 2,303 9,002 
ME 1 1,584 No data 0 250 0 1,584 250 1,834 
MI 66 30,954 470 0 193,543 25,652 35,641 214,978 250,618 
MN 30 23,317 6,323 0 2 9,435 29,640 9,437 39,077 
MO 48 6,234 0 0 62 325 6,296 325 6,621 
MS 10 70,756 24,005 0 1,040 0 94,766 1,035 95,801 
MT 7 2,838 1,210 0 37,778 263 41,798 291 42,088 
NC 59 426,179 19,421 0 49,957 20,065 456,210 59,412 515,622 
ND 5 0 0 0 0 2,898 0 2,898 2,898 
NE 9 6,952 0 0 2,471 1,358 7,023 3,758 10,781 
NH 2 250 No data 0 0 0 250 0 250 
NJ 49 21,757 2,579 0 2,648 3,491 24,438 6,037 30,475 
NM 9 2,157 10 2,737 0 2,953 2,167 5,690 7,857 
NV 4 6 No data 0 194,638 0 194,644 0 194,644 
NY 28 3,262 22,390 0 2 44,200 25,652 44,202 69,854 
OH 95 70,121 16,725 490,427 30,028 8,515 582,488 33,328 615,816 
OK 26 39,376 0 7,204 79,654 73 126,220 87 126,307 
OR 18 8,406 5 0 0 13 8,411 13 8,424 
PA 73 19,316 4,701 18,000 10,464 87,549 43,540 96,490 140,030 
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Ethylene Glycola 
 
 Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and 
off-site 
PR 16 26,960 0 0 164,831 0 26,960 164,831 191,791 
RI 9 1,129 0 0 130 0 1,129 130 1,259 
SC 49 537,162 43,890 0 4,290 25,449 581,051 29,739 610,790 
SD 1 0 No data 0 0 0 No data 0 0 
TN 28 185,878 246,538 0 141,436 260 442,297 131,815 574,112 
TX 154 259,642 110,634 1,297,195 104,527 38,215 1,360,388 449,824 1,810,213 
UT 8 20,792 No data 0 0 212 20,792 212 21,004 
VA 24 403,344 350 0 9,286 0 412,960 20 412,980 
VT 1 0 256 0 208 176 256 384 640 
WA 17 18,203 0 0 444 24,236 18,203 24,680 42,883 
WI 44 130,007 3,922 0 1,290 1,985 133,935 3,270 137,205 
WV 15 149,596 698 0 40,247 371 181,663 9,249 190,912 
WY 3 5 No data 0 250 0 5 250 255 
Total 1,487 2,851,624 543,926 1,847,006 1,724,741 329,338 5,694,311 1,602,323 7,296,634 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dNumber of reporting facilities. 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
 
Source:  TRI05 2007 (Data are from 2005) 
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in Utah, and airport runoff was found to contain up to 3,100 mg/L (ppm) at the Toronto International 
Airport in Canada and up to 5,050 mg/L (ppm) at the Denver Airport in Colorado (Sills and Blakeslee 
1992).  Ethylene glycol was detected, but not quantified, in effluents from a chemical plant in 
Brandenburg, Kentucky (EPA 1976).  
 
EPA (2000) estimated that 21 million gallons of aircraft deicing fluid (including both ethylene and 
propylene glycol-based fluids) are discharged to surface waters per year in the United States with an 
additional 2 million gallons discharged to publicly owned treatment works (POTWs).  These releases are 
expected to decrease as source reduction technologies and recycling/recovery systems are improved.  
Airports that have updated equipment and collection systems have achieved a 70% collection efficiency 
on average.   
 
Ethylene glycol that is released onto the ground when used in aircraft de-icing fluid may contaminate 
nearby groundwater (Corsi et al. 2001a).  Groundwater samples collected from a perched water table at 
the Ottawa Airport in Canada contained 415 mg/L (ppm) of ethylene glycol (Sills and Blakeslee 1992).   
 
Ethylene glycol has been identified in surface water and groundwater samples collected at 1 and 7 of the 
37 NPL hazardous waste sites, respectively, where it was detected in some environmental media (HazDat 
2007).   
 
6.2.3   Soil  
 
Estimated releases of 1.7 million pounds (780 metric tons) of ethylene glycol to soils from 
1,487 domestic manufacturing and processing facilities in 2005, accounted for about 17% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).  An additional 
1.9 million pounds (840 metric tons), constituting about 19% of the total environmental emissions, were 
released via underground injection (TRI05 2007).  These releases are summarized in Table 6-1. 
 
The major sources of ethylene glycol release to soil are from the disposal of used antifreeze fluids and de-
icing fluids containing this compound (EPA 1979, 1987a; Ware 1988).  Ethylene glycol may also be 
released to soil via natural processes associated with the metabolism of ethylene by plants (Blomstrom 
and Beyer 1980).  
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Ethylene glycol has been identified in soil and sediment samples collected at 2 and 1 of the 37 NPL 
hazardous waste sites, respectively, where it was detected in some environmental media (HazDat 2007).   
 
6.3   ENVIRONMENTAL FATE  
 
6.3.1   Transport and Partitioning  
 
Ethylene glycol has a low vapor pressure (0.089 mm Hg at 25 °C) and is miscible with water (see 
Table 4-2).  If released to the atmosphere (e.g., as vapors generated at elevated temperatures), ethylene 
glycol should exist almost entirely in the vapor phase (Eisenreich et al. 1981).  The high solubility of 
ethylene glycol in water ensures that at least partial removal of the compound will occur by wet 
deposition.  The low Henry's law constant value for this compound (6.00x10-8 atm-m3/mole, see 
Table 4-2) suggests that ethylene glycol released to surface water will not partition to the atmosphere via 
volatilization (Simmons et al. 1976; Thomas 1990).  Ethylene glycol is not expected to adsorb to 
sediment or soil particulates based on an estimated Koc value of 1 (see Table 4-2).  Based on the low Koc 
value (see Table 4-2), ethylene glycol is expected to have a very high mobility in soil and could leach into 
groundwater (Swann et al. 1983). 
 
The low octanol/water partition coefficient (Kow) value of -1.36 (see Table 4-2) suggests that 
bioconcentration and biomagnification of ethylene glycol are not likely to occur.  Laboratory testing with 
this compound confirms insignificant bioconcentration in fish (Freitag et al. 1985).  The bioconcentration 
factor (BCF) for ethylene glycol in fish (Golden ide) was 10 after 3 days of exposure.  
  
Ethylene glycol is expected to be highly mobile, particularly in moist soils, and it may leach into 
groundwater upon release to surface soils.  In laboratory studies, ethylene glycol was found to percolate 
rapidly through soil columns with little or no adsorption (LA DOTD 1989; Løkke 1984); however, rapid 
biodegradation is expected to limit the extent of leaching through soil (see Section 6.3.2.3).  The 
compound may also volatilize from dry surface soils (EPA 1979, 1987a; Hine and Mookerjee 1975).  In 
dry soils, ethylene glycol liquid can enter the soil system and travel through the porous media before 
contacting free water.  Amoozegar et al. (1986) reported that in dry soils (<1% water) the rate of ethylene 
glycol movement was the slowest of 6 organic liquids tested (toluene, xylene, kerosene, acetone, and 
isopropyl alcohol).  
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6.3.2   Transformation and Degradation  
 
6.3.2.1   Air  
 
Ethylene glycol released to the atmosphere is expected to undergo rapid photochemical oxidation via 
reaction with hydroxyl radicals.  The half-life for the photochemical oxidation of ethylene glycol is 
1.4 days calculated using a measured reaction rate constant of 7.7x10-12 cm3/molecule-second at 25 °C, 
assuming a 12-hour day and an average day-light atmospheric hydroxyl radical concentration of 
1.5x106 radicals/cm3 (Atkinson 1989; EPA 1993e).  Direct photolysis of ethylene glycol is not expected 
since alcohols do not absorb UV light at environmental wavelengths (above 295 nm) (Boethling and 
Mackay 2000). 
 
6.3.2.2   Water  
 
Biodegradation is the most important transformation process for ethylene glycol in surface waters under 
both aerobic and anaerobic conditions (Staples et al. 2001).  In screening tests using aerobic sewage 
sludge inocula, the incubation time for the majority of the biodegradation of ethylene glycol to take place 
ranges from within a day to a few weeks (Bridie et al. 1979; Conway et al. 1983; Ettinger 1956; 
Heukelekian and Rand 1955; Lamb and Jenkins 1952; Means and Anderson 1981; Pitter 1976; Price et al. 
1974; Slave et al. 1974; Wagner 1976; Young et al. 1968).  Evans and David (1974) performed river 
die-away tests in which ethylene glycol, added to river water at concentrations ≤10 mg/L (ppm), was 
completely biodegraded after 3 days at 20 °C and after 14 days at 8 °C.   
 
Other reports of biotransformation of ethylene glycol include anaerobic metabolism (Battersby and 
Wilson 1989; Bieszkiewicz et al. 1979; Dwyer and Tiedje 1983; Hovious et al. 1973; Kameya et al. 1995; 
Watson and Jones 1977).  Based on available data, ethylene glycol appears to be completely degraded 
within 1–2 weeks under anaerobic conditions (Battersby and Wilson 1989; Dwyer and Tiedje 1983; 
Kameya et al. 1995).  Schoenberg et al. (2001) measured first-order biodegradation rate constants of 3.5–
5.2 per day for ethylene glycol-based deicing fluids under anaerobic conditions, corresponding to half-
lives of <1 day.  Dwyer and Tiedje (1983) proposed that the methanogenic degradation pathway proceeds 
through formation of ethanol followed by acetate. 
 
Waste water carrying ethylene glycol can be purified using the activated sludge method provided the 
concentration of ethylene glycol does not exceed 1,000 mg/L (ppm) (Bieszkiewicz et al. 1979).  Similar 
results were observed for the degradation of ethylene glycol in groundwater (McGahey and Bouwer 
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1992).  At an initial substrate concentration of 111 mg/L (ppm), naturally occurring microorganisms in 
groundwater biodegraded ethylene glycol with a calculated half-life of <1 day following a lag phase of 
<3 days. 
 
Ethylene glycol is not expected to undergo significant abiotic transformation in surface waters via 
hydrolysis or oxidation (EPA 1979; Harris 1990).  Glycols are resistant to hydrolysis (Harris 1990).  
Ethylene glycol is not expected to undergo direct photolysis in sunlit waters since alcohols do not absorb 
UV light at environmental wavelengths (above 295 nm) (Boethling and Mackay 2000).  However, 
indirect photolysis of ethylene glycol sorbed to goethite (a common natural constituent of surface water 
sediments) by near ultraviolet radiation (300–400 nm) has been demonstrated in the laboratory.  
Formaldehyde and glycolaldehyde were detected as degradation products (Cunningham et al. 1985). 
 
6.3.2.3   Sediment and Soil  
 
Biodegradation under both aerobic and anaerobic conditions is also the most important transformation 
process for ethylene glycol in soils, with half-lives similar to or less than those measured in surface waters 
(EPA 1987a). 
 
The rate of biodegradation of ethylene glycol in simulated subsurface soils is dependent on substrate 
concentrations, soil types, and ambient soil temperatures (McGahey and Bouwer 1992).  Greater than 
95% removal was consistently accomplished in <5 days and 7 days at ethylene glycol concentrations of 
100 and 1,000 ppm, respectively; however, substrate concentrations of 10,000 ppm showed negligible 
loss of ethylene glycol.  The rate of degradation was higher in soils with high organic matter.  A doubling 
in the degradation rate was also observed with a 10 °C increase in soil temperature.  McGahey and 
Bouwer (1992) concluded that microorganisms naturally occurring in soils and groundwater are effective 
in biodegrading ethylene glycol with the half-life ranging from 0.2 to 0.9 days.  Approximately 23–26% 
of ethylene glycol at 2.25 ppm was biodegraded in anaerobic sandy till soil grab sample tests run for 
86 and 140 days (Løkke 1984). 
 
Klecka et al. (1993) studied the biodegradation of aircraft de-icing fluids in soils adjacent to airport 
runways at various ethylene glycol concentrations and at various temperatures ranging from -2 to 25 °C.  
Generally, the rate of biodegradation of ethylene glycol was faster in soils with low glycol concentrations, 
high organic carbon content, and higher ambient soil temperatures.  Ethylene glycol present in soils at 
concentrations <6,000 mg/kg (ppm) biodegraded at an average rate of 3.0 mg/kg (ppm) soil/day at -2 °C, 
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at 19.7 mg/kg (ppm) soil/day at 8 °C, and at an average rate of 66.3 mg/kg (ppm) soil/day at 25 °C 
(Klecka et al. 1993).  Based on these results, biodegradation is expected to play a major role in removing 
ethylene glycol residues from soils adjacent to airport runways and taxiways.  Revitt and Worrall (2003) 
measured first-order biodegradation rate constants of 0.064 day-1 at 1 °C, 0.082 day-1 at 4 °C, and 
0.091 day-1 at 8 °C for an ethylene glycol-diethylene glycol de-icing formulation on paving blocks taken 
from an airport.  These rates correspond to half-lives of 10.8, 8.5, and 7.6 days, respectively.   
 
As in surface waters, abiotic transformation of ethylene glycol in soil is not expected to be a significant 
process (EPA 1987a). 
 
6.4   LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to ethylene glycol depends in part on the 
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of ethylene glycol in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits of current analytical methods.  In reviewing data on ethylene glycol levels 
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable.  The analytical methods 
available for monitoring ethylene glycol in a variety of environmental media are detailed in Chapter 7. 
 
6.4.1   Air  
 
Ethylene glycol was detected in ambient air samples, at time-weighted average (TWA) concentrations of 
<0.05–0.33 mg/m3 as aerosol and <0.05–10.4 mg/m3 as vapor, following spray application of de-icing 
fluids containing 50% solutions of the compound to the surfaces of bridges.  The ambient air samples 
were collected above the sprayed bridges (LA DOTD 1989).  Ethylene glycol was detected as a vapor 
above 2.5 mg/m3 in 18 out of 154 air samples collected during de-icing operations at a Montreal airport 
(Gérin et al. 1997).  The maximum concentration reported was 22.0 mg/m3.  Three of the air samples 
contained ethylene glycol as a mist at concentrations of 76, 91, and 190 mg/m3. 
 
Ethylene glycol was identified in air samples collected in four new manufactured houses and seven site-
built houses (Hodgson et al. 2000).  The range and geometric mean of ethylene glycol concentrations 
were <9.2–43.8 and 17.9 mg/m3, respectively, in the manufactured houses and 20.7–491 and 2.7 mg/m3, 
respectively, in the site-built houses.  Latex paint was indicated as a source for ethylene glycol emissions 
in the new houses. 
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Background concentrations of ethylene glycol in ambient air are not available. 
 
6.4.2   Water  
 
Monitoring data from several contractor and airport authority reports reveal that storm water runoff from 
airports may contain several hundred to several thousand mg/L (ppm) glycols (Sills and Blakeslee 1992).  
Ethylene and propylene glycol levels up to 19,000 mg/L (ppm) were detected in storm water from the Salt 
Lake City International Airport.  The concentration of ethylene glycol in runoff from runway apron areas 
at the Toronto International Airport ranged from 75.0 mg/L to 3,100 mg/L (ppm) and was up to 70 mg/L 
(ppm) in a stream that received runoff from the airport.  Ethylene glycol concentrations ranged from 2 to 
660 mg/L (ppm) and from 5 to 170 mg/L (ppm) in streams flowing through Winnipeg International 
Airport and St. John's International Airport (Newfoundland), respectively (Environment Canada 2000).  
Ethylene glycol concentrations were less than the detection limit (25 mg/L) in Etobicoke Creek, which 
receives storm water from Lester B. Pearson International Airport in Toronto.  The concentration of 
ethylene glycol in storm water runoff from Stapleton International Airport in Denver, Colorado ranged 
from near zero to 5,050 mg/L (ppm) (Sills and Blakeslee 1992).  Although the potential for groundwater 
contamination is quite low for many airports with predominantly heavy soil, the movement of glycols 
through unsaturated silty sand can be potentially high (Sills and Blakeslee 1992).  Thus, although 
ethylene glycol was not detected even in shallow soils at the edge of the runway at the Stapleton 
International Airport, the groundwater in the perched water table at Ottawa International Airport in 
Canada, which contained sandy soil, was found to contain ethylene glycol at levels up to 415 mg/L 
(ppm).  Peak concentrations occurred in June and declined to nondetectable levels by the fall.   
 
No information was found regarding background concentrations of ethylene glycol in surface water, 
groundwater, or drinking water. 
 
6.4.3   Sediment and Soil  
 
No information was found regarding the concentrations of ethylene glycol in soil or sediment. 
 
6.4.4   Other Environmental Media  
 
Ethylene glycol has been found to migrate into a number of foods from regenerated cellulose films 
containing triethylene glycol and polyethylene glycol as softening agents.  Ethylene glycol was detected 
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in fruit cakes at 27–34 mg/kg (ppm) after 84–336 days of storage, in meat pies at <10 mg/kg (ppm) after 
3–7 days of storage, in toffee at <10–22 mg/kg (ppm) after 168–450 days of storage, in madeira cake at 
<10–22 mg/kg (ppm) after 21–28 days storage, and in boiled sweets at 14–34 mg/kg (ppm) after 168–
450 days storage (Castle et al. 1988a).  According to Kashtock and Breder (1980), ethylene glycol can 
migrate into food simulants from polyethylene terephthalate (PET) bottles used in the packaging of 
carbonated beverages.  The compound was detected at a concentration of about 100 ppb (0.1 ppm) in a 
3% acetic acid solution used as a food simulant after 6 months of storage at 32 °C (Kashtock and Breder 
1980).  These authors stated that the source of ethylene glycol in this food simulant is the small amount of 
unreacted ethylene glycol in the polyethylene terephthalate polymer.  More recent information regarding 
levels of ethylene glycol in food is not available. 
 
Ethylene glycol has been identified in negligible amounts in the water-soluble component of cigarette 
smoke (Schumacher et al. 1977). 
 
6.5   GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
 
Ethylene glycol concentrations in blood, urine, tissue, or breast milk are not available for the general 
population in the United States.  The most common route of human exposure to ethylene glycol for 
members of the general population is dermal contact with ethylene glycol-based automobile antifreeze.  
However, intentional or accidental ingestion of antifreeze is the most serious type of exposure, resulting 
in thousands of ethylene glycol poisonings including several deaths reported each year in the United 
States (Fraser 2002; Leth and Gregersen 2005).  
 
Exposure to ethylene glycol through consumption of foods or drinks stored in plastics made from this 
chemical may be possible if the plastic contains unreacted ethylene glycol that can migrate into the food 
(Kashtock and Breder 1980).  However, current levels of ethylene glycol in food have not been located; 
therefore, evidence is not available to indicate that this as an important route of human exposure to 
ethylene glycol. 
 
Background concentrations of ethylene glycol in air, surface water, groundwater, drinking water, soil, and 
sediment are not available.  Ethylene glycol is not expected to be found in the environment away from 
areas where it is released since this substance is degraded within days to a few weeks in air, water, and 
soil.  Therefore, inhalation of ambient air, ingestion of drinking water, and dermal contact with water or 
soil are not expected to be important routes of exposure of the general population to ethylene glycol. 
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Contact with the skin and eyes is the most likely route of worker exposure to ethylene glycol.  Inhalation 
may be an important route of human exposure under occupational conditions where the compound is 
heated or if mists are generated by heat or violent agitation (Rowe and Wolf 1982).  Individuals involved 
in airport de-icing operations are exposed to ethylene glycol through inhalation since the de-icing 
formulation is sprayed through the air, generating ethylene glycol vapor and mist.   
 
Gérin et al. (1997) measured urinary ethylene glycol concentrations for 33 aviation workers exposed to 
de-icing fluid over a winter period of 2 months.  Ethylene glycol was detected above 2.5 mg/m3 (limit of 
quantification) as vapor in only 18 out of 154 air samples collected during spray operations.  Reported 
concentrations ranged from 0.9 to 22 mg/m3.  Ethylene glycol was also detected as a mist in three of the 
air samples with concentrations of 76, 91, and 190 mg/m3.  Ethylene glycol quantities in post-shift and 
next-morning urine samples exceeded 5 mmol/mol creatinine in 16 of the 33 workers (5.2–129 mmol/mol 
creatinine).  Exposure was greatest for basket operators and coordinators.  Air samples taken from the 
breathing zones of workers applying de-icing fluids (50% ethylene glycol) to bridge surfaces contained 
the compound at concentrations of <0.05–2.33 mg/m3 as aerosols and <0.05–3.37 mg/m3 as vapors 
(LA DOTD 1989). 
 
Laitinen et al. (1995) measured urinary ethylene glycol concentrations in 10 car mechanics frequently 
exposed to ethylene glycol and a control group of 10 male office workers.  Levels were noticeably higher 
in the urine of the mechanics.  Ethylene glycol and oxalic acid concentrations were 7.3 and 47 mmol/mol 
creatinine, respectively, in the urine of the car mechanics and 1.7 and 36 mmol/mol creatinine, 
respectively, in the urine of the controls.  Ethylene glycol concentrations in the air of the mechanics' 
environment were negligible.  Letzel et al. (2000) reported mean and median ethylene glycol 
concentrations of 0.31 and 0.23 mg/L, respectively, measured in the urine of 16 individuals living in 
Germany who had no known occupational exposure to glycols. 
 
The National Occupational Exposure Survey (NOES) conducted by NIOSH during 1981–1983 estimated 
that 1.5 million workers are potentially exposed to ethylene glycol each year (NIOSH 1990). 
 
6.6   EXPOSURES OF CHILDREN  
 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
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Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
 
Ethylene glycol antifreeze is a brightly-colored liquid and can be confused for a beverage, especially 
when it is not kept in its original container (Leth and Gregersen 2005).  The sweet taste of ethylene glycol 
adds to this attraction.  For this reason, some states have mandated that the bittering agent, denatonium 
benzoate, be added to ethylene glycol antifreeze formulations (Hogue 2006).  Although the presence of a 
bittering agent is expected to deter children from accidentally ingesting ethylene glycol-based antifreeze, 
caution should still be used.  Harry et al. (1998) reported a case of accidental ingestion of ethylene glycol 
antifreeze by a 4-year-old child even though the formulation contained denatonium benzoate. 
 
Many ethylene glycol poisonings occur when an antifreeze bottle is in use (EPA 2004b; Leth and 
Gregersen 2005).  Children may touch or ingest ethylene glycol from an opened container of antifreeze 
that an adult has placed within reach.  Children may also play with a puddle of antifreeze that has been 
spilled onto the ground. 
 
Children who live near facilities that manufacture or use ethylene glycol may be exposed to this substance 
through contact with contaminated soil or water.  Children living near airports where ethylene glycol is 
used in de-icing operations may be exposed through ingestion of contaminated groundwater or inhalation 
of ethylene glycol vapor. 
 
Biomonitoring data for children, including levels of ethylene glycol measured in breast milk, neonatal 
blood, cord blood, and meconium fluid have not been located. 
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6.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
Workers in industries involved in the manufacture or use of products containing high concentrations of 
ethylene glycol (e.g., antifreeze, coolants, de-icing fluids, brakes fluids, solvents) may be exposed to 
concentrations of the compound at levels higher than the general population, particularly in operations 
involving heating or spraying of these materials.  
 
Members of the general population who currently have potentially high exposures to ethylene glycol 
include individuals living near sites where ethylene glycol is manufactured or used and individuals living 
near waste disposal sites contaminated with ethylene glycol.  Persons living near airports where large 
amounts of ethylene glycol are used for de-icing of aircraft or near hazardous waste sites are potentially at 
greater risk of exposure, particularly from consumption of contaminated groundwater.  
 
6.8   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylene glycol is available.  Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of ethylene glycol.  
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
 
6.8.1   Identification of Data Needs  
 
Physical and Chemical Properties.    As seen in Table 4-2, the relevant physical and chemical 
properties of ethylene glycol are known (AIChE 1995; Forkner et al. 2004; Hansch et al. 1995; Hine and 
Mookerjee 1975; HSDB 2007; Lewis 2001; Lide 2005; O'Neil et al. 2001; Rebsdat and Mayer 2005) and 
predicting the environmental fate and transport of ethylene glycol based on these properties is possible.  
No further information is needed. 
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Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2005, became available in May of 2007.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
 
Production, Import/Export, Use, Release, and Disposal.    Knowledge of production and use 
data for a chemical is important in predicting its potential for environmental contamination and human 
exposure.  Both recent and historical production data are available for ethylene glycol (Brown et al. 1980; 
CMR 1981, 1984, 1987, 1990, 1993, 1998, 2001, 2004; Forkner et al. 2004; McClelland and Rector 1951; 
Miller 1966; Rebsdat and Mayer 2005; SRI 2006).  Similarly, data on the import/export volumes for 
ethylene glycol for the last several years are available (HSDB 2007; ITA 2007).  Information on the 
various uses of this compound is also available (Browning 1965; CMR 2004; Forkner et al. 2004; Lewis 
2001; O'Neil et al. 2001; Rebsdat and Mayer 2005; SRI 2006).  Ethylene glycol enters the environment 
primarily during its use as a component of automotive antifreeze/coolants, as a de-icing fluid for aircraft, 
and as an intermediate in the synthesis of polyester fibers (Klecka et al. 1993; Lewis 2001; O'Neil et al. 
2001; Rowe and Wolf 1982).  Major sources of ethylene glycol releases to soils are from the disposal of 
used antifreeze and de-icing solutions in hazardous waste sites (EPA 1979, 1987a; Ware 1988).  
Information regarding the disposal of ethylene glycol-containing waste waters (DOE 1993a, 1993b) and 
for remediation of ethylene glycol contaminated soils (Drajun 1991; Vesper et al. 1994) is available. 
 
Environmental Fate.    Information regarding the fate of ethylene glycol in the air is available that 
suggests that the compound would be primarily found in the vapor phase and would likely be removed 
from the atmosphere via wet deposition (Eisenreich et al. 1981; EPA 1979).  Ethylene glycol undergoes 
rapid photochemical oxidation via reaction with hydroxyl radicals with a half-life of 1.4 hours (Atkinson 
1989; EPA 1993e).  Because of its high solubility in water, the compound is expected to be transported 
primarily in aqueous media (EPA 1979) and will not partition to the atmosphere via volatilization from 
water (Thomas 1990).  Adsorption to sediment or soil particles is not expected to be significant based on 
the low Koc value; therefore, ethylene glycol is expected to have a high mobility in soil and the potential 
to leach into groundwater (Swann et al. 1983).  Ethylene glycol is degraded in both water (Battersby and 
Wilson 1989; Bieszkiewicz et al. 1979; Bridie et al. 1979; Caskey and Taber 1981; Dwyer and Tiedje 
1983; Evans and David 1974) and soil (Klecka et al. 1993; McGahey and Bouwer 1992; Revitt and 
Worrall 2003) primarily by biodegradation.  Based on available data, ethylene glycol is biodegraded 
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under both aerobic and anaerobic conditions from within a day to a few weeks.  No additional information 
on degradation of ethylene glycol in air, water or soil is required. 
 
Bioavailability from Environmental Media.    Available information regarding the rate of ethylene 
glycol absorption following inhalation, oral, or dermal contact has been discussed in the Toxicokinetics 
section (see Section 3.4).  Although no data on ethylene glycol's bioavailability from contaminated air are 
available, the bioavailability from inhalation exposure is expected to be high because ethylene glycol is 
likely to be present in the vapor phase (Eisenreich et al. 1981) and not in the particulate phase in the 
adsorbed state.  Similarly, no data on the bioavailability of ethylene glycol from water, soil, or plant 
material are available; however, ethylene glycol is miscible in water and does not adsorb readily to soil.  
Ethylene glycol, therefore, is expected to be readily bioavailable from soil and water.  Information on the 
bioavailability of ethylene glycol from actual environmental media needs further development. 
 
Food Chain Bioaccumulation.    Based on its low Koc value, ethylene glycol is not expected to 
bioconcentrate in aquatic food chains.  Freitag et al. (1985) reported a BCF value of 10 measured in fish.  
Information is also lacking regarding the biomagnification potential of ethylene glycol through aquatic 
food chains, although biomagnification is probably a minor process because of the rapid degradation rate 
for the chemical in aquatic systems.  No further information on the bioconcentration or biomagnification 
potential of ethylene glycol is needed.   
 
Exposure Levels in Environmental Media.    Reliable monitoring data for the levels of ethylene 
glycol in contaminated media at hazardous waste sites are needed so that the information obtained on 
levels of ethylene in the environment can be used in combination with the known body burden of ethylene 
glycol to assess the potential risk of adverse health effects in populations living in the vicinity of 
hazardous waste sites. 
 
Information on the number of hazardous waste sites on the NPL at which ethylene glycol was detected in 
air, surface water, groundwater, soil, and sediment is available (HazDat 2007).  However, more specific 
information, such as concentrations in these media, is needed to give a better indication of the potential 
for human exposure to ethylene glycol in areas near hazardous waste sites. 
 
No information was located on the concentration of ethylene glycol in ambient air.  Time weighted 
average concentrations of the compound as both an aerosol and a vapor were measured following the 
spray application of de-icing fluids containing ethylene glycol on a bridge (LA DOTD 1989) and at an 
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airport (Gérin et al. 1997).  These data are not general enough to estimate inhalation exposure to ethylene 
glycol for the general population in the United States.  No data on the level of ethylene glycol in drinking 
water were located, although ethylene glycol has been detected at up to 415 mg/L (ppm) in groundwater 
in the vicinity of an airport (Sills and Blakeslee 1992).  No information on the background levels of 
ethylene glycol in soil, surface water, or groundwater was located.  Additional information regarding the 
levels of ethylene glycol in ambient air, drinking water, surface water, groundwater, and soil is needed.  
Some older data on ethylene glycol levels in foods, particularly those stored in cellulose films or in PET 
bottles are available (Castle et al. 1988a; Kashtock and Breder 1980).  Additional quantitative information 
on current levels of ethylene glycol in various environmental media and levels of contamination in foods 
would be helpful in assessing the health risks to the general population and in occupational settings. 
 
Exposure Levels in Humans.    Little quantitative information on ethylene glycol levels in various 
human tissues and body fluids of a control population, populations near hazardous waste sites, or 
occupationally exposed groups in the United States is available.  Most information is available for oral 
exposures derived from intentional or accidental poisonings (Gabow et al. 1986; Hewlett et al. 1986; 
Jacobsen et al. 1988; Parry and Wallach 1974; Robinson and McCoy 1989; Vale 1979; Wiener and 
Richardson 1988).  Some information is available on plasma glycolate levels for poisoning victims 
admitted to a hospital (Jacobsen et al. (1984), and on urine and other tissues (Cheng et al. 1987; Rothman 
et al. 1986; Winek et al. 1978).  Data are needed on the levels of ethylene glycol and its metabolites in 
body tissues and fluids especially from dermal and inhalation studies.  Two studies have been located that 
report urinary concentrations for airport de-icing workers and car mechanics (Gérin et al. 1997; Laitinen 
et al. 1995).  Additional information on control populations, populations living in the vicinity of 
hazardous waste sites, and those who are occupationally exposed to ethylene glycol is needed.   
 
This information is necessary for assessing the need to conduct health studies on these populations. 
 
Exposures of Children.    Information regarding the background exposure of children to ethylene 
glycol is not available.  Body burden studies measuring the levels of ethylene glycol in the blood, urine, 
and body tissue of children would be helpful.  Studies measuring the levels of this chemical in the 
neonatal blood, cord blood, and meconium fluid of infants would also be helpful.  Levels of ethylene 
glycol in breastmilk have not been located.  Children are considered to be more susceptible to accidental 
ingestion of ethylene glycol than adults (Leth and Gregersen 2005).  Information is needed regarding how 
effective the use of a bittering agent has been in deterring accidental ingestion of ethylene glycol by 
children. 
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Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility. 
 
Exposure Registries.   No exposure registries for ethylene glycol were located.  This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance. 
 
6.8.2   Ongoing Studies  
 
Ongoing studies related to the potential for human exposure to ethylene glycol were not located. 
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7.  ANALYTICAL METHODS 
 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring ethylene glycol, its metabolites, and other biomarkers of exposure and 
effect to ethylene glycol.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis.  Many 
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  
Other methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
 
7.1   BIOLOGICAL MATERIALS  
 
Table 7-1 is a summary of some of the most commonly used methods reported in the literature for 
detecting ethylene glycol in biological samples.  The primary method for measuring ethylene glycol in 
biological samples is derivatization followed by gas chromatography (GC) using either a flame ionization 
detector (FID) or mass spectrometry (MS) for quantification.  GC is the preferred analytical method 
because of the ease of sample preparation and the accuracy of the quantification of sample concentrations.  
Alkali flame ionization detectors have also been used for ethylene glycol analysis and give a response 
ratio of 3:1 compared with FID (Bogusz et al. 1986).   
 
Sample preparation for GC is important and proceeds through several steps:  acidification, esterification, 
and extraction into an organic solvent.  The use of internal standards is necessary for quantification.   
 
Detection of ethylene glycol in biological samples using GC with either FID or MS is very sensitive, with 
detection limits ranging from sub to low ppm.  The coefficient of variation (CV) varies with the 
concentration of glycol used but typically ranges from 0.4 to 27% and is usually <10%.  In GC 
procedures, the glycols and their acid metabolites are derivatized to form esters in order to facilitate 
quantitative elution from the chromatographic columns (see Table 7-1).  Yao and Porter (1996) and Porter 
et al. (1999) have developed a procedure for the simultaneous determination of ethylene glycol and 
glycolic acid in human serum.  The entire procedure can be completed in <2 hours.  Simple and rapid 
methods are also available for the quantitation of the glycols in urine, serum, or deproteinated whole 
blood.  These methods use direct sample injection without prior solvent extraction and derivatization  
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Table 7-1.  Analytical Methods for Determining Ethylene Glycol in  
Biological Materials 
 








Human plasma  Deproteinization with acetic 
acid; vortex; centrifugation; 
supernatant spiked with 
internal standard; reaction 
with butyl-boronic acid; 




HRGC/MS 5 ppm  94–106 Giachetti et 
al. 1989 
Human serum  Internal standard (in 
acetonitrile) added to sample; 
centrifugation to remove 
protein precipitate; 
esterification with 
butylboronic acid and 
2,2-dimethoxypropane; 
neutralization with NH4OH in 
acetonitrile. 





Addition of internal standard 
(in acetonitrile) followed by 
centrifugation.  Supernate is 
treated with 2,2-dimethoxy-
propane/dimethylformamide.  
Volume is then reduced, but 
not to dryness. 






Porter et al. 
1999 
Human serum Deprotonization of samples 
via ultrafiltration followed by 
addition of internal standard 
to the filtrate and injection into 
the GC. 
CCGC 10 ppm NR Williams et 
al. 2000 
Human serum 
and urine  
Internal standard added; 
centrifugation; derivatization 
with phenylboronate in 
methanol. 




Anhydrous Na2SO4 ground 
with sample; derivatization 
with n-butylboronic acid in 
acetone containing internal 
standard; centrifugation or 
filtration. 
GC/FID/AFID NR 70 Bogusz et 
al. 1986 
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Table 7-1.  Analytical Methods for Determining Ethylene Glycol in  
Biological Materials 
 










Colorimetric: precipitation of 
protein with trichloroacetic 
acid followed by 
centrifugation, addition of 
chromotropic acid, heating, 
and dilution; gas 
chromatographic: addition of 
internal standard and acetone 
followed by centrifugation, 
addition of NaOH, 
evaporation to dryness, and 
formation of methyl ester. 
Absorbance at 





w/v) for both 
methods; 3–
6% RSD 





Extraction from salted, 
acidified serum using methyl 
ethyl ketone followed by 
removal of organic phase and 
evaporation to dryness and 
derivatization with PNBDI. 




NR Hewlett et 
al. 1986 
Urine Acidification; extraction with 
CHCl3; concentration; TLC. 








NR NR Winter et al. 
1990 
Dog urine 
(glycolic acid)  
Dilution; NaCl addition and 
acidification; extraction in 
MEK; evaporation; dissolution 
of residue in ethylacetate; 
derivatization with PNBDl. 





deproteinated by addition of 
acetonitrile and phosphate 
buffer (pH=7), centrifugation, 
removal of solvent and 
evaporation to dryness; 
derivatization as for urine; 
urine acidified and derivatized 
using 1,2-diaminobenzene, 














Tissue ground with acidic 
methanol; filtration; 
concentration; spot on 
254 nm TLC plate. 
TLC NR NR Riley et al. 
1982 
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Table 7-1.  Analytical Methods for Determining Ethylene Glycol in  
Biological Materials 
 








Human tissue Samples extraction in HPLC 
grade water for 24 hours; 
filtration of supernatant. 






AFID = alkali flame ionization detector; ATP = adenosine triphosphate; CHCl3 = chloroform; CH3OH = methanol; 
CCGC = Capillary column gas chromatography; ECD = electron capture detector; EG = ethylene glycol; FID = flame 
ionization detector; GC = gas chromatography; HCl = hydrochloric acid; HClO4 = chloroform; HPLC = high-
performance liquid chromatography; HRGC = high resolution gas chromatography; KOH = potassium hydroxide; 
MEK = methylethyl ketone; MgSO4 = magnesium sulfate; MS = mass spectrometry; NaCl = sodium chloride; 
NAD = nicotinamide adenine dinucleotide; Na2SO4 = sodium sulfate; NH4OH = ammonium hydroxide; NR = not 
reported; PG = propylene glycol; PNBDl = O-p-nitrobenzyl-N,N'-diisopropylisourea; RSD = relative standard 
deviation; RI = refractive index detector; TLC = thin-layer chromatography; UV = ultraviolet detector; 
w/v = weight:volume 
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(Aarstad et al. 1993; Edinboro et al. 1993; Jonsson et al. 1989).  However, such methods, particularly 
those that use packed columns may misidentify propionic acid (found in patients with methylmalonic 
acidemia) as ethylene glycol (Shoemaker et al. 1992).   
 
High performance liquid chromatography (HPLC) has also been used to identify ethylene glycol and its 
metabolites such as glycolate (Hewlett et al. 1983, 1986), hippurate (Riley et al. 1982), and oxalate 
(Brega et al. 1992) in biological samples, particularly blood and urine.  Positive results may be confirmed 
with GC/MS.  This makes GC/MS the preferred method since the HPLC step can be omitted.  However, 
HPLC methods to measure plasma levels of glycolate have been used to aid in diagnosis and treatment of 
ethylene glycol poisoning (Hewlett et al. 1986; Jacobsen et al. 1988).  Gas chromatographic and 
colorimetric methods for quantification of glycolate have been presented (Fraser and MacNeil 1993).   
 
Microscopy can be used to identify metabolic products of ethylene glycol.  Scanning electron microscopy 
(SEM) at 20 kilovolts will detect crystals of calcite, calcium oxalate monohydrate, and calcium oxalate 
dihydrate in kidney tissue (Siew et al. 1975b).  Phase-contrast polarization and light microscopy X-ray 
powder diffraction may be used to identify hippuric acid crystals in urine (Foit et al. 1985). 
 
The use of ethylene oxide to sterilize tissue for transplantation may result in the formation of ethylene 
glycol when ethylene oxide is in prolonged contact with tissue.  To quantify the formation of ethylene 
glycol in tissue, an HPLC method using a differential refractive index detector has been developed.  The 
HPLC system can be used to detect ppm levels of ethylene glycol with a sensitivity of 2x10-6 refractive 
index unit full scale.  This procedure has three advantages:  (1) requires only 4 minutes for analysis, 
(2) simple sample preparation, and (3) good reproducibility (Wu and Malinin 1987). 
 
Techniques using GC and various detection systems to detect and quantify ethylene glycol in human 
blood have been developed for use in hospital laboratories to assist in the diagnosis of ethylene glycol 
poisoning (caused by drinking antifreeze containing ethylene glycol).  These techniques are quite rapid, 
usually <30 minutes, and do not require elaborate sample preparation.  The specific techniques used for 
each analytical method are listed in the table if that information was provided by the author(s). 
 
An alternative method, developed in a hospital, for detecting ethylene glycol in blood is the use of the 
DuPont Automated Clinical Analyzer triglyceride assay pack.  This enzymatic method, while relatively 
simple, cannot be used when the triglyceride concentration of the serum exceeds 12 g/L and requires that 
positive results for ethylene glycol be confirmed using another method (Ochs et al. 1988; Ryder et al. 
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1986).  The enzymatic method has been modified to eliminate some of the interference problems present 
in the earlier methods (Blandford and Desjardins 1994). 
 
Thin-layer chromatography (TLC) with a chloroform solvent has been used to detect ethylene glycol and 
its metabolites in urine or renal tissue (Riley et al. 1982).  Metabolites of ethylene glycol in the blood may 
be detected by analytical isotachophoresis using a system equipped with both a conductivity detector and 
an ultraviolet detector.  Blood and serum samples should not have been previously treated with oxalate, 
citrate, or ethylene diamine tetracetic acid.  This technique may be of value when ethylene glycol 
poisoning is suspected but sufficient time has elapsed for metabolism of the compound to have occurred 
(Ovrebo et al. 1987).  A simple and rapid colorimetric method that uses chromatropic acid has been 
proposed for the quantitation of glycolic acid, the major toxic metabolite of ethylene glycol (Fraser and 
MacNeil 1993).   
 
No information was located on detecting ethylene glycol in feces, adipose tissue, or human milk. 
 
7.2   ENVIRONMENTAL SAMPLES  
 
As with biological samples, GC is the major technique used to determine ethylene glycol concentrations 
in environmental samples whether in air, water, food, drugs, or other substances.  Capillary gas 
chromatography with FID or ECD, possibly followed by MS, generally gives good quantitative results 
down to the ppm range with recovery usually >80%.  The determination of ethylene glycol in air requires 
adsorption onto a surface and subsequent extraction.  Water samples may be analyzed without preparation 
(EPA 1995a, 1995b).  Detection of ethylene glycol in foods and drugs may be accomplished by 
chromatography of the sample; for substances with a high fat content, extraction with hexane may be used 
to remove the fat.  Table 7-2 is a summary of some of the most commonly used methods reported in the 
literature for detecting ethylene glycol in environmental samples.  The specific techniques used for each 
analytical method are listed in the table if that information was provided by the author(s). 
 
Air sampling for ethylene glycol is performed by adsorption onto a resin column such as Amberlite 
XAD-2.  Although activated charcoal filters have some utility, recovery is greater with the Amberlite, and 
it is the preferred adsorption medium.  Ethylene glycol is then solvent-extracted with recovery of 98%.  If 
activated charcoal is used for adsorption, 5% methanol in dichloromethane is the best solvent with 
maximum recovery of 84% (Andersson et al. 1982, 1984).  An alternative method for sampling ethylene 
glycol involves passage of air through a glass fiber filter with a silica gel tube.  Ethylene glycol is then  
ETHYLENE GLYCOL  209 
 







***DRAFT FOR PUBLIC COMMENT*** 
 











Air Sample collection on 
glass fiber filters and silica 
gel; extraction with 
methanol; ultrasonic bath 
(Method 5523). 
GC/FID 0.05 ppm 93.4–101 NIOSH 1996 
Air Sample adsorbed on 
Amberlite® XAD-2 with 
personal sampling pump; 
extraction with diethyl 
ether. 
GC/FID NR 75–98 Andersson et al. 1982
Water Direct injection (Method 
8015C). 
GC/FID NR NR EPA 2000 
Water Direct injection (Method 
8430). 
GC/FTIR NR NR EPA 1996 
Plastics Sample extraction from 
plastic with carbon 
disulfide. 
GC/FID 16.5 ng 58–61 Muzeni 1985 
Plastics Sample extraction with 
solvent of ethylacetate-
water-methanol. 




Extraction with anhydrous 
methanol. 




then dilution with water; 
concentration with helium 
gas; redilution. 
GC/FID 50 ppb 97–103 Kashtock and Breder 
1980 
Beer Addition of ammonium 
sulfate and extract with 
ethyl acetate. 
HRGC/FID 0.73 ppm 88 Williamson and 
Iverson  1993 
Food Addition of hot water to 
sample to obtain slurry; 
extraction with hexane; 
precipitation of sugars 





10 ppm 78–107 Castle et al. 1988b 
Anchovies Extraction with methanol 
and concentration. 
HRGC/MS/
MS (PICI)  
12.5 ppb NR Matusik et al. 1993 
 
BSTFA = bis(trimethylsilyl)trifluoroacetamide; FID = flame ionization; GC = gas chromatography; HRGC = high 
resolution gas chromatography; MS = mass spectrometry; MS/MS = tandem mass spectrometry; PICI = positive ion 
chemical ionization 
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extracted in a 2-propanol:water solvent mixture and injected into the gas chromatograph (Tucker and 
Deye 1981).  A similar version of this method is the NIOSH-approved method for the determination of 
ethylene glycol in occupational air (see Table 7-2). 
 
A portable, automated, photoionization gas chromatograph has been used to detect ethylene glycol in air 
samples in industrial facilities at levels as low as 0.05 ppm (Adams and Collins 1988). 
 
Ethylene glycol may be detected by a colorimetric reaction with 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride after oxidation of the glycols to the corresponding aldehydes with acidified permanganate.  
The solution is read at 630 nm in a spectrophotometer.  This method may be used for ethylene glycol in 
water (Evans and Dennis 1973) or to detect ethylene oxide in air (Kring et al. 1984); however, this 
method is not quantitative and is relatively insensitive compared with GC/MS. 
 
The migration of ethylene glycol from plastics into solution can be studied with GC.  Sample preparation 
methods include extraction in hydrochloric acid (Ball 1984), distilled water (Spitz and Weinberger 1971), 
carbon disulfide (Muzeni 1985), dimethylformamide (Danielson et al. 1990), and a mixture of ethyl 
acetate, water, and methanol (De Rudder et al. 1986).  Other methods for detecting ethylene glycol in 
industrial products include HPLC (Aboul-Enein and Islam 1989) and a periodate flow-through ion-
selective electrode (Diamandis et al. 1980). 
 
The presence of ethylene glycol in foods packaged with plastic films containing the compounds has been 
studied, as have ethylene glycol levels in drugs sterilized with ethylene oxide.  Sample preparation is 
important because procedures vary depending on the fat content of the food sample.  Foods with low fat 
content can be extracted with ethyl acetate, derivatized to a trimethylsilyl ether, and then injected into the 
gas chromatograph.  For foods with a high fat content, hexane is used as the defatting agent prior to 
derivatization.  Quantifying ethylene glycol in wines requires no preparation of the samples prior to 
analysis (Kaiser and Rieder 1987; Klaus and Fischer 1987).  Drugs in aqueous solutions may be analyzed 
directly, water insoluble drugs should be extracted in water, and ointments may be dissolved in hexane 
and then extracted with water.  Recovery is between 80 and 114%, with detection limits in the low-ppm 
range (Hartman and Bowman 1977; Manius 1979).  Although the use of TLC (Ballarin 1980) has been 
recommended, it has been superseded by GC. 
 
No information was located on techniques for detecting and analyzing ethylene glycol in soil. 
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7.3   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylene glycol is available.  Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of ethylene glycol.  
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
 
7.3.1   Identification of Data Needs  
 
Methods for Determining Biomarkers of Exposure and Effect.     
 
Exposure.  Methods are available for the determination of ethylene glycol in blood, tissue, and urine 
(Bogusz et al. 1986; Giachetti et al. 1989; Houzé et al. 1993; Riley et al. 1982; Smith 1984; Wu and 
Malinin 1987) with sensitivities in the low and sub-ppm range.  Methods are also available for 
metabolites of ethylene glycol (glycolic acid, oxalic acid) in blood and urine (Brega et al. 1992; Fraser 
and MacNeil 1993; Hewlett et al. 1986) with sensitivities as low as 3 ppm for glycolic acid and of 
0.15 ppm for oxalic acid.  Glycolic acid was identified in Chapter 3 as a sensitive biomarker of exposure 
to ethylene glycol.  These methods seem to be adequate for the measurement of ethylene glycol and its 
metabolites in the human population.  
 
Effect.  Serum concentrations of blood urea nitrogen (BUN) or creatinine can serve as indicators of renal 
toxicity induced by exposure to ethylene glycol, but these are not specific for ethylene glycol intoxication 
(Grauer et al. 1987). 
 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Methods for the determination of ethylene glycol have been reported for air (Andersson et al. 
1982; NIOSH 1996), water or aqueous solutions (EPA 1996, 2000; Kashtock and Breder 1980), and 
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foods (Castle et al. 1988b; Matusik et al. 1993; Williamson and Iverson 1993).  Methods have also been 
developed for the determination of glycols that leach from plastics (De Rudder et al. 1986; Muzeni 1985) 
and can end up in foods stored in containers made from the plastics.   
 
The MRL for inhalation exposure to ethylene glycol is 0.5 ppm and thus requires a method level of 
detection (LOD) of 0.5 ppm.  This value is below the LODs of the methods reported.  Although it should 
be possible to increase the sampling volumes and increase the sensitivities of the methods, this would 
need to be shown to be free of problems.  Oral MRLs have been established to be 2 mg/kg/day for acute 
exposure and 0.2 mg/kg/day for chronic exposure.  Assuming a 70-kg individual and oral intakes of either 
2 L/day of water or 2 kg/day of food, analytical methods would need sensitivities <70 ppm in water or 
food.  The methods reported for aqueous solutions (LOD=50 ppb, Kashtock and Breder 1980), beer 
(LOD=0.73 ppm, Williamson and Iverson 1993), and foods (LOD=10 ppm, Castle et al. 1988b; 
LOD=12.5 ppb, Matusik et al. 1993) should be adequate to measure acute exposure.  However, chronic 
exposure requires method LODs of approximately 7 ppm and only the methods of Kashtock and Breder 
(1980) for aqueous solutions, Williamson and Iverson (1993) for beer, and Matuslik et al. (1993) for 
anchovies can meet this requirement.  The applicability of these methods to other beverages and foods has 
not been demonstrated.  Thus, additional methods should be developed and validated for ethylene glycol 
in other beverages and foods at concentrations relevant to the chronic oral MRL.   
 
7.3.2   Ongoing Studies  
 
Ongoing studies related to the potential for human exposure to ethylene glycol were not located. 
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8.  REGULATIONS AND ADVISORIES 
 
The international and national regulations and guidelines regarding ethylene glycol in air, water, and other 
media are summarized in Table 8-1. 
 
An MRL of 2 mg/m3 has been derived for acute-duration inhalation exposure (14 days or less) to ethylene 
glycol.  The MRL is based on a NOAEL of 23 mg/m3 for respiratory tract irritation and systemic toxicity 
in humans (Wills et al. 1974), which was divided by an uncertainty factor of 10 (for human variability). 
 
An MRL of 0.8 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to ethylene 
glycol.  BMD dose modeling was conducted using developmental toxicity data in mice (total 
malformations and a skeletal variation) (Neeper-Bradley et al. 1995; Tyl 1989).  The resulting BMDL10 of 
76 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans 
and 10 for human variability) to derive an MRL of 0.8 mg/kg/day for acute-duration oral exposure to 
ethylene glycol.   
 
The acute-duration oral MRL of 0.8 mg/kg/day has been adopted for intermediate-duration oral exposure 
(15–364 days) to ethylene glycol.  The critical effect for intermediate-duration exposure is kidney lesions 
in male Wistar rats (Cruzan et al. 2004).  Basing the intermediate-duration MRL on the NOAEL for this 
effect yielded a value that is higher than the acute-duration MRL.  It is against ATSDR policy to derive an 
intermediate-duration MRL that is higher than the acute-duration MRL.  Because available evidence 
indicates that the acute-duration MRL should be protective for kidney effects following longer-term 
exposure, the acute-duration value of 0.8 mg/kg/day was adopted for intermediate-duration exposure. 
 
EPA (IRIS 2007) assigned ethylene glycol an oral reference dose (RfD) of 2.0 mg/kg/day with an 
uncertainty factor of 100 (10 for interspecies extrapolation and 10 for differences in individual human 
sensitivity) based on kidney toxicity in rats (DePass et al. 1986a). 
 
EPA has not derived an inhalation reference concentration (RfC) for ethylene glycol. 
 
Neither the International Agency for Research on Cancer (IARC) nor the EPA has classified ethylene 
glycol for human carcinogenicity (IARC 2006; IRIS 2007).  The American Conference of Governmental 
Industrial Hygienists (ACGIH) has classified ethylene glycol as an A4 carcinogen (not classifiable as a 
human carcinogen) (ACGIH 2006).  The National Toxicology Program (NTP) has not classified ethylene  
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Table 8-1.  Regulations and Guidelines Applicable to Ethylene Glycol 
 
Agency Description Information Reference 
INTERNATIONAL    
Guidelines:    
 IARC Carcinogenicity classification No data IARC 2006 
 WHO Air quality guidelines No data WHO 2000a 
 Drinking water quality guidelines No data WHO 2004 
NATIONAL    
Regulations and 
Guidelines: 
   
a.  Air    
 ACGIH TLV (8-hour TWA) No data 
 TLV-ceiling (aerosol only) 100 mg/m3 
ACGIH 2006 
 EPA The Second List of AEGL priority 
chemicals for guideline developmenta 
Yes EPA 2007a 
 Hazardous air pollutant Yes EPA 2007b 
42 USC 7412 
 NIOSH REL (10-hour TWA) Not establishedb 
 IDLH No data 
NIOSH 2005 
 OSHA PEL (8-hour TWA) for general industry No data OSHA 2006 
29 CFR 1910.1000 
b.  Water    
 EPA Drinking water standards and health 
advisories 
 
  1-Day health advisory for a 10-kg 
child 
20 mg/L 
  10-Day health advisory for a 10-kg 
child 
6 mg/L 
  DWEL 70 mg/L 
  Lifetime 14 mg/L 
  10-4 Cancer risk No data 
EPA 2006b 
 National primary drinking water 
standards 
No data EPA 2003 
c.  Food    
 EPA Inert ingredients in pesticide products List 3c EPA 2004a 
 Exempt from the requirement of a 
tolerance 
When used in foliar 
applications to peanut 
plants 
EPA 2007f 
40 CFR 180.1040 
 FDA Substance for use only as components 
of adhesives 
Yes FDA 2006 
21 CFR 175 
d.  Other    
 ACGIH Carcinogenicity classification A4d ACGIH 2006 
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Table 8-1.  Regulations and Guidelines Applicable to Ethylene Glycol 
 
Agency Description Information Reference 
NATIONAL (cont.)    
 CPSC Designated a hazardous substance 
under Section 3(b) of the Federal 
Hazardous Substances Act and 
requires special labeling 
Ethylene glycol and 
mixtures containing 
10% or more by weight 
of ethylene glycole 
CPSC 2007 
 EPA Carcinogenicity classification No data 
 RfC No data 
 RfD 2 mg/kg/day 
IRIS 2007 
 Master Testing List Yesf EPA 2007c 
 Superfund, emergency planning, and 
community right-to-know 
  
  Designated CERCLA hazardous 
substance 
Yesg 
   Reportable quantity 5,000 pounds 
EPA 2007d 
40 CFR 302.4 
  Effective date of toxic chemical 
release reporting 
01/01/87 EPA 2007e 
40 CFR 372.65 
 NTP Carcinogenicity classification No datah NTP 2005 
 
aThe Second List of AEGL priority chemicals is a composite of 371 priority chemicals from numerous priority lists of 
acutely toxic chemicals and represents the selection of chemicals for AEGL development by the NAC/AEGL (EPA 
2007a). 
bNIOSH has not established a REL for ethylene glycol under the “Proposed Rule on Air Contaminants" (29 CFR 
1910, Docket No. H-020) in which NIOSH questioned whether the OSHA PEL for ethylene glycol (ceiling 50 ppm) 
was adequate enough to protect workers from potential health hazards (NIOSH 2005). 
cList 3:  Inerts of unknown toxicity are placed on this list if there was no basis for listing it on any of the other lists.  
EPA continues to evaluate ethylene glycol as additional information becomes available, to determine if 
reclassification to List 1, 2, or 4 is appropriate (EPA 2004a). 
dA4:  not classifiable as a human carcinogen 
eEthylene glycol requires special labeling with the word “warning”' and the statement “harmful or fatal if swallowed” 
because ethylene glycol and mixtures containing 10% or more by weight of ethylene glycol are commonly marketed, 
stored, and used in a manner that increases the possibility of accidental ingestion (CPSC 2007). 
fEthylene glycol was recommended to the MTL by the U.S. EPA’s Office of Air and Radiation on the basis that it is a 
hazardous air pollutant.  Ethylene glycol was added to the MTL in 1995 and EPA is initiating development of a testing 
action via TSCA Section 4 FRM, a TSCA Section 4 ECA, or a VTA (EPA 2007c).  The testing needs indicated for 
health effects include acute, subchronic toxicity/90 day, neurotoxicity, and immunotoxicity studies. 
gDesignated CERCLA hazardous substance pursuant to Section 112 of the Clean Air Act. 
hEthylene glycol has undergone the following testing at NTP: toxicology, carcinogenesis, reproductive, 
developmental, and genetic toxicity studies (NTP 2007). 
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal 
Regulations; CPSC = Consumer Product Safety Commission; DWEL = drinking water equivalent level; 
ECA = Enforceable Consent Agreement; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; FRM = Final Rule-Making; IARC = International Agency for Research on Cancer; IDLH = immediately 
dangerous to life or health; IRIS = Integrated Risk Information System; MTL = Master Testing List; NIOSH = National 
Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and 
Health Administration; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation 
reference concentration; RfD = oral reference dose; STEL = short-term expoure limit; TLV = threshold limit values; 
TSCA = Toxic Substances Control Act; TWA = time-weighted average; USC = United States Code; VTA = Voluntary 
Testing Agreement; WHO = World Health Organization 
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glycol for human carcinogenicity, but it appears on the Testing Status of Agents at NTP and has 
undergone standard toxicology, carcinogenesis, reproductive, developmental, and genetic toxicity studies 
(NTP 2007). 
 
OSHA (2006) and NIOSH (2005) have not established a permissible exposure limit (PEL) or a 
recommended exposure limit (REL) for ethylene glycol.  Under the “Proposed Rule on Air 
Contaminants" (29 CFR 1910, Docket No. H-020), NIOSH questioned whether the OSHA PEL for 
ethylene glycol (ceiling 50 ppm) was adequate to protect workers from potential health hazards (NIOSH 
2005).  ACGIH (2006) has established a 100 mg/m3 ceiling limit for ethylene glycol. 
 
EPA (2007b) has designated ethylene glycol as a hazardous air pollutant (HAP) under the Clean Air Act 
(CAA).  Ethylene glycol is on the list of chemicals appearing in “Toxic Chemicals Subject to Section 313 
of the Emergency Planning and Community Right-to-Know Act of 1986" and has been assigned a 
reportable quantity (RQ) limit of 5,000 pounds (EPA 2007d).  The RQ represents the amount of a 
designated hazardous substance which, when released to the environment, must be reported to the 
appropriate authority. 
 
Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), ethylene glycol is exempt from 
tolerances for residues when used in foliar applications to peanut plants (EPA 2007f). 
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10.  GLOSSARY 
 
 
Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
 
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
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Immunological Effects—Functional changes in the immune response. 
 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.  
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.  
 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
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variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
 
Xenobiotic—Any chemical that is foreign to the biological system. 
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
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the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical name(s): Ethylene glycol 
CAS number(s): 107-21-1 
Date: August 2007 
Profile status: Final Draft Pre-Public Comment 
Route: [X] Inhalation [ ] Oral 
Duration: [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure: 2 
Species: Human 
 
MRL:  2 [ ] mg/kg/day  [ ] ppm  [X] mg/m3 
 
Reference:  Wills JH, Coulston F, Harris ES, et al.  1974.  Inhalation of aerosolized ethylene glycol by 
man.  Clin Toxicol 7(5):463-476. 
 
Experimental design:  Health effects were assessed in 19 male prisoners who voluntarily were exposed to 
ethylene glycol aerosol for 20–22 hours/day for 30 days.  The diameter of the aerosol droplets ranged 
from 1 to 5 μm.  Mean daily and mean weekly concentrations during the first 14 days of the study ranged 
from 0.8 to 44.8 and from 17 to 29 mg/m3, respectively.  Mean daily and mean weekly concentrations 
during the entire 30-day exposure period were 0.8–67 and 17–49 mg/m3, respectively.  The average mean 
weekly exposure was 23 mg/m3 for days 1–14 and 30 mg/m3 for days 1–30.  The average exposure levels 
did not include brief periods in which the concentration was intentionally raised to higher levels to assess 
acute responses.  A control group consisted of 14 male prisoners; 10 of these men were never exposed to 
ethylene glycol, whereas the remaining 4 men had been exposed to a mean concentration of 37 mg/m3 for 
20–22 hours/day for 7 days during the week that preceded the start of the study.  Subjective responses 
(symptoms) were monitored throughout the study.  During the last 10 days of the study, the concentration 
of ethylene glycol was occasionally intentionally increased to various high levels (up to 308 mg/m3) when 
the volunteers left the exposure chamber during meals; subjective responses to short exposures to the high 
concentrations were assessed when they reentered the chamber.  Complete physical examinations that 
included slit-lamp, electrocardiographic, and electroencephalographic studies, and a battery of 
psychological tests designed to reveal effects on simple reaction time, reaction time with discrimination, 
visual-motor coordination, depth perception, and mental ability (encoding and subtraction accuracy), were 
conducted on all subjects pre-exposure and after 14 and 30 days of exposure.  Blood samples were 
collected on days 0, 1, 3, 5, 8, 12, 19, 22, 26, and 29 for evaluation of hematology, clinical chemistry 
(including blood urea nitrogen, serum creatinine, and liver enzymes), and ethylene glycol concentration.  
Urine was evaluated daily for oxalate crystals, erythrocytes, and ethylene glycol, and twice weekly for 
volume, specific gravity, color, clarity, pH, amino acid nitrogen, and creatinine.   
 
Effects noted in study and corresponding doses:  Concentrations of ethylene glycol in the blood and urine 
were similar in the exposed and control groups.  The near-continuous exposure levels (average 23 mg/m3 
for days 1–14 and 30 mg/m3 for days 1–30) were tolerated with effects that were limited to occasional 
complaints of upper respiratory tract irritation, slight headache, and low backache (incidences and other 
information not reported).  The short-term, high-exposure sessions showed that the irritation became 
common at approximately 140 mg/m3, and tolerated for only 15 minutes at 188 mg/m3, 2 minutes at 
244 mg/m3, and one or two breaths at 308 mg/m3.  Based on these results and those of other trials, the 
investigators concluded that concentrations of about ≥200 mg/m3 were intolerable due to strong irritation 
of the upper respiratory tract that included a burning sensation in the trachea and a burning cough.  
Because the near-continuous exposures were tolerated with respiratory irritation that was infrequent and 
not serious, and not accompanied by neurological, hematology, clinical chemistry, or urinalysis findings 
indicative of renal or other systemic effects, the interim (12–14-day) findings in this study identified a 
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NOAEL of 23 mg/m3 for acute-duration exposure in humans.  The LOAEL was 140 mg/m3 because brief 
exposures to this concentration commonly caused respiratory irritation. 
 
Dose and end point used for MRL derivation: 
 
[X] NOAEL [ ] LOAEL 
 
Uncertainty factors used in MRL derivation: 
 
[ ] 10 for use of a LOAEL 
[ ] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(inhalation study). 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable (human study).  
 
Exposure concentrations were not converted from mg/m3 to ppm because ppm is unsuitable for aerosols. 
 
Was a conversion used from intermittent to continuous exposure?  The NOAEL of 23 mg/m3 was not 
adjusted for discontinuous daily exposure (20 hours/24 hours) because the critical effect is concentration 
dependent and not duration dependent. 
 
Other additional studies or pertinent information that lend support to this MRL:  The only other 
information on effects of acute-duration inhalation exposure to ethylene glycol is available from three 
developmental toxicity studies in rats and mice (Tyl 1988a; Tyl et al. 1995a, 1995b). 
 
In a developmental toxicity study in CD-1 mice using whole-body exposure to nominal concentrations of 
0, 150, 1,000, or 2,500 mg/m3 for 6 hours/day on Gd 6–15, maternal body weight gain was decreased, but 
corrected weight was unaffected, at concentrations ≥1,000 mg/m3 (Tyl 1988a; Tyl et al. 1995a).  
Significant effects on implant viability, weight of live fetuses, and on the incidence of external, visceral, 
and skeletal malformations were observed at concentrations ≥1,000 mg/m3.  Maternal toxicity (e.g., 
increased liver weight in rats and reduced body weight gain in mice) was evident at 2,500 and 
1,000 mg/m3 in rats and mice, respectively (Tyl et al. 1995a).  In CD rats exposed similarly in the same 
study, there were significant increases in absolute and relative liver weight among maternal animals 
exposed to 2,500 mg/m3; kidney weights were unchanged, and liver and kidney histopathology was not 
evaluated.  In addition, reduced ossification at some sites in the axial skeleton was observed with 
exposure to 1,000 and 2,500 mg/m3; however, in an Expert Panel Review of this study, NTP-CERHR 
(2004) concluded that the relationship of this effect to treatment was uncertain due to the lack of a dose-
response relationship.  Both of the whole-body experiments were confounded by significant ingestion of 
ethylene glycol deposited on the fur and consumed during grooming; the authors estimated that the 
ingestion dose comprised the majority of exposure (Tyl 1985, 1988a; Tyl et al. 1995a).   
 
In a follow-up developmental study aimed at reducing the confounding from ingestion exposure, pregnant 
CD-1 mice were exposed nose-only to target concentrations of 0, 500, 1,000, or 2,500 mg/m3 aerosolized 
ethylene glycol for 6 hours/day on Gd 6–15 (Tyl 1988a; Tyl et al. 1995b).  In maternal animals, there 
were no effects other than changes in kidney weights.  Absolute kidney weight was significantly 
increased at 1,000 and 2,500 mg/mg3, and relative kidney weight was increased at 2,500 mg/m3; however, 
microscopic examination of kidneys did not indicate any histopathological changes.  At 2,500 mg/m3, live 
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fetal body weight was significantly reduced, and there was a significant increase in the one type of 
skeletal malformation (fused ribs).  Increases in some skeletal variations were observed at 2,500 mg/m3, 
and one type (extra ossification sites in the sagittal suture) was significantly increased at concentrations 
≥500 mg/m3.  The authors designated the 1,000 mg/m3 concentration a developmental NOAEL and the 
500 mg/m3 concentration a NOAEL for maternal effects.  However, the authors noted that the animals in 
the nose-only experiment were also exposed by ingestion of ethylene glycol during preening of the face 
after exposure (Tyl 1988a; Tyl et al. 1995b).  Furthermore, NTP-CERHR (2004) noted that stress from 
restraint in the single nose-only exposure study may have contributed to the developmental effects 
observed with ethylene glycol, which were similar in nature to effects observed in a study of restrained 
nose-only exposure to water vapor (Tyl et al. 1994).   
 
Because of the confounding oral exposures in both the whole-body and nose-only developmental toxicity 
studies, NTP-CERHR (2004) concluded that the data from these studies were not suitable for evaluation 
of effect levels from inhalation exposure to ethylene glycol.  The available data do, however, provide a 
conservative estimate of the inhalation NOAEL, with the caveat that total exposure to ethylene glycol in 
these studies included intake via ingestion.  Collectively, these studies suggest that inhalation exposure to 
ethylene glycol at a nominal concentration of about 150 mg/m3 is not associated with developmental 
toxicity in mice or rats, or renal toxicity in mice (kidney histopathology not assessed in rats).  The next 
highest concentration (500 mg/m3 in the nose-only study) was associated with developmental effects 
(increased incidence of skeletal variations), but it is not possible to conclusively relate these effects to 
inhalation of ethylene glycol. 
 
As indicated above, the developmental studies (Tyl 1988a; Tyl et al. 1995a, 1995b) collectively suggest 
that 150 mg/m3 is a conservative NOAEL for developmental toxicity in rats and kidney toxicity in mice.  
This concentration is similar to the 140 mg/m3 LOAEL for respiratory tract irritation in humans (Wills et 
al. 1974).  The human NOAEL of 23 mg/m3 is a suitable basis for MRL derivation because it is based on 
evaluations for renal and other systemic effects as well as for local irritation, and is well within the 
NOAEL range for developmental toxicity in animals.   
 
Agency Contacts (Chemical Managers):  Obaid Faroon, Carolyn Tylenda, Carolyn C. Harper 
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 MINIMAL RISK LEVEL WORKSHEET 
 
Chemical name(s): Ethylene glycol 
CAS number(s): 107-21-1 
Date: August 2007 
Profile status: Final Draft Pre-Public Comment 
Route: [ ] Inhalation [X] Oral 
Duration: [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure: 51 
Species: Mouse 
 
MRL:  0.8 [X] mg/kg/day  [ ] ppm  [ ] mg/m3 
 
References:  Neeper-Bradley TL, Tyl RW, Fisher LC, et al.  1995.  Determination of a no-observed-effect 
level for developmental toxicity of ethylene glycol administered by gavage to CD rats and CD-1 mice.  
Fundam Appl Toxicol 27:121-130.   
 
Tyl RW.  1989.  Developmental toxicity evaluation of ethylene glycol administrated by gavage to 
CD-1 mice:  Determination of a "no-observed-effect-level" (NOEL).  Bushy Run Research Center, CMA 
Project Report 51-591. 
 
Experimental design:  Groups of 30 timed-pregnant CD-1 mice were given doses of 50, 150, 500, or 
1,500 mg/kg ethylene glycol daily by gavage on Gd 6–15; vehicle controls were given water on the same 
schedule (Neeper-Bradley et al. 1995; Tyl 1989).  Maternal animals were observed daily for clinical signs 
and weighed periodically; water intake was measured throughout gestation.  At sacrifice on Gd 18, body 
weight, gravid uterine weight, liver weight, and kidney weight were measured in dams.  Kidneys from 
control and high-dose dams were examined microscopically.  Corpora lutea and uterine contents were 
evaluated, and live fetuses were weighed and sexed.  External, visceral, and skeletal malformations and 
variations in the fetuses were evaluated.   
 
Effects noted in study and corresponding doses:  No effects on maternal body weight, water consumption, 
or liver or kidney weight were observed.  There were no significant effects on the number of corpora 
lutea/dam, on the number of total, nonviable, or viable implants/litter, or on sex ratio.  Average fetal body 
weight per litter was reduced (13% below controls) at 1,500 mg/kg/day.  The incidence of individual 
external or visceral malformations was not significantly increased in any treatment group relative to the 
vehicle control; however, exencephaly (a malformation observed by Price et al. [1985] at higher doses) 
was observed in two fetuses in the 500 mg/kg/day group and in three fetuses of the 1,500 mg/kg/day dose 
group.  There was a significant increase in the incidence of two skeletal malformations (fused ribs or 
thoracic arches) in the 1,500 mg/kg/day group (15/21 litters with fused ribs vs. 1/19 controls; 8/21 litters 
with fused thoracic arches vs. 0/19 controls).  Further, the incidence of total malformations per litter 
(external, visceral, and skeletal) was significantly increased both at 500 and 1,500 mg/kg/day (3/19, 7/20, 
5/24, 12/24, and 17/21 from control to high dose).  The incidences of 23 skeletal variations were 
increased in the 1,500 mg/kg/day group.  One of these variations (bilateral extra rib 14) was also 
significantly increased at ≥500 mg/kg/day (4/19, 4/20, 6/24, 17/24, and 21/21 in control through high 
dose groups, respectively).  This study identified a developmental NOAEL of 150 mg/kg/day and 
LOAEL of 500 mg/kg/day for increased incidence of total malformations and bilateral extra rib 14.  The 
high dose (1,500 mg/kg/day) was a NOAEL for maternal effects. 
 
Dose and end point used for MRL derivation: 
 
[ ] NOAEL [ ] LOAEL [X] BMDL 
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To derive a point of departure for MRL derivation, BMD dose modeling was conducted using the mouse 
data on the incidence of litters with malformations (of any kind) and on the incidence of one skeletal 
variation (bilateral extra rib 14).  The incidences for both end points are presented in Table A-1.  These 
two end points were observed at lower doses than other observed effects (skeletal malformations, pup 
body weight reductions).   
 
Table A-1.  Incidences of Developmental Effects in Offspring of Mice Exposed 
to Ethylene Glycol by Gavage on Gestation Days 6–15 
 
Dose (mg/kg/day) 
Effecta 0 50 150 500 1,500 
Extra lumbar ribb 4/19 4/20 6/24 17/24c 21/21c 
Total malformations 3/19 7/20 5/24 12/24d 17/21c 
 
aNumber of litters with effects/number of litters examined. 




Sources:  Neeper-Bradley et al. 1995; Tyl 1989 
 
All dichotomous variable models in the EPA Benchmark Dose Software (Version 1.4.1) were fit to the 
malformation and skeletal variation data.  Although one of the end points modeled (total malformations) 
represents a more serious effect, the group sizes in this study (19–24 litters/dose examined) did not 
support a BMR lower than 10%; thus, an extra risk incidence of 10% above controls was selected as the 
BMR.  Model results for the data on total malformations are shown in Table A-2.  All available 
dichotomous models provided adequate fit to the data (p>0.1).  Comparing across models, a better fit is 
generally indicated by a lower Akaike’s Information Criteria (AIC).  The multistage and quantal linear 
models converged on the same model providing the best fit (as assessed by AIC) to the data on total 
malformations; these models both predicted a BMD10 of 113.84 mg/kg/day and a BMDL10 of 
75.59 mg/kg/day.  Figure A-1 shows the fit of the multistage (1-degree polynomial) model to the 
malformation data. 
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Table A-2.  Model Predictions for the Incidence of Total Malformations in 
Offspring of Mice Exposed to Ethylene Glycol by  






(mg/kg/day) χ2 p-value AIC 
Gammaa 162.51 75.95 0.27 129.33 
Logistic 211.23 156.53 0.41 127.64 
Log-logisticb 213.64 48.14 0.28 129.24 
Multi-stagec 113.84 75.59 0.44 127.40 
Probit  208.48 159.25 0.41 127.66 
Log-probitb 242.07 140.87 0.28 129.21 
Quantal linear 113.84 75.59 0.44 127.40 
Quantal quadratic 392.59 307.59 0.26 128.84 
Weibulla 152.27 75.98 0.27 129.33 
 
aPower restricted to ≥1. 
bSlope restricted to ≥1. 
cBetas restricted to ≥0; lowest degree polynomial with adequate fit is reported; degree of polynomial = 1. 
 
Sources:  Neeper-Bradley et al. 1995; Tyl 1989 
 
Figure A-1.  Predicted and Observed Incidence of Total Malformations in 
Offspring of Mice Exposed to Ethylene Glycol  

















Multistage Model with 0.95 Confidence Level
10:49 04/02 2007
BMDBMDL
   
Multistage
 
*BMD and BMDL associated with a 10% extra risk increase over control are shown; doses given in units of 
mg/kg/day. 
 
Sources:  Neeper-Bradley et al. 1995; Tyl 1989 
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Model results for the data on bilateral extra rib 14 are shown in Table A-3.  For these data, the probit 
model provided the best fit (as assessed by AIC); a BMD10 of 99.35 mg/kg/day and BMDL10 of 
75.56 mg/kg/day were predicted.  Figure A-2 shows the fit of the probit model to the skeletal variation 
data. 
 
Table A-3.  Model Predictions for the Incidence of Bilateral Extra Lumbar  
Ribs in Offspring of Mice Exposed to Ethylene Glycol  






(mg/kg/day) χ2 p-value AIC 
Gammaa 200.86 64.02 0.98 101.59 
Logistic 103.80 77.82 0.90 100.16 
Log-logisticb 419.85 101.67 0.91 101.72 
Multi-stagec 49.956 35.31 0.36 103.53 
Probit  99.35 75.56 0.90 100.12 
Log-probitb 353.71 97.62 0.91 101.72 
Quantal linear 49.96 35.31 0.36 103.53 
Weibulla 192.89 60.78 0.99 101.55 
 
aPower restricted to ≥1. 
bSlope restricted to ≥1. 
cBetas restricted to ≥0; lowest degree polynomial with adequate fit is reported; degree of polynomial = 1. 
 
Sources:  Neeper-Bradley et al. 1995; Tyl 1989 
 









***DRAFT FOR PUBLIC COMMENT*** 
Figure A-2.  Predicted and Observed Incidence of Extra Lumbar Ribs in Offspring 

















Probit Model with 0.95 Confidence Level
10:27 04/02 2007
BMDL BMD




*BMD and BMDL associated with a 10% extra risk increase over control are shown; doses given in units of 
mg/kg/day. 
 
Sources:  Neeper-Bradley et al. 1995; Tyl 1989 
 
Modeling of both the malformation and skeletal variation end points resulted in the same BMDL10, 
indicating that an acute oral MRL based on this point of departure should provide protection against both 
effects. 
 
Uncertainty factors used in MRL derivation: 
 
[ ] 10 for use of a LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
 
Although some mechanistic information suggests that humans may be less sensitive than rodents to the 
developmental effects of ethylene glycol, the available data are not adequate to support a lower 
interspecies uncertainty factor; thus, a full 10-fold uncertainty factor was used for interspecies 
extrapolation.  While in vitro data suggest that humans metabolize glycolic acid (the proximate 
developmental toxicant) more efficiently than rats (Booth et al. 2004; Corley et al. 2005a), NTP-CERHR 
(2004) observed that the data supporting the glycolic acid metabolic rate in humans are limited.  In 
addition, NTP-CERHR (2004) reviewed preliminary data indicating that the inverted yolk sac placenta, a 
stage in placental development that does not exist in humans, tends to concentrate weak acids such as 
glycolic acid in the embryonic fluids.  These data suggest enhanced sensitivity to ethylene glycol 
developmental effects in rodents compared with humans; however, NTP-CERHR (2004) characterized 
the available data as inconclusive.  A 10-fold uncertainty factor for interindividual variability was also 
used.  Ethylene glycol metabolism is known to involve alcohol dehydrogenase and aldehyde 
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dehydrogenase, and may also involve cytochrome p450 isozymes (NTP-CERHR 2004).  Polymorphisms 
in the genes encoding these enzymes may lead to wide variability in the production and elimination of 
glycolic acid and other metabolites in humans exposed to ethylene glycol, but data quantifying the range 
of variability are not currently available (NTP-CERHR 2004).  In addition, fetal and/or placental 
differences in expression of these enzymes over the course of gestation will affect local concentrations of 
glycolic acid and other metabolites to which the developing conceptus is exposed, yet little is known 
about these differences (NTP-CERHR 2004). 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(gavage study). 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable. 
 
Other additional studies or pertinent information that lend support to this MRL:  In acute-duration oral 
developmental toxicity studies in rodents, fetal effects have consistently been observed at doses that are 
not maternally toxic.  Furthermore, the teratogenic effects observed after ethylene glycol exposure appear 
to be generally consistent across studies and across species, with the primary end point consisting of 
skeletal malformations.  The incidence of malformations was increased in CD-1 mice at doses of 
≥500 mg/kg/day when administered by gavage during gestation (Gd 6–15) (Neeper-Bradley et al. 1995; 
Tyl 1989).  Embyrotoxicity was also manifested as a reduction in fetal body weight in CD-1 mice given 
doses of ≥750 mg/kg/day on Gd 6–15 (Neeper-Bradley 1990; Price et al. 1985; Tyl 1989).  In rats, doses 
of ≥1,000 mg/kg/day by gavage on Gd 6–15 resulted in an increased incidence of skeletal malformations 
in offspring (Neeper-Bradley 1990; Neeper-Bradley et al. 1995; Price et al. 1985).  Decreases in pup body 
weight and increases in both the number of litters with malformations and the number of malformed 
fetuses per litter were observed in rats treated during Gd 6–15 with doses ≥2,500 mg/kg/day (Price et al. 
1985; Neeper-Bradley 1990; Neeper-Bradley et al. 1995).  In mice given doses of 3,000 mg/kg/day during 
Gd 6–15, neural tube and craniofacial defects were increased, and the number of live fetuses per litter was 
decreased (Price et al. 1985).  In contrast to the results in rodents, no teratogenic effects were observed in 
rabbits exposed to maternally lethal doses of 2,000 mg/kg/day during gestation (Tyl et al. 1993). 
 
No effects were observed on hematology parameters, but dose-related effects on bone marrow and 
erythropoiesis were observed when doses of 0, 50, 100, or 250 mg/kg/day ethylene glycol were given for 
4 consecutive days by gavage to B6C3F1 mice.  Seven mice per sex were sacrificed on 1 day 
postexposure for measurement of body, liver, thymus, spleen, kidney, and testis weights, and 
histopathology of these organs as well as the lung, heart, adrenals, stomach, bone marrow, urinary 
bladder, intestines, and uterus.  Hematology, bone marrow parameters, and erythropoiesis were evaluated 
in other groups of mice evaluated between 1 and 14 days after exposure.  Microscopic examination of the 
spleen and bone marrow did not reveal any histopathological changes, and there were no significant 
changes to hematological parameters (hemoglobin, hematocrit, mean corpuscular volume, erythrocyte and 
leukocyte counts) evaluated 5 days after exposure termination.  Exposure to ethylene glycol resulted in 
statistically significant decreases in bone marrow cellularity (up to about 25% below control values) at 
doses of ≥100 mg/kg/day; this effect persisted up to 14 days after exposure in males.  Granulocyte-
macrophage progenitor formation was suppressed (~15% below controls) at 50 mg/kg/day in males 
evaluated 14 days postexposure and at higher doses in both males and females evaluated at earlier time 
points.  The magnitude of reduction in granulocyte-macrophage progenitor formation ranged up to 40% 
below controls at 250 mg/kg/day.  Iron uptake in the bone marrow was suppressed (38% below controls) 
in males exposed to 250 mg/kg/day. 
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While bone marrow effects were observed in male mice exposed to doses of 50–250 mg/kg/day in this 
study, the biological significance of these effects is uncertain.  No effects were observed on any 
hematological parameters, or on bone marrow or spleen histology (Hong et al. 1988).  Histology was 
evaluated only 1 day after exposure, and hematological parameters were evaluated 5 days postexposure; 
thus, these evaluations would not have captured delayed effects on these parameters.  However, studies 
using much higher doses and longer durations have failed to indicate effects on bone marrow, spleen, or 
hematology in mice, and provide inconsistent findings in rats.  No histological changes in the bone 
marrow were observed in mice or rats exposed to higher doses of ethylene glycol for longer durations; 
these included B6C3F1 mice exposed to ≤16,000 mg/kg/day in diet for 13 weeks or ≤12,000 mg/kg/day 
in diet for 2 years (Melnick 1984; NTP 1993), F344 rats exposed to ≤10,000 mg/kg/day in diet for 
13 weeks (Melnick 1984), and Sprague-Dawley rats exposed to ≤7,327 mg/kg/day in drinking water for 
10 or 90 days (Robinson et al. 1990).  Results of routine hematology evaluations in these studies were 
unremarkable except for some alterations in the 10- and 90-day studies in rats.  In the 10-day study, 
statistically significant decreases in hemoglobin, hematocrit, erythrocytes, and total leukocytes (7.3, 8.9, 
8.5, and 34.8% less than controls, respectively) occurred in female rats at 7,327 mg/kg/day (Robinson et 
al. 1990).  In the 90-day study, total leukocyte counts were significantly reduced in female rats at 597, 
3,087, and 5,744 mg/kg/day (32, 30, and 50% less than controls, respectively) (Robinson et al. 1990).  
Results of differential counts were not reported, and no clear hematological changes occurred in male rats 
in either study.  Hematology evaluations were also negative in other studies that did not examine bone 
marrow histology; these included studies of B6C3F1 mice exposed to ≤12,000 mg/kg/day in diet for 
2 years (DePass et al. 1986a), Wistar rats exposed to ≤2,000 mg/kg/day by gavage for 4 weeks (Schladt et 
al. 1998), and Wistar rats exposed to ≤1,128 mg/kg/day in diet for 16 weeks (Gaunt et al. 1974).  In male 
F344 rats exposed to 1,000 mg/kg/day in the diet for 2 years, significant hematological changes were 
observed, but this dose also caused mortality due to renal toxicity (DePass et al. 1986a).   
 
The hematopoietic system is an established target system for several ethylene glycol ethers (e.g., ethylene 
glycol monomethyl ether, ethylene glycol monobutyl ether (IRIS 2007).  For these compounds, 
hematological effects are consistently observed across different species, doses, and exposure durations.  
In contrast, few studies have suggested hematological effects from ethylene glycol exposure, and those 
with positive findings were at higher doses than Hong et al. (1988) and gave inconsistent results.  Given 
the lack of supporting evidence for hematological, bone marrow, or splenic effects in mice and rats 
exposed to much higher doses of ethylene glycol and for longer durations, the biological significance of 
the effects observed by Hong et al. (1988) is considered uncertain, and this study was not used to derive 
the acute oral MRL. 
 
In a 10-day drinking water study, groups of 10 male and 10 female Sprague-Dawley rats were 
administered 0, 0.5, 1.0, 2.0, or 4.0% ethylene glycol; reported mean compound consumption was 649, 
1,343, 2,615, and 5,279 mg/kg/day in males, and 794, 1,506, 2,953, and 7,327 mg/kg/day in females 
(Robinson et al. 1990).  The incidence and severity of renal lesions were significantly increased and dose-
related in males at ≥2,615 mg/kg/day; effects included tubular dilation, degeneration, necrosis, and 
intratubular calcium oxalate crystals.  Effects on body weight, organ weights, and hematological 
parameters were observed at the high dose only.  Changes in serum chemistry parameters were observed 
at lower doses in both males and females; however, these were not accompanied by histopathological 
changes in the liver.  This study identified a LOAEL of 2,615 mg/kg/day for renal toxicity in male rats.  
As discussed above, other studies identified bone marrow effects and developmental toxicity at lower 
doses; thus, this study was not considered for use in acute oral MRL derivation. 
 
Corley et al. (2005a) published a PBPK model for rats, but no model has yet been developed for mice, the 
species used in the study selected for MRL derivation.  As a result, available data do not support the use 
of PBPK modeling to derive an acute oral MRL for ethylene glycol based on developmental toxicity in 
mice. 
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A key uncertainty in the acute-duration oral MRL stems from the use of gavage administration in the 
critical study.  Bolus doses from gavage administration lead to higher peak concentrations of glycolic acid 
in the blood than occur with equivalent doses at slower dose-rates associated with environmentally-
relevant exposures (Carney et al. 2001; NTP-CERHR 2004).  Because the key study used gavage 
administration, the dose at which effects were observed may be lower than would be observed with non-
bolus dosing.  In support of this, Maronpot et al. (1983) observed neither fetal nor maternal toxicity at 
dietary doses up to 1,000 mg/kg in F344 rats, while Neeper-Bradley et al. (1995) reported skeletal 
malformations and effects on fetal body weight in CD rats given 1,000 mg/kg via gavage.  While strain 
differences in susceptibility to ethylene glycol cannot be ruled out as the source of the differing results, 
the data supporting glycolic acid as the proximate toxicant, and the evidence for much lower serum levels 
of glycolic acid with continuous dosing than with bolus dosing, suggest that the lack of developmental 
toxicity observed by Maronpot et al. (1983) likely resulted from the difference in dose-rate. 
 
Agency Contacts (Chemical Managers):  Obaid Faroon, Carolyn Tylenda, Carolyn C. Harper 
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Public Health Statement 
 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 




Relevance to Public Health 
 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.   
 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
 
Interpretation of Minimal Risk Levels 
 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 







Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
 
 









***DRAFT FOR PUBLIC COMMENT*** 
LEGEND 
See Sample LSE Table 3-1 (page B-6) 
 
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
 
(2) Exposure Period.  Three exposure periods—acute (less than 15 days), intermediate (15–
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
 
(3) Health Effect.  The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
 
(4) Key to Figure.  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
 
(5) Species.  The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
 
(6) Exposure Frequency/Duration.  The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
 
(7) System.  This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
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(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
 
(10) Reference.  The complete reference citation is given in Chapter 9 of the profile. 
 
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
 
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 




See Sample Figure 3-1 (page B-7) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure Period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
 
(14) Health Effect.  These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table. 
 
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) NOAEL.  In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
 
(17) CEL.  Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
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(18) Estimated Upper-Bound Human Cancer Risk Levels.  This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
 















































   ↓ 
Nitschke et al. 1981 
 
 










(CEL, lung tumors, 
nasal tumors) 


























































































a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
    NA/IMCO     North America/Intergovernmental Maritime Dangerous Goods Code 
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DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System   
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
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mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
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PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 








q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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APPENDIX D.  INDEX 
 
absorbed dose............................................................................................................................................ 145 
adipose tissue ............................................................................................................................................ 208 
adrenals ................................................................................................................................... 27, 43, 96, 140 
adsorbed ............................................................................................................................................ 199, 209 
adsorption.................................................................................................................................. 183, 189, 208 
aerobic....................................................................................................................... 182, 183, 190, 191, 199 
alanine aminotransferase (see ALT) ........................................................................................................... 42 
ALT (see alanine aminotransferase) ..................................................................................................... 42, 89 
ambient air ........................................................................................................................ 192, 193, 194, 199 
anaerobic ........................................................................................................................... 183, 190, 191, 199 
anion gap..................................................................................................................... 98, 136, 146, 147, 164 
antiestrogenic ............................................................................................................................................ 140 
aspartate aminotransferase (see AST)......................................................................................................... 42 
AST (see aspartate aminotransferase)................................................................................................... 42, 89 
bioavailability ........................................................................................................................................... 199 
bioconcentration factor ............................................................................................................................. 189 
biodegradation........................................................................................................... 182, 189, 190, 191, 199 
biomarker .......................................................................................... 144, 145, 146, 148, 163, 164, 203, 211 
blood cell count........................................................................................................................................... 43 
body weight effects ................................................................................................................. 37, 48, 96, 112 
breast milk......................................................................................................................... 4, 9, 144, 194, 196 
cancer .................................................................................................. 3, 12, 21, 46, 113, 141, 153, 158, 162 
carcinogen ......................................................................................................................................... 213, 215 
carcinogenic .................................................................................................................................... 12, 16, 36 
carcinogenicity.......................................................................................................... 109, 155, 158, 213, 216 
cardiac arrhythmia ...................................................................................................................................... 85 
cardiovascular ................................................................................................. 41, 48, 85, 110, 136, 152, 153 
cardiovascular effects............................................................................................................................ 41, 85 
clearance ............................................................................................................................... 29, 94, 117, 132 
cranial nerves .............................................................................................................................. 10, 101, 161 
death................................................................................ 3, 11, 31, 35, 36, 37, 47, 48, 85, 95, 102, 110, 137 
deoxyribonucleic acid (see DNA)............................................................................................................. 113 
dermal effects...................................................................................................................................... 96, 110 
developmental effects .................................. 11, 12, 13, 14, 17, 18, 21, 23, 45, 46, 105, 106, 107, 108, 109, 
 112, 113, 133, 137, 138, 143, 144, 159, 160, 165, 166, 168 
DNA (see deoxyribonucleic acid)..................................................................... 113, 114, 115, 137, 143, 145 
elimination half-time................................................................................................................................. 133 
endocrine................................................................................................... 37, 43, 48, 96, 110, 139, 140, 143 
endocrine effects ........................................................................................................................... 43, 96, 140 
erythema...................................................................................................................................................... 43 
estrogen receptor....................................................................................................................................... 140 
estrogenic .................................................................................................................................................. 140 
fetus....................................................................................................................... 11, 21, 134, 140, 143, 156 
gastrointestinal effects ................................................................................................................................ 86 
general population................................................................................... 9, 35, 144, 162, 183, 194, 197, 200 
genotoxic............................................................................................................................................. 36, 113 
genotoxicity............................................................................................................................... 113, 143, 159 
groundwater ...................................... 2, 9, 162, 183, 188, 189, 190, 191, 193, 194, 196, 197, 198, 199, 200 
half-life................................................................................ 10, 119, 125, 135, 145, 163, 183, 190, 191, 198 
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hematological effects ............................................................................................................................ 41, 87 
hematopoietic.............................................................................................................................................. 11 
hepatic effects ......................................................................................................................... 12, 42, 88, 110 
hydrolysis.................................................................................................................................. 175, 179, 191 
hydroxyl radical ................................................................................................................................ 190, 198 
immunological .................................................................................................. 11, 35, 43, 99, 100, 112, 160 
immunological effects................................................................................................................................. 43 
Kow .................................................................................................................................................... 173, 189 
LD50............................................................................................................................................... 47, 48, 161 
lymphoreticular ..................................................................................................... 11, 99, 100, 112, 155, 160 
metabolic acidosis................................................................ 10, 11, 12, 14, 97, 98, 101, 135, 136, 137, 138, 
 142, 143, 146, 147, 151, 152, 163, 167, 168 
metabolic effects ..................................................................................................................... 37, 97, 98, 110 
milk ........................................................................................................................................................... 208 
musculoskeletal effects ............................................................................................................................... 88 
neonatal ..................................................................................................................................... 144, 196, 200 
neurobehavioral................................................................................. 11, 16, 19, 44, 102, 139, 155, 156, 162 
neurological effects ............................................................................... 43, 44, 100, 103, 112, 148, 155, 161 
neurophysiological .................................................................................................................................... 100 
ocular effects................................................................................................................................. 43, 96, 110 
odds ratio..................................................................................................................................................... 46 
osmolal gap ................................................................................................................. 98, 135, 142, 146, 148 
oxidative phosphorylation......................................................................................................................... 137 
partition coefficients ................................................................................................................................. 130 
PBPK model ....................................................................................................... 24, 127, 128, 130, 144, 166 
pharmacodynamic ..................................................................................................................................... 127 
pharmacokinetic.......................................................................................... 14, 127, 128, 129, 130, 133, 141 
photolysis .......................................................................................................................................... 190, 191 
placenta ............................................................................................................... 24, 134, 135, 138, 166, 169 
rate constant .............................................................................................................................. 130, 190, 192 
renal effects................................................................... 12, 14, 15, 20, 32, 42, 90, 91, 92, 95, 110, 148, 152 
reproductive effects............................................................................................. 44, 103, 104, 105, 112, 159 
respiratory effects............................................................................................................................ 37, 48, 85 
skeletal malformations ................................ 11, 12, 13, 17, 21, 22, 23, 24, 45, 105, 106, 107, 108, 143, 160 
solubility ........................................................................................................................... 123, 183, 189, 198 
spermatogonia ........................................................................................................................................... 104 
spermatozoa .............................................................................................................................................. 104 
systemic effects....................................................................... 11, 16, 18, 19, 20, 37, 48, 110, 153, 155, 156 
thyroid..................................................................................................................................... 27, 43, 96, 140 
toxicokinetics ................................................ 14, 35, 133, 135, 143, 144, 158, 159, 163, 164, 165, 166, 168 
vapor phase ............................................................................................................................... 189, 198, 199 
vapor pressure ................................................................................................................................... 185, 189 
volatilization ..................................................................................................................................... 189, 198 
weanling...................................................................................................................................................... 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
